On August 23, 2021, Triple-S
Management Corporation, a Puerto Rico corporation (“Triple-S”), entered into a definitive merger agreement with GuideWell
Mutual Holding Corporation, a Florida not-for-profit mutual insurance holding company (“Parent”), and GuideWell Merger, Inc.,
a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), as may be amended from time to time (the “merger
agreement”). Pursuant to the terms of the merger agreement, Merger Sub will be merged with and into Triple-S, with Triple-S surviving
the merger as a wholly owned subsidiary of Parent (the “merger”).
If the merger is completed,
Triple-S stockholders will have the right to receive $36.00 in cash, without interest and less any applicable withholding taxes, for each
share of common stock, par value $1.00 per share, of Triple-S that they own immediately prior to the effective time of the merger unless
they have properly demanded appraisal rights for such shares in accordance with Puerto Rico law. The purchase price represents a premium
of approximately 49% over Triple-S’s closing share price on August 23, 2021, the last trading day prior to the announcement that
Triple-S had entered into the merger agreement and a premium of approximately 49% to Triple-S’s ninety (90)-trading-day volume-weighted
average stock price on the same date.
We will hold a virtual special
meeting of our stockholders in connection with the proposed merger on [●], 2021 at [●], Eastern Time (the “special meeting”)
(unless the special meeting is adjourned or postponed). The special meeting is scheduled to be held exclusively online via live webcast.
There will not be a physical meeting location. You will be able to attend the special meeting by first registering at [●]. You will
receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. Stockholders will be
able to listen, vote and submit questions during the virtual meeting. Please note you will not be able to attend the special meeting in
person. We have chosen to hold a virtual meeting rather than an in-person meeting given the current public health implications of COVID-19
(novel coronavirus) and our desire to promote the health and welfare of our stockholders.
At the special meeting (or
any adjournment or postponement thereof), stockholders will be asked to vote on, among other things, the proposal to approve and adopt
the merger agreement, as it may be amended from time to time (the “merger proposal”). Under Puerto Rico law, approval of the
merger proposal requires the affirmative vote of at least a majority of the shares of Triple-S common stock issued and outstanding at
the close of business on the record date. A failure to vote your shares of Triple-S common stock or an abstention from voting will have
the same effect as a vote against the merger proposal.
We cannot complete the merger
unless Triple-S stockholders approve the merger proposal. Your vote is very important, regardless of the number of shares you own.
Whether or not you are able to attend the special meeting via the virtual meeting website, please complete, sign and date the enclosed
proxy card and return it in the envelope provided or vote by telephone (at the toll-free number indicated on the proxy card) or via the
internet (at the voting site indicated on the proxy card) as promptly as possible so that your shares may be represented and voted at
the special meeting (or any adjournment or postponement thereof).
In addition, the Securities
and Exchange Commission (the “SEC”) has adopted rules that require us to seek a non-binding, advisory vote with respect to
certain compensation that will or may be paid by Triple-S to its named executive officers that is based on or otherwise relates to the
merger. The Triple-S board of directors recommends that Triple-S stockholders vote “FOR” the named executive officer merger-related
compensation proposal described in the accompanying proxy statement.
The proposal to approve an
adjournment or postponement of the special meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient
votes to approve the merger proposal requires the affirmative vote of the holders of a majority of the shares of our common stock in attendance
via the virtual meeting website or represented by proxy at the special meeting. The Triple-S board of directors recommends that Triple-S
stockholders vote “FOR” the proposal to approve an adjournment of the special meeting, if necessary or appropriate, to solicit
additional proxies in favor of the merger proposal, if there are not sufficient votes at the time of such adjournment to approve the merger
proposal.
The obligations of Triple-S
and Parent to complete the merger are subject to the satisfaction or waiver of certain conditions. The accompanying proxy statement contains
detailed information about Triple-S, the special meeting, the merger agreement, the merger and the other transactions contemplated by
the merger agreement.
If you have any questions
or need assistance voting your shares of our common stock, please contact Innisfree M&A Incorporated, our proxy solicitor, by calling
toll-free at (877) 750-0537.
Thank you for your consideration
of this matter and your continued confidence in Triple-S.
The accompanying proxy statement
is dated [●], 2021 and, together with the enclosed form of proxy, is first being mailed to Triple-S stockholders on or about [●],
2021.
PROXY STATEMENT
SPECIAL MEETING OF STOCKHOLDERS
TABLE
OF CONTENTS
SUMMARY
|
1
|
THE COMPANIES
|
1
|
Triple-S Management Corporation
|
1
|
Parent
|
1
|
Merger Sub
|
2
|
THE MERGER
|
2
|
Effects of the Merger
|
2
|
Merger Consideration
|
2
|
Treatment of Triple-S Equity Awards
|
2
|
Recommendation of the Triple-S Board of Directors
|
3
|
Opinion of Triple-S’s Financial Advisor
|
3
|
Material U.S. Federal Income Tax Consequences of the Merger
|
4
|
Material Puerto Rico Income Tax Consequences of the Merger
|
4
|
Regulatory Approvals Required for the Merger
|
4
|
Expected Timing of the Merger
|
5
|
Conditions to Completion of the Merger
|
5
|
Restrictions on Solicitation of Company Takeover Proposal
|
5
|
Changes in Board Recommendation
|
6
|
Termination of the Merger Agreement
|
7
|
Termination Fee Payable by Triple-S and Reverse Termination Fee Payable by Parent
|
8
|
Remedies; Maximum Liability
|
9
|
Specific Performance
|
10
|
Appraisal Rights
|
10
|
The Special Meeting
|
10
|
Interests of Triple-S’s Directors and Executive Officers in the Merger
|
11
|
Directors’ and Officers’ Indemnification and Insurance
|
11
|
Market Prices of Triple-S Common Stock
|
12
|
Litigation Related to the Merger
|
12
|
QUESTIONS AND ANSWERS
|
13
|
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
|
22
|
THE COMPANIES
|
24
|
Triple-S Management Corporation
|
24
|
Parent
|
24
|
Merger Sub
|
24
|
THE SPECIAL MEETING
|
25
|
Date, Time and Place
|
25
|
Purpose of the Special Meeting
|
25
|
Recommendation of the Triple-S Board of Directors
|
26
|
Record Date; Stockholders Entitled to Vote
|
26
|
Quorum
|
26
|
Required Vote
|
27
|
Abstentions and Broker Non-Votes
|
27
|
Failure to Vote
|
27
|
Voting by Triple-S’s Directors and Executive Officers
|
27
|
Voting at the Special Meeting
|
28
|
Shares Held in Name of Broker
|
29
|
Tabulation of Votes
|
29
|
Solicitation of Proxies
|
29
|
Adjournment
|
29
|
Other Information
|
29
|
THE MERGER (PROPOSAL 1)
|
30
|
Effects of the Merger
|
30
|
Effects on Triple-S If the Merger Is Not Completed
|
30
|
Background of the Merger
|
31
|
Triple-S’s Reasons for the Merger
|
38
|
Recommendation of the Triple-S Board of Directors
|
41
|
Opinion of Triple-S’s Financial Advisor
|
41
|
Projected Financial Information
|
46
|
Interests of Triple-S’s Directors and Executive Officers in the Merger
|
48
|
Directors’ and Officers’ Indemnification and Insurance
|
52
|
Regulatory Approvals Required for the Merger
|
53
|
Accounting Treatment
|
53
|
Material U.S. Federal Income Tax Consequences of the Merger
|
53
|
Material Puerto Rico Income Tax Consequences of the Merger
|
53
|
Delisting and Deregistration of Triple-S Common Stock
|
54
|
Appraisal Rights
|
54
|
Litigation Related to the Merger
|
54
|
THE MERGER AGREEMENT
|
55
|
Explanatory Note Regarding the Merger Agreement
|
55
|
Structure of the Merger
|
55
|
Closing and Effective Time of the Merger
|
55
|
Effect of the Merger on Triple-S Common Stock
|
56
|
Procedures for Surrendering Shares for Payment
|
56
|
Withholding
|
57
|
Treatment of Triple-S Equity Awards
|
57
|
Representations and Warranties
|
58
|
Definition of “Company Material Adverse Effect”
|
59
|
Conduct of the Business Pending the Merger
|
60
|
Board Obligation to Call a Stockholders Meeting
|
63
|
Restrictions on Solicitation of Company Takeover Proposals
|
64
|
Changes in Board Recommendation
|
66
|
Regulatory Approvals Required for the Merger
|
68
|
Litigation Related to the Merger
|
70
|
Employee Matters
|
70
|
Directors’ and Officers’ Indemnification and Insurance
|
70
|
Other Covenants
|
71
|
Conditions to Completion of the Merger
|
71
|
Termination of the Merger Agreement
|
72
|
Termination Fee Payable by Triple-S and Reverse Termination Fee Payable by Parent
|
74
|
Remedies; Maximum Liability
|
75
|
Specific Performance
|
75
|
Fees and Expenses
|
75
|
Amendments and Waivers
|
75
|
Governing Law and Venue, Waiver of Jury Trial
|
76
|
MARKET PRICES OF TRIPLE-S COMMON STOCK
|
77
|
Dividends
|
77
|
APPRAISAL RIGHTS OF STOCKHOLDERS
|
78
|
Filing Written Demand
|
78
|
Notice by the Surviving Corporation
|
79
|
Filing a Petition for Appraisal
|
79
|
Determination of Fair Value
|
80
|
ADVISORY VOTE ON NAMED EXECUTIVE OFFICER MERGER-RELATED COMPENSATION ARRANGEMENTS (PROPOSAL 2)
|
82
|
VOTE ON ADJOURNMENT (PROPOSAL 3)
|
83
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
84
|
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE MERGER
|
86
|
U.S. Holders
|
87
|
Non-U.S. Holders
|
87
|
Information Reporting and Backup Withholding
|
87
|
MATERIAL PUERTO RICO INCOME TAX CONSEQUENCES OF THE MERGER
|
89
|
P.R. Holders
|
89
|
Non-P.R. Holders
|
90
|
FUTURE TRIPLE-S STOCKHOLDER PROPOSALS
|
91
|
MULTIPLE STOCKHOLDERS SHARING ONE ADDRESS
|
92
|
WHERE YOU CAN FIND MORE INFORMATION
|
93
|
ANNEX A
|
—
|
AGREEMENT AND PLAN OF MERGER
|
ANNEX B
|
—
|
OPINION OF GOLDMAN SACHS & CO. LLC
|
ANNEX C
|
—
|
ARTICLE 10.13 OF THE GENERAL CORPORATIONS ACT (2009) OF THE COMMONWEALTH OF PUERTO RICO
|
SUMMARY
This summary highlights
information contained elsewhere in this proxy statement and may not contain all the information that is important to you with respect
to the merger. We urge you to read carefully the remainder of this proxy statement, including the attached annexes, and the other documents
to which we have referred you. For additional information on Triple-S included in documents incorporated by reference into this proxy
statement, see the section entitled “Where You Can Find More Information” beginning on page [●] of this proxy statement.
We have included page references in this summary to direct you to a more complete description of the topics presented below.
All references to “Triple-S,”
“we,” “us” or “our” in this proxy statement refer to Triple-S Management Corporation, a Puerto Rico
corporation; all references to “Parent” refer to GuideWell Mutual Holding Corporation, a Florida not-for-profit mutual insurance
holding company; all references to “Merger Sub” refer to GuideWell Merger, Inc., a Delaware corporation and a direct, wholly
owned subsidiary of Parent formed for the sole purpose of effecting the merger; all references to “Triple-S common stock”
refer to the common stock, par value $1.00 per share, of Triple-S; all references to the “Triple-S board” or “Triple-S
board of directors” refer to the board of directors of Triple-S; all references to “special meeting” refer to the special
meeting of stockholders of Triple-S; all references to the “merger” refer to the merger of Merger Sub with and into Triple-S
with Triple-S surviving as a wholly owned subsidiary of Parent; and, unless otherwise indicated or as the context requires, all references
to the “merger agreement” refer to the Agreement and Plan of Merger, dated as of August 23, 2021, as may be amended from time
to time, by and among Triple-S, Parent, and Merger Sub, a copy of which is included as Annex A to this proxy statement. Triple-S, following
the completion of the merger, is sometimes referred to in this proxy statement as the “surviving corporation.”
THE COMPANIES
Triple-S Management Corporation (see
page [●])
Triple-S, a health services
company, serves more than 1 million customers in Puerto Rico, which represents nearly one-third of the island’s population. With
over 60 years of experience, it is the premier insurance and managed care brand, with the largest customer base and broadest provider
networks on the island. Triple-S has the exclusive right to use the Blue Cross Blue Shield name and mark throughout Puerto Rico, the U.S.
Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla, and offers a broad portfolio of managed care and related products
in the commercial, Medicare Advantage and Medicaid segments. Triple-S is also a well-known brand in the life insurance and property and
casualty insurance segments in Puerto Rico, with strong customer relationships and a significant market share.
Triple-S’s principal
executive office is located at 1441 F.D. Roosevelt Avenue, San Juan, Puerto Rico 00920. Triple-S’s telephone number is (787) 749-4949.
Triple-S’s internet website address is www.triplesmanagement.com. The information provided on the Triple-S website is not part of
this proxy statement and is not incorporated in this proxy statement by reference by this or any other reference to its website provided
in this proxy statement.
Shares of Triple-S common
stock are listed and trade on the New York Stock Exchange (the “NYSE”) under the symbol “GTS.”
Parent (see page [●])
Parent is a not-for-profit
mutual holding company and the parent to a family of forward-thinking companies focused on transforming health care. The Parent organization
includes Florida Blue, the leading health insurance company in Florida; GuideWell Health, a portfolio of clinical delivery organizations;
GuideWell Venture Group, a portfolio of companies, including Onlife Health and PopHealthCare, focused on creating human-first and innovative
health solutions for health plans; GuideWell Source, a provider of administrative services to state and federal health care programs;
and WebTPA, a market leading administrator of self-funded employer health plans. In total, Parent and its affiliated companies serve more
than 45 million people in 45 states.
Parent’s principal executive
office is located at 4800 Deerwood Campus Pkwy., Jacksonville, Florida 32246. Parent’s telephone number is (855) 204-4084. Parent’s
internet website address is www.guidewell.com. The information provided on the Parent website is not part of this proxy statement and
is not incorporated in this proxy
statement by reference by this or any other reference to its website provided in this proxy statement.
Merger Sub (see page [●])
Merger Sub is a Delaware corporation
and wholly owned subsidiary of Parent. Merger Sub exists for the sole purpose of entering into the merger agreement and, subject to the
terms and conditions thereof, completing the transactions contemplated thereby and the related financing transactions. Merger Sub will
cease to exist and Triple-S will continue as the surviving company and as a wholly owned subsidiary of Parent.
THE MERGER
A copy of the merger agreement
is attached as Annex A to this proxy statement. We encourage you to read the entire merger agreement carefully because it is the principal
document governing the merger. For more information on the merger agreement, see the section entitled “The Merger Agreement”
beginning on page [●] of this proxy statement.
Effects of the Merger (see page [●])
If the merger is completed,
then, at the effective time of the merger, Merger Sub will be merged with and into Triple-S in accordance with the General Corporations
Act (2009) of the Commonwealth of Puerto Rico (“Puerto Rico law”) and the General Corporation Law of the State of Delaware
(“Delaware law”). As a result of the merger, the separate existence of Merger Sub will cease, and Triple-S will survive the
merger as a wholly owned subsidiary of Parent.
Upon consummation of the merger,
your shares of Triple-S common stock will be converted into the right to receive the per share merger consideration described below unless
you have properly demanded appraisal rights in accordance with Puerto Rico law. As a result, you will not own any shares of the surviving
corporation, and you will no longer have any interest in its future earnings or growth. Following the merger, Triple-S will cease to be
a publicly-traded company and will be wholly owned by Parent, and the surviving corporation will terminate the listing of Triple-S’s
common stock on the NYSE and deregister under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and no
longer be subject to reporting obligations under the Exchange Act.
Merger Consideration (see page [●])
Upon the terms and subject
to the conditions of the merger agreement, at the effective time of the merger, Triple-S stockholders will have the right to receive $36.00
in cash, without interest and less any applicable withholding taxes (the “merger consideration”), for each share of Triple-S
common stock that they own immediately prior to the effective time of the merger.
Treatment of Triple-S Equity Awards
(see page [●])
The merger agreement provides
that, prior to the effective time of the merger, the Triple-S board of directors shall adopt resolutions to effect the following treatment
of the equity awards of Triple-S:
Each award of (or with respect
to) Triple-S common stock that is outstanding as of the date of the merger agreement and immediately prior to the effective time of the
merger shall, at the effective time of the merger:
|
·
|
With respect to restricted share awards outstanding under the Triple-S Management Corporation 2017 Incentive
Plan, as amended (the “Triple-S equity plan”), whether or not vested, be converted into the right to receive an amount in
cash equal to the product of the merger consideration and the number of shares of Triple-S common stock underlying the Triple-S restricted
share award;
|
|
·
|
With respect to restricted stock units outstanding under the Triple-S equity plan, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S restricted stock unit award as of immediately prior to the effective time of
the merger; and
|
|
·
|
With respect to performance share units outstanding under the Triple-S equity plan, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S performance share unit award as of immediately prior to the effective time
of the merger, determined based on achievement of target performance.
|
Each award of (or with respect
to) Triple-S common stock with respect to any restricted stock unit or performance share unit that is granted following the date of the
merger agreement and outstanding immediately prior to the effective time of the merger, at the effective time of the merger, shall be
canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number of
shares of Triple-S common stock underlying such award as of immediately prior to the effective time (determined, in the case of performance
share units, based on target performance), payable on the date the award would have otherwise vested pursuant to its vesting schedule,
subject to the holder’s continuing employment as of each such vesting date or as otherwise provided in the applicable award agreements.
Recommendation of the Triple-S Board of
Directors (see page [●])
After careful consideration,
the Triple-S board of directors unanimously approved the merger agreement, the merger and the other transactions contemplated by the merger
agreement. Certain factors considered by the Triple-S board of directors in reaching its decision to approve and adopt the merger agreement,
the merger and the other transactions contemplated by the merger agreement can be found in the section entitled “The Merger (Proposal
1)—Triple-S’s Reasons for the Merger” beginning on page [●] of this proxy statement.
The Triple-S board of directors
recommends that Triple-S stockholders vote:
|
·
|
“FOR” the proposal to approve and adopt the merger agreement (the “merger proposal”);
|
|
·
|
“FOR” the proposal to approve, on a non-binding, advisory basis, certain compensation
that will or may be paid by Triple-S to its named executive officers that is based on or otherwise relates to the merger; and
|
|
·
|
“FOR” the proposal to approve an adjournment of the special meeting, if necessary or
appropriate, to solicit additional proxies in favor of the merger proposal, if there are not sufficient votes at the time of such adjournment
to approve the merger proposal.
|
Opinion of Triple-S’s Financial Advisor
(see page [●])
Goldman Sachs & Co. LLC
(“Goldman Sachs”) delivered its opinion to the Triple-S board that, as of August 23, 2021 and based upon and subject to the
factors and assumptions set forth therein, the $36.00 in cash per share of the Triple-S common stock to be paid to the holders (other
than Parent and its affiliates) of the outstanding shares of Triple-S common stock pursuant to the merger agreement was fair from a financial
point of view to such holders.
The full text of the written
opinion of Goldman Sachs, dated August 23, 2021, which sets forth assumptions made, procedures followed, matters considered and limitations
on the review undertaken in connection with the opinion, is attached as Annex B. Goldman Sachs provided financial advisory services and
its opinion for the information and assistance of the Triple-S board in connection with its consideration of the merger. The Goldman Sachs
opinion is not a recommendation as to how any holder of shares of Triple-S common stock should vote with respect to the merger or any
other matter.
Pursuant to an engagement
letter between Triple-S and Goldman Sachs, Triple-S has agreed to pay Goldman Sachs a transaction fee of approximately $11.6 million,
all of which is contingent upon consummation of the merger.
For additional information,
see the section entitled “Opinion of Triple-S’s Financial Advisor” beginning on page [●] and Annex B to this proxy
statement.
Material U.S. Federal Income Tax Consequences
of the Merger (see page [●])
The exchange of Triple-S common
stock for cash in the merger will be a taxable transaction for U.S. federal income tax purposes and may also be taxable under state and
local and other tax laws. Accordingly, a stockholder that is a “U.S. holder” (as defined in the section entitled “Material
U.S. Federal Income Tax Consequences of the Merger” beginning on page [●] of this proxy statement) will generally recognize
taxable gain or loss in an amount equal to the difference, if any, between (i) the merger consideration received by such U.S. holder in
the merger and (ii) such U.S. holder’s adjusted tax basis in the shares of Triple-S common stock exchanged therefor. With respect
to a stockholder that is a “non-U.S. holder” (as defined in the section entitled “Material U.S. Federal Income Tax Consequences
of the Merger” beginning on page [●] of this proxy statement), the exchange of shares of Triple-S common stock for the merger
consideration pursuant to the merger generally will not result in U.S. federal income tax to such non-U.S. holder unless such non-U.S.
holder has certain connections with the United States. Backup withholding may apply to the cash payment made pursuant to the merger unless
the stockholder or other payee provides a valid taxpayer identification number and complies with certain certification procedures (generally,
by providing a properly completed and executed U.S. Internal Revenue Service (“IRS”) Form W-9 or IRS Form W-8 or applicable
successor form). You should read the section entitled “Material U.S. Federal Income Tax Consequences of the Merger” beginning
on page [●] of this proxy statement and consult your tax advisors regarding the U.S. federal income tax consequences of the merger
to you in your particular circumstances, as well as tax consequences arising under the laws of any state, local or foreign taxing jurisdiction.
Material Puerto Rico Income Tax Consequences
of the Merger (see page [●])
The exchange of Triple-S common
stock for cash in the merger will be a taxable transaction for Puerto Rico income tax purposes. Accordingly, a stockholder that is a “P.R.
holder” (as defined in the section entitled “Material Puerto Rico Income Tax Consequences of the Merger” beginning on
page [●] of this proxy statement) will generally recognize taxable gain or loss in an amount equal to the difference, if any, between
(i) the merger consideration received by such P.R. holder in the merger and (ii) such P.R. holder’s adjusted tax basis in the shares
of Triple-S common stock exchanged therefor. With respect to a stockholder that is a “non-P.R. holder” (as defined in the
section entitled “Material Puerto Rico Income Tax Consequences of the Merger” beginning on page [●] of this proxy statement),
the exchange of shares of Triple-S common stock for the merger consideration pursuant to the merger generally will not result in Puerto
Rico income tax to such non-P.R. holder unless such non-P.R. holder has certain connections with Puerto Rico which can make the gain effectively
connected income to a Puerto Rico trade or business. You should read the section entitled “Material Puerto Rico Income Tax Consequences
of the Merger” beginning on page [●] of this proxy statement and consult your tax advisors regarding the Puerto Rico income
tax consequences of the merger to you in your particular circumstances, as well as tax consequences arising under the laws of any non-Puerto
Rico taxing jurisdiction.
Regulatory Approvals Required for the Merger
(see page [●])
The completion of the merger
is conditioned on, among other things, certain specified regulatory approvals having been obtained and remaining in full force and effect
(or, in the case of certain specified regulatory approvals that are statutory waiting periods, having expired or been terminated), including
the expiration or termination of any applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended
(the “HSR Act”). In addition, prior to the effective time of the merger, Triple-S and Parent are required to obtain regulatory
approvals from the Office of the Commissioner of Insurance of Puerto Rico, the Office of Industrial Tax Exemption of Puerto Rico, the
Puerto Rico Health Insurance Administration, the BVI Financial Services Commission and the Anguilla Financial Services Commission.
Under the terms of the merger
agreement, each of Triple-S and Parent have agreed to use their respective reasonable best efforts to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary, proper or advisable under applicable law to consummate the transactions
contemplated by the merger agreement as promptly as reasonably practicable, including preparing and filing as promptly as practicable
with any government authority or other third party all documentation to effect all necessary filings and obtaining certain specified regulatory
approvals, subject to certain limitations set forth in the merger agreement.
See the section entitled “The
Merger Agreement—Regulatory Approvals Required for the Merger” beginning on page [●] of this proxy statement for a more
detailed discussion of the parties’ obligations with respect to obtaining regulatory approvals in connection with the merger.
Expected Timing of the Merger (see
page [●])
We expect to complete the
merger in the first half of 2022. The merger is subject to various conditions, however, and it is possible that factors outside the control
of Triple-S or Parent could result in the merger being completed at a later time, or not at all. There may be a substantial amount of
time between the special meeting and the completion of the merger. We expect to complete the merger promptly following the satisfaction
or, to the extent permitted by law, waiver of the other conditions to the consummation of the merger.
See the section entitled “The
Merger Agreement—Conditions to Completion of the Merger” beginning on page [●] of this proxy statement.
Conditions to Completion of the Merger
(see page [●])
As more fully described in
this proxy statement and in the merger agreement, each party’s obligation to consummate the merger depends on a number of conditions
being satisfied (or, to the extent permitted by law, waived), including:
|
·
|
Approval and adoption of the merger agreement by an affirmative vote of the holders of a majority of the
shares of Triple-S common stock issued and outstanding at the close of business on the record date in accordance with Puerto Rico law;
|
|
·
|
The absence of any law, judgment, or other legal restraint or prohibition (in each case whether temporary,
preliminary or permanent in nature) or binding order or determination by any governmental entity (collectively, the “legal restraints”)
restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the merger;
|
|
·
|
Certain specified regulatory approvals having been obtained (or, in the case of certain specified regulatory
approvals that are statutory waiting periods, such waiting periods having expired or been terminated);
|
|
·
|
The other party having performed in all material respects all of its obligations under the merger agreement
contemplated to be performed by it at or prior to the effective time of the merger; and
|
|
·
|
Subject to certain qualifications, the accuracy of representations and warranties made by the other party
in the merger agreement (subject generally to a material adverse effect standard, with different standards applicable to certain representations
and warranties).
|
In addition, as more fully
described in this proxy statement and in the merger agreement, Parent and Merger Sub’s obligations to consummate the merger also
depend on the following conditions being satisfied (or, to the extent permitted by law, waived):
|
·
|
There having not occurred a “company material adverse effect” (as defined in the section entitled
“The Merger Agreement—Definition of ‘Company Material Adverse Effect’”) on Triple-S;
|
|
·
|
The absence of pending lawsuit brought by any governmental entity or other adjudicatory action initiated
by or at the behest of any governmental entity (and not upon the filing of a claim, challenge or complaint by any person other than such
governmental entity) seeking either to (i) restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the merger
or the other transactions or (ii) impose a “burdensome condition” (as defined in the section entitled “The Merger Agreement—Regulatory
Approvals Required for the Merger’”);
|
|
·
|
The absence of a legal restraint imposing a burdensome condition; and
|
|
·
|
Certain specified consents and approvals of third parties with respect to certain specified contracts
having been obtained.
|
Restrictions on Solicitation of Company
Takeover Proposal (see page [●])
Triple-S has agreed that it
will not, and will cause its subsidiaries and all of its and their respective directors, officers, employees, financial advisors, legal
counsel, accountants and other agents, advisors or representatives not to, directly or indirectly:
|
·
|
Solicit, initiate, encourage or facilitate any inquiries regarding, or the submission of any proposal
or offer that constitutes, or would reasonably be expected to lead to, any “company takeover proposal” (as defined in the
section entitled “The Merger Agreement—Restrictions on Solicitation of Company Takeover Proposals”);
|
|
·
|
Solicit, initiate, encourage or participate in any discussions or negotiations regarding, or furnish to
any person (other than Parent or Merger Sub) any nonpublic information with respect to or in connection with, or take any other action
to facilitate or encourage the making of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any company
takeover proposal;
|
|
·
|
Grant a waiver, amendment or release under a standstill provision in any agreement to which Triple-S or
any of its subsidiaries is a party; provided that Triple-S or any of its subsidiaries shall not be prohibited from amending, modifying
or granting any waiver or release of any standstill provision contained in any agreement of Triple-S or any of its subsidiaries, in each
case solely to the extent the Triple-S board or any committee thereof determines in good faith, after consultation with its outside legal
counsel, that the failure to do so would violate the directors’ fiduciary duties under applicable law; or
|
|
·
|
Execute or enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition
agreement, option agreement, merger agreement, joint venture agreement, partnership agreement or any other agreement, arrangement or understanding
(whether or not binding) relating to any company takeover proposal (a “company acquisition agreement”).
|
Notwithstanding anything to
the contrary described above, at any time prior to obtaining the approval of Triple-S stockholders, in response to a bona fide, written
company takeover proposal that did not result from a material breach of the restrictions set forth above and that the Triple-S board or
any committee thereof determines in good faith (after consultation with its outside counsel and financial advisor) constitutes or would
reasonably be expected to lead to a superior proposal from the person or group submitting such bona fide, written company takeover proposal
and that the failure to take such action would violate the directors’ fiduciary duties under applicable law (a “qualifying
company takeover proposal”), Triple-S may (A) enter into an acceptable confidentiality agreement with such person or group making
the qualifying company takeover proposal and thereafter furnish information with respect to Triple-S to such person or group and its representatives
pursuant to such acceptable confidentiality agreement so long as Triple-S also provides Parent promptly, and in no event later than 24
hours after the time such information is provided or made available to such person or group or any of its representatives, any information
furnished to such person or group or any of its representatives which was not previously furnished to Parent and (B) participate in discussions
or negotiations with such person or group and its representatives regarding such qualifying company takeover proposal. Triple-S is required
to notify Parent prior to furnishing any information and/or entering into any discussions or negotiations.
Changes in Board Recommendation (see
page [●])
Under the merger agreement,
prior to obtaining the Triple-S stockholder approval, the Triple-S board or any committee thereof may make an adverse recommendation change
if (i) the Triple-S board or any committee thereof determines in good faith (after consultation with its outside counsel and financial
advisor) that, as a result of an intervening event, failure to take such action would violate the directors’ fiduciary duties under
applicable law or (ii) Triple-S receives a company takeover proposal after the date of the merger agreement that did not result from a
material breach of its non-solicitation obligations and for which the Triple-S board or any committee thereof determines in good faith
(after consultation with its outside counsel and financial advisor) that such company takeover proposal constitutes a superior proposal
and that the failure to take such action would violate the directors’ fiduciary duties under applicable law; provided that:
|
·
|
Triple-S has provided written notice to Parent (a “notice of adverse recommendation change”)
advising Parent that the Triple-S board or any such committee intends to take such action and the reasons therefor;
|
|
·
|
In the case of any notice of adverse recommendation change provided in connection with an intervening
event, such notice of adverse recommendation change contains a reasonably detailed description of such intervening event;
|
|
·
|
In the case of any notice of adverse recommendation change provided in connection with a company takeover
proposal, such notice of adverse recommendation change specifies the material
|
terms and conditions
of the related superior proposal, identifying the person or group making such superior proposal and including a copy of the most current
version of the agreement or proposal and all material related documentation with respect to such superior proposal;
|
·
|
a period of at least four business days has elapsed following Parent’s receipt of such notice of
adverse recommendation change (it being understood that any amendment or modification to any company takeover proposal that is the basis
for such proposed adverse recommendation change shall require a new notice of adverse recommendation change and an additional notice period
(which shall be the longer of (x) two business days and (y) the period remaining under the initial notice period));
|
|
·
|
If requested by Parent, Triple-S has negotiated, and has caused its subsidiaries and its and their representatives
to negotiate, in good faith with Parent and its representatives during such four-business day period (as may be extended as set forth
in the preceding bullet) with respect to any changes to the terms of the merger agreement proposed by Parent during such period; and
|
|
·
|
Taking into account any changes to the terms of the merger agreement proposed by Parent, the Triple-S
board or any committee thereof has determined in good faith (after consultation with its outside counsel and financial advisor) (1) that
it would continue to violate the directors’ fiduciary duties under applicable law not to effect the adverse recommendation change
and (2) in connection with a company takeover proposal, that the company takeover proposal received by the Company would continue
to constitute a superior proposal, in each case, if such changes offered by Parent were given effect.
|
Notwithstanding the foregoing,
Triple-S is required to submit the matters to obtain approval of Triple-S stockholders at the special meeting; provided, however,
that (i) if the Triple-S board has made an adverse recommendation change, then in submitting such matters to the special meeting,
the Triple-S board may recommend against such matters or submit such matters without recommendation, in which event the Triple-S board
will communicate the basis for its recommendation or lack thereof to Triple-S’s stockholders in the proxy statement or an appropriate
amendment or supplement thereto to the extent it determines, after consultation with its outside legal counsel, that such action is compelled
by applicable law and (ii) Triple-S shall have the right to terminate the merger agreement if the Triple-S board makes an adverse recommendation
change concurrently with its entry into a definitive agreement concerning a superior proposal so long as it pays the termination fee (as
defined below).
In addition, if the Triple-S
board of directors changes its recommendation with respect to the merger agreement, Parent may terminate the merger agreement and collect
a termination fee as described in the section entitled “The Merger Agreement—Termination Fee Payable by Triple-S and Reverse
Termination Fee Payable by Parent” beginning on page [●] of this proxy statement.
Termination of the Merger Agreement
(see page [●])
The merger agreement may be
terminated and the merger may be abandoned at any time prior to the effective time of the merger (whether before or after receipt of the
approval of Triple-S stockholders, except as otherwise expressly noted):
|
·
|
At any time prior to the effective time of the merger, by mutual written consent of Triple-S, Parent and
Merger Sub;
|
|
·
|
At any time prior to the effective time of the merger, by either Triple-S or Parent if:
|
|
·
|
The merger has not been consummated on or before May 23, 2022 (the “outside date”); provided
that this termination right will not be available to a party if the failure of the merger to be consummated on or before the outside date
is the result of a material breach of the merger agreement by such party;
|
|
·
|
Any legal restraint permanently restraining, enjoining, preventing, prohibiting or otherwise making illegal
the consummation of the merger is in effect and has become final and non-appealable;
|
|
·
|
If approval of Triple-S’s stockholders have not been obtained at the special meeting (or any adjournment
or postponement thereof) and at which a vote by Triple-S’s stockholders on the adoption of the merger agreement was taken; or
|
|
·
|
(i) a governmental entity has brought a lawsuit or (ii) an adjudicatory action has been initiated by or
at the behest of a governmental entity (and not upon the filing of a claim, challenge or complaint by any person other than such governmental
entity), in either case, seeking to (A) restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the merger or
the other transactions contemplated under the merger agreement or (B) impose a burdensome condition, and Parent or Merger Sub has notified
Triple-S that it refuses, or has withheld its consent from Triple-S, to defend such lawsuit or adjudicatory action.
|
|
·
|
At any time prior to the effective time of the merger, by Parent if:
|
|
·
|
Prior to the receipt of Triple-S’s stockholder approval, an adverse recommendation change has occurred,
or Triple-S committed a material breach of its obligations relating to non-solicitation of company takeover proposals or its obligations
related to stockholder approval and board recommendation and did not cure such breach within five (5) days after Parent has given written
notice to Triple-S of such breach;
|
|
·
|
Triple-S has breached any representation or warranty or failed to perform any covenant or agreement on
the part of Triple-S set forth in the merger agreement that would cause or result in any closing conditions related to Triple-S’s
representations and warranties or performance of its obligations under the merger agreement not being satisfied and such breach or failure
to perform is not capable of being cured or, if capable of being cured, is not cured prior to the earlier of thirty (30) days following
written notice to Parent or by the outside date; provided that, Parent and Merger Sub are not then in material breach of the merger
agreement; or
|
|
·
|
Any legal restraint imposing a burdensome condition is in effect and has become final and non-appealable.
|
|
·
|
At any time prior to the effective time of the merger, by Triple-S if:
|
|
·
|
Parent or Merger Sub has breached any representation or warranty or failed to perform any covenant or
agreement on the part of Triple-S set forth in the merger agreement that would cause or result in any closing conditions related to Triple-S’s
representations and warranties or performance of its obligations under the merger agreement not being satisfied and such breach or failure
to perform is not capable of being cured or, if capable of being cured, is not cured prior to the earlier of thirty (30) days following
written notice to Parent or by the outside date; provided that, Triple-S is not then in material breach of the merger agreement;
or
|
|
·
|
Prior to the receipt of Triple-S’s stockholder approval, the Triple-S board effects an adverse recommendation
change and concurrently enters into a definitive agreement concerning a superior proposal, subject to compliance with the restrictions
on solicitation of company takeover proposals; provided that concurrently with such termination, Triple-S pays to Parent the termination
fee required to be paid to Parent as described in the section entitled “The Merger Agreement—Termination Fee Payable by Triple-S
and Reverse Termination Fee Payable by Parent” beginning on page [●] of this proxy statement.
|
Termination Fee Payable by Triple-S and
Reverse Termination Fee Payable by Parent (see page [●])
|
·
|
Triple-S has agreed to pay Parent a fee of $17,985,000 by wire transfer of same-day funds (the
“termination fee”) upon termination of the merger agreement if:
|
|
·
|
Triple-S terminates the merger agreement, prior to receipt of Triple-S’s stockholder approval, in
order to effect an adverse recommendation change and concurrently enter into a definitive agreement providing for a superior proposal,
subject to compliance with its obligations relating to non-solicitation of company takeover proposals or its obligations related to stockholder
approval and board recommendation;
|
|
·
|
Parent terminates the merger agreement (or would have been entitled to terminate the merger agreement),
prior to receipt of Triple-S’s stockholder approval, because an adverse recommendation change has occurred or Triple-S has materially
breached its obligations relating to non-solicitation of company takeover proposals or its obligations related to stockholder approval
and board recommendation and did not cure such breach within five (5) days after Parent has given written notice to Triple-S of such breach;
or
|
|
·
|
(i) Parent terminates the merger agreement because Triple-S has breached any of its representations
or warranties or failed to perform any of its covenants or obligations contained in the merger agreement, which breach or failure to perform
would give rise to the failure of any closing conditions related to Triple-S’s representations and warranties or performance of
its obligations under the merger agreement and such breach or failure to perform is not capable of being cured or, if capable of being
cured, is not cured prior to the earlier of (a) thirty (30) days following written notice to Parent and (b) the outside date or (ii) either
Parent or Triple-S terminates the merger agreement because the merger has not been consummated on or before the outside date or (iii) Triple-S’s
stockholders did not approve the merger at the special meeting (or any adjournment or postponement thereof) and:
|
|
·
|
After the date of the merger agreement, a company takeover proposal is proposed to Triple-S board, or
is made public or a public announcement of intention to make a company takeover proposal was made and not publicly withdrawn prior to
the event that gave rise to the applicable termination right; and
|
|
·
|
Within (12) months of such termination, a company takeover proposal (whether or not the same one) is consummated
or Triple-S or its subsidiaries enters into a definitive agreement relating to a company takeover proposal (whether or not the same one)
(provided that all references to “15%” in the definition of company takeover proposal will be deemed to be a reference
to “50%”).
|
|
·
|
Parent has agreed to pay Triple-S a reverse termination fee of $17,985,000 by wire transfer of
same-day funds (the “reverse termination fee”) upon termination of the merger agreement if:
|
|
·
|
Triple-S or Parent terminates the merger agreement because the merger has not been consummated on or before
the outside date and Triple-S did not commit a material breach of the merger agreement and, at the time of such termination, (A) any condition
related to absence of legal restraints relevant to the required regulatory approvals, required regulatory approvals, absence of certain
proceedings, no legal restraint imposing a burdensome condition or third-party consent was not satisfied (or, in the case of any of the
last three mentioned above, was not waived by Parent) and (B) all other conditions set forth in the merger agreement have been satisfied
(or, to the extent permitted by law, waived by the parties entitled thereto) (or in the case of conditions which by their nature are to
be satisfied at the closing, were capable of being satisfied as of such time);
|
|
·
|
Triple-S or Parent terminates the merger agreement because a legal restraint that restrains, enjoins,
prevents, prohibits or otherwise makes illegal the consummation of the merger is in effect and has become final and non-appealable (but
only if the applicable legal restraint relates to the required regulatory approvals);
|
|
·
|
Parent terminates the merger agreement because a legal restraint that imposes a burdensome condition is
in effect and has become final and non-appealable; or
|
|
·
|
Triple-S or Parent terminates the merger agreement because (i) a governmental entity has brought a lawsuit
or (ii) an adjudicatory action has been initiated by or at the behest of a governmental entity (and not upon the filing of a claim, challenge
or complaint by any person other than such governmental entity), in either case, seeking to (A) restrain, enjoin, prevent, prohibit or
otherwise make illegal the consummation of the merger or the other transactions contemplated by the merger agreement or (B) impose a burdensome
condition, and Parent or Merger Sub has notified Triple-S that it refuses, or has withheld its consent from Triple-S, to defend such lawsuit
or adjudicatory action.
|
Remedies; Maximum Liability (see page
[●])
The merger agreement provides
that in no event will Triple-S be required to pay the termination fee on more than one occasion, whether or not the termination fee may
be payable under more than one provision of the merger agreement at the same or at different times and the occurrence of different events.
If the termination fee becomes payable in accordance with the merger agreement, the payment to Parent or its designee of the termination
fee will be the sole and exclusive remedy of Parent and Merger Sub for any loss suffered by Parent or Merger Sub as a result of the failure
of the transactions to be consummated and, upon such payment in accordance with the merger agreement, Triple-S will not have any further
liability or
obligation relating to or arising
out of the merger agreement or the transactions, except in the case of fraud or willful or intentional breach of the merger agreement
by Triple-S.
In addition, the merger agreement
provides that in no event will Parent be required to pay the reverse termination fee on more than one occasion, whether or not the reverse
termination fee may be payable under more than one provision of the merger agreement at the same time or at different times and the occurrence
of different events. If the reverse termination fee becomes payable in accordance with the merger agreement, the payment to Triple-S or
its designee of the reverse termination fee will be the sole and exclusive remedy of Triple-S for any loss suffered by Triple-S as a result
of the failure of the transactions to be consummated and, upon such payment in accordance with the merger agreement, neither Parent nor
Merger Sub will have any further liability or obligation relating to or arising out of the merger agreement or the transactions, except
in the case of fraud or willful or intentional breach of the merger agreement by Parent or Merger Sub, as applicable.
Specific Performance (see page [●])
The merger agreement provides
that the parties will be entitled to an injunction or injunctions, or any other appropriate form of equitable relief, to prevent breaches
of the merger agreement and to specifically enforce the performance of the terms and provisions of the merger agreement in any court,
without the necessity of providing any bond or other security or proving actual damages or the inadequacy of monetary damages as a remedy.
Each of the parties further agrees not to oppose a remedy of specific enforcement on the basis that the other party has an adequate alternative
remedy at law.
Appraisal Rights (page [●])
Under Puerto Rico law, any
record holder of Triple-S common stock at the close of business on the record date who does not vote in favor of the merger proposal,
and who exercises its appraisal rights and fully complies with all of the provisions of Article 10.13 of Puerto Rico law (but not otherwise),
will be entitled to demand and receive payment of the “fair value” as determined pursuant to Article 10.13 of Puerto Rico
law for all (but not less than all) of his or her shares of Triple-S common stock if the merger is completed. See the section entitled
“Appraisal Rights of Stockholders” beginning on page [●] of this proxy statement. The full text of Article 10.13 of
Puerto Rico law is attached to this proxy statement (in English and Spanish) as Annex C.
The Special Meeting (see page [●])
The special meeting of Triple-S’s
stockholders is scheduled to be held exclusively online via live webcast on [●], 2021 at [●], Eastern Time. You will be able
to attend the special meeting by first registering at [●]. You will receive a meeting invitation by e-mail with your unique join
link along with a password prior to the meeting date. Stockholders will be able to listen, vote and submit questions during the virtual
meeting. Instructions on how to attend and participate online are also posted online at [●]. We elected to use a virtual meeting
given the current public health implications of COVID-19 (novel coronavirus) and our desire to promote the health and welfare of our stockholders.
The special meeting is being
held in order to consider and vote on the following:
|
·
|
A proposal to approve and adopt the merger agreement, which is further described in the sections entitled
“The Merger (Proposal 1)” and “The Merger Agreement,” beginning on pages [●] and [●], respectively,
of this proxy statement;
|
|
·
|
A proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid
by Triple-S to its named executive officers that is based on or otherwise relates to the merger, which is discussed under the section
entitled “The Merger (Proposal 1)—Interests of Triple-S’s Directors and Executive Officers in the Merger” beginning
on page [●] of this proxy statement; and
|
|
·
|
A proposal to approve an adjournment of the special meeting, if necessary or appropriate, to solicit additional
proxies in favor of the merger proposal if there are not sufficient votes at the time of such adjournment to approve the merger proposal.
|
Only holders of record of
Triple-S common stock at the close of business on [●], 2021, the record date for the special meeting, are entitled to notice of,
and to vote at, the special meeting or any adjournments or postponements thereof. At the close of business on the record date, [●]
shares of Triple-S common stock were issued and outstanding, approximately [●] of which were held by Triple-S’s directors
and executive
officers. We currently expect
that all of Triple-S’s directors and executive officers will vote their shares in favor of the merger proposal and the other proposals
to be considered at the special meeting, although no director or executive officer is obligated to do so.
The presence at the special
meeting, by attendance via the virtual meeting website or by proxy, of the holders of one-third of the shares of Triple-S common stock
issued and outstanding and entitled to vote at the close of business on the record date will constitute a quorum. There must be a quorum
for business to be conducted at the special meeting. If you submit a properly executed proxy card, even if you abstain from voting, your
shares will be counted for purposes of calculating whether a quorum is present at the special meeting. Failure of a quorum to be present
at the special meeting will necessitate an adjournment or postponement and will subject Triple-S to additional expense.
You may cast one vote for
each share of Triple-S common stock that you own at the close of business on the record date. Approval and adoption of the merger agreement
requires the affirmative vote of the majority of the shares of Triple-S common stock issued and outstanding at the close of business on
the record date in accordance with Puerto Rico law. The proposal to approve, on a non-binding, advisory basis, certain compensation that
will or may be paid by Triple-S to its named executive officers that is based on or otherwise relates to the merger requires the affirmative
vote of at least a majority of the outstanding shares of Triple-S common stock present via the virtual meeting website or represented
by proxy and entitled to vote and voting on the proposal at the special meeting (provided that a quorum is present). The proposal
to adjourn the special meeting, if necessary or appropriate, to permit further solicitation of proxies in favor of the merger proposal,
requires the affirmative vote of at least a majority of the outstanding shares of Triple-S common stock present via the virtual meeting
website or represented by proxy (whether or not a quorum is present).
An abstention occurs when
a stockholder attends a meeting, either via the virtual meeting website or by proxy, but abstains from voting. At the special meeting,
abstentions will be counted in determining whether a quorum is present. Because under Puerto Rico law the approval and adoption of the
merger agreement requires the affirmative vote of the majority of the shares of Triple-S common stock issued and outstanding at the close
of business on the record date, abstentions and a complete failure to vote (including the failure of a record owner to execute and return
a proxy card and the failure of a beneficial owner of shares held in “street name” by a broker, bank or other nominee to give
voting instructions to the broker, bank or other nominee) will have the same effect as a vote “AGAINST” the merger
proposal. Because the other two proposals require the affirmative vote of at least a majority of the outstanding shares of Triple-S common
stock present via the virtual meeting website or represented by proxy and entitled to vote and voting at the special meeting, abstentions
and a failure to vote (including the failure of a record owner to execute and return a proxy card and the failure of a beneficial owner
of shares held in “street name” by a broker, bank or other nominee to give voting instructions to the broker, bank or other
nominee) will have no effect on the outcome of such proposals.
If no instruction as to how
to vote is given (including an instruction to abstain) in an executed, duly returned and not revoked proxy, the proxy will be voted for
(i) the merger proposal; (ii) the proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid
by Triple-S to its named executive officers that is based on or otherwise relates to the merger; and (iii) the proposal to approve the
adjournment of the special meeting, if necessary or appropriate to solicit additional proxies, if there are not sufficient votes at the
time of such adjournment to approve the merger proposal.
Interests of Triple-S’s Directors
and Executive Officers in the Merger (see page [●])
In considering the recommendation
of the Triple-S board of directors to approve and adopt the merger agreement, you should be aware that Triple-S’s directors and
executive officers have interests in the merger that are different from, or in addition to, those of Triple-S’s stockholders generally.
The Triple-S board of directors was aware of these interests and considered them, among other matters, in evaluating the merger agreement,
in reaching its decision to approve the merger agreement and in recommending to Triple-S stockholders that the merger agreement be approved
and adopted. These interests are described in further detail and quantified below under “The Merger (Proposal 1)—Interests
of Triple-S’s Directors and Executive Officers in the Merger” beginning on page [●] of this proxy statement.
Directors’ and Officers’ Indemnification
and Insurance (see page [●])
Parent has agreed to assume
the obligations with respect to all rights to indemnification, advancement of expenses and exculpation from liabilities, for acts or omissions
occurring at or prior to the effective time of the merger now existing in favor of the current or former directors or officers (the “indemnified
persons”) of
Triple-S or any of its subsidiaries
as provided in Triple-S’s articles and bylaws, the organizational documents of any Triple-S subsidiary or any indemnification agreement
between an indemnified person and Triple-S or any of its subsidiaries as of the effective time of the merger, and such obligations will
survive the merger and will continue in full force and effect in accordance with their terms.
For additional information
regarding directors’ and officers’ indemnification and insurance, please see the section entitled “The Merger Agreement—Directors’
and Officers’ Indemnification and Insurance” beginning on page [●].
Market Prices of Triple-S Common Stock
(see page [●])
The merger consideration of $36.00
per share represents a premium of approximately 49% over Triple-S’s closing share price on August 23, 2021, the last trading day
prior to the announcement that Triple-S had entered into the merger agreement and a premium of approximately 49% to Triple-S’s ninety
(90)-day volume-weighted average stock price on the same date. The closing price of Triple-S common stock on the NYSE on [●], 2021,
the most recent practicable date prior to the date of this proxy statement, was $[●] per share. You are encouraged to obtain current
market prices of Triple-S common stock in connection with voting your shares of Triple-S common stock.
Litigation Related to the Merger (see
page [●])
As of the date of this proxy
statement, there are no pending lawsuits challenging the merger. However, potential plaintiffs may file lawsuits challenging the merger.
The outcome of any future litigation is uncertain.
Such litigation, if not resolved,
could prevent or delay consummation of the merger and result in substantial costs to Triple-S, including any costs associated with the
indemnification of directors and officers. One of the conditions to the consummation of the merger is that no applicable law or order
issued by a court of competent jurisdiction or other legal restraint which is then in effect renders illegal or enjoins the consummation
of the merger whether on a preliminary or permanent basis. Therefore, if a plaintiff were successful in obtaining an injunction prohibiting
the consummation of the merger on the agreed-upon terms, then such injunction may prevent the merger from being consummated, or from being
consummated within the expected time frame.
For additional information
regarding the pending litigation, please see the section entitled “The Merger (Proposal 1)—Litigation Related to the Merger”
beginning on page [●].
QUESTIONS
AND ANSWERS
The following are some
questions that you, as a stockholder of Triple-S, may have regarding the merger and the special meeting and the answers to those questions.
Triple-S urges you to carefully read the remainder of this proxy statement because the information in this section does not provide all
the information that might be important to you with respect to the merger and the special meeting. Additional important information is
also contained in the annexes to and the documents incorporated by reference into this proxy statement.
|
Q:
|
What is the purpose of the special meeting?
|
|
A:
|
At the special meeting, stockholders will consider and act upon the matters outlined in the notice of
meeting on the cover page of this proxy statement, namely:
|
|
·
|
A proposal to approve and adopt the merger agreement, which is further described in the sections entitled
“The Merger (Proposal 1)” and “The Merger Agreement,” beginning on pages [●] and [●], respectively,
of this proxy statement;
|
|
·
|
A proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid
by Triple-S to its named executive officers that is based on or otherwise relates to the merger, which is discussed under the section
entitled “The Merger (Proposal 1)—Interests of Triple-S’s Directors and Executive Officers in the Merger” beginning
on page [●] of this proxy statement; and
|
|
·
|
A proposal to approve an adjournment of the special meeting, if necessary or appropriate, to solicit additional
proxies in favor of the merger proposal if there are not sufficient votes at the time of such adjournment to approve the merger proposal.
|
|
Q:
|
Where and when is the special meeting?
|
|
A:
|
The special meeting is scheduled to be held exclusively online via live webcast on [•], 2021 at [•],
Eastern Time. There will not be a physical meeting location. You will be able to attend the special meeting by first registering at [●].
You will receive a meeting invitation by e-mail with your unique join link along with a password prior to the meeting date. Stockholders
will be able to listen, vote and submit questions during the virtual meeting. Instructions on how to attend and participate online are
also posted online at [●]. We encourage you to allow ample time for online check-in, which will open at [•], Eastern Time.
Please note that you will not be able to attend the special meeting in person. We elected to use a virtual meeting given the current public
health implications of COVID-19 (novel coronavirus) and our desire to promote the health and welfare of our stockholders.
|
|
Q:
|
What do I need in order to be able to attend the special meeting online?
|
|
A:
|
The special meeting will be held via live webcast only. Any stockholder of record can attend the special
meeting live by pre-registering online at [●]. The webcast will start at [●], Eastern Time on [●], 2021. Stockholders
may vote and submit questions while attending the special meeting online. In order to be able to enter the special meeting, you will need
to pre-register at [●]. You will receive a meeting invitation by e-mail with your unique join link along with a password prior to
the meeting date. Stockholders will be able to listen, vote and submit questions during the virtual meeting. Instructions on how to attend
and participate online are also posted online at [●].
|
|
Q:
|
How does the Triple-S board of directors recommend that I vote on the proposals?
|
|
A:
|
The Triple-S board of directors determined that the adoption of the merger agreement and consummation
of the merger are in the best interests of Triple-S and its shareholders and thus recommends that you vote as follows:
|
|
·
|
“FOR” the merger proposal;
|
|
·
|
“FOR” the approval, on a non-binding, advisory basis, of certain compensation that will or
may be paid by Triple-S to its named executive officers that is based on or otherwise relates to the merger; and
|
|
·
|
“FOR” the approval of an adjournment of the special meeting, if necessary or appropriate to
solicit additional proxies in favor of the merger proposal, if there are not sufficient votes at the time of such adjournment to approve
the merger proposal.
|
|
Q:
|
How does the per share merger consideration compare to the market price of Triple-S common stock
prior to announcement of the merger?
|
|
A:
|
The merger consideration of $36.00 per share represents a premium of approximately 49% over Triple-S’s
closing share price on August 23, 2021, the last trading day prior to the announcement that Triple-S had entered into the merger agreement.
The closing price of Triple-S common stock on the NYSE on [●], 2021, the most recent practicable date prior to the date of this
proxy statement, was $[●] per share. You are encouraged to obtain current market prices of Triple-S common stock in connection with
voting your shares of Triple-S common stock.
|
|
Q:
|
What will happen in the merger?
|
|
A:
|
If the merger is completed, Merger Sub will merge with and into Triple-S, whereupon the separate existence
of Merger Sub will cease and Triple-S will be the surviving corporation and a wholly owned subsidiary of Parent. As a result of the merger,
Triple-S common stock will no longer be publicly traded, and you will no longer have any interest in Triple-S’s future earnings
or growth. In addition, Triple-S common stock will be delisted from the NYSE and deregistered under the Exchange Act, and Triple-S will
no longer be required to file periodic reports with the Securities and Exchange Commission (the “SEC”) with respect to Triple-S
common stock, in each case in accordance with applicable law, rules and regulations.
|
|
Q:
|
Who will own Triple-S after the merger?
|
|
A:
|
Immediately following the merger, Triple-S will be a wholly owned subsidiary of Parent.
|
|
Q:
|
What will I receive in the merger?
|
|
A:
|
Upon the terms and subject to the conditions of the merger agreement, if the merger is completed, the
holders of Triple-S common stock will have the right to receive $36.00 in cash, without interest and less any applicable withholding taxes
(the “merger consideration”), for each share of Triple-S common stock that they own immediately prior to the effective time
of the merger.
|
|
Q:
|
What will happen in the merger to Triple-S equity awards?
|
|
A:
|
The merger agreement provides that, prior to the effective time of the merger, the Triple-S board of directors
shall adopt resolutions to effect the following treatment of the equity awards of Triple-S:
|
|
·
|
Each restricted share award under the Triple-S equity plan that is outstanding as of the date of the merger
agreement and immediately prior to the effective time of the merger shall, at the effective time of the merger, whether or not vested,
be converted into the right to receive an amount in cash equal to the product of the merger consideration and the number of shares of
Triple-S common stock underlying the Triple-S restricted share award;
|
|
·
|
Each restricted stock unit under the Triple-S equity plan that is outstanding as of the date of the merger
agreement and immediately prior to the effective time of the merger shall, at the effective time of the merger, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S restricted stock unit award as of immediately prior to the effective time of
the merger;
|
|
·
|
Each performance share unit under the Triple-S equity plan that is outstanding as of the date of the merger
agreement and immediately prior to the effective time of the merger shall, at the effective time of the merger, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S performance share unit award as of immediately
|
prior to the effective
time of the merger, determined based on achievement of target performance; and
|
·
|
Each award of (or with respect to) Triple-S common stock with respect to any restricted stock unit or
performance share unit that is granted following the date of the merger agreement and outstanding immediately prior to the effective time
of the merger, at the effective time of the merger, shall be canceled and converted into the right to receive an amount in cash equal
to the product of the merger consideration and the number of shares of Triple-S common stock underlying such award as of immediately prior
to the effective time (determined, in the case of performance share units, based on target performance), payable on the date the award
would have otherwise vested pursuant to its vesting schedule, subject to the holder’s continuing employment as of each such vesting
date or as otherwise provided in the applicable award agreements.
|
|
Q:
|
Am I entitled to exercise appraisal rights instead of receiving the merger consideration for my
shares of Triple-S common stock?
|
|
A:
|
If you comply with all the requirements of Article 10.13 of Puerto Rico law (including not voting in favor
of the adoption of the merger agreement), you are entitled to have the “fair value” (as defined pursuant to Article 10.13
of Puerto Rico law) of your shares of Triple-S common stock determined by the Court of First Instance of the Commonwealth of Puerto Rico,
Superior Court, and to receive payment based on that valuation instead of receiving the merger consideration. The ultimate amount you
would receive in an appraisal proceeding may be more than, the same as, or less than the amount you would have received under the merger
agreement. To exercise your appraisal rights, you must comply with the requirements of Puerto Rico law. See “Appraisal Rights of
Stockholders” beginning on page [●] of this proxy statement and the text of the Puerto Rico appraisal provisions set forth
in Article 10.13 of Puerto Rico law, which is reproduced in its entirety (in English and Spanish) as Annex C to this proxy statement.
|
|
Q:
|
What vote is required to approve the merger proposal?
|
|
A:
|
The merger proposal requires the affirmative vote of at least a majority of the shares of Triple-S common
stock issued and outstanding at the close of business on the record date. In addition, under the merger agreement, the receipt of such
required vote is a condition to the consummation of the merger. A failure to vote your shares of Triple-S common stock or an abstention
from voting will have the same effect as a vote against the merger proposal.
|
|
Q:
|
What vote is required to approve, on a non-binding, advisory basis, certain compensation that will
or may be paid by Triple-S to its named executive officers that is based on or otherwise relates to the merger?
|
|
A:
|
The named executive officer merger-related compensation proposal, approval of which is not required to
complete the merger, requires the affirmative vote of at least a majority of the outstanding shares of Triple-S common stock present via
the virtual meeting website or represented by proxy and entitled to vote and voting on the proposal at the special meeting (provided a
quorum is present or represented by proxy).
|
|
Q:
|
Why am I being asked to consider and act upon a proposal to approve, on a non-binding, advisory
basis, certain compensation that will or may be paid by Triple-S to its named executive officers that is based on or otherwise relates
to the merger?
|
|
A:
|
SEC rules require Triple-S to seek a non-binding, advisory vote to approve any agreements or understandings
and compensation that will or may be paid by Triple-S to its named executive officers that is based on or otherwise relates to in connection
with the merger. Approval of this proposal by Triple-S’s stockholders is not required to complete the merger.
|
|
Q:
|
What vote is required to approve the proposal to adjourn the special meeting, if necessary or appropriate,
to solicit additional proxies in favor of the merger proposal if there are not sufficient votes at the time of such adjournment to approve
the merger proposal?
|
|
A:
|
The proposal to adjourn the special meeting, the approval of which is not required to complete the merger,
requires the affirmative vote of at least a majority of the outstanding shares of Triple-S common stock present via the virtual meeting
website or represented by proxy (whether or not a quorum is present).
|
|
Q:
|
Do any of Triple-S’s directors or officers have interests in the merger that may differ from
or be in addition to my interests as a stockholder?
|
|
A:
|
In considering the recommendation of the Triple-S board of directors with respect to the merger proposal,
you should be aware that our directors and executive officers have certain interests in the merger that may be different from, or in addition
to, the interests of Triple-S stockholders generally. The Triple-S board of directors was aware of and considered these interests, among
other matters, in evaluating and negotiating the merger agreement and the merger, and in recommending that the merger agreement be approved
by the stockholders of Triple-S. See “The Merger (Proposal 1)—Interests of Triple-S’s Directors and Executive Officers
in the Merger” beginning on page [●] and “Advisory Vote on Named Executive Officer Merger-Related Compensation Arrangements
(Proposal 2)” beginning on page [●].
|
|
Q:
|
When do you expect the merger to be completed?
|
|
A:
|
In order to complete the merger, Triple-S must obtain stockholder approval of the merger proposal described
in this proxy statement and the other closing conditions under the merger agreement must be satisfied or waived. The parties to the merger
agreement currently expect to complete the merger in the first half of 2022, although Triple-S cannot assure completion by any particular
date, if at all. Because the merger is subject to a number of conditions, the exact timing of the merger cannot be determined at this
time.
|
|
Q:
|
What conditions must be satisfied to complete the merger?
|
|
A:
|
There are several conditions which must be satisfied to complete the merger, including, among other things,
the expiration or termination of any applicable waiting period under the HSR Act, compliance with certain other regulatory filings and
obtaining certain other regulatory approvals and third-party consents. The obligation of each party to consummate the merger is also conditioned
on the other party’s representations and warranties being true and correct (subject generally to a material adverse effect standard,
with different standards applicable to certain representations and warranties) and the other party having performed in all material respects
its obligations under the merger agreement (subject to certain qualifications). The obligation of Parent and Merger Sub to consummate
the merger is also conditioned on, among other things, the absence of a pending lawsuit brought by any governmental entity seeking to
(A) restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the merger or (B) impose a “burdensome condition”
(as defined in the section entitled “The Merger Agreement—Regulatory Approvals Required for the Merger’”), the
absence of a “company material adverse effect” (as defined in the section entitled “The Merger Agreement—Definition
of ‘Company Material Adverse Effect’’”), and the absence of a legal restraint imposing a burdensome condition.
Consummation of the merger is not subject to any financing condition.
|
|
Q:
|
Do you expect the merger to be taxable to Triple-S stockholders?
|
|
A:
|
The exchange of Triple-S common stock for cash in the merger will be a taxable transaction for U.S. federal
and Puerto Rico income tax purposes and may also be taxable under state and local and other tax laws. In general, you will recognize gain
or loss equal to the difference between (1) the merger consideration you receive and (2) the adjusted tax basis of the shares of Triple-S
common stock you surrender in the merger. U.S. holders should read the section titled “Material U.S. Federal Income Tax Consequences
of the Merger” beginning on page [●] and P.R. holders should read the section titled “Puerto Rico Income Tax Consequences
of the Merger” beginning on page [●] of this proxy statement. If you are a non-U.S. holder, your exchange of shares of Triple-S
common stock for the merger consideration generally will not result in U.S. federal income tax unless you have certain connections with
the United States. If you are a non-P.R. holder, your exchange of shares of Triple-S common stock for the merger consideration generally
will not result in Puerto Rico income tax unless you have certain connections with Puerto Rico rendering the gain as income effectively
connected to a Puerto Rico trade or business. You should read the sections titled “Material U.S. Federal Income Tax Consequences
of the Merger” and “Material Puerto Rico Income Tax Consequences of the Merger” beginning on pages [●] and [●],
respectively, of this proxy statement and consult your tax advisors regarding the U.S. federal and Puerto Rico income tax consequences
of the merger to you in your particular circumstances, as well as tax consequences arising under the laws of any state, local or foreign
taxing jurisdiction.
|
|
Q:
|
Who is entitled to vote at the special meeting?
|
|
A:
|
The record date for the special meeting is [●], 2021. Only stockholders of record at the close of
business on that date are entitled to attend and vote at the special meeting or any adjournment or postponement thereof. The only class
of stock that can be voted at the meeting is Triple-S common stock. Each outstanding share of Triple-S common stock is entitled to one
vote on all matters that come before the special meeting. At the close of business on the record date, there were [●] shares of
Triple-S common stock issued and outstanding, approximately [●]% of which were held by Triple-S’s directors and executive
officers. We currently expect that all of Triple-S’s directors and executive officers will vote their shares in favor of the merger
proposal and the other proposals to be considered at the special meeting, although no director or executive officer is obligated to do
so.
|
|
Q:
|
Who may attend the special meeting?
|
|
A:
|
Only stockholders as of the close of business on [●], 2021, or their duly appointed proxies, and
invited guests of Triple-S may attend the meeting via the virtual meeting website. “Street name” holders (those whose shares
are held through a broker, bank or other nominee) who wish to vote at the special meeting must obtain a proxy, executed in your favor,
from your broker, bank or other nominee giving you the right to vote your shares at the special meeting.
|
|
Q:
|
Who is soliciting my vote?
|
|
A:
|
The Triple-S board of directors is soliciting your proxy, and Triple-S will bear the cost of soliciting
proxies. Innisfree M&A Incorporated (“Innisfree”) has been retained to assist with the solicitation of proxies. Innisfree
will be paid a solicitation fee of approximately $20,000 and will be reimbursed for its reasonable out-of-pocket expenses for these and
other advisory services in connection with the special meeting. Solicitation initially will be made by mail. Forms of proxies and proxy
materials may also be distributed through brokers, custodians, and other like parties to the beneficial owners of shares of Triple-S common
stock, in which case these parties will be reimbursed for their reasonable out-of-pocket expenses. Proxies may also be solicited in person
or by telephone, facsimile, electronic mail or other electronic medium by Innisfree or, without additional compensation, by certain of
Triple-S’s directors, officers and employees.
|
|
Q:
|
What do I need to do now?
|
|
A:
|
Carefully read and consider the information contained in and incorporated by reference into this proxy
statement, including its annexes. Whether or not you expect to attend the special meeting, please submit a proxy to vote your shares as
promptly as possible so that your shares may be represented and voted at the special meeting.
|
|
Q:
|
How do I vote if my shares are registered directly in my name?
|
|
A:
|
If you are a stockholder of record, there are four methods by which you may vote at the special meeting:
|
|
·
|
Internet: To vote over the internet, log on to the voting site indicated on your proxy card. If
you vote over the internet, you do not have to mail in a proxy card.
|
|
·
|
Telephone: To vote by telephone, call the toll-free number indicated on your proxy card. If you
vote by telephone, you do not have to mail in a proxy card.
|
|
·
|
Mail: To vote by mail, complete, sign and date a proxy card and return it promptly in the postage
paid envelope provided. If you return your signed proxy card to us before the special meeting, we will vote your shares as you direct.
|
|
·
|
Virtually During Meeting: To vote your shares during the special meeting, click on the vote button
provided on the screen and follow the instructions provided. If you encounter any difficulties accessing the special meeting during the
check-in or meeting time, please call the technical support number that will be posted on the log in page.
|
Whether or not you plan to attend the
meeting, we urge you to vote by proxy, whether by internet, by telephone or by mail, to ensure your vote is counted. You may still attend
the meeting and vote your shares via the virtual meeting website, even if you have already voted by proxy. If you later decide to vote
at the special meeting, your proxy prior to the special meeting will be revoked. Please choose only one method to cast your vote by proxy.
We encourage you to vote over the internet, which is a convenient, cost-effective and reliable alternative to returning a proxy card
by mail.
|
Q:
|
How do I vote if my shares are held in the name of my broker (street name)?
|
|
A:
|
If your shares are held by your broker, bank or other nominee, often referred to as held in “street
name,” you will receive a form from your broker, bank or other nominee seeking instruction as to how your shares should be voted.
You should contact your broker, bank or other nominee with questions about how to provide or revoke your instructions.
|
|
Q:
|
Can I change my vote after I submit my proxy?
|
|
A:
|
Yes. You can change or revoke your proxy at any time before the final vote at the special meeting or any
adjournment or postponement thereof. If you are the record holder of your shares, you may change or revoke your proxy in any one of three
ways:
|
|
·
|
You may submit another properly completed proxy bearing a later date, whether over the internet, by telephone
or by mail;
|
|
·
|
You may send a written notice prior to the special meeting (or any adjournment or postponement thereof)
that you are revoking your proxy to the Office of the Secretary, Triple-S Management Corporation, 1441 F.D. Roosevelt Avenue, San Juan,
Puerto Rico 00920; or
|
|
·
|
You may attend the special meeting (or any adjournment or postponement thereof) and vote via the virtual
meeting website.
|
If your shares are held by your broker,
bank or other nominee, you will have to follow the instructions provided by your broker, bank or other nominee to change or revoke your
proxy.
If you have questions about how to vote
or change your vote, please contact Innisfree, the firm assisting us in the solicitation of proxies, toll-free at (877) 750-0537.
|
Q:
|
What happens if I sell my shares of Triple-S common stock before the special meeting?
|
|
A:
|
The record date for the special meeting is earlier than the expected date of the merger. If you own shares
of Triple-S common stock as of the close of business on the record date but transfer your shares prior to the date of the special meeting,
you will retain your right to vote at the special meeting, but the right to receive the merger consideration will pass to the person who
holds your shares immediately prior to the effective time of the merger.
|
|
Q:
|
What happens if I sell my shares of Triple-S common stock after the special meeting but before the
effective time?
|
|
A:
|
If you transfer your shares after the special meeting but before the effective time, you will have transferred
the right to receive the merger consideration to the person to whom you transfer your shares. In order to receive the merger consideration,
you must hold your shares of Triple-S common stock through completion of the merger.
|
|
Q:
|
Should I send in my stock certificates now?
|
|
A:
|
No. If the merger is completed, the paying agent for the merger will send you a letter of transmittal
and instructions for exchanging your shares of Triple-S common stock for the merger consideration. PLEASE DO NOT SEND ANY STOCK CERTIFICATES
WITH YOUR PROXY OR OTHERWISE SEND THEM TO TRIPLE-S, PARENT OR THE PROXY SOLICITOR.
|
|
Q:
|
How many shares must be present to constitute a quorum for the meeting?
|
|
A:
|
The presence at the special meeting, by attendance via the virtual meeting website or by proxy, of the
holders of one-third of the shares of Triple-S common stock issued and outstanding and entitled to vote at the close of business on the
record date will constitute a quorum. There must be a quorum for business to be conducted at the special meeting. Failure of a quorum
to be present at the special meeting will necessitate an adjournment or postponement and will subject Triple-S to additional expense.
|
|
Q:
|
What if I abstain from voting?
|
|
A:
|
If you attend the special meeting or send in your signed proxy card, but abstain from voting on any proposal,
your shares will still be counted for purposes of determining whether a quorum exists. If you abstain from voting on the merger proposal
at the special meeting, it will have the same effect as a vote “AGAINST” such proposal. If you abstain from voting on the
other two proposals, it will have no effect on the outcome of such proposals.
|
|
Q:
|
Will my shares be voted if I do not sign and return my proxy card or vote over the internet, by
mail, by telephone or by attendance via the virtual meeting website?
|
|
A:
|
If you are a registered stockholder and you do not sign and return your proxy card or vote over the internet,
by telephone, by mail or by attendance via the virtual meeting website, your shares will not be voted at the special meeting and will
not be counted for purposes of determining whether a quorum exists.
|
If your shares are held in street name
and you do not issue instructions to your broker, bank or other nominee, your broker, bank or other nominee may vote your shares at its
discretion on routine matters, but may not vote your shares on non-routine matters. Under NYSE rules, all of the proposals in this proxy
statement are non-routine matters. Accordingly, if your shares are held in “street name” and you do not issue instructions
to your broker, bank or other nominee, your shares will not be voted at the special meeting and will not be counted for purposes of determining
whether a quorum exists.
If you fail to complete, sign, date
and return your proxy card by mail, or vote via the internet, by telephone or by attendance via the virtual meeting website, it will have
the same effect as a vote “AGAINST” the merger proposal, but will have no effect on the other proposals.
|
Q:
|
What is a broker non-vote?
|
|
A:
|
Broker non-votes are shares held by brokers and other record holders that are present or represented by
proxy at the special meeting, but with respect to which the broker or other record holder is not instructed by the beneficial owner of
such shares how to vote on a particular proposal and the broker does not have discretionary voting power on such proposal. Because brokers
and other record holders do not have discretionary voting authority with respect to any of the three proposals described in this proxy
statement, if a beneficial owner of shares of Triple-S common stock held in “street name” does not give voting instructions
to the broker or other holder of record, then those shares will not be present or represented by proxy at the special meeting. As a result,
it is expected that there will not be any broker non-votes in connection with any of the three proposals described in this proxy statement.
|
If you do not instruct your broker,
bank or other nominee to vote your shares, your shares will not be voted and the effect will be the same as a vote “AGAINST”
the merger proposal. However, a failure to instruct your broker, bank or other nominee to vote on the non-binding proposal regarding merger-related
compensation for Triple-S’s named executive officers (assuming a quorum is present) or the proposal to adjourn the special meeting,
if necessary or appropriate, to solicit additional proxies for the approval and adoption of the merger agreement, will have no effect
on the outcome of such proposals.
|
Q:
|
Will my shares held in “street name” or another form of record ownership be combined
for voting purposes with shares I hold of record?
|
|
A:
|
No. Because any shares you may hold in “street name” will be deemed to be held by a different
stockholder than any shares you hold of record, any shares so held will not be combined for voting purposes with shares you hold of record.
Similarly, if you own shares in various registered forms, such as jointly with your spouse, as trustee of a trust or as custodian for
a minor, you will receive, and will need to sign and return, a separate proxy card for those shares because they are held in a different
form of record ownership. Shares held by a corporation or business entity must be voted by an authorized officer of the entity. Shares
held in an individual retirement account must be voted under the rules governing the account.
|
|
Q:
|
What does it mean if I receive more than one set of proxy materials?
|
|
A:
|
This means you own shares of Triple-S common stock that are registered under different names or are in
more than one account. For example, you may own some shares directly as a stockholder of record and other shares through a broker or you
may own shares through more than one broker. In these situations, you will receive multiple sets of proxy materials. You must vote, sign
and return all of the proxy cards or follow the instructions for any alternative voting procedure on each of the proxy cards
|
that you receive in
order to vote all of the shares you own. Each proxy card you receive comes with its own prepaid return envelope. If you submit your proxy
by mail, make sure you return each proxy card in the return envelope that accompanies that proxy card.
|
Q:
|
Who will count the votes?
|
|
A:
|
A representative from Broadridge Financial Solutions, Inc. will serve as the inspector of election.
|
|
Q:
|
Can I participate if I am unable to attend the special meeting?
|
|
A:
|
If you are unable to attend the special meeting, we encourage you to complete, sign, date and return your
proxy card or to vote over the internet or by telephone.
|
|
Q:
|
Where can I find the voting results of the special meeting?
|
|
A:
|
Triple-S intends to announce preliminary voting results at the special meeting and publish final results
in a Current Report on Form 8-K that will be filed with the SEC following the special meeting. All reports that Triple-S files with the
SEC are publicly available when filed.
|
|
Q:
|
What happens if the merger is not completed?
|
|
A:
|
If the merger agreement is not approved and adopted by Triple-S stockholders or if the merger is not completed
for any other reason, Triple-S stockholders will not receive any payment for their shares of Triple-S common stock in connection with
the merger. Instead, Triple-S will remain an independent public company, the shares of Triple-S common stock will continue to be listed
and traded on the NYSE and Triple-S will continue to be subject to reporting obligations under the Exchange Act.
|
The merger agreement provides that,
upon termination of the merger agreement under certain circumstances, Triple-S will be required to pay to Parent a termination fee of
$17,985,000, or under specified circumstances, Triple-S may be entitled to receive a reverse termination fee of $17,985,000 from
Parent. If Parent commences an action or proceeding that results in a judgment against Triple-S for the payment of the termination fee,
Triple-S shall pay to Parent its costs and expenses (including attorneys’ fees and expenses incurred by Parent in connection with
such action or proceeding), together with interest on the payment from the date such payment was required to be made until the date of
payment. If Triple-S commences an action or proceeding that results in a judgment against Parent for the payment of the reverse termination
fee, Parent shall pay to Triple-S its costs and expenses (including attorneys’ fees and expenses incurred by Triple-S in connection
with such action or proceeding), together with interest on the payment from the date such payment was required to be made until the date
of payment.
See the section entitled “The
Merger Agreement—Termination Fee Payable by Triple-S and Reverse Termination Fee Payable by Parent” beginning on page [●]
of this proxy statement for a discussion of the circumstances under which such a termination fee or a reverse termination fee will be
required to be paid.
|
Q:
|
How can I obtain additional information about Triple-S?
|
|
A:
|
Triple-S will provide copies of this proxy statement and its [2020 Annual Report to Stockholders], including
its Annual Report on Form 10-K for the fiscal year ended December 31, 2020, without charge to any stockholder who makes a written request
to our Secretary at Triple-S Management Corporation, 1441 F.D. Roosevelt Avenue, San Juan, Puerto Rico 00920. Triple-S’s Annual
Report on Form 10-K and other SEC filings may also be accessed at www.sec.gov or on the Investor Relations section of Triple-S’s
website at www.triplesmanagement.com. Triple-S’s website address is provided as an inactive textual reference only. The information
provided on or accessible through our website is not part of this proxy statement and is not incorporated in this proxy statement by reference
by this or any other reference to our website provided in this proxy statement.
|
|
Q:
|
How many copies of this proxy statement and related voting materials should I receive if I share
an address with another stockholder?
|
|
A:
|
The SEC has adopted rules that permit companies and intermediaries, such as brokers, to satisfy the delivery
requirements for proxy statements and annual reports with respect to two or more stockholders sharing the same address by delivering a
single annual report or proxy statement, as applicable,
|
addressed to those
stockholders. This process, which is commonly referred to as “householding,” potentially provides extra convenience for stockholders
and cost savings for companies.
Triple-S and some brokers may be householding
our proxy materials by delivering proxy materials to multiple stockholders who request a copy and share an address, unless contrary instructions
have been received from the affected stockholders. Once you have received notice from your broker or us that they or we will be householding
materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If at any time
you no longer wish to participate in householding and would prefer to receive a separate proxy statement and annual report, please notify
your broker if your shares are held in a brokerage account or Triple-S if you are a stockholder of record. You can notify us by sending
a written request to Triple-S Management Corporation, 1441 F.D. Roosevelt Avenue, San Juan, Puerto Rico 00920, Attn: Secretary, or calling
(787) 749-4949. Stockholders who share a single address, but receive multiple copies of the proxy statement, may request that in the future
they receive a single copy by notifying Triple-S at the telephone and address set forth in the prior sentence. In addition, Triple-S will
promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of the proxy statement to a stockholder
at a shared address to which a single copy of the documents was delivered pursuant to a prior request.
|
Q:
|
Whom should I contact if I have any questions?
|
|
A:
|
If you have questions about the merger or the other matters to be voted on at the special meeting or desire
additional copies of this proxy statement or additional proxy cards or otherwise need assistance voting, you should contact:
|
Innisfree M&A Incorporated
501 Madison Avenue, 20th Floor
New York, New York 10022
Shareholders may call toll-free: (877) 750-0537
Banks and brokers may call collect: (212) 750-5833
CAUTION
REGARDING FORWARD-LOOKING STATEMENTS
This proxy statement, and
the documents incorporated by reference or otherwise referred to in this proxy statement, contain “forward-looking statements”
within the meaning of Section 21E of the Exchange Act. Any statements contained in this proxy statement, and the documents incorporated
by reference or otherwise referred to in this proxy statement, that are not statements of historical fact may be deemed to be forward-looking
statements. All such forward-looking statements are intended to provide management’s current expectations for the future operating
and financial performance of Triple-S based on current assumptions relating to Triple-S’s business, the economy and future conditions.
Forward-looking statements generally can be identified through the use of words such as “believes,” “anticipates,”
“may,” “should,” “will,” “plans,” “projects,” “expects,” “expectations,”
“estimates,” “forecasts,” “predicts,” “targets,” “prospects,” “strategy,”
“signs” and other words of similar meaning in connection with the discussion of future operating or financial performance.
Forward-looking statements may include, among other things, statements relating to future sales, earnings, cash flow, results of operations,
uses of cash and other measures of financial performance. Because forward-looking statements relate to the future, they are subject to
inherent risks, uncertainties and changes in circumstances that are difficult to predict. Accordingly, Triple-S’s actual results
may differ materially from those contemplated by the forward-looking statements. Investors, therefore, are cautioned against relying on
any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Forward-looking statements in this proxy statement, and the documents incorporated by reference or otherwise referred to in this proxy
statement, include, among others, statements relating to:
|
·
|
Expected impact of COVID-19 on Triple-S’s businesses;
|
|
·
|
The occurrence of any event, change or other circumstance that could give rise to the termination of the
merger agreement, including a termination of the merger agreement under circumstances that could require Triple-S to pay a termination
fee;
|
|
·
|
The failure to receive, on a timely basis or otherwise, the required approvals by Triple-S stockholders
with regard to the merger agreement;
|
|
·
|
The risk that a closing condition to the merger agreement may not be satisfied;
|
|
·
|
Triple-S’s and Parent’s ability to complete the proposed merger on a timely basis or at all;
|
|
·
|
The failure of the merger to be completed on a timely basis or at all for any other reason;
|
|
·
|
The risks that Triple-S’s business may suffer as a result of uncertainties surrounding the merger;
|
|
·
|
The ability of Triple-S to retain and hire key personnel and maintain relationships with providers pending
the consummation of the merger;
|
|
·
|
The possibility of disruption to Triple-S’s business from the proposed merger, including increased
costs and diversion of management time and resources;
|
|
·
|
Limitations placed on Triple-S’s ability to operate its business under the merger agreement;
|
|
·
|
General economic, business and political conditions;
|
|
·
|
The outcome of any legal proceedings that may be instituted against Triple-S or others relating to the
merger agreement or the merger; and
|
|
·
|
Other financial, operational and legal risks and uncertainties detailed from time to time in Triple-S’s
SEC reports.
|
All forward-looking statements
are inherently subject to a number of risks and uncertainties that could cause the actual results of Triple-S to differ materially from
those reflected in forward-looking statements made in this proxy statement, and the documents incorporated by reference or otherwise referred
to in this proxy statement, as well as in press releases and other statements made from time to time by Triple-S’s authorized officers.
Such risks and uncertainties include, among others, the risk factors included in Item 1A of Triple-S’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2020 and under Part II, Item 1A I Triple-S’s Quarterly Report on Form 10-Q for the fiscal
quarter ended June 30, 2021. Triple-S does
not assume any obligation to
update any forward-looking statements, whether as a result of new information, future events or otherwise.
THE
COMPANIES
Triple-S Management Corporation
Triple-S, a health services
company, serves more than 1 million customers in Puerto Rico, which represents nearly one-third of the island’s population. With
over 60 years of experience, it is the premier insurance and managed care brand, with the largest customer base and broadest provider
networks on the island. Triple-S has the exclusive right to use the Blue Cross Blue Shield name and mark throughout Puerto Rico, the U.S.
Virgin Islands, Costa Rica, the British Virgin Islands and Anguilla, and offers a broad portfolio of managed care and related products
in the commercial, Medicare Advantage and Medicaid segments. Triple-S is also a well-known brand in the life insurance and property and
casualty insurance segments in Puerto Rico, with strong customer relationships and a significant market share.
Triple-S’s principal
executive office is located at 1441 F.D. Roosevelt Avenue, San Juan, Puerto Rico 00920. Triple-S’s telephone number is (787) 749-4949.
Triple-S’s internet website address is www.triplesmanagement.com. The information provided on the Triple-S website is not part of
this proxy statement and is not incorporated in this proxy statement by reference by this or any other reference to its website provided
in this proxy statement.
Shares of Triple-S common
stock are listed and trade on the NYSE under the symbol “GTS.”
Parent
Parent is a not-for-profit
mutual holding company and the parent to a family of forward-thinking companies focused on transforming health care. The Parent organization
includes Florida Blue, the leading health insurance company in Florida; GuideWell Health, a portfolio of clinical delivery organizations;
GuideWell Venture Group, a portfolio of companies, including Onlife Health and PopHealthCare, focused on creating human-first and innovative
health solutions for health plans; GuideWell Source, a provider of administrative services to state and federal health care programs;
and WebTPA, a market leading administrator of self-funded employer health plans. In total, Parent and its affiliated companies serve more
than 45 million people in 45 states.
Parent’s principal executive
office is located at 4800 Deerwood Campus Pkwy., Jacksonville, Florida 32246. Parent’s telephone number is (855) 204-4084. Parent’s
internet website address is www.guidewell.com. The information provided on the Parent website is not part of this proxy statement and
is not incorporated in this proxy statement by reference by this or any other reference to its website provided in this proxy statement.
Merger Sub
Merger Sub is a Delaware corporation
and wholly owned subsidiary of Parent. Upon consummation of the transactions contemplated by the merger agreement, Merger Sub exists for
the sole purpose of entering into the merger agreement and, subject to the terms and conditions thereof, completing the transactions contemplated
thereby and the related financing transactions. Merger Sub will cease to exist and Triple-S will continue as the surviving company and
as a wholly owned subsidiary of Parent.
THE
SPECIAL MEETING
This proxy statement is
being provided to the stockholders of Triple-S as part of a solicitation of proxies by the Triple-S board of directors for use at the
special meeting to be held at the time specified below, and at any properly convened meeting following an adjournment or postponement
thereof. This proxy statement provides stockholders of Triple-S with the information they need to know to be able to vote or instruct
their vote to be cast at the special meeting or any adjournment or postponement thereof.
Date, Time and Place
The special meeting is scheduled
to be held exclusively online via live webcast on [●], 2021 at [●], Eastern Time. You will be able to attend the special meeting
by first registering at [●]. You will receive a meeting invitation by e-mail with your unique join link along with a password prior
to the meeting date. Stockholders will be able to listen, vote and submit questions during the special meeting. We encourage you to allow
ample time for online check-in, which will open at [●], Eastern Time. Please note that you will not be able to attend the special
meeting in person. We elected to use a virtual meeting given the current public health implications of COVID-19 (novel coronavirus) and
our desire to promote the health and welfare of our stockholders.
We have created and implemented
the virtual format in order to facilitate stockholder attendance and participation by enabling stockholders to participate fully, and
equally, from any location around the world, at no cost. However, you will bear any costs associated with your Internet access, such as
usage charges from Internet access providers and telephone companies. A virtual special meeting makes it possible for more stockholders
(regardless of size, resources or physical location) to have direct access to information more quickly, while saving Triple-S and its
stockholders time and money, especially as physical attendance at meetings has dwindled. We also believe that the online tools we have
selected will increase stockholder communication. For example, the virtual format allows stockholders to communicate with us in advance
of, and during, the special meeting so they can ask questions of our board of directors or management. During the live Q&A session
of the special meeting, we may answer questions as they come in and address those asked in advance, to the extent relevant to the business
of the special meeting, as time permits.
Both stockholders of record
and street name stockholders will be able to attend the special meeting via live audio webcast, submit their questions during the meeting
and vote their shares electronically at the special meeting.
If you are a registered holder,
your virtual control number will be on your proxy card.
If you hold your shares beneficially
through a bank or broker, you must provide a legal proxy from your bank or broker during registration and you will be assigned a virtual
control number in order to vote your shares during the special meeting. If you are unable to obtain a legal proxy to vote your shares,
you will still be able to attend the 2021 special meeting (but will not be able to vote your shares) so long as you demonstrate proof
of stock ownership. Instructions on how to connect and participate via the Internet, including how to demonstrate proof of stock ownership,
are posted at [●]. On the day of the special meeting, you may only vote during the meeting by e-mailing a copy of your legal proxy
to [●] in advance of the meeting.
Technical Difficulties
There will be technicians
ready to assist you with any technical difficulties you may have accessing the special meeting live audio webcast. Please be sure to check
in by [●] Eastern Time on [●], 2021, (fifteen (15) minutes prior to the start of the meeting is recommended) the day of the
meeting, so that any technical difficulties may be addressed before the special meeting live audio webcast begins. If you encounter any
difficulties accessing the webcast during the check-in or meeting time, please email [●] or call [●].
Purpose of the Special Meeting
At the special meeting, Triple-S
stockholders will be asked to consider and vote on the following:
|
·
|
A proposal to approve and adopt the merger agreement, which is further described in the sections entitled
“The Merger (Proposal 1)” and “The Merger Agreement,” beginning on pages [●] and [●], respectively,
of this proxy statement;
|
|
·
|
A proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid
by Triple-S to its named executive officers that is based on or otherwise relates to the merger, which is discussed under the section
entitled “The Merger (Proposal 1)—Interests of Triple-S’s Directors and Executive Officers in the Merger” beginning
on page [●] of this proxy statement; and
|
|
·
|
A proposal to approve an adjournment of the special meeting, if necessary or appropriate, to solicit additional
proxies in favor of the merger proposal, if there are not sufficient votes at the time of such adjournment to approve the merger proposal.
|
Triple-S stockholders must
approve the merger proposal for the merger to occur. If Triple-S stockholders fail to approve the merger proposal, the merger will not
occur. The vote on executive compensation payable in connection with the merger is a vote separate and apart from the vote to approve
the merger proposal. Accordingly, a stockholder may vote to approve the executive compensation payable in connection with the merger and
vote not to approve the merger proposal and vice versa. Because the vote on executive compensation is advisory in nature only, it will
not be binding on either Triple-S or Parent. Accordingly, because Triple-S is contractually obligated to pay the compensation, the compensation
will be payable, subject only to the conditions applicable thereto, if the merger agreement is approved and adopted and the merger is
consummated, and regardless of the outcome of the advisory vote.
Triple-S does not expect a
vote to be taken on any other matters at the special meeting or any adjournment or postponement thereof. If any other matters are properly
presented at the special meeting or any adjournment or postponement thereof for consideration, however, the holders of the proxies will
have discretion to vote on these matters.
Recommendation of the Triple-S Board of Directors
After careful consideration,
the Triple-S board of directors, by a unanimous vote, approved the merger agreement, the merger and the other transactions contemplated
by the merger agreement. Certain factors considered by the Triple-S board of directors in reaching its decision to authorize and approve
the merger agreement and the merger can be found in the section entitled “The Merger (Proposal 1)—Triple-S’s Reasons
for the Merger” beginning on page [●] of this proxy statement.
The Triple-S board of directors
recommends that the Triple-S stockholders vote “FOR” the merger proposal, “FOR” the proposal to approve, on a
non-binding, advisory basis, certain compensation that will or may be paid by Triple-S to its named executive officers that is based on
or otherwise relates to the merger and “FOR” the proposal to adjourn the special meeting, if necessary or appropriate, to
solicit additional proxies in favor of the merger proposal, if there are not sufficient votes at the time of such adjournment to approve
the merger proposal.
Record Date; Stockholders Entitled to Vote
Only holders of record of
Triple-S common stock at the close of business on [●], 2021, the record date for the special meeting, will be entitled to notice
of, and to vote at, the special meeting or any adjournments or postponements of the special meeting. At the close of business on the record
date, [●] shares of Triple-S common stock were issued and outstanding and held by [●] holders of record.
Holders of record of Triple-S
common stock are entitled to one vote for each share of Triple-S common stock they own at the close of business on the record date.
Quorum
The presence at the special
meeting, by attendance via the virtual meeting website or by proxy, of the holders of one-third of the shares of Triple-S common stock
issued and outstanding and entitled to vote at the close of business on the record date will constitute a quorum. Any shares of Triple-S
common stock held by Triple-S are not considered to be outstanding for purposes of determining a quorum. There must be a quorum for business
to be conducted at the special meeting. Failure of a quorum to be represented at the special meeting will necessitate an adjournment or
postponement and will subject Triple-S to additional expense. Once a share is represented at the special meeting, it will be counted for
the purpose of determining a quorum at the special meeting and any adjournment of the special meeting. However, if a new record date is
set for the adjourned special meeting, then a new quorum will have to be established. If you submit a properly executed proxy card, even
if you abstain from voting, your shares will be counted for purposes of calculating whether a quorum is present at the special meeting.
Required Vote
Approval and adoption of the
merger agreement requires the affirmative vote of a majority of the shares of Triple-S common stock issued and outstanding at the close
of business on the record date. The proposal to adjourn the special meeting, if necessary or appropriate, to permit further solicitation
of proxies in favor of the merger proposal, requires the affirmative vote of at least a majority of the outstanding shares of Triple-S
common stock present via the virtual meeting website or represented by proxy (whether or not a quorum is present). The proposal to approve,
on a non-binding, advisory basis, certain compensation that will or may be paid by Triple-S to its named executive officers that is based
on or otherwise relates to the merger requires the affirmative vote of at least a majority of the outstanding shares of Triple-S common
stock present via the virtual meeting website or represented by proxy and entitled to vote and voting on the proposal at the special meeting
(provided that a quorum is present).
Abstentions and Broker Non-Votes
An abstention occurs when
a stockholder attends a meeting, either by attendance via the virtual meeting website or by proxy, but abstains from voting. At the special
meeting, abstentions will be counted in determining whether a quorum is present, and will be counted as a vote “AGAINST”
the merger proposal. At the special meeting, abstentions will have no effect on the outcomes of the proposal to adjourn the special meeting,
if necessary or appropriate, to permit further solicitation of proxies in favor of the merger proposal, and the advisory vote on named
executive officer merger-related compensation arrangements.
If no instruction as to how
to vote is given (including an instruction to abstain) in an executed, duly returned and not revoked proxy, the proxy will be voted “FOR”
(i) the merger proposal; (ii) the proposal to approve, on a non-binding, advisory basis, certain compensation that will or may be paid
by Triple-S to its named executive officers that is based on or otherwise relates to the merger; and (iii) the proposal to approve the
adjournment of the special meeting, if necessary or appropriate, to solicit additional proxies, if there are not sufficient votes at the
time of such adjournment to approve the merger proposal.
Broker non-votes are shares
held by brokers and other record holders that are present or represented by proxy at the special meeting, but with respect to which the
broker or other record holder is not instructed by the beneficial owner of such shares how to vote on a particular proposal and the broker
does not have discretionary voting power on such proposal. Because brokers and other record holders do not have discretionary voting authority
with respect to any of the three proposals described in this proxy statement, if a beneficial owner of shares of Triple-S common stock
held in “street name” does not give voting instructions to the broker or other holder of record, then those shares will not
be present or represented by proxy at the special meeting. As a result, it is expected that there will not be any broker non-votes in
connection with any of the three proposals described in this proxy statement. If you do not instruct your broker, bank or other nominee
to vote your shares, your shares will not be voted and the effect will be the same as a vote “AGAINST” the merger proposal.
However, a failure to instruct your broker, bank or other nominee to vote on the proposal to adjourn the special meeting, if necessary
or appropriate, to solicit additional proxies for the approval of the merger proposal or, assuming a quorum is present, the proposal regarding
the advisory vote on named executive officer merger-related compensation arrangements, will have no effect on the outcome of such proposals.
Failure to Vote
If you are a registered stockholder
and you do not sign and return your proxy card or vote over the internet, by telephone or by attendance via the virtual meeting website,
your shares will not be voted at the special meeting and will not be counted for purposes of determining whether a quorum exists. If you
are the record owner of your shares and you fail to vote, it will have the same effect as a vote “AGAINST” the merger
proposal but will have no effect on the proposal to adjourn the special meeting (whether or not a quorum is present), if necessary or
appropriate, to permit further solicitation of proxies in favor of the merger proposal, and the advisory vote on named executive officer
merger-related compensation arrangements (assuming a quorum is present).
Voting by Triple-S’s Directors and Executive
Officers
At the close of business on
the record date, directors and executive officers of Triple-S and their affiliates were entitled to vote [●] shares of Triple-S
common stock, or approximately [●]% of the shares of Triple-S common stock issued and outstanding on that date.
Voting at the Special Meeting
To participate in the special
meeting, visit please click on the voting link provided from your registration e-mail and enter the control number included on your proxy
card or on the instructions that accompanied your proxy materials. If you wish to submit a question during the special meeting, type your
question into the “Ask a Question” field, and click “Submit.” If your question is properly submitted during the
relevant portion of the meeting agenda, we will respond to your question during the live webcast.
If we experience technical
difficulties during the special meeting (e.g., a temporary or prolonged power outage), we will determine whether the meeting can be promptly
reconvened (if the technical difficulty is temporary) or whether the meeting will need to be reconvened on a later day (if the technical
difficulty is more prolonged). In any situation, we will promptly notify stockholders of the decision via [●]. If you encounter
any difficulties accessing the webcast during the check-in or meeting time, please email [●] or call [●].
Please note that if your shares
of Triple-S common stock are held by a broker, bank or other nominee, and you wish to vote at the special meeting, you must obtain a proxy,
executed in your favor, from your broker, bank or other nominee giving you the right to vote your shares at the special meeting.
You may also authorize the
persons named as proxies on the proxy card to vote your shares by (i) signing, dating, completing and returning the proxy card by mail;
(ii) over the internet; or (iii) by telephone. Triple-S encourages you to vote over the internet as Triple-S believes this is the most
cost-effective method. We also recommend that you vote as soon as possible, even if you are planning to attend the special meeting,
so that the vote count will not be delayed. The internet provides a convenient, cost-effective alternative to returning your proxy card
by mail or voting by telephone. If you vote your shares over the internet, you may incur costs associated with electronic access, such
as usage charges from internet access providers. If you choose to vote your shares over the internet, there is no need for you to mail
back your proxy card.
To Vote Over the Internet:
To vote over the internet,
log on to the voting site indicated on your proxy card. If you vote over the internet, you do not have to mail in a proxy card.
To Vote By Telephone:
To vote by telephone, call
the toll-free number indicated on your proxy card. If you vote by telephone, you do not have to mail in a proxy card.
To Vote By Mail:
To vote by mail, complete,
sign, date and return the enclosed proxy card and mail it to the address indicated on the proxy card.
If you return your signed
proxy card without indicating how you want your shares of Triple-S common stock to be voted with regard to a particular proposal, your
shares of Triple-S common stock will be voted in favor of each such proposal. Proxy cards that are returned without a signature will not
be counted as present at the special meeting and cannot be voted.
If your shares are held by
your broker, bank or other nominee, you will receive a form from your broker, bank or other nominee seeking instruction as to how your
shares should be voted. You should contact your broker, bank or other nominee with questions about how to provide or revoke your instructions.
If you hold shares in more
than one account, you may receive more than one proxy or voting instruction card. To be sure that all of your shares are represented at
the meeting, you must submit your proxy or voting instructions with respect to each proxy or voting instruction card you receive.
Revocation of Proxies
You can revoke your proxy
at any time before the final vote at the special meeting or any adjournment or postponement thereof. If you are the record holder of your
shares, you may revoke your proxy in any one of three ways:
|
·
|
You may submit another properly completed proxy bearing a later date, whether over the internet, by telephone
or by mail;
|
|
·
|
You may send a written notice prior to the special meeting (or any adjournment or postponement thereof)
that you are revoking your proxy to the Office of the Secretary, Triple-S Management Corporation, 1441 F.D. Roosevelt Avenue, San Juan,
Puerto Rico 00920; or
|
|
·
|
You may attend the special meeting (or any adjournment or postponement thereof) and vote via the virtual
meeting website.
|
If your shares are held by
your broker, bank or other nominee, you will have to follow the instructions provided by your broker, bank or other nominee to revoke
your proxy.
If you have questions about
how to vote or change your vote, you should contact the firm assisting us with the solicitation of proxies, Innisfree, toll-free at (877)
750-0537.
Shares Held in Name of Broker
If your shares are held by
your broker, bank or other nominee, often referred to as held in “street name,” you will receive a form from your broker,
bank or other nominee seeking instruction as to how your shares should be voted. You should contact your broker, bank or other nominee
with questions about how to provide or revoke your instructions.
Tabulation of Votes
A representative from Broadridge
Financial Solutions, Inc. will serve as the inspector of election.
Solicitation of Proxies
The Triple-S board of directors
is soliciting your proxy, and Triple-S will bear the cost of soliciting proxies. Innisfree has been retained to assist with the solicitation
of proxies. Innisfree will be paid a solicitation fee of approximately $20,000 and will be reimbursed for its reasonable out-of-pocket
expenses for these and other advisory services in connection with the special meeting. Solicitation initially will be made by mail. Forms
of proxies and proxy materials may also be distributed through brokers, custodians and other like parties to the beneficial owners of
shares of Triple-S common stock, in which case these parties will be reimbursed for their reasonable out-of-pocket expenses. Proxies may
also be solicited in person or by telephone, facsimile, electronic mail, or other electronic medium by Innisfree or, without additional
compensation, by certain of Triple-S’s directors, officers and employees.
Adjournment
In addition to the merger
proposal and the advisory vote on named executive officer merger-related compensation arrangements, Triple-S stockholders are also being
asked to approve a proposal to, as permitted under the terms of the merger agreement, adjourn the special meeting for the purpose of soliciting
additional proxies in favor of the merger proposal if there are not sufficient votes at the time of the special meeting to approve the
merger proposal. The special meeting could be adjourned by Triple-S as permitted under the terms of the merger agreement to any date.
In addition, Triple-S could postpone the meeting before it commences, whether for the purpose of soliciting additional proxies or for
other reasons. If the special meeting is adjourned for the purpose of soliciting additional proxies, stockholders who have already submitted
their proxies will be able to revoke them at any time prior to their use at the special meeting or any adjournment or postponement thereof.
If you return a proxy and do not indicate how you wish to vote on any proposal, your shares will be voted in favor of such proposal.
The Triple-S board of directors
recommends a vote “FOR” the proposal to adjourn the special meeting, if necessary or appropriate, to solicit additional proxies
in favor of the merger proposal, if there are not sufficient votes at the time of such adjournment to approve the merger proposal.
THE
MERGER (PROPOSAL 1)
The discussion of the merger
in this proxy statement is qualified in its entirety by reference to the merger agreement, a copy of which is attached to this proxy statement
as Annex A and incorporated by reference into this proxy statement. You should read the merger agreement carefully as it is the legal
document that governs the merger.
Effects of the Merger
Pursuant to the terms of the
merger agreement, at the effective time of the merger, Merger Sub will be merged with and into Triple-S in accordance with the Puerto
Rico law and Delaware law. As a result of the merger, the separate existence of Merger Sub will cease, and Triple-S will survive the merger
as a wholly owned subsidiary of Parent.
At the effective time of the
merger, each outstanding share of Triple-S common stock (other than any shares held by Triple-S (as treasury stock), Parent or Merger
Sub, or any stockholder who has properly demanded and not failed to perfect or validly withdrawn appraisal rights in accordance with Puerto
Rico law) will be automatically converted into the right to receive $36.00 in cash, without interest and less any applicable withholding
taxes (the “merger consideration”).
Upon consummation of the merger,
your shares of Triple-S common stock will no longer be outstanding and will automatically be canceled and cease to exist in exchange for
payment of the merger consideration described above unless you have properly demanded and not failed to perfect or validly withdrawn appraisal
rights in accordance with Puerto Rico law. As a result, you will not own any shares of the surviving corporation, and you will no longer
have any interest in its future earnings or growth. Following the merger, Triple-S will cease to be a publicly-traded company and will
be wholly owned by Parent, and the surviving corporation will terminate the listing of Triple-S’s common stock on the NYSE and deregister
under the Exchange Act and no longer be subject to reporting obligations under the Exchange Act.
Upon consummation of the merger,
each Triple-S restricted share award, restricted stock unit award and performance share unit award that is outstanding as of the date
of the merger agreement and immediately prior to the effective time of the merger, at the effective time of the merger, whether or not
vested and whether subject to time-based or performance-based vesting, shall be canceled and converted into the right to receive an amount
in cash equal to the product of the merger consideration and the number of shares of Triple-S common stock underlying the applicable Triple-S
award as of immediately prior to the effective time of the merger. In the case of any Triple-S performance share unit awards, performance
conditions will be deemed to have been earned at target performance.
Upon consummation of the merger,
each Triple-S restricted stock unit award and performance share unit award that is granted following the date of the merger agreement
and outstanding immediately prior to the effective time of the merger, at the effective time of the merger, shall be canceled and converted
into the right to receive an amount in cash equal to the product of the merger consideration and the number of shares of Triple-S common
stock underlying such award as of immediately prior to the effective time, payable on the date the award would have otherwise vested pursuant
to its vesting schedule, subject to the holder’s continuing employment as of each such vesting date or as otherwise provided in
the applicable award agreements. In the case of any Triple-S performance share unit awards, performance conditions will be deemed to have
been earned at target performance.
If, during the period between
the date of the merger agreement and the effective time of the merger, any change in the outstanding shares of Triple-S common stock occurs
by reason of any reclassification, recapitalization, stock split or combination or any stock dividend thereon with a record date during
such period, the merger consideration will be appropriately adjusted.
Effects on Triple-S If the Merger Is Not Completed
If the merger agreement is
not approved and adopted by Triple-S stockholders or if the merger is not completed for any other reason, Triple-S stockholders will not
receive any payment for their shares of Triple-S common stock in connection with the merger. Instead, Triple-S will remain an independent
public company, the shares of Triple-S common stock will continue to be listed and traded on the NYSE and Triple-S will continue to be
subject to reporting obligations under the Exchange Act. In addition, if the merger is not completed, Triple-S stockholders will continue
to be subject to the same risks and opportunities to which they are currently subject, as disclosed in Triple-S’s Annual Report
on Form 10-K.
Furthermore, if the merger
is not completed, and depending on the circumstances that would have caused the merger not to be completed, it is likely that the price
of Triple-S common stock will decline significantly. If that were to occur, it is uncertain when, if ever, the price of Triple-S common
stock would return to the price at which it trades as of the date of this proxy statement.
Accordingly, if the merger
is not completed, there can be no assurance as to the effect of these risks and opportunities on the future value of your shares of Triple-S
common stock. If the merger agreement is not approved and adopted by Triple-S stockholders or if the merger is not completed for any other
reason, there can be no assurance that any other transaction acceptable to Triple-S will be offered or that Triple-S’s business,
prospects or results of operation will not be adversely impacted.
In addition, the merger agreement
provides that, upon termination of the merger agreement under certain circumstances, Triple-S will be required to pay to Parent a termination
fee of $17,985,000, or under specified circumstances, Triple-S may be entitled to receive a reverse termination fee of
$17,985,000 from Parent. If Parent commences an action or proceeding that results in a judgment against Triple-S for the payment of the
termination fee, Triple-S shall pay to Parent its costs and expenses (including attorneys’ fees and expenses incurred by Parent
in connection with such action or proceeding), together with interest on the payment from the date such payment was required to be made
until the date of payment. If Triple-S commences an action or proceeding that results in a judgment against Parent for the payment of
the reverse termination fee, Parent shall pay to Triple-S its costs and expenses (including attorneys’ fees and expenses incurred
by Triple-S in connection with such action or proceeding), together with interest on the payment from the date such payment was required
to be made until the date of payment.
See the section entitled “The
Merger Agreement—Termination Fee Payable by Triple-S and Reverse Termination Fee Payable by Parent” beginning on page [●]
of this proxy statement for a discussion of the circumstances under which such a termination fee will be required to be paid.
Background of the Merger
As part of the ongoing evaluation
of Triple-S, the board of directors and management of Triple-S regularly evaluates its historical performance, future growth prospects
and overall strategic positioning and objectives and considers potential opportunities to enhance stockholder value. This review has included
consideration of various potential strategic alternatives, including potential strategic partnerships and business combination transactions.
In connection with this ongoing
review, Triple-S has relied on a team of advisors each of whom has a longstanding relationship with Triple-S and an extensive understanding
of Triple-S’s business, including Goldman Sachs, in its capacity as a financial advisor to Triple-S, and Pietrantoni Mendez &
Alvarez LLC (“PMA”) and Davis Polk & Wardwell LLP (“Davis Polk”), each in their capacities as a legal advisor
to Triple-S.
During the course of the reviews
by the board of directors and management of Triple-S described in the first paragraph of this section of this proxy statement, at various
meetings of the Triple-S board of directors, the board of directors and management of Triple-S reviewed and discussed, among other things,
the implications of transferring or terminating the Blue Cross and Blue Shield Association (“BCBSA”) licenses in a potential
sale of Triple-S to either a BCBSA member or a non-BCBSA member, respectively. As a result of this study, the board of directors and management
of Triple-S determined that terminating the BCBSA licenses in connection with the sale of Triple-S to a non-BCBSA member would have material
implications for the value such a buyer would be prepared to pay. Upon termination of Triple-S’s license agreements, the BCBSA would
impose a re-establishment fee upon Triple-S, which would allow the BCBSA to entitle another managed care company to use the Blue Cross
and Blue Shield (“BCBS”) name and marks in the service areas Triple-S currently serves. In addition, the BCBSA would transfer
a portion of the re-establishment fee paid by Triple-S to another BCBSA member to directly compete with Triple-S. The BCBSA re-establishment
fee is currently $98.33 per licensed enrollee. If the re-establishment fee were applied to Triple-S’s total BCBS enrollees as of
December 31, 2020, Triple-S estimated that it would be assessed approximately $96.0 million by the BCBSA. Triple-S also determined that
the BCBS name and mark are valuable identifiers of Triple-S’s products and services in the marketplace.
On June 14, 2016, following
discussion with the Triple-S board of directors, Roberto García-Rodríguez, the president and chief executive officer of
Triple-S, Joseph A. Frick, a director of Triple-S, and an executive of Company A, a leading US national healthcare benefits company, held
a meeting to informally explore Company A’s interest in acquiring Triple-S. In the ensuing year, Company A and Triple-S held additional
conversations, but the results of this initial outreach were inconclusive.
In January 2019, following
discussion with the Triple-S board of directors, Mr. García-Rodríguez reached out again to an executive of Company A to
see if Company A had any interest in a business combination with Triple-S, following which Triple-S provided certain preliminary information
to Company A to assist it with its evaluation of Triple-S.
On February 15, 2019, Triple-S
and Company A entered into a mutual confidentiality agreement regarding information to be disclosed in connection with a possible transaction.
The mutual confidentiality agreement with Company A contained a 12-month standstill provision that expired on February 15, 2020.
As a result of this initiative,
on April 23, 2019, Company A sent Triple-S a non-binding indication of interest to acquire Triple-S with a purchase price in the range
of 50-65% over the Triple-S closing share price on April 22, 2019, which equated to a range of $32.70 to $35.97 per share.
On April 26, 2019, the Triple-S
board of directors held a meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs, PMA and
Davis Polk, to discuss a potential transaction with Company A. At the meeting, the Triple-S board of directors authorized Triple-S management
to explore a potential transaction with Company A.
Over the next several months,
Triple-S continued to have discussions with Company A. During this time, the Triple-S board of directors continued to meet with Triple-S
management and its legal and financial advisors to discuss the ongoing negotiations with Company A and consider other strategic alternatives,
including the merits and impediments associated with engaging with other potentially interested parties in a sale of Triple-S.
On August 19, 2019, Company
A sent Triple-S a revised non-binding indication of interest to acquire Triple-S with a proposal of an all-cash offer to acquire all of
Triple-S’s outstanding common stock at a price of $30.00 per share.
Between August 2019 and October
2019, members of Triple-S’s management team and its legal and financial advisors met or had telephone conversations with members
of Company A’s management team and its legal and financial advisors to negotiate the terms of a potential transaction and to conduct
due diligence. During this time, Triple-S’s stock price experienced a material decline. As a result of this downward pressure on
Triple-S’s stock price and the resulting increased implied premium of Company A’s proposal relative to Triple-S’s stock
price, Company A informed Triple-S that Company A would be unable to proceed with a transaction with Triple-S.
On February 2, 2021, Anthem,
Inc. (“Anthem”) announced its entry into an agreement to acquire MMM Holdings, LLC (“MMM”), a healthcare benefits
provider in Puerto Rico and direct competitor of Triple-S, from InnovaCare Health, L.P.
On February 11, 2021, Mr.
García-Rodríguez reached out to an executive of Company B, a leading US national health care benefits company, as part of
a broader initiative by Triple-S to evaluate strategic alternatives for Triple-S in light of new market dynamics, including the entrance
of a new national competitor to the Puerto Rico market after the acquisition of MMM by Anthem.
On February 16, 2021, the
Triple-S board of directors held a meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs.
During the meeting, Mr. García-Rodríguez and other members of Triple-S management, with the assistance of representatives
of Goldman Sachs, presented the board of directors with various plans and alternatives regarding the implementation of Triple-S’s
long-term strategy, including (i) maintaining the status quo by focusing on the successful execution of the strategy, (ii) advancing the
strategy by pursuing partnerships with a financial sponsor or strategic partner, and (iii) pursuing a change of ownership of Triple-S
whereby Triple-S’s stockholders would sell their shares for cash and/or stock of the potential acquirer. The Triple-S board of directors
and members of Triple-S management also discussed Anthem’s recently announced transaction to acquire MMM and the impact this acquisition
would have on the Puerto Rico market and Triple-S. Following these discussions, the Triple-S board of directors determined to (i) continue
the strategic alternatives discussion at the regular meeting of the Triple-S board of directors in April 2021, and (ii) authorize Triple-S
management to hold informal discussions with third parties in order to explore strategic alternatives for Triple-S to accelerate its strategy.
Beginning on February 18,
2021, Carlos L. Rodriguez Ramos, the chief legal counsel of Triple-S, had informal discussions with Charles Joseph, the chief legal officer
of Parent, to discuss industry dynamics in light of Anthem’s recently announced transaction to acquire MMM. After a follow up discussion
with
business people from both companies
on the same topic, Parent expressed an interest in exploring business opportunities with Triple-S.
On February 19, 2021, Mr.
García-Rodríguez reached out to an executive of Company B to see if Company B was interested in exploring a strategic partnership
with Triple-S.
During this period and as
a result of Mr. García-Rodríguez’s February 19, 2021 outreach to the Company B executive, members of the management
teams of Triple-S and Company B held meetings to discuss the potential benefits of working closer together, including through a strategic
partnership, joint venture or other opportunity. Also discussed was a possible business combination involving Company B and Triple-S.
On February 24, 2021, Triple-S
and Company B entered into a mutual confidentiality agreement regarding information to be disclosed in connection with a possible strategic
relationship. The mutual confidentiality agreement with Company B does not contain a standstill provision.
On various dates between March
1, 2021 and April 1, 2021, members of the management team of Triple-S had discussions with their counterparts at Parent to discuss business
dynamics in Florida and Puerto Rico and potential benefits of working closer together on various complementary business initiatives, including
through a possible business combination.
On April 1, 2021, Francisco
Martorell Basanta, vice president of corporate development of Triple-S, and Chuck Divita, executive vice president, commercial markets
of Parent, met to discuss overall strategic perspectives, areas of organizational focus and developments in the health care industry.
After this discussion, Mr. Martorell Basanta and Mr. Divita agreed to schedule a call between Mr. García-Rodríguez and Patrick
J. Geraghty, the president and chief executive officer of Parent, to discuss their interest in a possible strategic relationship between
the companies.
On April 6, 2021, Mr. García-Rodríguez
and Mr. Geraghty held a telephonic meeting to discuss whether Parent was interested in pursuing a strategic partnership, joint venture
or potential business combination with Triple-S. During the call, Mr. Geraghty indicated that Parent was interested in a possible acquisition
of Triple-S.
On April 7, 2021, Triple-S
and Parent entered into a mutual confidentiality agreement regarding information to be disclosed in connection with a potential transaction.
On April 8, 2021, representatives
from the commercial and Medicare business areas of Triple-S and Parent held a meeting to explore opportunities to work together, with
a particular focus on Parent’s interest in serving the Florida Hispanic markets in the commercial and Medicare business areas.
On April 14, 2021, members
of management of Triple-S and Parent held a meeting to discuss their respective businesses and strategies.
On April 29, 2021, the Triple-S
board of directors held a meeting, which was attended by members of Triple-S management. During the meeting, Triple-S management provided
an update to the board of directors on the recent meetings and conversations held with Parent and Company B. Following these discussions,
the Triple-S board of directors authorized Triple-S management to continue to explore a strategic relationship with Company B and a potential
business combination with Parent.
On May 7, 2021, a subset of
the Triple-S board of directors and members of the executive committee of the board of directors of Parent held a meeting to discuss the
strategic and cultural affinity of the two companies. Following the meeting, the parties discussed potential next steps and information
that would be needed by both parties to progress forward and agreed to continue with a preliminary 30-day due diligence exercise.
On May 11, 2021, Mr. García-Rodríguez
had a meeting with an executive of Company B in the course of which he advised the Company B executive that an unidentified party was
interested in an acquisition of Triple-S.
On May 17, 2021, members of
management of Triple-S presented via video conference a management presentation to members of management of Parent. The management presentation
included Triple-S’s non-public financial forecasts.
On May 28, 2021, Mr. García-Rodríguez
had a telephone conversation with the Company B executive to discuss whether Company B was still considering a possible business combination
with Triple S. The Company B executive advised Mr. García-Rodríguez that, while Company B wanted to continue exploring strategic
opportunities with Triple-S, Company B was not interested in pursuing an acquisition of Triple-S.
On June 11, 2021, Parent provided
a non-binding indication of interest to acquire Triple-S with a proposal of an all-cash offer to acquire all of Triple-S’s outstanding
common stock at a price of $30.50 per share. The non-binding indication of interest provided that Parent would expect to secure appropriate
employment agreements or offer letters with certain key members of the Triple-S leadership team in connection with a transaction.
On June 11, 2021, following
receipt of Parent’s initial proposal, the Triple-S board of directors held a telephonic meeting, which was attended by members of
Triple-S management and representatives of Goldman Sachs. During the meeting, the Triple-S board of directors, Triple-S management and
Goldman Sachs reviewed and discussed Parent’s acquisition proposal. Following discussion, the Triple-S board of directors authorized
Triple-S management to commence negotiations on the terms and conditions of a potential transaction between the parties, but communicate
to Parent that Parent’s proposed purchase price of $30.50 per share would need to be increased meaningfully.
In the evening of June 11,
2021, following the Triple-S board of directors meeting, Mr. García-Rodríguez held a telephonic meeting with Mr. Geraghty
to discuss Parent’s proposal. During the call, Mr. García-Rodríguez indicated that, although the Triple-S board saw
significant value in the relationship that would result from a potential transaction between the parties, Parent’s proposal of $30.50
per share was far off from a range that the Triple-S board of directors would be willing to entertain and that any valuation of Triple-S
should recognize the strength of Triple-S’s balance sheet and book value.
On June 14, 2021, MHH Healthcare,
LLC, an Oklahoma-based health maintenance organization, announced its entry into an agreement to acquire Medical Card System, Inc. (“MCS”),
a Puerto Rico-based healthcare services organization and direct competitor of Triple-S.
On June 18, 2021, the Triple-S
board of directors held a meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs. During the
meeting, Goldman Sachs, with the assistance of Triple-S management, reviewed Triple-S’s management projections, preliminary financial
analyses with respect to Triple-S and led a discussion on the potential value of Triple-S in anticipation of further negotiations with
Parent. The Triple-S board of directors and members of Triple-S management also discussed MHH Healthcare, LLC’s recently announced
transaction to acquire MCS and how this acquisition could potentially strengthen MCS from a financial point of view. Following these discussions,
the Triple-S board of directors authorized Triple-S management to continue to explore a potential business combination with Parent.
On June 21, 2021 and June
22, 2021, members of the management teams of Triple-S and Parent held meetings in Puerto Rico to discuss, among other things, Triple-S’s
business, strategy and value drivers, the economic and market conditions in Puerto Rico and Triple-S’s financial forecasts.
On June 23, 2021 and June
24, 2021, members of the management teams of Triple-S and Company B held meetings to discuss various potential strategic partnership opportunities.
During the month of June 2021,
Mr. García-Rodríguez and Mr. Geraghty held several telephonic meetings to discuss Parent’s offer price for Triple-S.
On June 29, 2021, the Triple-S
board of directors held a meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs. During the
meeting, Triple-S management reviewed and discussed with the Triple-S board of directors the status of price discussions with Parent as
well as the partnership proposal with Company B, including the value implications, potential synergies and future growth potential of
such partnership proposal. Following discussion, the Triple-S board of directors authorized Triple-S management to continue to explore
both opportunities.
Also on June 29, 2021,
following a discussion with and authorization from the Triple-S board of directors, Mr. García-Rodríguez held a
telephonic meeting with Mr. Geraghty in which he advised Mr. Geraghty that the Triple-S board would be willing to consider a
transaction at an offer price in the range of $36-$38 per share. Following that initial conversation, Mr. Geraghty called Mr.
García-Rodriguez and informed him that the Parent board of directors’ expectation was to price the transaction at a
range of $34-$36 per share, given the board’s concerns with a transaction of $38 per share given its premium to
Triple-S’s market price (which closed at $22.70 per share on June
28, 2021). After discussion, Mr. García-Rodríguez and Mr. Geraghty agreed to propose to their respective boards to proceed
with full due diligence on the basis of a price of $36 per share, with Parent being willing to evaluate a higher price of up to $38 per
share if meaningful and compelling incremental value could be shown during due diligence.
On June 30, 2021, Mr. Garcia-Rodriguez
informed the Triple-S board that Parent would proceed with full due diligence on the basis of a price of $36 per share with the potential
for a higher price of up to $38 per share if meaningful and compelling incremental value could be shown during due diligence.
On July 6, 2021, the Triple-S
board of directors held a special meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs,
Davis Polk and PMA. At the meeting, Triple-S management, with the assistance of Goldman Sachs, led a discussion regarding the potential
business combination with Parent and the various strategic alternatives available to Triple-S (other than a transaction with Parent).
Triple-S management and representatives of Goldman Sachs reviewed with the Triple-S board of directors a wide range of potential strategic
and private equity buyers for Triple-S and discussed the likelihood of each such party’s interest in Triple-S and ability to pay
a higher price than Parent’s proposal. Representatives of Davis Polk and PMA then led a discussion regarding the legal and regulatory
considerations in connection with a potential business combination with Parent and the directors’ fiduciary duties in connection
with a proposed transaction. The Triple-S board or directors then considered the financial consequences if a non-BCBSA member were to
acquire Triple-S. The board also noted that Company A was no longer a potential bidder and that Company B had stated clearly that it was
not interested in an acquisition of Triple-S. In light of these factors, the Triple-S board of directors determined that it was unlikely
that any third party would be willing to meet the range implied in Parent’s proposal. Following further discussion, the Triple-S
board of directors determined that it was in the best interests of Triple-S to authorize Triple-S management to engage in additional due
diligence and hold formal negotiations with Parent regarding the proposed transaction.
Between July 2021 and August
2021, members of management of Triple-S and Parent met for due diligence meetings, during which their respective advisors were present.
During this period, the two parties held numerous telephonic due diligence sessions attended by employees from each company, and their
respective advisors, including Goldman and J.P. Morgan Securities LLC, financial advisor to Parent, covering a variety of financial, legal
and operational matters. During this timeframe, Triple-S also made available to Parent and its advisors an electronic data room containing
certain of its non-public financial, legal and other information. In addition, Triple-S and Parent entered into a “clean team”
addendum on July 26, 2021, setting forth customary “clean team” procedures to facilitate the sharing of limited non-public,
confidential and proprietary information regarding Triple-S’s business.
On July 16, 2021, Cravath,
Swaine & Moore LLP, legal counsel to Parent (“Cravath”), delivered an initial draft merger agreement for the proposed
transaction to Davis Polk. In their review of the initial draft of the merger agreement, Triple-S management and its legal advisors identified,
among other things, the following key issues with the draft merger agreement: (i) the number of Triple-S regulatory approvals and requested
contractual consents required as conditions to the closing of the transaction, (ii) the closing requirements that there be (A) no pending
or threatened proceeding brought by a governmental entity to prevent the merger or other transactions or impose a burdensome condition
and (B) no existing burdensome condition; (iii) the fact that, under the definition of burdensome condition, Parent was not required to
agree to any remedies if necessary to obtain regulatory approvals or third party consents for the transaction, (iv) a 15-month outside
date, with a 3-month extension at either party’s election if all conditions have been satisfied other than required regulatory approvals,
(v) a “force the vote” provision, (vi) a break-up fee payable by Triple-S to Parent equal to 3.75% of the transaction enterprise
value of Triple-S, (vii) a requirement for Triple-S to reimburse Parent’s expenses (up to 1.0% of the transaction enterprise value
of Triple-S) if the merger agreement was terminated for failure to obtain stockholder approval for the transaction and (viii) extensive
representations and restrictions on the conduct of the business between signing and closing. Triple-S management and its legal advisors
also noted that the draft merger agreement did not provide for management retention arrangements (as contemplated in Parent’s June
11, 2021 proposal letter) or include a “go-shop” provision, which would allow the Triple-S board of directors to actively
solicit competing bids for Triple-S.
On July 30, 2021, the Triple-S
board of directors held a special meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs,
Davis Polk and PMA. At the meeting, Triple-S management, with the assistance of Goldman Sachs, led a discussion regarding the due diligence
process conducted by Parent. Mr. Rodriguez Ramos and representatives of Davis Polk and PMA then updated the Triple-S board of directors
on the issues that had been identified in the initial draft of the merger agreement.
Also on July 30, 2021, Mr.
García-Rodríguez held a telephonic meeting with Mr. Geraghty to discuss the initial draft of the merger agreement. During
the call Mr. García-Rodríguez communicated Triple-S’s concern with Parent’s proposed merger agreement terms
and committed to communicating Triple-S’s position early the following week ahead of a meeting of the Parent board of directors
scheduled for that week.
On August 3, 2021, Davis Polk
delivered a revised draft of the merger agreement to Cravath. The revised draft of the merger agreement, among other things: (i) limited
the number of Triple-S regulatory approvals and contractual consents required as conditions to the closing of the transaction, (ii) eliminated
Parent’s ability not to close if there is any pending or threatened governmental or regulatory claim or investigation relating to
the transaction, (iii) proposed to limit burdensome conditions to the extent that they would not collectively have a material adverse
effect on the combined company, (iv) proposed that a reverse termination fee (in an amount to be determined) be paid by Parent if the
transaction fails due to any failure of the regulatory, BCBSA or contractual consent conditions, (v) eliminated the “force the vote”
provision, (vi) proposed a 60-day “go-shop” period, (vii) proposed a two-tier break-up fee of 1% of the transaction equity
value of Triple-S for transactions emerging during a “go-shop” period of 60 days from signing, and 2% of the transaction equity
value of Triple-S thereafter, (viii) eliminated the requirement for Triple-S to reimburse Parent’s expenses if the merger agreement
was terminated for failure to obtain Triple-S stockholder approval of the transaction, (ix) limited the scope of the Triple-S representations,
and (x) revised the interim operating covenants to provide operational flexibility for Triple-S during the period between signing and
closing.
On August 9, 2021, members
of management of each of Triple-S and Parent held a telephonic meeting to discuss Triple-S’s perspective on additional potential
drivers of value beyond the initial Triple-S baseline projections reflected in Triple-S’s financial forecasts. Following the call,
Triple-S provided Parent with a presentation that described Triple-S’s potential sources of incremental value. Representatives of
Parent indicated that these potential value drivers were considered and reflected in Parent’s indicative offer range.
Also on August 9, 2021, Cravath
delivered a revised draft of the merger agreement to Davis Polk that, in general, reverted the merger agreement to Parent’s initial
draft of the merger agreement. The revised draft of the merger agreement, among other things: (i) added back Parent’s ability not
to close if there is any pending or threatened governmental or regulatory claim or investigation relating to the transaction, (ii) rejected
the proposal to limit burdensome conditions (but added a requirement for Parent to agree to remedies that would be de minimis to the Company
and its subsidiaries, taken as a whole), (iii) rejected the proposed reverse termination fee, (iv) rejected the proposed 60-day “go-shop”
period, (v) rejected the proposed two-tier break-up fee and (vi) reiterated most of the Triple-S representations and interim operating
covenants to Parent’s initial draft. However, Parent’s revised draft (a) accepted Triple-S’s deletion of the “force
the vote” provision and elimination of the Parent’s expense reimbursement provision, (b) reduced the break-up fee from 3.75%
of the transaction enterprise value of Triple-S to 3.5% of the transaction enterprise value of Triple-S and (c) reduced the outside date
to 9 months, with a 3 month extension.
On August 11, 2021, the Triple-S
compensation and talent development committee (the “Triple-S compensation committee”) of the Triple-S board of directors held
a telephonic meeting with representatives of Pay Governance LLC, the Triple-S compensation committee’s independent compensation
consultant, to discuss, among other things, retention and severance in connection with a potential transaction with Parent.
On August 13, 2021, Triple-S,
Parent and their legal advisors held a call to discuss the merger agreement. In advance of the call, Davis Polk circulated to the parties
a call agenda of discussion topics, which included, among other topics: (i) the definition of burdensome condition, (ii) the condition
that there be no pending or threatened proceedings, (iii) a reverse termination fee, (iv) the interim operating covenants, (v) the approach
to representations and the associated scheduling burdens, (vi) the calculation of the termination fee, (vii) the two-tier break-up fee
/ go-shop and (viii) the need for a separate discussion of the employee matters issues.
On August 14, 2021 and August
15, 2021, Triple-S, Parent and their legal advisors held telephonic meetings to work through other open issues in the merger agreement
relating to the representations and warranties of Triple-S, the interim operating covenants and certain employee matters.
On August 17, 2021, Mr. García-Rodríguez
held a telephonic meeting with Mr. Geraghty. During the call, Mr. Geraghty proposed a reduction in the termination fee payable to Parent
to 3% of the transaction enterprise value of Triple-S, with a $2 million expense reimbursement fee payable to Triple-S in lieu of a reverse
termination fee if the transaction fails due to any failure of the regulatory, BCBSA or contractual consent conditions. On a call later
that day, Mr. García-Rodríguez proposed that the termination fee
payable to Parent be 3% of the
transaction equity value of Triple-S and that Triple-S receive a reciprocal reverse termination fee of 3% of the transaction equity value
of Triple-S. Following discussion, Mr. García-Rodríguez and Mr. Geraghty agreed to reciprocal 2% termination fees based
on the transaction equity value of Triple-S.
Later on August 17, 2021,
Cravath delivered a revised draft of the merger agreement to Davis Polk. That evening, representatives of Triple-S, Parent, PMA, Davis
Polk and Cravath held a telephonic meeting to discuss certain open commercial issues in the merger agreement as presented in the August
9 and August 17 drafts. After the meeting, and at the request of Triple-S, Davis Polk reached out to Cravath to set up a call to discuss
the open legal issues in the merger agreement that had not been discussed at the meeting.
On August 18, 2021, Cravath
delivered a revised draft of the merger agreement to Davis Polk which purported to settle all open legal points in the agreement.
Also on August 18, 2021, the
Triple-S board of directors held a telephonic special meeting, which was attended by members of Triple-S management and representatives
of Goldman Sachs, PMA and Davis Polk. During the meeting, Mr. García-Rodríguez updated the Triple-S board of directors on
the status of negotiations with Parent and Triple-S’s advisors then discussed with the Triple-S board of directors the remaining
open issues in the merger agreement.
From August 18, 2021 through
August 23, 2021, representatives of Triple-S, Parent, Davis Polk, PMA and Cravath held several telephonic discussions and continued to
exchange drafts of the merger agreement and finalized the remaining terms of the merger agreement and related documents.
On August 19, 2021, Mr. García-Rodríguez
called Mr. Geraghty to discuss Parent’s upcoming board meeting and to seek assurances from Mr. Geraghty that he would bring the
information that Triple-S had provided on incremental value to the Parent board of directors’ attention during their valuation assessment
discussion. Later that day, the Parent board of directors held a meeting to discuss the proposed transaction. Following the meeting, Mr.
Geraghty called Mr. García-Rodríguez to extend a final offer to acquire Triple-S for $36 per share. Mr. García-Rodríguez
then promptly communicated this final offer to the Triple-S board of directors.
On August 21, 2021, the Triple-S
compensation committee held a telephonic meeting, which was attended by representatives of Davis Polk and Pay Governance LLC, at which
Davis Polk reviewed with the Triple-S compensation committee the key employee matters in the merger agreement, including a discussion
on the retention and severance plan proposals and Mr. García-Rodríguez’s employment agreement.
On August 21, 2021, the Triple-S
board of directors held a meeting, which was attended by members of Triple-S management and representatives of Goldman Sachs, PMA and
Davis Polk. At the meeting, Goldman Sachs reviewed with the Triple-S board of directors Parent’s offer, the strategic and financial
rationale for the proposed transaction, and its preliminary standalone valuation analysis of Triple-S. Representatives of Davis Polk then
provided the Triple-S board of directors with a summary of the key terms of the merger agreement. Following these discussions, the Triple-S
board of directors directed Triple-S management to continue to negotiate the terms of the potential transaction, and determined to hold
another meeting to continue its discussion of the proposed transaction on August 23, 2021.
On August 23, 2021, the Triple-S
board of directors held a telephonic special meeting, which was attended by members of Triple-S management and representatives of Goldman
Sachs, PMA and Davis Polk. The Triple-S board of directors, Triple-S management and Triple-S’s advisors discussed the key terms
of the merger agreement and the changes to such terms since the Triple-S board of directors’ August 21, 2021 meeting. Also at this
meeting, Goldman Sachs reviewed with the Triple-S board of directors its financial analyses of the merger consideration, and separately
rendered an oral opinion, confirmed by delivery of a written opinion dated August 23, 2021, to the Triple-S board of directors to the
effect that, as of that date and based on and subject to various assumptions, limitations and qualifications described in the opinion,
the consideration to be paid to holders (other than Parent and its affiliates) of the outstanding shares of Triple-S’s common stock
in the merger was fair, from a financial point of view, to such holders. After discussion, including consideration of the factors described
in the section “Triple-S’s Reasons for the Merger; Recommendation of the Triple-S Board of Directors” beginning on page
[●] of this proxy statement, the Triple-S board of directors unanimously (i) determined that the merger agreement and the transactions
contemplated by the merger agreement, including the merger, are fair to and in the best interests of Triple-S and its stockholders, (ii)
approved, adopted and declared advisable the merger agreement and the
transactions contemplated by
the merger agreement (including the merger), (iii) directed that the merger agreement (including the merger) be submitted to a vote at
a meeting of Triple-S’s stockholders and (iv) recommended the approval and adoption of the merger agreement (including the merger)
by Triple-S’s stockholders.
That evening, following the
Triple-S board of directors meeting, Parent and Triple-S entered into the merger agreement, and the next morning issued a joint press
release announcing the transaction.
Triple-S’s Reasons for the Merger
The Triple-S board of directors
recommends that the Triple-S stockholders vote “FOR” the merger proposal.
In reaching its recommendation,
the Triple-S board of directors consulted with and received the advice of its independent financial and legal advisors, discussed certain
matters with Triple-S’s management team and considered a number of factors that the Triple-S board of directors believed supported
its recommendation, including the following factors (which are not necessarily presented in order of relative importance):
|
·
|
the consideration of $36.00 per share to be received by Triple-S common stockholders in the merger represents
a significant premium over the market prices at which Triple-S common stock had previously traded prior to the announcement and execution
of the merger agreement, including the fact that the consideration of $36.00 per share represented a premium of approximately 49% over
the closing price of Triple-S common stock of $24.19 per share on August 23, 2021, the last trading day prior to the announcement of the
execution of the merger agreement;
|
|
·
|
the proposed merger consideration is all cash, so the transaction provides stockholders of Triple-S certainty
of value for their shares of Triple-S common stock, especially when viewed against Triple-S’s competitive positioning and prospects
as a standalone company, taking into account the continued costs, risks and uncertainties associated with continuing to operate independently
as a public company, including:
|
|
o
|
the competitive nature of the industry in which Triple-S operates, including the increasing competition faced
by Triple-S from significantly larger competitors with significantly greater resources than Triple-S, including increased local competition
from MMM and MCS who have strengthened their respective financial positions as a result of their recent acquisitions by larger industry
participants;
|
|
o
|
Triple-S’s relatively small size as compared to its national competitors, which places Triple-S at
a significant scale disadvantage;
|
|
o
|
the risk that continued negotiations with Company B would not lead to a strategic partnership, joint venture
or other opportunity;
|
|
o
|
the implications of the changing demographic and economic conditions in Puerto Rico;
|
|
o
|
the fact that Triple-S’s businesses are subject to extensive government regulation, oversight and frequent
audit and its ability to continue to maintain compliance with all such rules, regulations and laws, including the costs thereof;
|
|
o
|
the current, historical and projected financial condition and results of operations of Triple-S on a stand-alone
basis, including the risks to achieving its projections and long-term results amid greater industry consolidation and the current and
prospective regulatory environment; and
|
|
o
|
the potential consolidation of insurance companies and other industry participants, recent and prospective
legislative and regulatory changes, and the potential impact of those industry risks and changes on Triple-S’s stand-alone operations
and financial prospects.
|
|
·
|
during a more than two (2)-year period leading up to the execution of the merger agreement, the Triple-S
board of directors explored and evaluated various potential strategic alternatives, including a sale of Triple-S, strategic partnerships
and remaining as a standalone public company, none of which alternatives was deemed more favorable to Triple-S’s stockholders than
the merger;
|
|
·
|
neither Company A nor Company B was in interested in an acquisition of Triple-S;
|
|
·
|
Triple-S’s legal and financial advisors assisted Triple-S throughout the process and negotiations and
updated the Triple-S board of directors directly and regularly, which provided the Triple-S board of directors with additional perspectives
on the negotiations in addition to those of Triple-S’s management;
|
|
·
|
the opinion, dated August 23, 2021, of Goldman Sachs to the Triple-S board of directors that, as of
that date and based upon and subject to the factors and assumptions set forth in the opinion, the $36.00 in cash per share of
Triple-S common stock to be paid to the holders (other than Parent and its affiliates) of the outstanding shares of Triple-S common
stock pursuant to the merger agreement was fair from a financial point of view to such holders (see “The Merger (Proposal
1)—Opinion of Triple-S’s Financial Advisor”);
|
|
·
|
terminating the BCBSA licenses in connection with the sale of Triple-S to a non-BCBSA member would have material
implications for the value such a buyer would be prepared to pay for an acquisition of Triple-S; and
|
|
·
|
the BCBSA would impose a re-establishment fee of $98.33 per licensed enrollee upon Triple-S (or $96.0 million
if the re-establishment fee were applied to Triple-S’s total BCBS enrollees as of December 31, 2020), which would allow the BCBSA
to entitle another managed care company to use the BCBS name and marks in the service areas Triple-S currently serves and transfer a portion
of such fee to a BCBSA member to directly compete with Triple-S.
|
The Triple-S board of directors,
in consultation with its legal, financial and other advisors, also considered the following specific aspects of the merger agreement (which
are not necessarily presented in order of relative importance):
|
·
|
the Triple-S board of directors’ belief that the terms of the merger agreement, including Triple-S’s
representations, warranties and covenants and the conditions to each party’s obligations, are reasonable in the circumstances and
that the risks associated with those terms are acceptable having regard to the alternatives;
|
|
·
|
if the merger is not completed on or before the outside date under the circumstances described in this proxy
statement, Parent will be required to pay Triple-S a reverse termination fee of $17,985,000;
|
|
·
|
Triple-S’s ability, under certain circumstances, and subject to certain conditions, to furnish information
to and to conduct negotiations with a third party that makes an unsolicited bona fide written proposal for a business combination or acquisition
of Triple-S that constitutes or would reasonably be expected to lead to a superior proposal;
|
|
·
|
Triple-S’s board of directors’ ability, under certain circumstances, subject to certain conditions,
to (i) change its recommendation of the transaction in response to a proposal to acquire Triple-S that is superior to the merger or an
intervening event with respect to Triple-S or (ii) terminate the merger agreement to enter into a definitive agreement providing for an
acquisition of Triple-S that is superior to the merger, in each case, if Triple-S’s board of directors determines that failure to
take such action would violate the directors’ fiduciary duties under applicable law;
|
|
·
|
the outside date under the merger agreement of May 23, 2022 allows for sufficient time to complete the merger;
and
|
|
·
|
Triple-S may seek specific performance of Parent’s obligations under the merger agreement.
|
In the course of its deliberations,
the Triple-S board of directors also considered a variety of risks, uncertainties and other potentially negative factors, including the
following (which are not necessarily presented in order of relative importance):
|
·
|
the risk that the merger may not be completed despite the parties’ efforts or that completion of the
merger may be delayed, even if the requisite approvals are obtained from Triple-S stockholders, including the possibility that conditions
to the parties’ obligations to complete the merger may not be satisfied, and the potential resulting disruptions to Triple-S’s
businesses;
|
|
·
|
the risk that the merger might not receive the necessary regulatory approvals, contractual consents and clearances
to complete the merger or that governmental authorities could attempt to condition their approval of the merger on the companies’
compliance with certain burdensome conditions;
|
|
·
|
the risk that Triple-S may become obligated to, under specified circumstances described in this proxy statement,
pay a termination fee of $17,985,000 in the event the merger agreement is terminated;
|
|
·
|
the amount of time it could take to complete the regulatory approval process and the merger, the potential
for diversion of management focus for an extended period and employee attrition, the potential inability to hire new employees and the
possible adverse effects of the announcement and pendency of the transaction on customers, providers, vendors, regulators and other business
relationships, and the communities in which Triple-S operates, in particular if the merger is not completed;
|
|
·
|
the fact that the merger consideration of $36.00 in cash per share is a discount to the book value and
tangible book value of Triple-S;
|
|
·
|
the fact that certain of Triple-S’s directors and executive officers may receive certain benefits that
are different from, and in addition to, those of Triple-S’s other stockholders (see “Interests of Triple-S’s Directors
and Executive Officers in the Merger”); and
|
|
·
|
the risks of the type and nature described in the sections entitled “Caution Regarding Forward-Looking
Statements”.
|
The Triple-S board of directors
considered all of these factors as a whole and expressly adopted the analyses and opinions of its financial advisors in reaching its determination
that the merger agreement and the transactions contemplated by the merger agreement, including the merger, are fair to and in the best
interests of Triple-S and its stockholders. The foregoing discussion of the information and factors considered by the Triple-S board of
directors is not exhaustive. In view of the wide variety of factors considered by the Triple-S board of directors in connection with its
evaluation of the merger and the complexity of these matters, the Triple-S board of directors did not consider it practical to, nor did
it attempt to, quantify, rank or otherwise assign relative weights to the specific factors that it considered in reaching its decision.
In considering the factors described above and any other factors, the individual members of the Triple-S board of directors may have viewed
factors differently or given different weight or merit to different factors.
In considering the recommendation
of the Triple-S board of directors that the Triple-S stockholders vote to approve the adoption of the merger agreement and the transactions
contemplated thereby, Triple-S stockholders should be aware that the officers, directors and employees of Triple-S may have certain interests,
including financial interests, in the merger that may be different from, or in addition to, the interests of Triple-S stockholders generally.
See “Interests of Triple-S’ Directors, Officers and Employees in the Merger.”
The foregoing discussion of
the information and factors considered by the Triple-S board of directors is forward-looking in nature. This information should be read
in light of the factors described in the section entitled “Caution Regarding Forward-Looking Statements.”
Recommendation of the Triple-S Board of Directors
After careful consideration,
the Triple-S board of directors, by a unanimous vote, approved the merger agreement and the transactions contemplated by the merger agreement,
including the merger.
The Triple-S board of directors
recommends that the Triple-S stockholders vote “FOR” the proposal to approve and adopt the merger agreement.
Opinion of Triple-S’s Financial Advisor
Goldman Sachs rendered its
opinion to the Triple-S board that, as of August 23, 2021 and based upon and subject to the factors and assumptions set forth therein,
the $36.00 in cash per share of Triple-S common stock to be paid to the holders (other than Parent and its affiliates) of the outstanding
shares of Triple-S common stock pursuant to the merger agreement was fair from a financial point of view to such holders.
The full text of the written
opinion of Goldman Sachs, dated August 23, 2021, which sets forth assumptions made, procedures followed, matters considered and limitations
on the review undertaken in connection with the opinion, is attached as Annex B. Goldman Sachs provided financial advisory services and
its opinion for the information and assistance of the Triple-S board in connection with its consideration of the merger. The Goldman Sachs
opinion is not a recommendation as to how any holder of shares of Triple-S common stock should vote with respect to the merger or any
other matter.
In connection with rendering
the opinion described above and performing its related financial analyses, Goldman Sachs reviewed, among other things:
|
·
|
annual reports to stockholders and Annual Reports on Form 10-K of Triple-S for the five fiscal years ended
December 31, 2020;
|
|
·
|
certain interim reports to stockholders and Quarterly Reports on Form 10-Q of Triple-S;
|
|
·
|
certain other communications from Triple-S to its stockholders;
|
|
·
|
certain publicly available research analyst reports for Triple-S;
|
|
·
|
certain internal financial analyses and forecasts for Triple-S prepared by management of Triple-S, as
approved for Goldman Sachs’ use by Triple-S, referred to in this section as the “Forecasts” which are summarized in
the section entitled “The Merger (Proposal 1)—Projected Financial Information” beginning on page [●]); and
|
|
·
|
certain analyses prepared by the management of Triple-S related to the expected impact of certain tax
attributes of Triple-S, as approved for Goldman Sachs’ use by Triple-S, referred to in this section as the “Tax Attributes”
which are summarized in the section entitled “The Merger (Proposal 1)—Projected Financial Information” beginning on
page [●]).
|
Goldman Sachs also held discussions
with members of the senior management of Triple-S regarding their assessment of the past and current business operations, financial condition
and future prospects of Triple-S; reviewed the reported price and trading activity for Triple-S common stock; compared certain financial
and stock market information for Triple-S with similar information for certain other companies the securities of which are publicly traded;
reviewed the financial terms of certain recent business combinations in the managed care industry and in other industries; and performed
such other studies and analyses, and considered such other factors, as it deemed appropriate.
For purposes of rendering
its opinion, Goldman Sachs, with Triple-S’s consent, relied upon and assumed the accuracy and completeness of all of the financial,
legal, regulatory, tax, accounting and other information provided to, discussed with or reviewed by it, without assuming any responsibility
for independent verification thereof. In that regard, Goldman Sachs assumed with Triple-S’s consent that the Forecasts and the Tax
Attributes were reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of Triple-S.
Goldman Sachs did not make an independent evaluation or appraisal of the assets and liabilities (including any contingent, derivative
or other off-balance-sheet assets and liabilities) of Triple-S or any of its subsidiaries and Goldman Sachs was not furnished with
any such evaluation or appraisal.
Goldman Sachs is not an actuary and Goldman Sachs’ services did not include any actuarial determination or evaluation by Goldman
Sachs or any attempt to evaluate actuarial assumptions and Goldman Sachs relied on Triple-S’s actuaries with respect to reserve
adequacy. In that regard, Goldman Sachs made no analysis of, and expressed no opinion as to, the adequacy of the loss and loss adjustments
expenses reserves of Triple-S. Goldman Sachs assumed that all governmental, regulatory or other consents and approvals necessary for the
consummation of the merger will be obtained without any adverse effect on the expected benefits of the merger in any way meaningful to
its analysis. Goldman Sachs has also assumed that the merger will be consummated on the terms set forth in the merger agreement, without
the waiver or modification of any term or condition the effect of which would be in any way meaningful to its analysis.
Goldman Sachs’ opinion
does not address the underlying business decision of Triple-S to engage in the merger or the relative merits of the merger as compared
to any strategic alternatives that may be available to Triple-S; nor does it address any legal, regulatory, tax or accounting matters.
Goldman Sachs’ opinion addresses only the fairness from a financial point of view, as of the date of the opinion, of the $36.00
in cash per share of Triple-S common stock to be paid to the holders (other than Parent and its affiliates) of the outstanding shares
of Triple-S common stock pursuant to the merger agreement. Goldman Sachs’ opinion does not express any view on, and does not address,
any other term or aspect of the agreement or the merger or any term or aspect of any other agreement or instrument contemplated by the
agreement or entered into or amended in connection with the merger, including, the fairness of the merger to, or any consideration received
in connection therewith by, the holders of any other class of securities, creditors, or other constituencies of Triple-S; nor as to the
fairness of the amount or nature of any compensation to be paid or payable to any of the officers, directors or employees of Triple-S,
or class of such persons in connection with the merger, whether relative to the $36.00 in cash per share of Triple-S common stock to be
paid to the holders (other than Parent and its affiliates) of the outstanding shares of Triple-S common stock pursuant to the merger agreement
or otherwise. Goldman Sachs does not express any opinion as to the prices at which the shares of Triple-S common stock will trade at any
time, as to the potential effects of volatility in the credit, financial and stock markets on Triple-S, Parent or the merger, or as to
the impact of the merger on the solvency or viability of Triple-S or Parent, or the ability of Triple-S or Parent to pay their respective
obligations when they come due. Goldman Sachs’ opinion was approved by a fairness committee of Goldman Sachs. In addition, Goldman
Sachs’ opinion was necessarily based on economic, monetary, market and other conditions, as in effect on, and the information made
available to it as of, the date of the opinion and Goldman Sachs assumed no responsibility for updating, revising or reaffirming its opinion
based on circumstances, developments or events occurring after the date of its opinion.
The following is a summary
of the material financial analyses delivered by Goldman Sachs to the Triple-S board in connection with rendering the opinion described
above. The following summary, however, does not purport to be a complete description of the financial analyses performed by Goldman Sachs,
nor does the order of analyses described represent relative importance or weight given to those analyses by Goldman Sachs. Some of the
summaries of the financial analyses include information presented in tabular format. The tables must be read together with the full text
of each summary and are alone not a complete description of Goldman Sachs’ financial analyses. Except as otherwise noted, the following
quantitative information, to the extent that it is based on market data, is based on market data as it existed on or before August 20,
2021, the last trading day prior to the date that Goldman Sachs rendered its opinion to the Triple-S board, and is not necessarily indicative
of current market conditions.
Historical Stock Trading
Analysis
Goldman Sachs reviewed the
historical trading prices for Triple-S common stock for the one-year period ending August 20, 2021. In addition, Goldman Sachs analyzed
the consideration to be paid to holders of the outstanding shares of Triple-S common stock (the “Shares”) pursuant to the
merger agreement in relation to:
|
·
|
$22.49, the closing price of the Shares on August 20, 2021 (which we refer to as the “Current Share
Price”);
|
|
·
|
$28.75, the highest closing trading price per share for the 52-week period ended August 20, 2021 (which
we refer to as the “52-Week High Price”);
|
|
·
|
$17.54, the lowest closing trading price per share for the 52-week period ended August 20, 2021 (which
we refer to as the “52-Week Low Price”);
|
|
·
|
$23.58, the volume weighted average price (which we refer to as the “VWAP”) of the Shares
over the 30-trading-day period ended August 20, 2021 (which we refer to as the “30-Day VWAP”);
|
|
·
|
$23.70, the VWAP of the Shares over the 60-trading-day period ended August 20, 2021 (which we refer to
as the “60-Day VWAP”); and
|
|
·
|
$24.20, the VWAP of the Shares over the 90-trading-day period ended August 20, 2021 (which we refer to
as the “90-Day VWAP”).
|
This analysis indicated that
the price per Share to be paid to Triple-S stockholders pursuant to the merger agreement represented:
|
Implied Premium Represented by $36.00 in Per Share merger Consideration
|
Reference Price Per Share:
|
|
Current Share Price of $22.49
|
60%
|
52-Week High Price of $28.75
|
25.2%
|
52-Week Low Price of $17.54
|
105.2%
|
30-Day VWAP of $23.58
|
52.7%
|
60-Day VWAP of $23.70
|
51.9%
|
90-Day VWAP of $24.20
|
48.8%
|
Illustrative Discounted
Cash Flow Analysis
Using the Forecasts and the
Tax Attributes, Goldman Sachs performed an illustrative discounted cash flow analysis on Triple-S to derive a range of illustrative present
values per Share.
Using discount rates ranging
from 9.00% to 11.50%, reflecting estimates of Triple-S’s weighted average cost of capital, Goldman Sachs derived a range of illustrative
enterprise values for Triple-S, by discounting to present value as of June 30, 2021, (i) the estimates of the unlevered free cash flow
to be generated by Triple-S for the period from July 1, 2021 to December 31, 2025, as derived from the Forecasts, and (ii) a range of
illustrative terminal values for Triple-S, which were calculated by applying exit terminal year EBITDA multiples ranging from 3.0x to
4.0x to a terminal year estimate of the EBITDA of Triple-S, as derived from the Forecasts (which analysis implied perpetuity growth rates
ranging from (4.2)% to 1.0%). Goldman Sachs derived such discount rates by application of the capital asset pricing model, which requires
certain company-specific inputs, including Triple-S’s target capital structure weightings, the cost of long-term debt, after-tax
yield on permanent excess cash, if any, future applicable marginal cash tax rate and a beta for Triple-S, as well as certain financial
metrics for the United States financial markets generally. The range of exit terminal year EBITDA multiples was estimated by Goldman Sachs
utilizing its professional judgment and experience, taking into account Forecasts.
Goldman Sachs derived ranges
of illustrative enterprise values for Triple-S by adding (i) the ranges of present values it derived as described in the above paragraph
and (ii) the estimated net present value of Triple-S’s future tax benefits, as calculated by Goldman Sachs using the Tax Attributes
and illustrative discount rates ranging from 9.00% to 11.50%, reflecting estimates of Triple-S’s weighted average cost of capital,
and subtracting the present value of the estimated outstanding claims and liabilities related to Hurricane Maria between 2025 and 2027
of approximately $17 million, as provided by Triple-S management. Goldman Sachs then subtracted Triple-S’s net debt and pension
liability of approximately $77 million and $132 million, respectively, as of June 30, 2021, in each case, as provided by Triple-S management,
to derive a range of illustrative equity values for Triple-S. Goldman Sachs then divided the range of illustrative equity values it derived
by the implied total number of fully diluted Shares outstanding as of August 19, 2021, calculated using information provided by management
and the treasury stock method, to derive a range of illustrative present values per Share of $33.60 to $45.28.
Illustrative Present Value
of Future Share Price Analysis
Goldman Sachs performed
an illustrative analysis of the implied present value of an illustrative future value per share of Triple-S common stock, which is designed
to provide an indication of the present value of a theoretical future value of a company’s equity as a function of such company’s
financial multiples. For this analysis, Goldman Sachs used the Forecasts and the Tax Attributes for each of the fiscal years 2022 to
2024. Goldman Sachs first calculated the implied values per share of common stock as of December 31 for each of the fiscal years 2021
to 2023, by applying next twelve month price to forward earnings per share multiples of 6.00x to 8.50x to estimates of Triple-S’s
adjusted earnings per share of common stock for each of the fiscal years 2022 to 2024, as reflected in the Forecasts and adjusted to
reflect the Tax Attributes in each of the respective years. These illustrative multiples were derived by Goldman Sachs utilizing its
professional judgment and experience, taking into account historical average P/E multiples for Triple-S common stock during the period
from August 18, 2018 to August 6, 2020. Goldman Sachs then discounted the implied values per share as of December 31, 2021, December
31, 2022 and December 31, 2023, respectively, back to June 30, 2021 using an illustrative discount rate of 10.20%, reflecting an estimate
of Triple-S’s cost of equity. Goldman Sachs derived such discount rate by application of the capital asset pricing model, which
requires certain company-specific inputs, including a beta for Triple-S, as well as certain financial metrics for the United States financial
markets generally. This analysis resulted in a range of implied present values of $23.46 to $45.00 per share.
Selected Precedent Transaction
Analysis
Goldman Sachs analyzed certain
publicly available information relating to certain acquisition transactions announced since 2002 involving target companies in the managed
care industry.
For each of the selected transactions,
Goldman Sachs calculated and compared the enterprise value as a multiple of the target company’s EBITDA as reported or calculated
using publicly available financial information for the relevant twelve month period (“EV / LTM EBITDA multiples”) of the applicable
transaction. While none of the target companies in the selected transactions are directly comparable to Triple-S and none of the selected
transactions are directly comparable to the merger, the target companies in the selected transactions are companies with certain operations
that, for the purposes of analysis, may be considered similar to certain operations of Triple-S.
The following table presents
the results of this analysis:
Announced
|
Acquiror
|
Target
|
EV / LTM EBITDA Multiple
|
October 27, 2003
|
Anthem Inc.
|
WellPoint Health Networks Inc.
|
10.7x
|
October 27, 2003
|
UnitedHealth Group Inc.
|
Mid-Atlantic Medical Services Inc.
|
10.6x
|
April 26, 2004
|
UnitedHealth Group Inc.
|
Oxford Health Plans, Inc.
|
7.8x
|
October 14, 2004
|
Coventry Health Care, Inc.
|
First Health Group Corp
|
6.6x
|
March 12, 2007
|
UnitedHealth Group Inc.
|
Sierra Health Services Inc.
|
11.1x
|
October 24, 2011
|
Cigna Corporation
|
HealthSpring, Inc.
|
7.8x
|
August 20, 2012
|
Aetna Inc.
|
Coventry Health Care, Inc.
|
7.4x
|
July 2, 2015
|
Centene Corporation
|
Health Net, Inc.
|
11.2x
|
July 16, 2019
|
Summit Partners LP
|
InnovaCare Inc.
|
6.4x
|
February 2, 2021
|
Anthem, Inc.
|
MMM Holdings, LLC
|
NA
|
Based on the results of
the foregoing calculations of EV / LTM EBITDA multiples and Goldman Sachs’ professional judgment and experience, Goldman Sachs
applied a reference range of enterprise value to LTM EBITDA multiples of 6.5x to 11.0x to Triple-S’s LTM EBITDA of approximately
$156 million as of June 30, 2021 as provided by the management of Triple-S to derive a range of implied enterprise values for Triple-S.
Goldman Sachs subtracted from this range of implied enterprise values Triple-S’s net debt and pension liability of approximately
$77 million and $132 million, respectively, as of June 30, 2021, in each case as provided by Triple-S management, and divided the result
by the implied total number of fully diluted Shares outstanding as of August 19, 2021, based on the derived range of illustrative equity
values, and calculated using information provided by management and the treasury stock method, to derive a range of implied values per
Share of $32.31 to $60.48.
Premia Paid Analysis
Goldman Sachs reviewed and
analyzed, using publicly available information, the acquisition premia for all-cash acquisition transactions announced during the time
period from January 1, 2010 through August 20, 2021 involving targets that were public healthcare companies based in the United States
and acquirers that
were based in the United States
in which the disclosed enterprise values for the transactions were between $100 million and $1.5 billion. This analysis excluded transactions
in the biotech and pharmaceutical sectors. For the entire period, using publicly available information, Goldman Sachs calculated the median,
25th percentile and 75th percentile of the premia paid in the 52 acquisitions announced during such period relative to the target’s
last closing stock price prior to announcement of the transaction. This analysis indicated (i) a median premium of approximately 41%,
(ii) a 25th percentile premium of approximately 23.5% and (iii) a 75th percentile premium of approximately 57.9% across the period. Using
this analysis and its professional judgment and experience, Goldman Sachs applied a reference range of illustrative premia of 23.5% to
57.9% to the undisturbed closing price per share on August 20, 2021 of $22.49 and calculated a range of implied values per Share of $27.78
to $35.51.
General
The preparation of a fairness
opinion is a complex process and is not necessarily susceptible to partial analysis or summary description. Selecting portions of the
analyses or of the summary set forth above, without considering the analyses as a whole, could create an incomplete view of the processes
underlying Goldman Sachs’ opinion. In arriving at its fairness determination, Goldman Sachs considered the results of all of its
analyses and did not attribute any particular weight to any factor or analysis considered by it. Rather, Goldman Sachs made its determination
as to fairness on the basis of its experience and professional judgment after considering the results of all of its analyses. No company
or transaction used in the above analyses as a comparison is directly comparable to Triple-S or Parent or the merger.
Goldman Sachs prepared these
analyses for purposes of Goldman Sachs’ providing its opinion to the Triple-S board as to the fairness from a financial point of
view, as of the date of the opinion, to the holders (other than Parent and its affiliates) of the outstanding shares of Triple-S common
stock of the $36.00 in cash per share of Triple-S common stock to be paid to such holders pursuant to the merger agreement. These analyses
do not purport to be appraisals nor do they necessarily reflect the prices at which businesses or securities actually may be sold. Analyses
based upon forecasts of future results are not necessarily indicative of actual future results, which may be significantly more or less
favorable than suggested by these analyses. Because these analyses are inherently subject to uncertainty, being based upon numerous factors
or events beyond the control of the parties or their respective advisors, none of Triple-S, Parent, Goldman Sachs or any other person
assumes responsibility if future results are materially different from those forecast.
The consideration of $36.00
in cash per share of Triple-S common stock was determined through arm’s-length negotiations between Triple-S and Parent and was
approved by the Triple-S board. Goldman Sachs provided advice to Triple-S during these negotiations. Goldman Sachs did not, however, recommend
any specific amount of consideration to Triple-S or the Triple-S board or that any specific amount of consideration constituted the only
appropriate consideration for the merger.
As described above, Goldman
Sachs’ opinion to the Triple-S board was one of many factors taken into consideration by the Triple-S board in making its determination
to approve the merger agreement. The foregoing summary does not purport to be a complete description of the analyses performed by Goldman
Sachs in connection with the fairness opinion and is qualified in its entirety by reference to the written opinion of Goldman Sachs attached
as Annex B.
Goldman Sachs and its
affiliates are engaged in advisory, underwriting and financing, principal investing, sales and trading, research, investment
management and other financial and non-financial activities and services for various persons and entities. Goldman Sachs and its
affiliates and employees, and funds or other entities they manage or in which they invest or have other economic interests or with
which they co-invest, may at any time purchase, sell, hold or vote long or short positions and investments in securities,
derivatives, loans, commodities, currencies, credit default swaps and other financial instruments of Triple-S, Parent, any of their
respective affiliates and third parties or any currency or commodity that may be involved in the merger. Goldman Sachs acted as
financial advisor to Triple-S in connection with, and has participated in certain of the negotiations leading to, the merger.
Goldman Sachs has provided certain financial advisory and/or underwriting services to Triple-S and/or its affiliates from time to
time. During the two year period ended August 23, 2021, the Investment Banking Division of Goldman Sachs has not been engaged by
Triple-S or its affiliates to provide financial advisory or underwriting services for which Goldman Sachs has recognized
compensation. Other than as described below, during the two year period ended August 23, 2021, the Investment Banking Division of
Goldman Sachs has not been engaged by Parent or its affiliates to provide financial advisory or underwriting services for which
Goldman Sachs has recognized compensation. In connection with a strategic investment in July 2021, Goldman Sachs acted as financial
advisor to Availity, LLC, a health information network in which an affiliate of Parent is a minority investor. Goldman Sachs may
also in the future provide financial
advisory and/or underwriting
services to Triple-S, Parent and their respective affiliates for which Goldman Sachs’ Investment Banking Division may receive compensation.
The Triple-S board selected
Goldman Sachs as its financial advisor because it is an internationally recognized investment banking firm that has substantial experience
in transactions similar to the merger. Pursuant to an engagement letter, dated June 10, 2019, as amended, Triple-S engaged Goldman Sachs
to act as its financial advisor in connection with the merger. The engagement letter between Triple-S and Goldman Sachs provides for a
transaction fee of approximately $11.6 million, all of which is contingent upon consummation of the merger. In addition, Triple-S has
agreed to reimburse Goldman Sachs for certain of its expenses, including attorneys’ fees and disbursements, and to indemnify Goldman
Sachs and related persons against various liabilities, including certain liabilities under the federal securities laws.
Projected Financial Information
Triple-S does not as a matter
of course make public projections as to future performance or earnings and is especially wary of making projections for extended earnings
periods given, among other reasons, the unpredictability and uncertainty of the underlying assumptions and estimates. However, Triple-S
management prepared certain financial projections in connection with the Triple-S board of directors’ review of potential strategic
alternatives to reflect Triple-S’s management’s then-current expectations of Triple-S’s financial performance for fiscal
years 2021 through 2024 and certain financial metrics for 2025 (the “Projections”). The Projections were also provided to
Triple-S’s financial advisor, Goldman Sachs, in connection with Triple-S’s strategic review process, and based on Triple-S
management’s assessments as to the relative likelihood of achieving the financial results reflected in the Projections and such
management’s judgment that the Projections best reflected the anticipated future financial performance of Triple-S, the Triple-S
board of directors directed Goldman Sachs to utilize and rely upon the Projections for purposes of its financial analyses and opinion
as described under “The Merger (Proposal 1)—Opinion of Triple-S’s Financial Advisor.”
We have included a summary
of the Projections to give stockholders access to certain nonpublic information prepared by Triple-S management for the Triple-S board
of directors in connection with Triple-S’s strategic review process, including the merger, and provided to Triple-S’s financial
advisor in connection with such process. The inclusion of the Projections should not be regarded as an indication that Triple-S, Parent,
Merger Sub or any of their respective affiliates, officers, directors, advisors or other representatives or any other recipient of this
information considered, or now considers, it to be an assurance of the achievement of actual future results.
The Projections and the underlying
assumptions upon which the Projections were based are subjective in many respects. The Projections reflect numerous estimates and assumptions
with respect to industry performance, general business, economic, market and financial conditions, changes to the business, financial
condition or results of operations of Triple-S and other matters, including those described under “Caution Regarding Forward-Looking
Statements,” many of which are difficult to predict, subject to significant economic and competitive uncertainties, are beyond Triple-S’s
control and may cause the Projections or the underlying assumptions not to be realized. Since the Projections cover multiple years, such
information by its nature becomes less predictive with each successive year. The Projections do not take into account any circumstances
or events occurring after the date they were prepared. As a result, there can be no assurance that the Projections will be realized or
that actual results will not be significantly higher or lower than projected. The Projections were not prepared with a view toward public
disclosure or toward complying with GAAP, the published guidelines of the SEC regarding projections or the guidelines established by the
American Institute of Certified Public Accountants for preparation and presentation of prospective financial information. For example,
certain metrics included in the Projections are non-GAAP measures, and the Projections do not include footnote disclosures as may be required
by GAAP. Neither Triple-S’s independent auditors, nor any other independent accountants, have compiled, examined, or performed any
procedures with respect to the prospective financial information contained herein, nor have they expressed any opinion or any other form
of assurance on such information or its achievability, and assume no responsibility for, and disclaim any association with, the prospective
financial information.
Adjusted EBITDA, adjusted
EBITDA margin, adjusted net income, adjusted net income margin and adjusted net earnings per share (as defined below) contained in the
management projections set forth below are non-GAAP financial measures, which are financial performance measures that are not calculated
in accordance with GAAP. These non-GAAP financial measures should not be viewed as substitutes for GAAP financial measures and may be
different from similarly titled non-GAAP financial measures used by other companies, which limits their usefulness as a comparative measure.
Furthermore, there are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required
to be included in a GAAP presentation. The items excluded from net income to common stockholders to arrive at
these non-GAAP financial measures
are significant components for understanding and assessing the Company’s financial performance and liquidity. Accordingly, these
non-GAAP financial measures should be considered together with, and not as an alternative to, financial measures prepared in accordance
with GAAP.
Financial measures used by
a financial advisor are excluded from the definition of non-GAAP financial measures under SEC rules and, therefore, are not subject to
SEC rules regarding disclosures of non-GAAP financial measures, which would otherwise require a reconciliation of a non-GAAP financial
measure to a GAAP financial measure. A reconciliation of the non-GAAP financial measures was not relied upon by Goldman Sachs for purposes
of its financial analysis as described above in “The Merger—Opinion of Triple-S’s Financial Advisor” or the Board
in connection with its consideration of the Merger. Accordingly, we have not provided a reconciliation of the non-GAAP financial measure
included in the management projections to the most directly comparable GAAP financial measure.
Readers of this proxy statement
are cautioned not to place undue reliance on the specific portions of the Projections below. No one has made or makes any representation
to any stockholder regarding the information included in the Projections.
For the foregoing reasons,
as well as the basis and assumptions on which the Projections were compiled, the inclusion of specific portions of the Projections in
this proxy statement should not be regarded as necessarily predictive of actual future events, and they should not be relied on as such.
Except as required by applicable securities laws, Triple-S does not intend to update or otherwise revise the Projections or the specific
portions presented to reflect circumstances existing after the date on which they were prepared or to reflect the occurrence of future
events, even in the event that any or all of the assumptions are shown not to be appropriate.
In preparing the Projections,
Triple-S management made the following material assumptions:
|
·
|
operating revenue growth of 9.3% in fiscal year 2021, and between 6.5% to 7% in each of fiscal years 2022
through 2024;
|
|
·
|
consolidated loss ratio of 83.5% in fiscal years 2021 and 2022 to 82.8% in fiscal year 2023 and 82.7%
in fiscal year 2024;
|
|
·
|
the consolidated loss ratio considers a medical loss ratio changing from 86.4% in fiscal year 2021 to
86.5% in fiscal year 2022, 85.7% in fiscal year 2023 and to 85.6% in fiscal year 2024;
|
|
·
|
operating expense ratio changing from 15.9% in fiscal year 2021 to 15.2% in fiscal year 2022 to 14.5%
in fiscal year 2023 and to 13.9% in fiscal year 2024;
|
|
·
|
change in net working capital of $9 million in fiscal year 2021, $24 million in fiscal year 2022 and $36
million in fiscal year 2024;
|
|
·
|
capital expenditures of $25 million in fiscal year 2021, $20 million in fiscal year 2022 and $15 million
in fiscal years 2023 and 2024;
|
|
·
|
a steady state level of retained cash relative to premium revenue;
|
|
·
|
depreciation and amortization of $15 million in fiscal year 2021 and $16 million in each fiscal year 2022
through 2024;
|
|
·
|
net debt of $77.5 million;
|
|
·
|
24.98 million fully diluted shares outstanding;
|
|
·
|
a terminal multiple of 3.5x; and
|
|
·
|
a weighted average cost of capital of 10.25%.
|
Summary of Projections
(dollars in millions)
|
|
|
2021E
|
|
|
|
2022E
|
|
|
|
2023E
|
|
|
|
2024E
|
|
Total Revenue
|
|
|
$4,033
|
|
|
|
$4,303
|
|
|
|
$4,605
|
|
|
|
$4,911
|
|
Adjusted EBITDA1
|
|
|
$158
|
|
|
|
$190
|
|
|
|
$262
|
|
|
|
$304
|
|
Adjusted EBITDA Margin
|
|
|
3.9
|
%
|
|
|
4.4
|
%
|
|
|
5.7
|
%
|
|
|
6.2
|
%
|
Adjusted Net Income
|
|
|
$71
|
|
|
|
$91
|
|
|
|
$137
|
|
|
|
$163
|
|
Adjusted Net Income Margin
|
|
|
1.8
|
%
|
|
|
2.1
|
%
|
|
|
3.0
|
%
|
|
|
3.3
|
%
|
Adjusted Earnings Per Share
|
|
|
$2.84
|
|
|
|
$3.65
|
|
|
|
$5.48
|
|
|
|
$6.54
|
|
Unlevered Free Cash Flow
|
|
|
$86
|
|
|
|
$122
|
|
|
|
$160
|
|
|
|
$173
|
|
1 Adjusted
EBITDA includes stock-based compensation expense of $10 million in 2021E through 2024E.
For purposes of Goldman
Sachs’ illustrative discounted cash flow analysis, 2025E Total Revenue is $5.06 billion, Adjusted EBITDA is $314 million, which
includes stock-based compensation expense of $10 million, and Unlevered Free Cash Flow is $141 million.
Interests of Triple-S’s Directors and
Executive Officers in the Merger
In considering the recommendation
of the Triple-S board of directors to approve the merger proposal, you should be aware that some of Triple-S’s directors and executive
officers have interests in the merger that are different from, or in addition to, those of Triple-S’s stockholders generally. The
Triple-S board of directors was aware of these interests and considered them, among other matters, in evaluating the merger agreement,
in reaching its decision to approve the merger agreement and in recommending to our stockholders that the merger agreement be approved.
These interests are described and quantified below.
Certain Assumptions
Except as otherwise specifically
noted, for purposes of quantifying the potential payments and benefits described in this section, the following assumptions were used:
|
·
|
The effective time is February 28, 2022, which is the assumed date of the closing of the merger solely
for purposes of the disclosure in this section; and
|
|
·
|
The employment of each executive officer of Triple-S will have been terminated by Triple-S without “cause”
or due to the executive officer’s resignation for “good reason” (as such terms are defined in the relevant plans and
agreements), in either case immediately following the assumed effective time of February 28, 2022, which is assumed solely for purposes
of the disclosure in this section.
|
As the amounts provided below
are estimates based on multiple assumptions that may or may not actually occur or be accurate as of the date referenced, the actual amounts,
if any, that may be paid or become payable may materially differ from the amounts set forth below.
Treatment and Quantification
of Equity-Based Awards
Triple-S’s executive
officers currently hold vested and unvested Triple-S restricted share awards, Triple-S restricted stock units and Triple-S performance
share units. Triple-S’s directors currently hold vested and unvested Triple-S restricted stock units.
The merger agreement provides
that, prior to the effective time of the merger, the Triple-S board of directors shall adopt resolutions to effect the following treatment
of the equity awards of Triple-S:
Each award of (or with respect
to) Triple-S common stock that is outstanding as of the date of the merger agreement and immediately prior to the effective time of the
merger shall, at the effective time of the merger:
|
·
|
With respect to restricted share awards outstanding under the Triple-S Management Corporation 2017 Incentive
Plan, as amended (the “Triple-S equity plan”), whether or not vested, be converted into the right to receive an amount in
cash equal to the product of the merger consideration and the number of shares of Triple-S common stock underlying the Triple-S restricted
share award;
|
|
·
|
With respect to restricted stock units outstanding under the Triple-S equity plan, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock
|
underlying the Triple-S
restricted stock unit award as of immediately prior to the effective time of the merger; and
|
·
|
With respect to performance share units outstanding under the Triple-S equity plan, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S performance share unit award as of immediately prior to the effective time
of the merger, determined based on achievement of target performance.
|
Each award of (or with respect
to) Triple-S common stock with respect to any restricted stock unit or performance share unit that is granted following the date of the
merger agreement and outstanding immediately prior to the effective time of the merger, at the effective time of the merger, shall be
canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number of
shares of Triple-S common stock underlying such award as of immediately prior to the effective time (determined, in the case of performance
share units, based on target performance), payable on the date the award would have otherwise vested pursuant to its vesting schedule,
subject to the holder’s continuing employment as of each such vesting date or as otherwise provided in the applicable award agreements.
See the section entitled “Golden
Parachute Compensation” beginning on page [●] of this proxy statement for an estimate of the amounts that would become payable
to each Triple-S named executive officer in respect of his or her unvested Triple-S restricted share awards, Triple-S restricted stock
unit awards and Triple-S performance share unit awards. Based on the assumptions described above under “Interests of Triple-S’s
Directors and Executive Officers in the Merger —Certain Assumptions,” the estimated aggregate amounts that would become
payable to Triple-S’s seven (7) executive officers who are not named executive officers (Ivelisse M. Fernández-Cruz, Victor
Haddock, Pedro Aponte Gil De Lamadrid, José M. Del Amo Mojica, Carlos L. Rodriguez-Ramos, Juan R. Serrano and Ilia S. Rodriguez-Torres)
and the eight (8) members of Triple-S’s board of directors (David H. Chafey, Jr., Manuel Figueroa-Collazo, Cari M. Dominguez, Roberta
Herman, Gail B. Marcus, Stephen L. Ondra, Luis A. Clavell-Rodriguez and Roberto Santa Maria) in respect of their unvested Triple-S restricted
share awards, Triple-S restricted stock units and Triple-S performance share unit awards are $8,314,092 and $1,277,280, respectively.
Employment Agreements /
Severance Arrangements / Retention Arrangements
Employment Agreements
Triple-S does not maintain
employment agreements with any of its named executive officers except Roberto García-Rodríguez, its chief executive officer.
Triple-S intends to enter
into an employment agreement, as amended, with Mr. García-Rodríguez (the “CEO Employment Agreement”). The CEO
Employment Agreement will provide that the chief executive officer will be eligible to receive the following severance benefits upon a
termination of employment by Triple-S without Cause (as defined below), or a resignation by the executive officer for Good Reason (as
defined below), in either case, in connection with a change in control during the term of his contract:
|
·
|
an amount equal to two (2) times the sum of (i) the highest base salary of the chief executive
officer paid to him in any of the three (3) years prior to the date of the change in control, and (ii) the average of the short-term discretionary
bonus of the three (3) years prior to the date of the change in control; and
|
|
·
|
the continuation of long-term disability insurance, life insurance and health and medical benefits for
the chief executive officer and his dependents for twenty-four (24) months or until the chief executive officer obtains employment with
comparable benefits.
|
For purposes of
the CEO Employment Agreement:
“Cause” means
any of the following: (a) a material breach of the chief executive officer’s obligations and duties as specified in the CEO Employment
Agreement; (b) a conviction or allegation of nolo contendere of any felony or certain misdemeanors; (c) his insubordination; (d)
his material non-compliance of the CEO Employment Agreement or the rules, regulations, guidelines, policies or code of ethics of Triple-S;
(e) his improper or disorderly conduct; or (f) the existence of a conflict of interest not previously disclosed to Triple-S’s board
of directors.
“Good Reason”
means any of the following: (a) a change in the nature or scope of the chief executive officer’s duties or functions from those
performed on the date immediately preceding a change in control of Triple-S; (b) a reduction in the chief executive officer’s base
salary from that received on the date immediately preceding a change in control of Triple-S; (c) a reduction in the chief executive officer’s
ability to participate in the compensation plans in which he participated on the date immediately preceding a change in control of Triple-S,
as determined in comparison to the opportunities that Triple-S provides to executives with comparable duties or the opportunities of participation
that the chief executive officer had under such plans immediate preceding such change in control; (d) a change in the location of the
chief executive officer’s principal place of employment of more than twenty-five (25) miles from the place where he maintained his
work office on the date immediately preceding a change in control of Triple-S; or (e) the reasonable determination by Triple-S’s
board of directors to the effect that, because of a change in control of Triple-S and a change in the circumstances thereafter affecting
the employment position of the chief executive officer, he is unable to exercise the authority, powers, functions or duties assigned to
his position in Triple-S on the date immediately preceding the date of the change of control.
Severance Arrangements
In connection with the merger,
Triple-S intends to establish a severance program under which any executive officer (other than Triple-S’s chief executive officer)
whose employment is terminated (i) due to job elimination, corporate reorganization, reduction in force or similar reason and not for
Cause (as defined below) or (ii) by the executive for Good Reason (as defined below), in each case on or after the consummation of the
transaction and prior to the twenty-four (24) month anniversary of the consummation of the merger, subject to execution and non-revocation
of a general release of claims, receives severance (in all cases, reduced by any statutory severance to which the employee is entitled)
in an amount equal to the sum of two (2) times the executive officer’s base salary and one times his or her target short-term incentive
opportunity.
Retention Arrangements
In connection with the merger,
Triple-S intends to establish a cash retention program under which it will grant retention bonuses to each executive officer (other than
Triple-S’s chief executive officer, president of Triple-S Vida, Inc. and executive officers who are not named executive officers)
in an amount between a minimum of $200,000 and a maximum equal to the sum of two (2) times the executive officer’s base salary and
one times his or her target short-term incentive opportunity, subject to the executive officer’s continued employment through the
applicable payment date (unless an executive officer’s employment is terminated (i) due to job elimination, corporate reorganization,
reduction in force or similar reason and not for Cause (as defined below) or (ii) by the executive officer for Good Reason (as defined
below), subject to the executive officer’s execution and non-revocation of a general release of claims), in each case, payable 40%
and 60% on the twelve (12) month and the twenty-four (24) month anniversaries of the consummation of the merger, respectively. Triple-S’s
chief executive officer is not eligible for any retention bonus, and the president of Triple-S Vida, Inc. is eligible for a retention
bonus in the amount of $200,000, subject to the continued employment terms described above.
If an executive officer experiences
a termination of employment that triggers payments under both the severance arrangements and retention arrangements, then the sum of (a)
their payments under the severance arrangements, (b) their payments under the retention arrangements and (c) any statutory severance they
are entitled to will be capped at two (2) times the sum of their (A) base salary and (B) target short-term incentive opportunity.
For purposes of the severance
arrangements and retention arrangements:
“Cause” shall
mean the definition of “Cause” (or words of similar import) set forth in any individual agreement with the applicable executive
or, if there is no such agreement or such term is not defined therein, the executive’s: (a) misuse of trade secrets or other confidential
or proprietary information; (b) conviction of or plea of nolo contendere to fraud, embezzlement, a felony or equivalent crime, or any
other crime involving moral turpitude; (c) committing an act of fraud or embezzlement against Triple-S; (d) gross negligence or willful
misconduct in the performance of, or willful failure to perform, his or her duties; (e) failure to comply with Triple-S’s written
policies or rules, which failure causes, or could cause, material harm to Triple-S; or (f) “just cause” as provided under
Puerto Rico’s Wrongful Discharge Act (Law 80) (other than due to job elimination, corporate reorganization, reduction in force or
similar reason)’ provided that, if an executive is offered a different position by Parent or its applicable affiliate in connection
with the consummation of the merger, and such executive’s employment terminates due to such employee’s refusal to accept such
offer, such termination shall not constitute a termination for Cause.
“Good Reason”
shall mean, without the executive’s written consent: (a) a reduction in base salary or target incentive opportunity, (b) relocation
outside of Puerto Rico or (c) a material and significant reduction in duties or responsibilities; provided that, Good Reason shall not
be triggered solely as a result of Triple-S becoming a wholly owned subsidiary of Parent as a result of the consummation of the merger;
and provided further that, in order for an executive to claim Good Reason, (i) the executive must give written notice to Parent or its
applicable affiliate of Good Reason within thirty (30) days after becoming aware of the condition giving rise to Good Reason, (ii) Parent
or its applicable affiliate must not cure the condition giving rise to Good Reason within 30 days after receiving written notice of such
condition from the executive and (iii) the executive must resign within thirty (30) days following the end of the cure period.
See “Interests of Triple-S’s
Directors and Executive Officers in the Merger —Golden Parachute Compensation” beginning on page [●] of this
proxy statement for the estimated amounts that each of Triple-S’s named executive officers would receive either under an employment
agreement or in connection with the severance arrangements and retention arrangements, as applicable, upon a qualifying termination of
employment. Based on the assumptions described above under “Interests of Triple-S’s Directors and Executive Officers in the
Merger —Certain Assumptions,” the estimated aggregate amounts of the payments (excluding amounts payable in respect
of unvested Triple-S restricted share awards, unvested Triple-S restricted stock unit awards and Triple-S performance share unit awards,
which are discussed and quantified above under the section entitled “Treatment and Quantification of Triple-S Equity Awards”)
to be provided to Triple-S’s seven (7) executive officers who are not named executive officers under the severance arrangements
and retention arrangements upon a qualifying termination of employment are $5,973,470 and $4,792,850, respectively.
Golden Parachute Compensation
In accordance with Item 402(t)
of Regulation S-K under the Securities Act, the table below sets forth the compensation that is based on, or otherwise relates to, the
merger that will or may become payable to each named executive officer of Triple-S in connection with the merger. For additional details
regarding the terms of the payments and benefits described below, see the discussion under the heading “Interests of Triple-S Directors
and Executive Officers in the Merger” above, which is incorporated herein.
The amounts shown in the table
below are estimates based on multiple assumptions that may or may not actually occur or be accurate on the relevant date, including the
assumptions described above under “Interests of Triple-S’s Directors and Executive Officers in the Merger —Certain
Assumptions” and in the footnotes to the table below, and do not reflect certain compensation actions that may occur prior to completion
of the merger that are unrelated to the merger, including any ordinary course equity award grants that may be made after the assumed effective
date of February 28, 2021.
Triple-S’s stockholders
are being asked to approve, on a non-binding, advisory basis, the compensation that will or may be paid by Triple-S to these named executive
officers that is based on or otherwise relates to the merger (see the section entitled “Advisory Vote on Named Executive Officer
Merger-Related Compensation Arrangements (Proposal 2)” beginning on page [●] of this proxy statement). Because the vote to
approve such compensation is advisory only, it will not be binding on either Triple-S or Parent. Accordingly, if the merger is approved
by Triple-S’s stockholders and the merger is completed, the compensation will be payable regardless of the outcome of the advisory
vote to approve such compensation, subject only to the conditions applicable to the vote to approve the merger, which are described in
the footnotes to the table and above under the section entitled “The Merger (Proposal 1)—Interests of Triple-S’s Directors
and Executive Officers in the Merger” beginning on page [●] of this proxy statement.
|
Cash ($)(1)
|
Equity ($)(2)
|
Perquisites/ Benefits ($)(3)
|
Total ($)
|
Roberto García-Rodríguez, President and Chief Executive Officer
|
2,935,350
|
10,594,296
|
28,201
|
13,557,847
|
Juan J. Román-Jiménez, Executive Vice President and Chief Financial Officer
|
—
|
1,598,832
|
—
|
1,598,832
|
Madeline Hernández-Urquiza, Executive Vice President and Chief Operating Officer
|
—
|
4,433,076
|
—
|
4,433,076
|
José E. Novoa-Loyola, Chief Medical Officer of Triple-S Salud, Inc.
|
1,107,000
|
2,064,276
|
—
|
3,171,276
|
Arturo L. Carrión-Crespo, President of Triple-S Vida, Inc.
|
1,010,761
|
1,871,964
|
—
|
2,882,725
|
|
(1)
|
For the chief executive officer, the amounts included in this column represent a double-trigger severance arrangement equal to two (2) times the sum of (i) the highest base salary of the chief executive officer paid to him in any of the three (3) years prior to the date of the change in control and (ii) the average of the short-term discretionary bonus of the three (3) years prior to the date of the change in control, payable in lump sum on or before the thirtieth (30th) day following the date of termination.
For the other named executive officers, other than the chief executive officer, the amounts included in this column represent: (A) with respect to the cash severance program, an amount equal to the sum of (x) two (2) times the named executive officer’s base salary plus (y) one times his or her target short-term incentive opportunity, in the event of a qualifying termination of employment that occurs prior to the twenty-four (24) month anniversary of the consummation of the merger and (B) with respect to the cash retention program, an amount between a minimum of $200,000 and a maximum of the sum of (x) two (2) times the named executive officer’s base salary plus (y) one times his or her target short-term incentive opportunity, subject to the executive officer’s continued employment through each applicable payment date on the twelve (12) month and twenty-four (24) month anniversaries of the consummation of the merger, unless the named executive officer’s employment is terminated by means of a qualifying termination, in both cases, subject to the cap noted above within the section entitled “Employment Agreements / Severance Arrangements / Retention Arrangements.”
|
|
(2)
|
The following table provides additional information regarding the equity holdings of each named executive
officer that will be canceled and exchanged on a “single trigger” basis for the merger consideration in connection with the
consummation of the merger.
|
|
Value of
Triple-S Restricted Share Awards ($)
|
Value of
Triple-S Restricted Stock Units ($)
|
Value of
Triple-S Performance Share Units (at target) ($)
|
Total ($)
|
Named Executive Officers
|
|
|
|
|
Roberto García-Rodríguez, President and Chief Executive Officer
|
2,172,600
|
—
|
8,421,696
|
10,594,296
|
Juan J. Román-Jiménez, Executive Vice President and Chief Financial Officer
|
—
|
—
|
1,598,832
|
1,598,832
|
Madeline Hernández-Urquiza, Executive Vice President and Chief Operating Officer
|
875,376
|
—
|
3,557,700
|
4,433,076
|
José E. Novoa-Loyola, Chief Medical Officer of Triple-S Salud, Inc.
|
390,168
|
—
|
1,674,108
|
2,064,276
|
Arturo L. Carrión-Crespo, President of Triple-S Vida, Inc.
|
373,356
|
—
|
1,498,608
|
1,871,964
|
|
(3)
|
For the chief executive officer, the amounts included in this column include $9,258.96 for
membership fees to a private club and $18,942.18 for the amount attributable to a double-trigger arrangement representing the
continuation of long-term disability insurance, life insurance and health and medical benefits for the chief executive officer and
his dependents for twenty-four (24) months which would become applicable only upon a qualifying termination of employment that
occurs in connection with a change in control.
|
Directors’ and Officers’ Indemnification
and Insurance
For information regarding
indemnification of Triple-S’s directors and executive officers, see the section entitled “The Merger Agreement—Directors’
and Officers’ Indemnification and Insurance” beginning on page [●] of this proxy statement.
Regulatory Approvals Required for the Merger
The completion of the merger
is conditioned on, among other things, certain specified regulatory approvals having been obtained and remaining in full force and effect
(or, in the case of certain specified regulatory approvals that are statutory waiting periods, having expired or been terminated), including
the expiration or termination of any applicable waiting period under the HSR Act. In addition, prior to the effective time of the merger,
Triple-S and Parent are required to obtain regulatory approvals from the Office of the Commissioner of Insurance of Puerto Rico, the Office
of Industrial Tax Exemption of Puerto Rico, the Puerto Rico Health Insurance Administration, the BVI Financial Services Commission and
the Anguilla Financial Services Commission. Under the terms of the merger agreement, each of Triple-S and Parent have agreed to use their
respective reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper
or advisable under applicable law to consummate the transactions contemplated by the merger agreement as promptly as reasonably practicable,
including preparing and filing as promptly as practicable with any government authority or other third party all documentation to effect
all necessary filings and obtaining certain specified regulatory approvals, subject to certain limitations set forth in the merger agreement.
See the section entitled “The
Merger Agreement—Regulatory Approvals Required for the Merger” beginning on page [●] of this proxy statement for a more
detailed discussion of the parties’ obligations with respect to obtaining regulatory approvals in connection with the merger.
Accounting Treatment
The merger will be accounted
for as a “purchase transaction” for financial accounting purposes.
Material U.S. Federal Income Tax Consequences
of the Merger
The exchange of Triple-S common
stock for cash in the merger will be a taxable transaction for U.S. federal income tax purposes and may also be taxable under state and
local and other tax laws. In general, a “U.S. holder” (as defined in the section entitled “Material U.S. Federal Income
Tax Consequences of the Merger” beginning on page [●] of this proxy statement) whose shares of Triple-S common stock are converted
into the right to receive cash in the merger will recognize capital gain or loss for U.S. federal income tax purposes in an amount equal
to the difference, if any, between the amount of cash received with respect to such shares and the U.S. holder’s adjusted tax basis
in such shares. With respect to a stockholder that is a “non-U.S. holder” (as defined in the section entitled “Material
U.S. Federal Income Tax Consequences of the Merger” beginning on page [●] of this proxy statement), the exchange of shares
of Triple-S common stock for the merger consideration pursuant to the merger generally will not result in U.S. federal income tax to such
non-U.S. holder unless such non-U.S. holder has certain connections with the United States. Backup withholding may apply to the cash payment
made pursuant to the merger unless the stockholder or other payee provides a valid taxpayer identification number and complies with certain
certification procedures (generally, by providing a properly completed and executed U.S. Internal Revenue Service (“IRS”)
Form W-9 or IRS Form W-8 or applicable successor form).
You should read the section
entitled “Material U.S. Federal Income Tax Consequences of the Merger” beginning on page [●] of this proxy statement
and consult your tax advisors regarding the U.S. federal income tax consequences of the merger to you in your particular circumstances,
as well as tax consequences arising under the laws of any state, local or foreign taxing jurisdiction.
Material Puerto Rico Income Tax Consequences
of the Merger
The exchange of Triple-S common
stock for cash in the merger will be a taxable transaction for Puerto Rico income tax purposes. Accordingly, a stockholder that is a “P.R.
holder” (as defined in the section entitled “Material Puerto Rico Income Tax Consequences of the Merger” beginning on
page [●] of this proxy statement) will generally recognize taxable gain or loss in an amount equal to the difference, if any, between
(i) the merger consideration received by such P.R. holder in the merger and (ii) such P.R. holder’s adjusted tax basis in the shares
of Triple-S common stock exchanged therefor. With respect to a stockholder that is a “non-P.R. holder” (as defined in the
section entitled “Material Puerto Rico Income Tax Consequences of the Merger” beginning on page [●] of this proxy statement),
the exchange of shares of Triple-S common stock for the merger consideration pursuant to the merger generally will not result in Puerto
Rico income tax to such non-P.R. holder unless such non-P.R. holder has certain connections with Puerto Rico which can make the gain effectively
connected income to a Puerto Rico trade or business.
You should read the section
entitled “Material Puerto Rico Income Tax Consequences of the Merger” beginning on page [●] of this proxy statement
and consult your tax advisors regarding the Puerto Rico income tax consequences of the merger to you in your particular circumstances,
as well as tax consequences arising under the laws of any non-Puerto Rico jurisdiction.
Delisting and Deregistration of Triple-S
Common Stock
Upon completion of the merger,
the Triple-S common stock currently listed on the NYSE will cease to be listed on the NYSE and will subsequently be deregistered under
the Exchange Act.
Appraisal Rights
Under Puerto Rico law, any
record holder of Triple-S common stock at the close of business on the record date who does not vote in favor of the merger proposal,
and who exercises its appraisal rights and fully complies with all of the provisions of Article 10.13 of Puerto Rico law (but not otherwise),
will be entitled to demand and receive payment of the “fair value” as determined pursuant to Article 10.13 of Puerto Rico
law for all (but not less than all) of his or her shares of Triple-S common stock if the merger is completed. See the section entitled
“Appraisal Rights of Stockholders” beginning on page [●] of this proxy statement. The full text of Article 10.13 of
Puerto Rico law is attached to this proxy statement (in English and Spanish) as Annex C.
Litigation Related to the Merger
As of the date of this proxy
statement, there are no pending lawsuits challenging the merger. However, potential plaintiffs may file lawsuits challenging the merger.
The outcome of any future litigation is uncertain.
Such litigation, if not resolved,
could prevent or delay consummation of the merger and result in substantial costs to Triple-S, including any costs associated with the
indemnification of directors and officers. One of the conditions to the consummation of the merger is that no applicable law or order
issued by a court of competent jurisdiction or other legal restraint which is then in effect renders illegal or enjoins the consummation
of the merger whether on a preliminary or permanent basis. Therefore, if a plaintiff were successful in obtaining an injunction prohibiting
the consummation of the merger on the agreed-upon terms, then such injunction may prevent the merger from being consummated, or from being
consummated within the expected time frame.
THE
MERGER AGREEMENT
The following is a summary
of the material terms and conditions of the merger agreement. This summary does not purport to be complete and may not contain all of
the information about the merger agreement that is important to you. This summary is qualified in its entirety by reference to the complete
text of the Agreement and Plan of Merger, dated as of August 23, 2021, a copy of which is attached to this proxy statement as Annex A,
and which is incorporated by reference into this proxy statement. We encourage you to read the merger agreement carefully and in its entirety
because it is the legal document that governs the merger.
Explanatory Note Regarding the Merger Agreement
The following summary of
the Agreement and Plan of Merger, dated as of August 23, 2021, a copy of which is attached hereto as Annex A to this proxy statement,
is intended to provide information regarding the terms of the merger agreement and is not intended to modify or supplement any factual
disclosures about Triple-S in its public reports filed with the SEC. In particular, the merger agreement and the related summary are not
intended to be, and should not be relied upon as, disclosures regarding any facts and circumstances relating to Triple-S or any of its
subsidiaries or affiliates. The merger agreement contains representations and warranties by Triple-S, Parent and Merger Sub which were
made only for purposes of that agreement and as of specified dates. The representations, warranties and covenants in the merger agreement
were made solely for the benefit of the parties to the merger agreement; may be subject to limitations agreed upon by the contracting
parties, including being qualified by the disclosure letters to the merger agreement; were made for the purposes of allocating contractual
risk between the parties to the merger agreement instead of establishing these matters as facts; and may apply contractual standards of
materiality or material adverse effect that generally differ from those applicable to investors. In addition, information concerning the
subject matter of the representations, warranties and covenants may change after the date of the merger agreement, which subsequent information
may or may not be fully reflected in Triple-S’s public disclosures.
Additional information
about Triple-S may be found elsewhere in this proxy statement and Triple-S’s other public filings. See the section entitled “Where
You Can Find More Information,” beginning on page [●] of this proxy statement.
Structure of the Merger
At the effective time of the
merger, Merger Sub will be merged with and into Triple-S in accordance with Puerto Rico law and Delaware law. As a result of the merger,
the separate corporate existence of Merger Sub will cease and Triple-S will continue as the surviving corporation. At the effective time
of the merger, the articles of incorporation of Triple-S (the “Triple-S articles”), as in effect immediately prior to the
effective time, will be the articles of incorporation of the surviving corporation, until thereafter amended in accordance with applicable
law. The bylaws of Triple-S (the “Triple-S bylaws”), as in effect immediately prior to the effective time, will be the bylaws
of the surviving corporation, until thereafter amended in accordance with applicable law. From and after the effective time of the merger,
until successors are duly elected or appointed and qualified in accordance with applicable law, the directors of Merger Sub immediately
prior to the effective time of the merger will be the directors of the surviving corporation and the officers of Triple-S immediately
prior to the effective time of the merger will be the officers of the surviving corporation.
Closing and Effective Time of the Merger
Unless another time, date
or place is mutually agreed in writing by Triple-S and Parent, the closing of the merger will take place as soon as possible, but in any
event no later than three (3) business days after the date the closing conditions set forth in the merger agreement and described in the
section entitled “The Merger Agreement—Conditions to Completion of the Merger” beginning on page [●] of this proxy
statement (other than conditions that by their nature are to be satisfied at the closing, but subject to the satisfaction or, to the extent
permissible, waiver of those conditions) have been satisfied or, to the extent permissible, waived by the party or parties entitled to
the benefit of such conditions. The merger will become effective at such time as the certificate of merger is duly filed with the Secretary
of State of the Commonwealth of Puerto Rico or at such later time as Triple-S and Parent shall agree and specify in the certificate of
merger. As of the date of this proxy statement, we expect to complete the merger in the first half of 2022. However, completion of the
merger is subject to the satisfaction or waiver of the conditions to the completion of the merger, which are described below, and it is
possible that factors outside the control of Triple-S or Parent could delay the completion of the merger, or prevent it from being completed
at all. There may be a
substantial amount of time between
the special meeting and the completion of the merger. We expect to complete the merger promptly following the receipt of all required
approvals.
Effect of the Merger on Triple-S Common Stock
At the effective time of the
merger, each share of Triple-S common stock issued and outstanding immediately prior to the effective time of the merger (other than (i) shares
owned by Triple-S (as treasury stock), Parent or Merger Sub; (ii) shares owned by any stockholder who has properly demanded appraisal
rights in accordance with Puerto Rico law; and (iii) restricted share awards) will be converted into the right to receive $36.00
in cash, without interest and less any applicable withholding taxes (the “merger consideration”). As of the effective time
of the merger, all such shares of Triple-S common stock will no longer be outstanding and will automatically be canceled and retired and
cease to exist, and will thereafter represent only the right to receive the merger consideration to be paid in accordance with the terms
of the merger agreement.
At the effective time of the
merger, each share of Triple-S common stock held by Triple-S (as treasury stock) or owned by Parent or Merger Sub will be canceled without
payment of any consideration. In addition, shares of Triple-S common stock issued and outstanding immediately prior to effective time
of the merger and held by a stockholder who has not voted in favor of the merger or consented thereto in writing and who has properly
demanded appraisal for such shares in accordance with Puerto Rico law will not be converted into the right to receive the merger consideration,
unless and until such holder fails to perfect, withdraws or otherwise loses the right to appraisal. If any holder of Triple-S common stock
that demands appraisal rights properly perfects such rights, such holder will be entitled to the fair value of such shares as determined
by the Court of First Instance of the Commonwealth of Puerto Rico, Superior Court, plus interest, if any, on the amount determined to
be the fair value, as further described in the section entitled “Appraisal Rights of Stockholders” beginning on page [●]
of this proxy statement.
Each share of common stock
of Merger Sub outstanding immediately prior to the effective time of the merger will be converted into one share of common stock of the
surviving corporation.
Procedures for Surrendering Shares for Payment
Prior to the effective time
of the merger, Parent will appoint an paying agent reasonably acceptable to Triple-S for the purpose of exchanging for the merger consideration
certificates representing shares of Triple-S common stock or uncertificated shares of Triple-S common stock. As promptly as practicable
after the effective time of the merger, Parent will make available to the paying agent the aggregate merger consideration to be paid in
respect of the certificates representing shares of Triple-S common stock or uncertificated shares of Triple-S common stock.
As promptly after the effective
time of the merger (but no later than five (5) business days thereafter), the paying agent will send to each holder of shares of Triple-S
common stock at the effective time of the merger a letter of transmittal and instructions (which will specify that the delivery will be
effected, and risk of loss and title will pass, only upon proper delivery of certificates representing shares of Triple-S common stock
or transfer of uncertificated shares of Triple-S common stock to the paying agent) for use in such exchange.
Each holder of shares of Triple-S
common stock that have been converted into the right to receive the merger consideration will be entitled to receive, upon (i) surrender
to the paying agent of a certificate, together with a properly completed letter of transmittal, or (ii) receipt of an “agent’s
message” by the paying agent (or such other evidence, if any, of transfer as the paying agent may reasonably request) in the case
of a book-entry transfer of uncertificated shares, in each case (i) or (ii), the merger consideration in respect of Triple-S common stock
represented by a certificate or uncertificated share. Until so surrendered or transferred, as the case may be, each such certificate or
uncertificated share will represent after the effective time of the merger for all purposes only the right to receive such merger consideration.
If any portion of the merger
consideration is to be paid to a person other than the person in whose name the surrendered certificate or the transferred uncertificated
share is registered, it will be a condition to such payment that (i) either such certificate be properly endorsed or otherwise be in proper
form for transfer or such uncertificated share be properly transferred and (ii) the person requesting such payment must pay to the paying
agent any transfer or other taxes required as a result of such payment or establish to the satisfaction of the paying agent that such
tax has been paid or is not payable.
After the effective time of
the merger, there will be no further registration of transfers of shares of Triple-S common stock. If, after the effective time of the
merger, certificates representing shares of Triple-S common stock or uncertificated shares of Triple-S common stock are presented to the
surviving corporation or the paying agent, they will be canceled and exchanged for the merger consideration.
Any portion of the merger
consideration made available to the paying agent for payment to the stockholders that remains unclaimed by the holders of Triple-S common
stock one year after the effective time of the merger will be returned to Parent, upon demand, and any such holder who has not exchanged
shares of Triple-S common stock will thereafter look only to Parent for payment of the merger consideration in respect of such shares
without any interest thereon.
If any certificate or uncertificated
share has not been surrendered prior to the 24-month anniversary of the effective time of the merger (or, if earlier, immediately prior
to the date on which the merger consideration in respect of such certificate or uncertificated share would otherwise escheat to or become
the property of any governmental entity), any such merger consideration in respect of such certificate or uncertificated share shall,
to the extent permitted by applicable law, become the property of the surviving corporation, free and clear of all claims or interest
of any person previously entitled thereto.
Withholding
Each of the surviving corporation,
Merger Sub, Parent and the paying agent will be entitled to deduct and withhold from the consideration otherwise payable pursuant to the
merger agreement such amounts as may be required to be deducted and withheld with respect to the making of such payment under any applicable
tax law. Amounts so withheld and paid over to the appropriate taxing authority will be treated for all purposes of the merger agreement
as having been paid to the person in respect of which such deduction or withholding was made.
Treatment of Triple-S Equity Awards
The merger agreement provides
that, prior to the effective time of the merger, the Triple-S board of directors shall adopt resolutions to effect the following treatment
of the equity awards of Triple-S:
Each award of (or with respect
to) Triple-S common stock that is outstanding as of the date of the merger agreement and immediately prior to the effective time of the
merger shall, at the effective time of the merger:
|
·
|
With respect to restricted share awards outstanding under the Triple-S Management Corporation 2017 Incentive
Plan, as amended (the “Triple-S equity plan”), whether or not vested, be converted into the right to receive an amount in
cash equal to the product of the merger consideration and the number of shares of Triple-S common stock underlying the Triple-S restricted
share award;
|
|
·
|
With respect to restricted stock units outstanding under the Triple-S equity plan, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S restricted stock unit award as of immediately prior to the effective time of
the merger; and
|
|
·
|
With respect to performance share units outstanding under the Triple-S equity plan, whether or not vested,
be canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number
of shares of Triple-S common stock underlying the Triple-S performance share unit award as of immediately prior to the effective time
of the merger, determined based on achievement of target performance.
|
Each award of (or with respect
to) Triple-S common stock with respect to any restricted stock unit or performance share unit that is granted following the date of the
merger agreement and outstanding immediately prior to the effective time of the merger, at the effective time of the merger, shall be
canceled and converted into the right to receive an amount in cash equal to the product of the merger consideration and the number of
shares of Triple-S common stock underlying such award as of immediately prior to the effective time (determined, in the case of performance
share units, based on target performance), payable on the date the award would have otherwise vested pursuant to its vesting schedule,
subject to the holder’s continuing employment as of each such vesting date or as otherwise provided in the applicable award agreements.
Representations and Warranties
Triple-S’s representations
and warranties to Parent in the merger agreement relate to, among other things:
|
·
|
The organization and good standing of Triple-S and its subsidiaries;
|
|
·
|
The capital structure of Triple-S, including the number of outstanding shares of Triple-S common stock,
Triple-S restricted share awards, Triple-S restricted stock units and Triple-S performance share units;
|
|
·
|
The corporate power and authority to execute, deliver and perform the merger agreement and to consummate
the transactions contemplated by the merger agreement, and no applicable takeover statutes;
|
|
·
|
The absence of certain breaches, violations, defaults or consent requirements under certain contracts,
organizational documents and laws, in each case arising out of the execution, delivery and performance of, and consummation of the transactions
contemplated by, the merger agreement and assuming approval of the shareholders;
|
|
·
|
Required regulatory filings and authorizations, consents or approvals of governmental entities;
|
|
·
|
The reports, schedules, forms, statements and other documents required to be filed with the SEC and other
regulatory agencies and the accuracy of the information contained in those documents;
|
|
·
|
The financial statements of Triple-S and Triple-S’s internal system of disclosure controls and procedures
concerning financial reporting;
|
|
·
|
The reserves and related actuarial items in the financial statements of Triple-S;
|
|
·
|
The absence of any requirement to maintain capital or surplus amounts or levels or any restriction on
the payment of dividends or other distributions;
|
|
·
|
Compliance with laws related to Triple-S’s policies with respect to the investment of the investment
assets (the “investment guidelines”) and the composition of the investment assets held by Triple-S;
|
|
·
|
Compliance with laws related to healthcare plans by Triple-S and its subsidiaries;
|
|
·
|
Compliance with laws related to soliciting, negotiating, issuing, selling, producing, placing managing
and marketing policies by Triple-S, its subsidiaries, and to the knowledge of Triple-S, their agents and administrators;
|
|
·
|
The accuracy of information in this proxy statement;
|
|
·
|
The absence of certain changes or events since December 31, 2020;
|
|
·
|
The payment of taxes, the filing of tax returns and other tax matters related to Triple-S and its subsidiaries;
|
|
·
|
Compliance with laws related to labor and employment by Triple-S and its subsidiaries;
|
|
·
|
Compensation and benefits plans, agreements and arrangements with or concerning employees of Triple-S
and its subsidiaries;
|
|
·
|
Real property owned or leased by Triple-S and its subsidiaries;
|
|
·
|
Certain material contracts of Triple-S and its subsidiaries;
|
|
·
|
The absence of certain claim, suit, action, investigation, arbitration, proceeding, inquiry, review, subpoena,
civil investigative demand or other request for information;
|
|
·
|
Compliance with laws by Triple-S and its subsidiaries since January 1, 2019;
|
|
·
|
Compliance with environmental laws, permits and licenses by Triple-S and its subsidiaries and other environmental
matters since January 1, 2019;
|
|
·
|
Ownership of or rights with respect to the intellectual property of Triple-S and its subsidiaries;
|
|
·
|
Certain matters related to the insurance policies and arrangements of Triple-S and its subsidiaries;
|
|
·
|
Brokers’ and finders’ fees and other expenses payable by Triple-S; and
|
|
·
|
Receipt of the opinion of Triple-S’s financial advisor.
|
Parent’s representations
and warranties to Triple-S in the merger agreement relate to, among other things:
|
·
|
The corporate organization and good standing of each of Parent and Merger Sub;
|
|
·
|
The Merger Sub and its outstanding shares of capital stock;
|
|
·
|
The corporate power and authority to execute, deliver and perform the merger agreement and to consummate
the transactions contemplated by the merger agreement;
|
|
·
|
The absence of certain breaches, violations, defaults or consent requirements under certain contracts,
organizational documents and laws, in each case arising out of the execution, delivery and performance of, and consummation of the transactions
contemplated by, the merger agreement;
|
|
·
|
Required regulatory filings and authorizations, consents or approvals of governmental entities;
|
|
·
|
The accuracy of information supplied by Parent or Merger Sub to be included in this proxy statement;
|
|
·
|
Sufficiency of funds by Parent and Merger Sub to consummate the merger; and
|
|
·
|
Brokers’ and finders’ fees and other expenses payable by Parent.
|
None of the representations
and warranties in the merger agreement survive the effective time of the merger.
Definition of “Company Material
Adverse Effect”
Many of Triple-S’s representations
and warranties in the merger agreement are qualified by a “company material adverse effect” standard (that is, they will not
be deemed to be untrue or incorrect unless their failure to be true or correct has had or would reasonably be expected to have, individually
or in the aggregate, a company material adverse effect). For purposes of the merger agreement, a “company material adverse effect”
means any change, event, effect, fact, circumstance, development or occurrence that, individually or in the aggregate with other changes,
events, effects, facts, circumstances, developments or occurrences, has a material adverse effect on the business, properties, assets,
financial condition, financial performance or results of operations of Triple-S and its subsidiaries, taken as a whole; provided,
however, that none of the following, nor any change, event, effect, fact, circumstance development or occurrence to the extent
or arising out of or relating to the following, shall be deemed either alone or in combination to constitute or be taken into account
in determining whether a “company material adverse effect” has occurred or may, would or could occur:
|
·
|
General conditions affecting the health care services or insurance industries in the geographic regions
or product markets in which Triple-S and its subsidiaries operate;
|
|
·
|
General market, economic or regulatory, legislative or political conditions or securities, credit, currency,
financial or other capital or credit markets conditions;
|
|
·
|
Any change (or proposed change) in applicable Law, COVID-19 Measures, GAAP, SAP, actuarial policies or
accounting standards (or interpretation or enforcement thereof);
|
|
·
|
Geopolitical conditions, the outbreak or escalation of hostilities, acts of war, cyberattacks, sabotage
or terrorism;
|
|
·
|
Any hurricane, tornado, flood, volcano, earthquake, epidemic, pandemic (including COVID-19) or other natural
or man-made disaster;
|
|
·
|
The failure, in and of itself, of Triple-S to meet any internal or published projections, forecasts, estimates
or predictions in respect of revenues, earnings or other financial or operating metrics (it being understood that the underlying factors
or occurrences giving rise or contributing to such failure shall be taken into account in determining whether there has been a company
material adverse effect);
|
|
·
|
The announcement, performance, pendency or consummation of the Transactions, including the impact of any
of the foregoing on any relationships, contractual or otherwise, with customers, suppliers, employees or regulators;
|
|
·
|
The taking of any action expressly required by the terms of the merger agreement; or
|
|
·
|
Any actions taken or omitted to be taken by Triple-S or its subsidiaries upon the prior written request
of Parent.
|
The exclusions set forth in
the first, second, third, fourth and fifth bullets above shall only be applicable to the extent they do not have a disproportionate impact
on Triple-S and its subsidiaries, taken as a whole, relative to other similarly sized participants in the health care services or insurance
industries in the geographic regions or product markets in which Triple-S and its subsidiaries operate.
Certain of Parent’s
representations and warranties in the merger agreement are qualified by a “parent material adverse effect” standard (that
is, they will not be deemed to be untrue or incorrect unless their failure to be true or correct has had or would reasonably be expected
to have, individually or in the aggregate, a parent material adverse effect). For purposes of the merger agreement, a “parent material
adverse effect” means any change, effect, event, circumstance, fact, development or occurrence that prevents or materially impairs
or delays the consummation of the merger and the other transactions contemplated by the merger agreement or the ability of Parent or Merger
Sub to perform its obligations under the merger agreement.
Conduct of the Business Pending the Merger
Triple-S has agreed to certain
covenants in the merger agreement restricting the conduct of its business between the date of the merger agreement and the effective time
of the merger. In general, except as set forth on the disclosure letters to the merger agreement, as expressly contemplated by the merger
agreement, as required by applicable law (including COVID-19 measures), or with the prior written consent of Parent (which shall not be
unreasonably withheld, conditioned or delayed), from the date of the merger agreement to the effective time, Triple-S will, and will cause
each of its subsidiaries to, conduct its business in the ordinary course of business consistent with past practice and use reasonable
best efforts to preserve its present organization, assets, employees, authorizations, contractors and relationships with customers, distributors,
strategic partners, governmental entities, licensors, licensees and others that, in each case, have material business dealings with it.
In addition, without limiting
the generality of the foregoing, except as set forth on the disclosure letters to the merger agreement, as expressly contemplated by the
merger agreement, as required by applicable law (including COVID-19 measures), or with the prior written consent of Parent (which shall
not be unreasonably withheld, conditioned or delayed), Triple-S will not, and will not permit any of its subsidiaries to:
|
·
|
(i) declare, set aside or pay any dividends on, or make any other distributions (whether in cash, stock
or property or any combination thereof) in respect of, any of its capital stock or other equity interests, other than dividends and distributions
by a wholly owned subsidiary of Triple-S to its parent, (ii) split, combine, reclassify, exchange or readjust any of its capital stock
or other equity interests or issue or authorize the issuance of any other securities in respect of, in lieu of or in substitution for
shares of its capital stock or other equity interests, other than with respect to the capital stock or other equity interests of a subsidiary
of Triple-S, in connection with transactions exclusively among Triple-S and any of its subsidiaries or exclusively among Triple-S’s
subsidiaries, or (iii) directly or indirectly redeem, repurchase or otherwise acquire any equity interests in the Triple-S and any of
its subsidiaries, except for (A) the withholding of shares of Triple-S common
|
stock to satisfy tax
obligations with respect to the vesting, exercise or settlement of Triple-S restricted share awards, restricted stock unit awards or performance
share unit awards outstanding as of the date of the merger agreement (or issued after the date of the merger agreement in accordance with
the terms of the merger agreement) in accordance with their respective terms in effect at such time, (B) the acquisition by Triple-S of
Triple-S restricted share awards, restricted stock unit awards or performance share unit awards in connection with the forfeiture of such
awards in accordance with their respective terms in effect at such time or (C) redemptions, repurchases or acquisitions of the capital
stock or other equity interests of a subsidiary of Triple-S, in connection with transactions exclusively among Triple-S and any of its
subsidiaries or exclusively among Triple-S’s subsidiaries;
|
·
|
issue any equity interests, other than (i) the issuance of shares of Triple-S common stock upon the settlement
of Triple-S restricted shares, performance share units or restricted stock units, in each case outstanding as of the date of the merger
agreement (or issued after the date thereof in accordance with the terms of the merger agreement) and in accordance with their respective
terms in effect at such time, or (ii) issuances by a subsidiary of Triple-S of capital stock or other equity interests to Triple-S or
another subsidiary of Triple-S;
|
|
·
|
amend (i) the Triple-S articles or the Triple-S bylaws or (ii) the certificate of incorporation, bylaws
or other comparable organizational documents of any Triple-S’s subsidiary in a manner adverse to Parent;
|
|
·
|
propose or adopt a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring,
recapitalization or other reorganization, other than the merger;
|
|
·
|
acquire (i) in a single transaction or a series of related transactions, whether by merging or consolidating
with, or by purchasing equity interests in or assets of, or by any other manner, any business or any corporation, partnership, limited
liability company, joint venture, association or other business organization or division thereof or any other person or (ii) any assets
or properties, other than, in the case of each of clauses (i) and (ii), (x) any specified permitted investment and (y) any unspecified
permitted investment so long as the amount of consideration paid or transferred by Triple-S and its subsidiaries in connection with such
unspecified permitted investment would not exceed $4,000,000 individually, or $10,000,000 in the aggregate when taken together with all
other unspecified permitted investments made under this bullet;
|
|
·
|
form any person that would constitute a subsidiary or affiliate of Triple-S, except for any person that
would constitute a subsidiary of Triple-S that is formed for the sole purpose of facilitating a specified permitted investment or unspecified
permitted investment not in violation of the bullet above;
|
|
·
|
except as required by the terms of any Triple-S benefit plan as in effect on the date of the merger agreement
or to the extent required by applicable law or, with respect to the actions specifically described in the Triple-S disclosure letters,
to the extent such actions are taken in the ordinary course of business consistent with past practice or are in connection with Triple-S’s
internal realignment plan: (i) adopt, enter into, terminate or amend any collective bargaining agreement or material Triple-S benefit
plan; (ii) increase in any manner the compensation, bonus or fringe or other benefits of any non-employee director or employee at the
level of Vice President or above; (iii) enter into or materially amend any employment, change in control, severance, retention or similar
contract with any non-employee director or employee at the level of Vice President or above (other than offer letters providing for employment
with newly hired employees who are hired in the ordinary course of business that do not contain any equity or equity-based compensation,
change in control, severance, retention or similar arrangements); (iv) grant any awards under any Triple-S benefit plan (including grants
of stock or stock-based awards) other than grants in connection with promotions or new hires in the ordinary course of business consistent
with past practice or waive any conditions on any awards under any Triple-S benefit plan; (v) take any action to accelerate the payment
of any compensation or benefit under any Triple-S benefit plan; or (vi) change any actuarial or other assumption used to calculate funding
obligations with respect to any Triple-S benefit plan or change the manner in which contributions are made or the basis on which contributions
are calculated;
|
|
·
|
terminate the employment of any employee at the level of vice president or above, other than due to such
individual’s death, disability or for cause (each as determined by Triple-S in the ordinary course of business) or hire any individual
at the level of vice president or above;
|
|
·
|
(i) change its fiscal year or revalue any of its material assets or (ii) make any change in accounting
methods, principles or practices used by it, except, in the case of each of clauses (i) and (ii), as may be required (A) by GAAP,
SAP or actuarial principles, as applicable, or (B) by applicable law, including Regulation S-X under the Securities Act;
|
|
·
|
sell, lease or sublease (as lessor or sublessor), license (as licensor) or otherwise dispose of, or pledge,
encumber or otherwise subject to any Lien (other than a permitted lien), any material properties or assets, except (i) sales, leases,
licenses, dispositions, pledges or encumbrances (A) of or on obsolete assets in the ordinary course of business consistent with past practice,
(B) of properties or assets (other than Triple-S intellectual property) with de minimis or no book value or (C) of investment assets
in accordance with the investment guidelines or (ii) permitted conduct under the merger agreement;
|
|
·
|
(i) incur, redeem, repurchase, prepay, defease, guarantee, assume or otherwise become liable for
or modify in any material respects the terms of any indebtedness or issue or sell any debt securities or warrants or other rights to acquire
any debt securities of Triple-S or any of its subsidiaries other than (A) any indebtedness of any wholly owned subsidiary of Triple-S
owing to Triple-S or to another wholly owned subsidiary of Triple-S and (B) any indebtedness under the Triple-S’s existing credit
facilities as in effect as of the date of the merger agreement that can be repaid at the closing without penalty (other than customary
break funding costs) or (ii) make any loans, advances, capital contributions or investments in (including by purchase of stock or
securities, property transfers or purchase of property or assets of any person or otherwise) any other person, in each case, other than
to or in (A) the Company or any wholly owned subsidiary of Triple-S, (B) any acquisition not in violation of clause (e) above, (C)
capital contributions or advances required by the terms of any contract in effect as of the date hereof or (D) any extensions of risk
sharing arrangements, provider capitation, related compensation mechanisms and advances of expenses to employees, in each case in the
ordinary course of business consistent with past practice;
|
|
·
|
make any capital expenditure or expenditures, or incur any obligations or liabilities in connection therewith,
which, individually, is equal to or in excess of $200,000 or, in the aggregate, are equal to or in excess of $1,000,000 (other than (i)
as reflected in the Triple-S’s capital expenditures forecast set forth in the disclosure letters and (ii) any specified permitted
investment or unspecified permitted investment not in violation of the merger agreement;
|
|
·
|
make, change or revoke any material tax election, change any material tax accounting method or period,
file any amended tax return in respect of a material amount of taxes, enter into any closing agreement with respect to material taxes,
request any material tax ruling, waive or extend the statute of limitations in respect of a material amount of taxes or settle or compromise
any material tax liability or refund;
|
|
·
|
(i) materially amend or modify, or renew, extend or terminate, or waive or release any material rights
under, any specified contract or any contract that would be a specified contract if in effect on the date of the merger agreement or (ii)
enter into any contract that would be a specified contract if in effect on the date of the merger agreement, in each case, other than
in the ordinary course of business consistent with past practice;
|
|
·
|
enter into or amend any contract if consummation of any of the transactions (alone or in combination with
any other event) or compliance by Triple-S or any of its subsidiaries with the provisions hereof will conflict with, or result in any
violation or breach of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of, or result in,
termination, cancelation or acceleration of any obligation, or give rise to a loss of a benefit under, or result in the creation of any
lien in or upon any of the properties or assets of Triple-S or any of its subsidiaries under, or require Parent to license or to transfer
any of its material intellectual property or other material assets under, or give rise to any increased, additional, accelerated or guaranteed
rights or entitlements under, any provision of such contract, other than any amendment of a contract that does not materially worsen any
of the provisions of such contract;
|
|
·
|
(i) settle any proceeding if such settlement (A) would require any payment by the Triple-S or any of its
subsidiaries equal to or in excess of $500,000, other than any settlement of any property and casualty insurance claim in the ordinary
course of business consistent with past practice that requires the payment of an amount which, when taken together with the settlement
amounts of all other property and casualty insurance claims settled pursuant to this clause (i)(A), does not exceed the amount held in
reserve by Triple-S and any of its subsidiaries for all outstanding property and
|
casualty insurance
claims as of June 30, 2021 or (B) would obligate Triple-S or any of its subsidiaries to take any material action or impose any material
restrictions on the business of the Triple-S or any of its subsidiaries or (ii) commence any comparable proceeding against a third party
other than any such proceeding commenced in the ordinary course of business consistent with past practice where the total amount of damages
sought does not equal or exceed $500,000;
|
·
|
(i) other than non-exclusive licenses and sublicenses granted in the ordinary course of business consistent
with past practice, assign, sell, lease, license, dispose, cancel, abandon, grant rights to or fail to renew, maintain or defend, any
material Triple-S intellectual property or (ii) disclose to any third party, other than representatives of Parent or under a confidentiality
agreement, any trade secrets included in any material Triple-S intellectual property in a way that results in the loss of intellectual
property protection for such material Triple-S intellectual property;
|
|
·
|
cancel, terminate or modify in any material respect, or take any action that could permit cancellation,
termination or material modification of, any material insurance policy;
|
|
·
|
enter into any real property lease or modify, amend, renew, extend, waive, or exercise any material right
or remedy under or terminate any lease, other than (i) leases with annual payments not to exceed $100,000 individually or $500,000 in
the aggregate and (ii) leases in respect of any space for use in connection with point of sales or marketing arrangements entered into
in the ordinary course of business consistent with past practice;
|
|
·
|
materially alter any existing underwriting, reserving, claim handling, loss control or actuarial practice,
guideline or policy of the Triple-S or any of its subsidiaries or any material assumption underlying any reserves or actuarial practice
or policy, except as may be required by GAAP, SAP or actuarial principles;
|
|
·
|
reduce or strengthen any reserves, provisions for losses or other liability amounts in respect of insurance
contracts and assumed reinsurance contracts, except (A) as may be required by GAAP, SAP or actuarial principles, (B) as a result of loss
or exposure payments to other parties in accordance with the terms of insurance contracts and assumed reinsurance contracts or (C) in
the ordinary course of business consistent with past practice;
|
|
·
|
reduce in any material respect the budget or scope of the Triple-S’s and the applicable subsidiary’s
program for, or otherwise reduce in any material respect the resources or efforts specifically dedicated by Triple-S and its subsidiaries
to, (i) the maintenance and improvement of their respective Medicare star ratings or (ii) retrospective chart review, coding audits or
the collection of prospective home assessments or patient assessment forms, in each case other than as a result of vendor-related cost
savings;
|
|
·
|
terminate, suspend, abrogate, amend or modify (i) any certificate of authority to conduct business as
an insurance company, health care services organization, agency or service provider issued by the applicable Insurance Regulator or health
regulatory governmental entity or (ii) any other material authorization, in each case of (i) and (ii) in a manner material and adverse
to Triple-S or any of its subsidiaries;
|
|
·
|
acquire or dispose of any material investment assets in any manner inconsistent with the investment guidelines;
|
|
·
|
materially amend or modify the investment guidelines; or
|
|
·
|
authorize, commit or agree to take any of the foregoing actions.
|
Board Obligation to Call a Stockholders Meeting
Triple-S has agreed under
the merger agreement to take all necessary actions in accordance with applicable law, the Triple-S articles and the Triple-S bylaws, and
the rules and regulations of NYSE to duly call, give notice of, convene and hold a stockholders meeting for the purpose of obtaining the
stockholder approval as soon as reasonably practicable after the SEC confirms that it will not review or that it has no further comments
on this proxy statement, including establishing a record date for such stockholders meeting promptly after the date on which the SEC confirms
that it will not review or that it has no further comments on this proxy statement and duly convening and holding the stockholders meeting
no later than 45 days after the record date. Unless the Triple-S board has made an adverse recommendation change in
accordance with the merger agreement, Triple-S will use reasonable best efforts to solicit and obtain stockholder approval, including engaging a proxy solicitation firm for
the purpose of assisting in the solicitation of proxies for the stockholders meeting. Triple-S may, after consultation with Parent, adjourn,
recess or postpone the stockholders meeting only (i) to the extent required by applicable law to ensure that any required supplement or
amendment to this proxy statement is provided to the stockholders of Triple-S within a reasonable amount of time in advance of the stockholders
meeting, (ii) to the extent required by a court of competent jurisdiction in connection with any proceedings in connection with the merger
agreement or the transactions contemplated by the merger agreement, (iii) if, as of the time for which the stockholders meeting is originally
scheduled (as set forth in this proxy statement), there are insufficient shares of Triple-S common stock represented (either in person
or by proxy) to constitute a quorum necessary to conduct the business of the stockholders meeting or Parent reasonably believes that Triple-S
will not receive proxies sufficient to obtain stockholder approvals, whether or not a quorum is present, or (iv) the Triple-S board or
any committee thereof determines in good faith (after consultation with its outside counsel) that the failure to adjourn, recess or postpone
the stockholders meeting would violate the directors’ fiduciary duties under applicable law. Notwithstanding the foregoing, Triple-S
will not adjourn, recess or postpone the stockholders meeting to a date that is (x) more than 30 days after the date on which the stockholders
meeting was originally scheduled or (y) less than five business days prior to the outside date, in the case of each of (x) and (y) without
the prior written consent of Parent. Unless the Triple-S board has made an adverse recommendation change in accordance with the merger
agreement, Triple-S will keep Parent updated with respect to proxy solicitation results as reasonably requested by Parent.
Restrictions on Solicitation of Company Takeover
Proposals
Triple-S has agreed that it
will not, and will cause its subsidiaries and all of its and their respective directors, officers, employees, financial advisors, legal
counsel, accountants and other agents, advisors or representatives (collectively, “representatives”) not to, directly or indirectly:
|
·
|
Solicit, initiate, encourage or facilitate any inquiries regarding, or the submission of any proposal
or offer that constitutes, or would reasonably be expected to lead to, any “company takeover proposal” (as described below);
|
|
·
|
Solicit, initiate, encourage or participate in any discussions or negotiations regarding, or furnish to
any person (other than Parent or Merger Sub) any nonpublic information with respect to or in connection with, or take any other action
to facilitate or encourage the making of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any company
takeover proposal;
|
|
·
|
Execute or enter into any letter of intent, memorandum of understanding, agreement in principle, acquisition
agreement, option agreement, merger agreement, joint venture agreement, partnership agreement or any other agreement, arrangement or understanding
(whether or not binding) relating to any company takeover proposal.
|
If any subsidiaries of Triple-S
or any of its or their representatives violates any of these restrictions, then Triple-S will be deemed to have breached such restrictions.
Triple-S has also agreed that
it will, and will cause its subsidiaries and all of its and their respective representatives to, immediately:
|
·
|
Cease all solicitation, encouragement, discussions and negotiations regarding any inquiry, proposal or
offer pending on the date of the merger agreement that constitutes, or would reasonably be expected to lead to, a company takeover proposal;
|
|
·
|
Request the prompt return or destruction of all confidential information previously furnished to any person
in connection with a possible company takeover proposal; and
|
|
·
|
Terminate access to any physical or electronic data rooms relating to a possible company takeover proposal.
|
In addition, Triple-S has
agreed that it will not, and will cause its subsidiaries and all of its and their respective representatives not to, release any person
from, or waive, amend or modify any provision of, or grant any permission under any “standstill” provision or similar provision
with respect to any of its capital stock in any agreement to which it or any of its subsidiaries is a party; provided that the
Triple-S board or any committee thereof will be permitted to grant waivers of, and not to enforce, any “standstill” or similar
provision to the extent that (x) the Triple-S board or any committee thereof determines in good faith (after
consultation with its outside
counsel) that the failure to take such action would violate the directors’ fiduciary duties under applicable law and (y) any such
action by the Triple-S board or any committee thereof does not violate any other provision of the merger agreement. Except to the extent
otherwise permitted by the foregoing sentence, Triple-S will, and will cause its affiliates to, (i) enforce the “standstill”
or similar provisions of any such agreement and (ii) immediately take all reasonable steps within their power to terminate any waiver
under any such provisions that may have been heretofore granted to any person other than Parent and any of Parent’s affiliates.
Notwithstanding anything to
the contrary described above, at any time prior to obtaining the approval of Triple-S stockholders, in response to a qualifying company
takeover proposal, Triple-S may (A) enter into an acceptable confidentiality agreement with such person or group making the qualifying
company takeover proposal and thereafter furnish information with respect to Triple-S to such person or group and its representatives
pursuant to such acceptable confidentiality agreement so long as Triple-S also provides Parent promptly, and in no event later than 24
hours after the time such information is provided or made available to such person or group or any of its representatives, any information
furnished to such person or group or any of its representatives which was not previously furnished to Parent and (B) participate in discussions
or negotiations with such person or group and its representatives regarding such qualifying company takeover proposal. Triple-S is required
to notify Parent prior to furnishing any information and/or entering into any discussions or negotiations.
Triple-S is required to promptly,
and in no event later than 24 hours after receipt thereof, (i) advise Parent in writing of Triple-S’s or any of its subsidiaries’
or its or their respective representatives’ receipt of any company takeover proposal or any inquiries regarding, or the submission
of any proposal or offer that constitutes, or would reasonably be expected to lead to, any company takeover proposal and (ii) provide
to Parent an unredacted copy of any such company takeover proposal or such inquiry made in writing (including any financing commitments
or other agreements related thereto) (or if such company takeover proposal or inquiry is not in writing, a written description of the
material terms and conditions thereof) and unredacted copies of all other written materials, draft and final agreements (including all
schedules and exhibits thereto) and correspondence exchanged between Triple-S or any of its affiliates or its or their representatives,
on the one hand, and the person or group or its representatives, on the other hand, making such company takeover proposal or inquiry in
connection with such company takeover proposal or inquiry. From and after such notification, Triple-S is required to keep Parent reasonably
informed on a reasonably current basis of any material developments, discussions or negotiations regarding, or changes to the material
terms and conditions of, any such company takeover proposal or inquiry, including providing to Parent promptly, and in no event later
than 24 hours after receipt thereof, unredacted copies of any additional proposals, counterproposals, written materials, draft and final
agreements (including all schedules and exhibits thereto) and correspondence exchanged between Triple-S or any of its affiliates or its
or their representatives, and the person or group or its representatives making such company takeover proposal or inquiry in connection
with such company takeover proposal or inquiry.
For purposes of the merger
agreement, “company takeover proposal” means, any inquiry, proposal or offer from any person or group relating to, in a single
transaction or series of related transactions, any:
|
·
|
direct or indirect acquisition or license of 15% or more of the consolidated assets of Triple-S and its
subsidiaries (based on the fair market value thereof) or assets comprising 15% or more of the consolidated revenues, net income or EBITDA
of Triple-S and its subsidiaries, including in any such case through the acquisition of one or more subsidiaries of Triple-S owning such
assets;
|
|
·
|
direct or indirect acquisition of 15% or more of the outstanding Triple-S common stock or the outstanding
voting power of Triple-S (or any other equity interests representing such voting power giving effect to any right of conversion or exchange
thereof);
|
|
·
|
tender offer or exchange offer that if consummated would result directly or indirectly in any person or
group (or the stockholders of any person or group) beneficially owning 15% or more of the outstanding Triple-S common stock or the outstanding
voting power of Triple-S (or any other equity interests representing such voting power giving effect to any right of conversion or exchange
thereof);
|
|
·
|
merger, consolidation, share exchange, business combination, reorganization, recapitalization, liquidation,
dissolution or other transaction involving Triple-S or any of its subsidiaries which would result in any person or group (or the stockholders
of any person or group) beneficially owning, directly or indirectly, 15% or more of the outstanding Triple-S common stock or the outstanding
voting power of Triple-S or of the surviving entity in a merger involving Triple-S or the resulting
|
direct or indirect
parent of Triple-S or such surviving entity (or any equity interests representing such voting power giving effect to any right of conversion
or exchange thereof); or
|
·
|
any combination of the foregoing.
|
For purposes of the merger
agreement, “superior proposal” means any bona fide binding written offer which is made by a third party or group which, if
consummated, would result in such third party or group (or in the case of a direct merger, consolidation, share exchange or other similar
transaction between such third party or group and Triple-S, the stockholders of such third party or group) beneficially owning, directly
or indirectly, more than 50% of the outstanding Triple-S common stock or the outstanding voting power of the Triple-S (or any other equity
interests representing such voting power giving effect to any right of conversion or exchange thereof) or all or substantially all the
consolidated assets of Triple-S and its subsidiaries that the Triple-S board or any committee thereof determines in good faith, after
consultation with its outside counsel and financial advisor, (a) is more favorable to the Triple-S’s stockholders from a financial
point of view than the transactions contemplated by the merger agreement, taking into account all terms and conditions of such offer (including
all legal, regulatory, financial, timing and other aspects of such offer, including the identity of the person making the proposal) as
well as the merger agreement and all changes to the terms of the transactions proposed by Parent in response to such offer or otherwise
and (b) is reasonably likely to be completed on the terms proposed, taking into account all terms and conditions of such offer (including
all legal, regulatory, financial, timing and other aspects of such offer, including the identity of the person making the proposal) as
well as the merger agreement and all changes to the terms of the transactions proposed by Parent in response to such offer or otherwise.
Changes in Board Recommendation
Under the merger agreement,
prior to obtaining the Triple-S stockholder approval, the Triple-S board or any committee thereof may make an adverse recommendation change
if (i) the Triple-S board or any committee thereof determines in good faith (after consultation with its outside counsel and financial
advisor) that, as a result of an intervening event, failure to take such action would violate the directors’ fiduciary duties under
applicable law or (ii) Triple-S receives a company takeover proposal after the date of the merger agreement that did not result from a
material breach of its non-solicitation obligations and for which the Triple-S board or any committee thereof determines in good faith
(after consultation with its outside counsel and financial advisor) that such company takeover proposal constitutes a superior proposal
and that the failure to take such action would violate the directors’ fiduciary duties under applicable law; provided that:
|
·
|
Triple-S has provided a notice of adverse recommendation change to Parent advising Parent that the Triple-S
board or any such committee intends to take such action and the reasons therefor;
|
|
·
|
In the case of any notice of adverse recommendation change provided in connection with an intervening
event, such notice of adverse recommendation change contains a reasonably detailed description of such intervening event;
|
|
·
|
In the case of any notice of adverse recommendation change provided in connection with a company takeover
proposal, such notice of adverse recommendation change specifies the material terms and conditions of the related superior proposal, identifying
the person or group making such superior proposal and including a copy of the most current version of the agreement or proposal and all
material related documentation with respect to such superior proposal;
|
|
·
|
a period of at least four business days has elapsed following Parent’s receipt of such notice of
adverse recommendation change (it being understood that any amendment or modification to any company takeover proposal that is the basis
for such proposed adverse recommendation change shall require a new notice of adverse recommendation change and an additional notice period
(which shall be the longer of (x) two business days and (y) the period remaining under the initial notice period));
|
|
·
|
If requested by Parent, Triple-S has negotiated, and has caused its subsidiaries and its and their representatives
to negotiate, in good faith with Parent and its representatives during such four-business day period (as may be extended as set
forth in the preceding bullet) with respect to any changes to the terms of the merger agreement proposed by Parent during such period;
and
|
|
·
|
Taking into account any changes to the terms of the merger agreement proposed by Parent, the Triple-S
board or any committee thereof has determined in good faith (after consultation with its
|
outside counsel and
financial advisor) (1) that it would continue to violate the directors’ fiduciary duties under applicable law not to effect the
adverse recommendation change and (2) in connection with a company takeover proposal, that the company takeover proposal received
by the Company would continue to constitute a superior proposal, in each case, if such changes offered by Parent were given effect.
Notwithstanding the foregoing,
Triple-S is required to submit the matters to obtain approval of Triple-S stockholders at the stockholders meeting; provided, however,
that (i) if the Triple-S board has made an adverse recommendation change, then in submitting such matters to the stockholders meeting,
the Triple-S board may recommend against such matters or submit such matters without recommendation, in which event the Triple-S board
will communicate the basis for its recommendation or lack thereof to Triple-S’s stockholders in the proxy statement or an appropriate
amendment or supplement thereto to the extent it determines, after consultation with its outside legal counsel, that such action is compelled
by applicable law and (ii) Triple-S shall have the right to terminate the merger agreement if the Triple-S board makes an adverse
recommendation change concurrently with its entry into a definitive merger agreement concerning a superior proposal so long as it pays
the termination fee.
Nothing in the merger agreement
prevents Triple-S from:
|
·
|
taking and disclosing a position contemplated by Rule 14d-9, Rule 14e-2(a)(2) or (3) or Item 1012(a)
of Regulation M-A promulgated under the Exchange Act;
|
|
·
|
making any disclosure that constitutes a “stop, look and listen” communication pursuant to
Section 14d-9(f) promulgated under the Exchange Act; or
|
|
·
|
making any disclosure to Triple-S’s stockholders that is required by applicable law, which actions
shall not constitute or be deemed to constitute an adverse recommendation change;
|
provided, however,
that (A) any such disclosure permitted under the first bullet above that relates to a company takeover proposal (other than a “stop,
look and listen” communication) shall be deemed an adverse recommendation change unless the Triple-S board expressly publicly reaffirms
the company board recommendation in connection with such disclosure and (B) any adverse recommendation change may only be made in accordance
with “Merger Agreement—Changes in Board Recommendation”.
For purposes of the merger
agreement, “company board recommendation” means the Triple-S board, at a meeting duly called and held, duly and unanimously
adopted resolutions (i) determining that the merger agreement and the transactions contemplated by the merger agreement, including the
merger, are in the best interests of Triple-S and its stockholders, (ii) approving, adopting and declaring advisable the merger agreement
and the transactions contemplated by the merger agreement, including the merger, in each case on the terms and subject to the conditions
set forth in the merger agreement and (iii) recommending that the holders of shares of Triple-S common stock adopt the merger agreement
and directing that the merger agreement be submitted to the Triple-S’s stockholders at the stockholders meeting.
For purposes of the merger
agreement, “adverse recommendation change” means the Triple-S board or any committee thereof (A) withdraw, withhold,
qualify or modify in a manner adverse to Parent or Merger Sub, or propose publicly to withdraw, withhold, qualify or modify in a manner
adverse to Parent or Merger Sub, the company board recommendation, or authorize, resolve or agree to take any such action, (B) adopt,
endorse, approve or recommend, or propose publicly to adopt, endorse, approve or recommend, or submit to the vote of any securityholders
of Triple-S, any company takeover proposal, or authorize, resolve or agree to take any such action, (C) fail to include the company board
recommendation in the proxy statement or to recommend against any company takeover proposal that is a tender offer or exchange offer within
10 business days after the commencement thereof or, (D) make any public statement inconsistent with the company board recommendation.
For purposes of the merger
agreement, “intervening event” means a material development or change in circumstances relating to Triple-S or any of its
subsidiaries (other than (a) a company takeover proposal, (b) changes in the price of Triple-S common stock, in and of itself (however,
the underlying reasons for such changes may constitute an intervening event) or (c) the fact that, in and of itself, Triple-S exceeds
any internal or published projections, estimates or expectations of its revenue, earnings or other financial performance or results of
operations for any period (however, the underlying reasons for such events may constitute an intervening event)) that occurs or arises
after the execution and delivery of the merger agreement and on or prior to the date of Triple-S’s stockholder approval and was
not known to or reasonably
foreseeable by the Triple-S board
or any committee thereof prior to the execution and delivery of the merger agreement.
Regulatory Approvals Required for the Merger
The completion of the merger
is conditioned on, among other things, certain specified regulatory approvals having been obtained and remaining in full force and effect
(or, in the case of certain specified regulatory approvals that are statutory waiting periods, having expired or been terminated). Under
the terms of the merger agreement, each of Triple-S and Parent agrees to use their respective reasonable best efforts to take, or cause
to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary,
proper or advisable to cause the conditions to closing to be satisfied as promptly as reasonably practicable and to consummate and make
effective, in the most expeditious manner reasonably practicable, the transactions, including (i) obtaining all necessary or advisable
consents from, making all necessary registrations, declarations and filings with and taking all reasonable steps as may be necessary to
obtain a consent from or avoid a proceeding by any governmental entity or other third party with respect to the merger agreement or the
transactions, (ii) furnishing all information required to be furnished in connection with obtaining any consents from or making any filings
with any governmental entity or other third party, and promptly cooperating with and furnishing information in connection with any such
requirements imposed upon any party or any of their respective subsidiaries in connection with the merger agreement or the consummation
of the transactions, (iii) executing and delivering any additional instruments necessary to consummate the transactions and to fully carry
out the purposes of the merger agreement and (iv) defending or contesting in good faith any proceeding brought by a third party that could
otherwise prevent or impede, interfere with, hinder or delay in any material respect the consummation of the transactions, in the case
of each of clauses (i) through (iv), other than with respect to consents, registrations, declarations, filings, instruments and proceedings
relating to or under applicable antitrust laws, health care laws and insurance laws.
Notwithstanding anything to
the contrary, with respect to any consent, none of Parent, Merger Sub or any of their respective subsidiaries will be required to, and
Triple-S and its subsidiaries will not, without the prior written consent of Parent, pay or agree to pay any amount as consideration therefor
to, or grant or agree to grant any financial, contractual or other concession in favor of, the person from whom such consent is sought,
other than (i) filing and processing fees and (ii) any such payment or concession that is solely applicable to Triple-S and its subsidiaries
(a “company concession”) and, when taken together with all company concessions and company restrictions (as defined below),
is de minimis to Triple-S and its subsidiaries, taken as a whole.
Parent will use its reasonable
best efforts to take, or cause to be taken, all actions necessary to assist the Company in obtaining all consents and approvals under
the license agreements with the Blue Cross and Blue Shield Association (“BCBSA”), including any other transfer or change of
control consents or approvals of the BCBSA needed as a result of the merger agreement, the merger or the other transactions. Parent will
use its reasonable best efforts to cooperate in all respects with the Company in connection with any filings or submissions requested
or required by the BCBSA.
Each of Triple-S and Parent
will (i) make an appropriate filing of a Notification and Report Form pursuant to the HSR Act within 30 days after the date of the
merger agreement, unless otherwise mutually agreed to by the parties, and to make any other required filings pursuant to applicable antitrust
laws, health care Laws or insurance laws with respect to the transactions as promptly as reasonably practicable and advisable, (ii) supply
as promptly as practicable and advisable any additional information and documentary material that may be requested by any governmental
entity with competent jurisdiction, including pursuant to the HSR Act or any other applicable antitrust laws, health care laws or insurance
laws, (iii) cooperate with any investigation, review or other inquiry by or before a governmental entity of competent jurisdiction relating
to the transactions and (iv) use reasonable best efforts to take or cause to be taken all other actions necessary to cause as promptly
as reasonably practicable the expiration or termination of the applicable waiting periods under the HSR Act and any other applicable antitrust
laws and to obtain as promptly as reasonably practicable all consents under any applicable antitrust laws, health care laws and insurance
laws that may be required by the United Stated Federal Trade Commission (“FTC”), the United States Department of Justice (the
“DOJ”) or any other governmental entity with competent jurisdiction. Each of Triple-S and Parent shall use reasonable best
efforts to take or cause to be taken as promptly as practicable all actions necessary to resolve objections, if any, as may be asserted
with respect to the transactions under any applicable antitrust law, health care laws or insurance laws; provided, however, without
the prior written consent of each party, none of Parent, Merger Sub or Triple-S shall be required to defend any lawsuit brought by a governmental
entity or other adjudicatory action initiated by or at the behest of a governmental entity (and not upon the filing of a claim, challenge
or complaint by any person other than such
governmental entity), in each
case, seeking to either (i) restrain, enjoin, prevent, prohibit, or otherwise make illegal the consummation of the Merger or the other
Transactions or (ii) impose a Burdensome Condition (as defined below). Parent, Merger Sub, or any of their respective subsidiaries, and
Triple-S and its subsidiaries shall not, without the prior written consent of Parent, propose, negotiate, effect or agree to, or execute
any settlements, undertakings, consent decrees, stipulations or other agreements with any governmental entity (including ASES) or with
any other person (including the BCBSA) obligating Parent, the Company or any of their respective subsidiaries, (i) sell, divest, license
or otherwise convey or hold separate any asset or business of Parent, Triple-S or any of their respective subsidiaries, (ii) terminate
or alter any existing relationship, contractual right or obligation of Parent, Triple-S or any of their respective subsidiaries, (iii)
create any relationship, contractual right or obligation, including any payment obligation (other than customary filing fees), of Parent,
Triple-S or any of their respective subsidiaries or (iv) implement any limitations or restrictions on the ability of Parent, Merger Sub
or any of their respective subsidiaries to hold and exercise full rights of ownership of any equity interests in the surviving corporation,
including the right to vote such equity interests, or to effectively control the business or operations of Triple-S or any of its subsidiaries,
in each case other than any action or condition described in the immediately preceding clauses (i)-(iv) that applies solely to Triple-S
and its subsidiaries (a “company restriction”) and, when taken together with all company concessions and company restrictions,
is de minimis to Triple-S and its subsidiaries, taken as a whole (a “de minimis company restriction”). The term “burdensome
condition” means any action or condition described in clauses (i)-(iv) of the immediately preceding sentence other than any de minimis
company restriction.
Each of Parent and the Company
will (i) cooperate in all respects with each other in connection with any filing or submission with a governmental entity by any
person in connection with the transactions, and in connection with any investigation or other inquiry by or before a governmental entity
relating to the transactions, (ii) give the other party reasonable prior notice of any such filings or submissions and, to the extent
reasonably practicable, of any communication with, and any inquiries or requests for additional information from, the FTC, the DOJ, the
Puerto Rico Commissioner of Insurance (the “OCI”) and any other governmental entity regarding the merger or any of the other
transactions, and permit the other party to review and discuss in advance, and consider in good faith the views of, and secure the participation
of, the other party in connection with, any such filings, submissions, communications, inquiries or requests, (iii) unless prohibited
by applicable law or by the applicable governmental entity, and to the extent reasonably practicable, (A) not participate in or attend
any meeting, or engage in any substantive conversation, with any governmental entity in respect of the Merger or any of the other transactions
without the other party, (B) give the other party reasonable prior notice of any such meeting or conversation, (C) in the event one party
is prohibited by applicable law or by the applicable governmental entity from participating in or attending any such meeting or engaging
in any such conversation, keep such party apprised, (D) cooperate with one another in the filing of any substantive memoranda, white
papers, filings, correspondence or other written communications explaining or defending the merger agreement, the merger or any of the
other transactions, articulating any regulatory or competitive argument or responding to requests or objections made by any governmental
entity and (E) furnish the other party with copies of all filings, submissions, correspondence and communications (and memoranda setting
forth the substance) between it and its affiliates and their respective representatives, on the one hand, and any governmental entity
or members of any governmental entity’s staff, on the other hand, with respect to the merger agreement, the merger and the other
transactions, (iv) comply with any inquiry or request from the FTC, the DOJ, the OCI or any other governmental entity as promptly as reasonably
practicable and (v) consult with one another in connection with any inquiry, hearing, investigation, proceeding or litigation by, or negotiations
with, any governmental entity relating to the merger agreement, the merger or any of the other transactions. Parent shall control and
lead all communications and strategy for dealing with the FTC, the DOJ, the OCI and any other governmental entity with respect to the
HSR Act and any other applicable Law, including antitrust laws, health care laws or insurance laws.
In addition, Triple-S and
the Triple-S board will (i) take all action necessary to ensure that no state or territorial takeover statute, “business combination”,
“control share acquisition”, “fair price”, “moratorium” or similar Law is or becomes applicable to
any Transaction or the merger agreement and (ii) if any state or territorial takeover statute, “business combination”,
“control share acquisition”, “fair price”, “moratorium” or similar law becomes applicable to any transaction
or the merger agreement, take all action necessary to ensure that the transactions may be consummated as promptly as practicable on the
terms contemplated by the merger agreement and otherwise to minimize the effect of such statute or regulation on the transactions and
the merger agreement.
Litigation Related to the Merger
From the date of the merger
agreement and until the termination of the merger agreement, Triple-S will promptly advise Parent of any proceeding commenced or, to the
knowledge of Triple-S, threatened by a stockholder or holder of any equity interests of Triple-S against Triple-S or its directors or
executive officers relating to the merger or any of the other transactions, and will keep Parent reasonably informed, consult with Parent
regarding and give Parent the opportunity to participate, but not control, the defense and settlement of any such proceeding. Neither
Triple-S nor any of the its subsidiaries, nor any of their respective representatives, will agree to or propose any settlement of any
such proceeding without Parent’s prior written consent (which consent may not be unreasonably withheld, conditioned or delayed).
Employee Matters
For a period from the closing
of the merger through the first anniversary of the closing of the merger, each Triple-S employee who remains employed (the “Triple-S
continuing employees”) shall receive (i) a base salary, wage or commission rate at least equal to the base salary, wage or commission
rate provided to such Triple-S continuing employee by Triple-S immediately prior to the closing of the merger, (ii) incentive compensation
opportunities no less favorable than the incentive compensation opportunities provided to such Triple-S continuing employee by Triple-S
immediately prior to the closing of the merger (including the target value of annual equity-based compensation awards historically granted
to such Triple-S continuing employee prior to the closing of the merger, but excluding any one-time, special or transaction-related incentive
compensation opportunities), which incentive compensation opportunities will be subject to the terms and conditions of Parent’s
incentive compensation programs and (iii) other employee benefits that are no less favorable in the aggregate to the benefits provided
by Triple-S to such Triple-S continuing employee immediately prior to the closing of the merger.
On or after the closing of
the merger, Parent will, or will cause its affiliates, including the surviving corporation, to recognize the service of each Triple-S
continuing employee for all purposes under any employee benefit plan, other than (i) any post-employment health plan or post-employment
welfare plan or defined benefit pension plan or (ii) any severance plan to the extent that a Triple-S continuing employee is covered under
another severance arrangement with Triple-S, but excluding any severance payable pursuant to applicable law, to the same extent such service
credit was granted under any Triple-S benefit plan or arrangement and not in the case where such service credit would result in a duplication
of benefits.
In addition, following the
closing of the merger, the merger agreement provides that Parent will use reasonable best efforts to cause its affiliates to (i) waive
all limitations as to preexisting conditions or exclusions, actively-at-work requirements and waiting periods with respect to participation
and coverage requirements applicable to each Triple-S continuing employee (and eligible dependents) to the extent such conditions and
exclusions were satisfied or did not apply to such employees under the welfare plans of Triple-S prior to the closing of the merger and
(ii) provide each Triple-S continuing employee (and eligible dependents) with credit for any co-payments, deductibles and similar expenses
incurred by each Triple-S continuing employee during the calendar year in which the closing of the merger occurs in satisfying any analogous
deductible or out-of-pocket requirements to the extent applicable under the relevant benefit plan in which each Triple-S continuing employee
will be eligible to participate from and after the closing of the merger.
Directors’ and Officers’ Indemnification
and Insurance
Parent has agreed to assume
the obligations with respect to all rights to indemnification, advancement of expenses and exculpation from liabilities, for acts or omissions
occurring at or prior to the effective time of the merger now existing in favor of the current or former directors or officers (the “indemnified
persons”) of Triple-S or any of its subsidiaries as provided in the Triple-S articles and the Triple-S bylaws, the organizational
documents of any Triple-S’s subsidiary or any indemnification agreement between an indemnified person and Triple-S or any of its
subsidiaries as of the effective time of the merger, and such obligations will survive the merger and will continue in full force and
effect in accordance with their terms.
Parent will obtain, or will
cause the surviving corporation to obtain, at or prior to the effective time of the merger, a prepaid (or “tail”) directors’
and officers’ liability insurance policy in respect of acts or omissions occurring at or prior to the effective time of the merger,
covering each person currently covered by the Triple-S’s or any Triple-S’s subsidiary’s directors’ and officers’
liability insurance policies, with coverage for six years following the effective time on terms with respect to such coverage and amounts
no less favorable to the insureds than those of such policy in effect immediately prior to the effective time; provided, however,
that in no event will Parent or the surviving corporation be required to expend an amount in excess of 300%
of the most recent annual premium
paid by Triple-S or any of its subsidiaries for such insurance for its current fiscal year (such 300% threshold, the “maximum premium”);
provided further that, if the amount necessary to procure such prepaid (or “tail”) insurance coverage exceeds such
maximum premium, Parent or the surviving corporation, as the case may be, shall only be obligated to provide as much coverage as may be
obtained for such maximum premium. Triple-S may, prior to the effective time, purchase for an aggregate amount not to exceed the maximum
premium, a six-year prepaid (or “tail”) policy on terms and conditions providing at least substantially equivalent benefits
as the current policies of directors’ and officers’ liability insurance maintained by Triple-S and its subsidiaries in respect
of acts or omissions occurring at or prior to the effective time. If such prepaid (or “tail”) policy has been obtained by
Triple-S, it will be deemed to satisfy all obligations to obtain insurance pursuant to the merger agreement and the surviving corporation
will use its reasonable best efforts to cause such policy to be maintained in full force and effect, for its full term, and to honor all
of its obligations thereunder.
In the event that Parent,
the surviving corporation or any of their respective successors or assigns (i) consolidates with or merges into any other person
and is not the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys all or
substantially all of its properties and assets to any person, then, in each such case, Parent or the surviving corporation will make proper
provision so that the successors and assigns of Parent or the surviving corporation, as the case may be, or at Parent’s option,
Parent, assume the obligations set forth in the merger agreement.
Other Covenants
The merger agreement contains
other covenants, including those relating to access to information, notices, and employee matters.
Conditions to Completion of the Merger
The obligations of Triple-S,
Parent and Merger Sub to consummate the merger are subject to the satisfaction (or, to the extent permitted by applicable law, waiver
by the parties entitled thereto) of the following conditions:
|
·
|
The absence of any legal restraints restraining, enjoining, preventing, prohibiting or otherwise making
illegal the consummation of the merger;
|
|
·
|
Certain specified regulatory approvals having been obtained (or, in the case of certain specified regulatory
approvals that are statutory waiting periods, such waiting periods having expired or been terminated);
|
|
·
|
Approval and adoption of the merger agreement by an affirmative vote of the holders of a majority of the
shares of Triple-S common stock issued and outstanding at the close of business on the record date in accordance with Puerto Rico law;
|
The obligations of Parent
and Merger Sub to consummate the merger are also subject to the satisfaction (or, to the extent permitted by law, waiver by Parent and
Merger Sub) at or prior to the effective time of the merger, of each of the following conditions:
|
·
|
Certain of Triple-S’s representations and warranties relating to absence of certain changes or events
shall be true and correct in all respects at and as of the closing date as though made at and as of such date;
|
|
·
|
Certain of Triple-S’s representations and warranties relating to capital structure shall be true
and correct (for purposes of determining the satisfaction of this condition, without regard to any “materiality”, “company
material adverse effect” or similar qualifications and exceptions contained therein) at and as of the closing date as though made
at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in which case at
and as of such specified date)) except for any de minimis inaccuracies;
|
|
·
|
Certain of Triple-S’s representations and warranties relating to organization, standing and power,
Triple-S’s subsidiaries, equity interests, authority, execution and delivery, enforceability, and brokers and other advisors shall
be true and correct in all material respects, at and as of the closing date as though made at and as of such date (except to the extent
such representation and warranty expressly relates to a specified date (in which case at and as of such specified date));
|
|
·
|
All other representations and warranties of Triple-S set forth in the merger agreement, shall be true
and correct (for purposes of determining the satisfaction of this condition, without regard to any “materiality”, “company
material adverse effect” or similar qualifications and exceptions contained therein) at and as of the closing date as though made
at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in which case at
and as of such specified date)), other than for such failures to be true and correct that have not had and would not reasonably be expected
to have, individually or in the aggregate, a company material adverse effect;
|
|
·
|
Triple-S shall have performed in all material respects all of its obligations required to be performed
by it under the merger agreement at or prior to the effective time of the merger agreement;
|
|
·
|
Since the date of the merger agreement, there shall not have occurred any change, event, effect, fact,
circumstance, development or occurrence that has had or would reasonably be expected to have, individually or in the aggregate, a company
material adverse effect;
|
|
·
|
The absence of pending lawsuit brought by any governmental entity or other adjudicatory action initiated
by or at the behest of any governmental entity (and not upon the filing of a claim, challenge or complaint by any person other than such
governmental entity) seeking to restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the merger or the other
transactions or impose a burdensome condition;
|
|
·
|
The absence of legal restraint imposing a burdensome condition;
|
|
·
|
Certain specified consents and approvals of third parties with respect to certain specified contracts
having been obtained; and
|
|
·
|
Parent and Merger Sub shall have received from Triple-S a certificate, dated the closing date and signed
on behalf of Triple-S by Triple-S’s chief executive officer or chief financial officer, certifying that the first six conditions
in this section have been satisfied.
|
The obligation of Triple-S
to consummate the merger is also subject to the satisfaction (or, to the extent permitted by law, waiver by Triple-S) at or prior to the
effective time of the merger of each of the following conditions:
|
·
|
the representations and warranties of Parent and Merger Sub relating to organization, standing and power,
Merger Sub, authority, execution and deliver, enforceability and brokers and other advisors shall be true and correct in all material
respects, at and as of the closing date as though made at and as of such date (except to the extent such representation and warranty expressly
relates to a specified date (in which case at and as of such specified date));
|
|
·
|
All other representations and warranties of Parent and Merger Sub set forth in the merger agreement shall
be true and correct (for purposes of determining the satisfaction of this condition, without regard to any “materiality”,
“parent material adverse effect” (as described in the section entitled “The Merger Agreement—Definition of
‘Parent Material Adverse Effect’”) or similar qualifications and exceptions contained therein) at and as of the closing
date as though made at and as of such date (except to the extent such representation and warranty expressly relates to a specified date
(in which case at and as of such specified date)), other than for such failures to be true and correct that have not had and would not
reasonably be expected to have, individually or in the aggregate, a parent material adverse effect;
|
|
·
|
Each of Parent and Merger Sub shall have performed in all material respects all of its obligations required
to be performed by it under the merger agreement as of the effective time of the merger; and
|
|
·
|
Triple-S shall have received from Parent a certificate, dated the closing date and signed on behalf of
Parent by a duly authorized officer of Parent certifying that the above conditions have been satisfied.
|
Termination of the Merger Agreement
|
·
|
The merger agreement may be terminated and the merger may be abandoned at any time prior to the effective
time of the merger (whether before or after receipt of any approval of the merger agreement by Triple-S stockholders, except as otherwise
expressly noted):
|
|
·
|
by mutual written consent of Triple-S, Merger Sub and Parent;
|
|
·
|
by either Triple-S or Parent if:
|
|
·
|
The merger has not been consummated on or before May 23, 2022; provided that this termination right
will not be available to a party if the failure of the merger to be consummated on or before the outside date is the result of a material
breach of the merger agreement by such party;
|
|
·
|
Any legal restraint permanently restraining, enjoining, preventing, prohibiting or otherwise making illegal
the consummation of the merger is in effect and has become final and non-appealable;
|
|
·
|
If approval of Triple-S’s stockholders have not been obtained at the stockholders meeting (or any
adjournment or postponement thereof) and at which a vote by Triple-S’s stockholders on the adoption of the merger agreement was
taken; or
|
|
·
|
(i) a governmental entity has brought a lawsuit or (ii) an adjudicatory action has been initiated by or
at the behest of a governmental entity (and not upon the filing of a claim, challenge or complaint by any person other than such governmental
entity), in either case, seeking to (A) restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the merger or
the other transactions contemplated under the merger agreement or (B) impose a burdensome condition, and Parent or Merger Sub has notified
Triple-S that it refuses, or has withheld its consent from Triple-S, to defend such lawsuit or adjudicatory action.
|
|
·
|
Prior to the receipt of Triple-S’s stockholder approval, an adverse recommendation change has occurred,
or Triple-S committed a material breach of its obligations relating to non-solicitation of company takeover proposals or its obligations
related to stockholder approval and board recommendation and did not cure such breach;
|
|
·
|
Triple-S has breached any representation or warranty or failed to perform any covenant or agreement on
the part of Triple-S set forth in the merger agreement that would cause or result in any closing conditions related to Triple-S’s
representations and warranties or performance of its obligations under the merger agreement not being satisfied and such breach or failure
to perform is not capable of being cured or, if capable of being cured, is not cured prior to the earlier of thirty (30) days following
written notice to Parent or by the outside date; provided that, Parent and Merger Sub are not then in material breach of the merger
agreement; or
|
|
·
|
Any legal restraint imposing a burdensome condition is in effect and has become final and non-appealable.
|
|
·
|
Parent or Merger Sub has breached any representation or warranty or failed to perform any covenant or
agreement on the part of Parent or Merger Sub set forth in the merger agreement that would cause or result in any closing conditions related
to Parent or Merger Sub’s representations and warranties or performance of its obligations under the merger agreement not being
satisfied and such breach or failure to perform is not capable of being cured or, if capable of being cured, is not cured prior to the
earlier of thirty (30) days following written notice to Parent or by the outside date; provided that, Triple-S is not then in material
breach of the merger agreement; or
|
|
·
|
Prior to the receipt of Triple-S’s stockholder approval, the Triple-S board effects an adverse recommendation
change and concurrently enters into a definitive agreement concerning a superior proposal, subject to compliance with the restrictions
on solicitation of company takeover proposals; provided that concurrently with such termination, Triple-S pays to Parent the termination
fee required to be paid to Parent as described in the section entitled “The Merger Agreement—Termination Fee Payable by Triple-S
and
|
Reverse Termination Fee
Payable by Parent” beginning on page [●] of this proxy statement.
Termination Fee Payable by Triple-S and Reverse
Termination Fee Payable by Parent
|
·
|
Triple-S has agreed to pay Parent a fee of $17,985,000 by wire transfer of same-day funds (the
“termination fee”) upon termination of the merger agreement if:
|
|
·
|
Triple-S terminates the merger agreement, prior to receipt of Triple-S’s stockholder approval, in
order to effect an adverse recommendation change and concurrently enter into a definitive agreement providing for a superior proposal,
subject to compliance with its obligations relating to non-solicitation of company takeover proposals or its obligations related to stockholder
approval and board recommendation;
|
|
·
|
Parent terminates the merger agreement (or would have been entitled to terminate the merger agreement),
prior to receipt of Triple-S’s stockholder approval, because an adverse recommendation change has occurred or Triple-S has materially
breached its obligations relating to non-solicitation of company takeover proposals or its obligations related to stockholder approval
and board recommendation and did not cure such breach within five (5) days after Parent has given written notice to Triple-S of such breach;
or
|
|
·
|
(i) Parent terminates the merger agreement because Triple-S has breached any of its representations
or warranties or failed to perform any of its covenants or obligations contained in the merger agreement, which breach or failure to perform
would give rise to the failure of any closing conditions related to Triple-S’s representations and warranties or performance of
its obligations under the merger agreement and such breach or failure to perform is not capable of being cured or, if capable of being
cured, is not cured prior to the earlier of (a) thirty (30) days following written notice to Parent and (b) the outside date or (ii) either
Parent or Triple-S terminates the merger agreement because the merger has not been consummated on or before the outside date or (iii) Triple-S’s
stockholders did not approve the merger at the special meeting (or any adjournment or postponement thereof) and:
|
|
·
|
After the date of the merger agreement, a company takeover proposal is proposed to Triple-S board, or
is made public or a public announcement of intention to make a company takeover proposal was made and not publicly withdrawn prior to
the event that gave rise to the applicable termination right; and
|
|
·
|
Within twelve (12) months of such termination, a company takeover proposal (whether or not the same
one) is consummated or Triple-S or its subsidiaries enters into a definitive agreement relating to a company takeover proposal
(whether or not the same one) (provided that all references to “15%” in the definition of company takeover
proposal will be deemed to be a reference to “50%”).
|
|
·
|
Parent has agreed to pay Triple-S a reverse termination fee of $17,985,000 by wire transfer of
same-day funds (the “reverse termination fee”) upon termination of the merger agreement if:
|
|
·
|
Triple-S or Parent terminates the merger agreement because the merger has not been consummated on or before
the outside date and Triple-S did not commit a material breach of the merger agreement and, at the time of such termination, (A) any condition
related to absence of legal restraints relevant to the required regulatory approvals, required regulatory approvals, absence of certain
proceedings, no legal restraint imposing a burdensome condition or third-party consent was not satisfied (or, in the case of any of the
last three mentioned above, was not waived by Parent) and (B) all other conditions set forth in the merger agreement have been satisfied
(or, to the extent permitted by law, waived by the parties entitled thereto) (or in the case of conditions which by their nature are to
be satisfied at the closing, were capable of being satisfied as of such time);
|
|
·
|
Triple-S or Parent terminates the merger agreement because a legal restraint that restrains, enjoins,
prevents, prohibits or otherwise makes illegal the consummation of the merger is in effect and has become final and non-appealable (but
only if the applicable legal restraint relates to the required regulatory approvals);
|
|
·
|
Parent terminates the merger agreement because a legal restraint that imposes a burdensome condition is
in effect and has become final and non-appealable; or
|
|
·
|
Triple-S or Parent terminates the merger agreement because (i) a governmental entity has brought a lawsuit
or (ii) an adjudicatory action has been initiated by or at the behest of a governmental entity (and not upon the filing of a claim, challenge
or complaint by any person other than such governmental entity), in either case, seeking to (A) restrain, enjoin, prevent, prohibit or
otherwise make illegal the consummation of the merger or the other transactions contemplated by the merger agreement or (B) impose a burdensome
condition and Parent or Merger Sub has notified Triple-S that it refuses, or has withheld its consent from Triple-S, to defend such lawsuit
or adjudicatory action.
|
Remedies; Maximum Liability
The merger agreement provides
that in no event will Triple-S be required to pay the termination fee on more than one occasion, whether or not the termination fee may
be payable under more than one provision of the merger agreement at the same or at different times and the occurrence of different events.
If the termination fee becomes payable in accordance with the merger agreement, the payment to Parent or its designee of the termination
fee will be the sole and exclusive remedy of Parent and Merger Sub for any loss suffered by Parent or Merger Sub as a result of the failure
of the transactions to be consummated and, upon such payment in accordance with the merger agreement, Triple-S will not have any further
liability or obligation relating to or arising out of the merger agreement or the transactions, except in the case of fraud or willful
or intentional breach of the merger agreement by Triple-S.
In addition, the merger agreement
provides that in no event will Parent be required to pay the reverse termination fee on more than one occasion, whether or not the reverse
termination fee may be payable under more than one provision of the merger agreement at the same time or at different times and the occurrence
of different events. If the reverse termination fee becomes payable in accordance with the merger agreement, the payment to Triple-S or
its designee of the reverse termination fee will be the sole and exclusive remedy of Triple-S for any loss suffered by Triple-S as a result
of the failure of the transactions to be consummated and, upon such payment in accordance with the merger agreement, neither Parent nor
Merger Sub will have any further liability or obligation relating to or arising out of the merger agreement or the transactions, except
in the case of fraud or willful or intentional breach of the merger agreement by Parent or Merger Sub, as applicable.
Specific Performance
The merger agreement provides
that the parties will be entitled to an injunction or injunctions, or any other appropriate form of equitable relief, to prevent breaches
of the merger agreement and to specifically enforce the performance of the terms and provisions of the merger agreement in any court,
without the necessity of providing any bond or other security or proving actual damages or the inadequacy of monetary damages as a remedy.
Each of the parties further agrees not to oppose a remedy of specific enforcement on the basis that the other party has an adequate alternative
remedy at law.
Fees and Expenses
Except as set forth in the
section “The Merger Agreement—Termination Fee Payable by Triple-S and Reverse Termination Fee Payable by Parent” beginning
on page [●] of this proxy statement, all fees and expenses incurred in connection with the merger agreement will be paid by the
party incurring such fees or expense.
Amendments and Waivers
The merger agreement may be
amended, modified and supplemented in any and all respects only by an instrument in writing signed on behalf of each of the parties. Any
agreement on the part of a party to any extension or waiver with respect to the merger agreement shall be valid only if set forth in an
instrument in writing signed on behalf of such party. At any time prior to the effective time of the merger, the parties (treating Parent
and Merger Sub as one party for this purpose) may (i) extend the time for the performance of any of the obligations or other acts of the
other party, (ii) waive any inaccuracies in the representations and warranties of the other party contained in the merger agreement or
in any document delivered pursuant to the merger agreement or (iii) waive compliance by the other party with any of the agreements or
conditions contained in the merger agreement. Notwithstanding the foregoing, there will be made no amendment, modification or supplement
to the merger agreement (i) after receipt of the Triple-S stockholder
approval which requires further
approval by the stockholders of Triple-S without the further approval of such stockholders or (ii) after the effective time of the merger.
The failure of any party to the merger agreement to assert any of its rights under the merger agreement or otherwise shall not constitute
a waiver of such rights.
Governing Law and Venue, Waiver of Jury Trial
The parties agreed that the
merger agreement will be governed by, and construed in accordance with, the laws of the State of Delaware, regardless of the laws that
might otherwise govern under applicable principles of conflicts of laws, except to the extent that the Laws of the Commonwealth of Puerto
Rico are mandatorily applicable to the merger agreement, the transactions or the certificate of merger filed in Puerto Rico.
Each of the parties irrevocably
submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware (or, if such court is unavailable, any state or
federal court sitting in the State of Delaware) for the purpose of any proceeding arising out of or relating to the merger agreement,
the merger or any of the other transactions, and each of the parties irrevocably agrees that all claims with respect to such proceeding
may be heard and determined exclusively in such court. Each of the parties (i) consents to submit itself to the personal jurisdiction
of the Court of Chancery of the State of Delaware (or, if such court is unavailable, any state or federal court sitting in the State of
Delaware) in the event any proceeding arises out of the merger agreement, the merger or any of the other transactions, (ii) agrees that
it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court, (iii) irrevocably
consents to the service of process in any Proceeding arising out of or relating to the merger agreement, the merger or any of the other
transactions, on behalf of itself or its property, in accordance with the merger agreement (provided that nothing in the
merger agreement will affect the right of any party to serve legal process in any other manner permitted by law) and (iv) agrees that
it will not bring any proceeding relating to the merger agreement, the merger or any of the other transactions in any court other than
the Court of Chancery of the State of Delaware (or, if such court is unavailable, any state or federal court sitting in the State of Delaware).
The parties agree that a final trial court judgment in any such proceeding will be conclusive and may be enforced in other jurisdictions
by suit on the judgment or in any other manner provided by Law. The foregoing statement will not restrict any party’s right to seek
any post-judgment relief regarding, or any appeal from, such final trial court judgment, or to bring suit for the recognition or enforcement
of any judgment obtained in any court sitting in the State of Delaware or in any other court of competent jurisdiction following final
determination of the applicable matter.
Each party further waived,
to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect of any proceeding arising out of
or relating to the merger agreement, the merger or any of the other transactions. Each party (a) certifies that no representative agent
or attorney of any other party has represented expressly or otherwise, that such party would not, in the event of any proceeding, seek
to enforce this waiver and (b) acknowledges that it makes this waiver voluntarily and that the other parties have been induced to enter
into the merger agreement by, among other things, the mutual waiver and certifications described in this paragraph.
MARKET
PRICES OF TRIPLE-S COMMON STOCK
Triple-S common stock is listed
on the NYSE under the symbol “GTS.” The following table sets forth on a per share basis the high and low intra-day prices
of Triple-S common stock as reported in published financial sources. At the close of business on [●], 2021, there were [●]
holders of record of Triple-S common stock. A number of Triple-S stockholders have their shares in street name; therefore, Triple-S believes
that there are substantially more beneficial owners of Triple-S common stock.
|
|
High
|
|
Low
|
|
Dividends
|
Fiscal Year 2021
|
|
|
|
|
|
|
Second Quarter
|
|
$
|
26.75
|
|
|
$
|
22.08
|
|
|
|
—
|
|
First Quarter
|
|
$
|
28.84
|
|
|
$
|
20.95
|
|
|
|
—
|
|
Fiscal Year 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
24.70
|
|
|
$
|
17.55
|
|
|
|
—
|
|
Third Quarter
|
|
$
|
20.82
|
|
|
$
|
17.01
|
|
|
|
—
|
|
Second Quarter
|
|
$
|
21.51
|
|
|
$
|
11.92
|
|
|
|
—
|
|
First Quarter
|
|
$
|
19.45
|
|
|
$
|
9.13
|
|
|
|
—
|
|
Fiscal Year 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
20.25
|
|
|
$
|
12.66
|
|
|
|
—
|
|
Third Quarter
|
|
$
|
27.64
|
|
|
$
|
13.10
|
|
|
|
0.051107*
|
|
Second Quarter
|
|
$
|
26.51
|
|
|
$
|
19.42
|
|
|
|
—
|
|
First Quarter
|
|
$
|
26.46
|
|
|
$
|
15.93
|
|
|
|
—
|
|
Fiscal Year 2018
|
|
|
|
|
|
|
|
|
|
|
|
|
Fourth Quarter
|
|
$
|
22.16
|
|
|
$
|
15.45
|
|
|
|
—
|
|
Third Quarter
|
|
$
|
40.44
|
|
|
$
|
18.65
|
|
|
|
—
|
|
Second Quarter
|
|
$
|
44.01
|
|
|
$
|
25.65
|
|
|
|
—
|
|
First Quarter
|
|
$
|
28.66
|
|
|
$
|
22.75
|
|
|
|
—
|
|
* On August 6, 2019, all holders of class B shares
at the close of business on July 26, 2019 received a share dividend of 0.051107 class B shares for every class B share they owned as of
that time.
The closing price of Triple-S
common stock on the NYSE on [●], 2021, the most recent practicable date prior to the date of this proxy statement, was $[●]
per share. As of [●], 2021, Triple-S had [●] shares of Triple-S common stock issued and outstanding, and Triple-S
had approximately [●] holders of record. You are encouraged to obtain current market prices of Triple-S common stock in connection
with voting your shares of Triple-S common stock.
Dividends
On July 16, 2019, Triple-S
announced that the Triple-S board of directors authorized the conversion of Triple-S’s then remaining issued and outstanding class
A common shares into class B common shares, effective August 7, 2019. In connection with the conversion, all holders of class B shares
at the close of business on July 26, 2019 received a share dividend of 0.051107 class B shares for every class B share they owned as of
that time, as determined by the anti-dilution formula in Triple-S’s articles of incorporation. The class B share dividend was paid
on August 6, 2019; cash was paid in lieu of fractional shares. Effective upon Triple-S’s public announcement on August 7, 2019,
all class A holders of record received one class B share for each class A share held. Upon the conversion of the class A common shares,
all remaining outstanding Class A shares were automatically cancelled and extinguished, and Triple-S now maintains a single class of common
shares.
Other than as described above,
Triple-S did not declare any cash dividends during the four most recent fiscal years and does not expect to pay any cash dividends in
the near future. Under the terms of the merger agreement, from the date of the merger agreement until the earlier of the effective time
of the merger or the termination of the merger agreement, Triple-S may not declare, set aside or pay any dividend or other distribution
(whether in cash, stock or property or any combination thereof) in respect of its capital stock or other equity interests, except for
dividends or other such distributions by any of its wholly owned subsidiaries, without the prior written consent of Parent.
APPRAISAL
RIGHTS OF STOCKHOLDERS
The following discussion summarizes
appraisal rights under Puerto Rico law. The following discussion is not a complete statement of the law relating to appraisal rights and
is qualified in its entirety by the full text of Article 10.13 of Puerto Rico law, referred to as “Article 10.13,” which is
attached to this proxy statement (in English and Spanish) as Annex C. The following summary does not constitute legal or other advice,
nor does it constitute a recommendation that stockholders exercise their appraisal rights under Article 10.13.
Under Article 10.13, holders
of shares of Triple-S common stock who do not vote in favor of the adoption of the merger agreement and who otherwise follow the procedures
set forth in Article 10.13 will be entitled to have their shares appraised by the Puerto Rico Court of First Instance, Superior Court,
and to receive payment in cash of the “fair value” of the shares, exclusive of any element of value arising from the accomplishment
or expectation of the merger, as determined by the Puerto Rico Court of First Instance, Superior Court, together with interest, if any,
to be paid upon the amount determined to be the fair value.
Under Article 10.13, where
a merger agreement is to be submitted for adoption and approval at a meeting of stockholders, the corporation, not less than 20 days prior
to the meeting, must notify each of its stockholders entitled to appraisal rights that appraisal rights are available and include in the
notice a copy of Article 10.13. This proxy statement shall constitute such notice, and the full text of Article 10.13. is attached
to this proxy statement (in English and Spanish) as Annex C.
ANY HOLDER OF TRIPLE-S COMMON
STOCK WHO WISHES TO EXERCISE APPRAISAL RIGHTS, OR WHO WISHES TO PRESERVE SUCH HOLDER’S RIGHT TO DO SO, SHOULD CAREFULLY REVIEW THE
FOLLOWING DISCUSSION AND ANNEX C BECAUSE FAILURE TO TIMELY AND PROPERLY COMPLY WITH THE PROCEDURES SPECIFIED WILL RESULT IN THE LOSS OF
APPRAISAL RIGHTS. MOREOVER, BECAUSE OF THE COMPLEXITY OF THE PROCEDURES FOR EXERCISING THE RIGHT TO SEEK APPRAISAL OF SHARES OF TRIPLE-S
COMMON STOCK, TRIPLE-S BELIEVES THAT, IF A STOCKHOLDER CONSIDERS EXERCISING SUCH RIGHTS, SUCH STOCKHOLDER SHOULD SEEK THE ADVICE OF LEGAL
COUNSEL.
Filing Written Demand
Any holder of Triple-S common
stock wishing to exercise appraisal rights must, before the stockholder vote on the adoption of the merger agreement at the special meeting
is taken, deliver to Triple-S a written demand for the appraisal of the stockholder’s shares, and not vote in favor of the adoption
of the merger agreement. A holder of Triple-S common stock wishing to exercise appraisal rights must hold of record the shares on the
date the written demand for appraisal is made and must continue to hold the shares of record through the effective date of the merger.
The holder must not vote in favor of the adoption of the merger agreement. A proxy that is submitted and does not contain voting instructions
will, unless revoked, be voted in favor of the adoption of the merger agreement, and it will effectively constitute a waiver of the stockholder’s
right of appraisal and will effectively nullify any previously delivered written demand for appraisal. Therefore, a stockholder who submits
a proxy and who wishes to exercise appraisal rights must submit a proxy containing instructions to vote against the adoption of the merger
agreement or abstain from voting on the adoption of the merger agreement. Neither voting against the merger proposal, nor abstaining from
voting or failing to vote on the merger proposal, will in and of itself constitute a written demand for appraisal satisfying the requirements
of Article 10.13. The written demand for appraisal must be in addition to and separate from any proxy or vote on the adoption of the merger
agreement. The demand must reasonably inform Triple-S of the identity of the holder as well as the intention of the holder to demand an
appraisal of the “fair value” of the shares held by the holder. A stockholder’s failure to make the written demand prior
to the taking of the vote on the adoption of the merger agreement at the special meeting of stockholders will constitute a waiver of appraisal
rights.
Only a holder of record of
shares of Triple-S common stock is entitled to demand an appraisal of the shares registered in that holder’s name. A demand for
appraisal in respect of shares of Triple-S common stock should be executed by or on behalf of the holder of record. The demand should
set forth the registered holder’s name as it appears on the holder’s stock certificates. A demand for appraisal will be sufficient
if it reasonably informs Triple-S of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal
of such stockholder’s shares. If the shares are owned of record in a fiduciary capacity, such as by a trustee, guardian or custodian,
execution of the demand must be made in that capacity, and if the shares are owned of record by more than one person, as in a joint tenancy
and tenancy-in-common, the demand must be executed by or on behalf of all joint owners. An authorized agent, including an agent for two
or more joint owners, may execute a demand for appraisal on behalf of a holder of record; however, the
agent must identify the record
owner or owners and expressly disclose that, in executing the demand, the agent is acting as agent for the record owner or owners. If
the shares are held in “street name” by a broker, bank or nominee, the broker, bank or nominee may exercise appraisal rights
with respect to the shares held for one or more beneficial owners while not exercising the rights with respect to the shares held for
other beneficial owners; in such case, however, the written demand should set forth the number of shares as to which appraisal is sought.
Where no number of shares is expressly mentioned, the demand will be presumed to cover all shares of Triple-S common stock held in the
name of the record owner. If a stockholder holds shares of Triple-S common stock through a broker who in turn holds the shares through
a central securities depository nominee such as Cede & Co., a demand for appraisal of such shares must be made by or on behalf of
the depository nominee and must identify the depository nominee as record holder. Stockholders who hold their shares in brokerage accounts
or other nominee forms and who wish to exercise appraisal rights are urged to consult with their brokers or other nominees to determine
the appropriate procedures for the making of a demand for appraisal by such a nominee.
All written demands for appraisal
pursuant to Article 10.13 should be sent or delivered to Triple-S at:
Triple-S Management Corporation
1441 F.D. Roosevelt Avenue
San Juan, Puerto Rico 00920
Attention: General Counsel and Secretary
At any time within sixty (60)
days after the effective date of the merger, any stockholder who has not commenced an appraisal proceeding or joined that proceeding as
a named party may withdraw his, her or its demand for appraisal and accept the consideration offered pursuant to the merger agreement
by delivering to Triple-S, as the surviving corporation, a written withdrawal of the demand for appraisal. However, any such attempt to
withdraw the demand made more than sixty (60) days after the effective date of the merger will require written approval of Triple-S, as
the surviving corporation. No appraisal proceeding in the Puerto Rico Court of First Instance, Superior Court, will be dismissed as to
any stockholder without the approval of the Puerto Rico Court of First Instance, Superior Court, and such approval may be conditioned
upon such terms as the Puerto Rico Court of First Instance, Superior Court deems just; provided, however, that any stockholder who has
not commenced an appraisal proceeding or joined that proceeding as a named party may withdraw his, her or its demand for appraisal and
accept the merger consideration offered pursuant to the merger agreement within sixty (60) days after the effective date of the merger.
If Triple-S, as the surviving corporation, does not approve a request to withdraw a demand for appraisal when that approval is required,
or, except with respect to any stockholder who withdraws such stockholder’s demand in accordance with the proviso in the immediately
preceding sentence, if the Puerto Rico Court of First Instance, Superior Court, does not approve the dismissal of an appraisal proceeding
with respect to a stockholder, the stockholder will be entitled to receive only the appraised value determined in any such appraisal proceeding,
which value could be less than, equal to or more than the consideration being offered pursuant to the merger agreement.
Notice by the Surviving Corporation
Within ten (10) days after
the effective date of the merger, Triple-S, as the surviving corporation, must notify each holder of Triple-S common stock who has complied
with Article 10.13, and who has not voted in favor of the adoption of the merger agreement, of the date on which the merger became effective.
Filing a Petition for Appraisal
Within one hundred twenty
(120) days after the effective date of the merger, but not thereafter, Triple-S, as the surviving corporation, or any holder of Triple-S
common stock who has complied with Article 10.13 and is entitled to appraisal rights under Article 10.13, may commence an appraisal proceeding
by filing a petition in the Puerto Rico Court of First Instance, Superior Court, with a copy served upon the surviving corporation in
the case of a petition filed by a stockholder, demanding a determination of the fair value of the shares held by all such holders. Triple-S,
as the surviving corporation, is under no obligation to and has no present intention to file a petition and holders should not assume
that Triple-S as the surviving corporation will file a petition. Accordingly, any holders of Triple-S common stock who desire to have
their shares appraised should initiate all necessary action to perfect their appraisal rights in respect of shares of Triple-S common
stock within the time prescribed in Article 10.13. Within one hundred twenty (120) days after the effective date of the merger, any holder
of common stock who has complied with the requirements of Article 10.13 will be entitled, upon written request, to receive from Triple-S
as the surviving corporation a statement setting forth the aggregate number of shares not voted in favor of the adoption of the merger
agreement and with respect to which demands for appraisal have been received and the aggregate number of holders of
such shares. The statement must
be mailed within ten (10) days after a written request therefor has been received by Triple-S as the surviving corporation or within ten
(10) days after the expiration of the period for delivery of demands for appraisal, whichever is later. The foregoing notwithstanding,
a person who is the beneficial owner of shares of Triple-S common stock held either in a voting trust or by a nominee on behalf of such
person may, in such person’s own name, file a petition or request from Triple-S as the surviving corporation the statement described
in this paragraph. If a petition for appraisal is not timely filed, then the right to appraisal will cease.
If a petition for an appraisal
is timely filed by a holder of shares of Triple-S common stock and a copy thereof is served upon Triple-S as the surviving corporation,
Triple-S as the surviving corporation will then be obligated within twenty (20) days to file with the Puerto Rico Department of State
a duly verified list containing the names and addresses of all stockholders who have demanded an appraisal of their shares and with whom
agreements as to the value of their shares have not been reached. After notice to the stockholders, the Puerto Rico Court of First Instance,
Superior Court, will conduct a hearing on the petition to determine those stockholders who have complied with Article 10.13 and who have
become entitled to appraisal rights thereunder. The Puerto Rico Court of First Instance, Superior Court, may require the stockholders
who demanded payment for their shares to submit their stock certificates to the Puerto Rico Department of State for notation thereon of
the pendency of the appraisal proceeding; and if any stockholder fails to comply with the direction, the Puerto Rico Court of First Instance,
Superior Court, may dismiss the proceedings as to such stockholder.
Determination of Fair Value
After the Puerto Rico Court
of First Instance, Superior Court, determination of the stockholders entitled to appraisal of their shares of Triple-S common stock, an
appraisal proceeding shall be conducted in accordance with the rules of the Puerto Rico Court of First Instance, Superior Court, including
any rules specifically governing appraisal proceedings. Through this proceeding, the Puerto Rico Court of First Instance, Superior Court,
will determine the fair value of the shares of Triple-S common stock as of the effective time of the merger exclusive of any element of
value arising from the accomplishment or expectation of the merger, together with interest, if any, to be paid upon the amount determined
to be the fair value. When the value is determined, the Puerto Rico Court of First Instance, Superior Court, will direct the payment of
such fair value, with interest, if any, by the surviving corporation to the stockholders entitled thereto. Upon application by the surviving
corporation or by any stockholder entitled to participate in the appraisal proceeding, the Puerto Rico Court of First Instance, Superior
Court, may, in its discretion, proceed to trial upon the appraisal prior to the final determination of the stockholders entitled to an
appraisal. Any stockholder whose name appears on the list filed by the surviving corporation pursuant to Article 10.13 of Puerto Rico
law and who has submitted such stockholder’s stock certificates to the Puerto Rico Department of State, if such is required, may
participate fully in all proceedings until it is finally determined that such stockholder is not entitled to appraisal rights under Article
10.13 of Puerto Rico law.
No representation is made
as to the outcome of the appraisal of fair value as determined by the Puerto Rico Court of First Instance, Superior Court. In addition,
Puerto Rico courts have not decided whether the statutory appraisal remedy would be a dissenter’s exclusive remedy. You should
be aware that the fair value of your shares as determined under Article 10.13 of Puerto Rico law could be greater than, the same as, or
less than the merger consideration that you would otherwise be entitled to receive under the terms of the merger agreement. Triple-S does
not anticipate offering an amount greater than the merger consideration to any stockholder who exercises appraisal rights and reserves
the right to assert, in any appraisal proceeding, that, for purposes of Article 10.13 of Puerto Rico law, the fair value of the Triple-S
common stock shares is less than the merger consideration.
Costs of the appraisal proceeding
may be imposed upon the surviving corporation and the stockholders participating in the appraisal proceeding by the Puerto Rico Court
of First Instance, Superior Court, as the Puerto Rico Court of First Instance, Superior Court, deems equitable in the circumstances. Upon
the application of a stockholder, the Puerto Rico Court of First Instance, Superior Court, may order all or a portion of the expenses
incurred by any stockholder in connection with the appraisal proceeding, including, without limitation, reasonable attorneys’ fees
and the fees and expenses of experts, to be charged pro rata against the value of all shares entitled to appraisal. Any stockholder who
has demanded appraisal rights will not, after the effective date of the merger, be entitled to vote such shares for any purpose or to
receive payments of dividends or any other distribution with respect to those shares, other than dividends or other distributions payable
to stockholders of record at a date prior to the effective date of the merger; however, if no petition for appraisal is filed within one
hundred twenty (120) days after the effective date of the merger, or if the stockholder delivers a written withdrawal of his, her or its
demand for appraisal and an acceptance of the terms of the merger, either within 60 days after the effective date of the merger or thereafter
with the
written approval of the corporation, then the right
of that stockholder to appraisal will cease and that stockholder will be entitled to receive the merger consideration for shares of his,
her or its common stock pursuant to the merger agreement.
In view of the complexity
of Article 10.13 of Puerto Rico law, our stockholders who may wish to dissent from the merger and pursue appraisal rights should consult
their legal advisor. To the extent there are any inconsistencies between the foregoing summary and Article 10.13 of Puerto Rico law, Puerto
Rico law shall govern.
ADVISORY
VOTE ON NAMED EXECUTIVE OFFICER MERGER-RELATED
FUTURE
TRIPLE-S STOCKHOLDER PROPOSALS
If the merger is completed,
we may not hold an annual meeting of stockholders in 2022. If the merger is not completed, you will continue to be entitled to attend
and participate in our annual meetings of stockholders, and we will hold a 2022 annual meeting of stockholders, in which case we will
provide notice of or otherwise publicly disclose the date on which such 2022 annual meeting will be held. If the 2022 annual meeting is
held, stockholder proposals will be eligible for consideration for inclusion in the proxy statement and form of proxy for our 2022 annual
meeting of stockholders in accordance with Rule 14a-8 under the Exchange Act and our bylaws, as described below.
Consistent with SEC regulations,
proposals of stockholders of Triple-S that are intended to be presented at the annual meeting to be held in 2022, and which stockholders
desire to have included in Triple-S’s proxy materials relating to such annual meeting, must be received by Triple-S no later than
November 12, 2021, which is one hundred twenty (120) calendar days prior to the first anniversary of the mailing date for the 2021 annual
meeting’s proxy statement, and must be in compliance with applicable laws and regulations, as outlined in our 2021 proxy statement,
in order to be considered for possible inclusion in the proxy statement for that annual meeting. Please refer to our 2021 proxy statement
for further details.
MULTIPLE
STOCKHOLDERS SHARING ONE ADDRESS
The SEC has adopted rules
that permit companies and intermediaries, such as brokers, to satisfy the delivery requirements for proxy statements and annual reports
with respect to two or more stockholders sharing the same address by delivering a single annual report or proxy statement, as applicable,
addressed to those stockholders. This process, which is commonly referred to as “householding,” potentially provides extra
convenience for stockholders and cost savings for companies.
Triple-S and some brokers
may be householding our proxy materials by delivering proxy materials to multiple stockholders who request a copy and share an address,
unless contrary instructions have been received from the affected stockholders. Once you have received notice from your broker or us that
they or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke
your consent. If at any time you no longer wish to participate in householding and would prefer to receive a separate proxy statement
and annual report, please notify your broker if your shares are held in a brokerage account or Triple-S if you are a stockholder of record.
You can notify us by sending a written request to Triple-S Management Corporation, 1441 F.D. Roosevelt Avenue, San Juan, Puerto Rico 00920,
Attn: Secretary, or calling (787) 749-4949. Stockholders who share a single address, but receive multiple copies of the proxy statement,
may request that in the future they receive a single copy by notifying Triple-S at the telephone and address set forth in the prior sentence.
In addition, Triple-S will promptly deliver, upon written or oral request to the address or telephone number above, a separate copy of
the proxy statement to a stockholder at a shared address to which a single copy of the documents was delivered pursuant to a prior request.
WHERE
YOU CAN FIND MORE INFORMATION
Triple-S is subject to the
reporting requirements of the Exchange Act. Accordingly, Triple-S files annual, quarterly and current reports, proxy statements and other
information with the SEC. You may read and copy any document that we file with the SEC at the Public Reference Room of the SEC at 100
F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at
1-800-SEC-0330. In addition, Triple-S’s SEC filings also are available to the public at the internet website maintained by the SEC
at www.sec.gov. Triple-S also makes available free of charge on the Investor Relations section of its website its Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section
13(a) or 15(d) of the Exchange Act, its definitive proxy statements and Section 16 reports on Forms 3, 4 and 5, as soon as reasonably
practicable after it electronically files such reports or amendments with, or furnishes them to, the SEC. Triple-S’s internet website
address is www.triplesmanagement.com. The information located on, or hyperlinked or otherwise connected to Triple-S’s website is
not, and will not be deemed to be, a part of this proxy statement or incorporated into any other filings that we make with the SEC.
The SEC allows Triple-S to
“incorporate by reference” the information we file with the SEC into this proxy statement, which means that we can disclose
important information to you by referring you to other documents filed separately with the SEC. The information incorporated by reference
is deemed to be part of this proxy statement, except that information that we file later with the SEC will automatically update and supersede
this information. This proxy statement incorporates by reference the documents listed below that have been previously filed with the SEC
(other than, in each case, documents or information deemed to have been furnished and not filed in accordance with SEC rules):
|
·
|
Triple-S’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the
SEC on February 26, 2021;
|
|
·
|
Triple-S’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2021, filed with
the SEC on August 5, 2021; and
|
|
·
|
Triple-S’s Current Report on Form 8-K filed with the SEC on March 25, 2021, May 6, 2021, August
24, 2021 and September 15, 2021.
|
We also incorporate by reference
into this proxy statement additional documents that Triple-S may file with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange
Act, from the date of this proxy statement until the date of the special meeting; provided, however, that we are not incorporating
by reference any additional documents or information furnished and not filed with the SEC.
You may request a copy of
documents incorporated by reference at no cost, by writing or telephoning the office of the Secretary at Triple-S Management Corporation,
1441 F.D. Roosevelt Avenue, San Juan, Puerto Rico 00920, Tel. (787) 749-4949.
THIS PROXY STATEMENT DOES
NOT CONSTITUTE THE SOLICITATION OF A PROXY IN ANY JURISDICTION TO OR FROM ANY PERSON TO WHOM OR FROM WHOM IT IS UNLAWFUL TO MAKE SUCH
PROXY SOLICITATION IN THAT JURISDICTION. YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED OR INCORPORATED BY REFERENCE INTO THIS PROXY
STATEMENT TO VOTE YOUR SHARES AT THE SPECIAL MEETING OR ANY ADJOURNMENT OR POSTPONEMENT THEREOF. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE
YOU WITH INFORMATION THAT IS DIFFERENT FROM WHAT IS CONTAINED IN THIS PROXY STATEMENT. THIS PROXY STATEMENT IS DATED [•], 2021. YOU
SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED IN THIS PROXY STATEMENT IS ACCURATE AS OF ANY DATE OTHER THAN THAT DATE, AND THE MAILING
OF THIS PROXY STATEMENT TO STOCKHOLDERS DOES NOT CREATE ANY IMPLICATION TO THE CONTRARY.
YOUR VOTE IS EXTREMELY
IMPORTANT. Whether or not you plan to attend the special meeting, please complete, sign, date and return your proxy card by mail or submit
your proxy over the internet as promptly as possible. If you attend the special meeting and wish to vote your shares personally, you may
do so.
|
By Order of the Board of Directors of
Triple-S Management Corporation
|
|
|
|
|
|
Carlos L. Rodríguez-Ramos
|
|
Secretary
|
San Juan, Puerto Rico
[•], 2021
ANNEX A
CONFIDENTIAL
EXECUTION VERSION
AGREEMENT AND PLAN OF MERGER
dated as of
August 23, 2021,
among
GUIDEWELL MUTUAL
HOLDING CORPORATION,
GUIDEWELL MERGER,
INC.
and
TRIPLE-S MANAGEMENT
CORPORATION
|
TABLE OF CONTENTS
Page
ARTICLE I
The Merger
|
|
|
|
|
|
|
SECTION
1.01. The Merger
|
|
|
1
|
|
SECTION
1.02. Closing
|
|
|
1
|
|
SECTION
1.03. Effective Time
|
|
|
2
|
|
SECTION
1.04. Effects of Merger
|
|
|
2
|
|
SECTION
1.05. Articles of Incorporation and Bylaws
|
|
|
2
|
|
SECTION
1.06. Directors and Officers
|
|
|
2
|
|
|
|
|
|
|
ARTICLE II
Effect on
Capital Stock; Payment for Shares
|
|
|
|
|
|
|
SECTION
2.01. Effect on Capital Stock
|
|
|
3
|
|
SECTION
2.02. Payment of Merger Consideration
|
|
|
4
|
|
|
|
|
|
|
ARTICLE III
Representations
and Warranties of the Company
|
|
|
|
|
|
|
SECTION
3.01. Organization, Standing and Power
|
|
|
7
|
|
SECTION
3.02. Capital Structure
|
|
|
7
|
|
SECTION
3.03. Company Subsidiaries; Equity Interests
|
|
|
10
|
|
SECTION
3.04. Authority; Execution and Delivery; Enforceability
|
|
|
10
|
|
SECTION
3.05. No Conflicts; Consents
|
|
|
11
|
|
SECTION
3.06. SEC Documents; Undisclosed Liabilities; Internal Controls
|
|
|
12
|
|
SECTION
3.07. Statutory Statements; Examinations; Filings
|
|
|
15
|
|
SECTION
3.08. Insurance Contract Benefits
|
|
|
17
|
|
SECTION
3.09. Reserves
|
|
|
17
|
|
SECTION
3.10. Capital or Surplus Maintenance
|
|
|
17
|
|
SECTION
3.11. Investments
|
|
|
18
|
|
SECTION
3.12. Medicare Secondary Payer Rules
|
|
|
18
|
|
SECTION
3.13. Insurance Agents and Administrators
|
|
|
18
|
|
SECTION
3.14. The Proxy Statement
|
|
|
19
|
|
SECTION
3.15. Absence of Certain Changes or Events
|
|
|
19
|
|
SECTION
3.16. Taxes
|
|
|
19
|
|
SECTION
3.17. Labor Relations
|
|
|
21
|
|
SECTION
3.18. Employee Benefits
|
|
|
22
|
|
SECTION
3.19. Title to Properties
|
|
|
24
|
|
SECTION
3.20. Contracts
|
|
|
26
|
|
SECTION
3.21. Litigation
|
|
|
29
|
|
SECTION
3.22. Compliance with Laws; Authorizations; Policies
|
|
|
29
|
|
SECTION
3.23. Environmental Matters
|
|
|
32
|
|
SECTION
3.24. Intellectual Property
|
|
|
32
|
|
SECTION
3.25. Insurance
|
|
|
34
|
|
SECTION
3.26. Brokers and Other Advisors
|
|
|
35
|
|
SECTION
3.27. Opinions of Financial Advisors
|
|
|
35
|
|
|
|
|
|
|
ARTICLE IV
Representations
and Warranties of Parent and Merger Sub
|
|
|
|
|
|
|
SECTION
4.01. Organization, Standing and Power
|
|
|
35
|
|
SECTION
4.02. Merger Sub
|
|
|
35
|
|
SECTION
4.03. Authority; Execution and Delivery; Enforceability
|
|
|
36
|
|
SECTION
4.04. No Conflicts; Consents
|
|
|
36
|
|
SECTION
4.05. Information Supplied
|
|
|
37
|
|
SECTION
4.06. Available Funds
|
|
|
37
|
|
SECTION
4.07. Brokers and Other Advisors
|
|
|
37
|
|
|
|
|
|
|
ARTICLE V
Covenants
Relating to Conduct of Business
|
|
|
|
|
|
|
SECTION
5.01. Conduct of Business of the Company
|
|
|
38
|
|
SECTION
5.02. No Solicitation
|
|
|
43
|
|
|
|
|
|
|
ARTICLE VI
Additional
Agreements
|
|
|
|
|
|
|
SECTION
6.01. Company Stockholders Meeting; Preparation of the Proxy Statement
|
|
|
47
|
|
SECTION
6.02. Access to Information; Confidentiality
|
|
|
48
|
|
SECTION
6.03. Consents and Approvals
|
|
|
49
|
|
SECTION
6.04. Equity Awards
|
|
|
52
|
|
SECTION
6.05. Continuing Employee Matters
|
|
|
54
|
|
SECTION
6.06. Indemnification
|
|
|
55
|
|
SECTION
6.07. Fees and Expenses
|
|
|
56
|
|
SECTION
6.08. Public Announcements
|
|
|
59
|
|
SECTION
6.09. Tax Matters
|
|
|
59
|
|
SECTION
6.10. Stockholder Litigation
|
|
|
59
|
|
SECTION
6.11. Section 16 Matters
|
|
|
60
|
|
SECTION
6.12. Merger Sub and Surviving Corporation Compliance
|
|
|
60
|
|
SECTION
6.13. Advice of Changes
|
|
|
60
|
|
ARTICLE VII
Conditions
Precedent to the Merger
|
|
|
|
|
|
|
SECTION
7.01. Conditions to Each Party’s Obligation
|
|
|
60
|
|
SECTION
7.02. Conditions to Obligations of Parent and Merger Sub
|
|
|
61
|
|
SECTION
7.03. Conditions to Obligations of the Company
|
|
|
62
|
|
|
|
|
|
|
ARTICLE VIII
Termination;
Amendment and Waiver
|
|
|
|
|
|
|
SECTION
8.01. Termination
|
|
|
63
|
|
SECTION
8.02. Effect of Termination
|
|
|
64
|
|
SECTION
8.03. Amendment; Extension; Waiver
|
|
|
64
|
|
|
|
|
|
|
ARTICLE IX
General Provisions
|
|
|
|
|
|
|
SECTION
9.01. Nonsurvival of Representations and Warranties
|
|
|
65
|
|
SECTION
9.02. Notices
|
|
|
65
|
|
SECTION
9.03. Definitions
|
|
|
66
|
|
SECTION
9.04. Interpretation
|
|
|
76
|
|
SECTION
9.05. Severability
|
|
|
77
|
|
SECTION
9.06. Counterparts
|
|
|
77
|
|
SECTION
9.07. Entire Agreement; Third-Party Beneficiaries; No Other Representations or Warranties
|
|
|
78
|
|
SECTION
9.08. Governing Law
|
|
|
78
|
|
SECTION
9.09. Assignment
|
|
|
78
|
|
SECTION
9.10. Specific Enforcement; Jurisdiction
|
|
|
79
|
|
SECTION
9.11. WAIVER OF JURY TRIAL
|
|
|
80
|
|
INDEX OF DEFINED TERMS
Defined Term
|
Location
of Definition
|
|
|
Acceptable Confidentiality Agreement
|
9.03
|
Administrator
|
9.03
|
Adverse Recommendation Change
|
5.02(e)
|
affiliate
|
9.03
|
Agent
|
9.03
|
Agreement
|
Preamble
|
Antitrust Approvals
|
3.05(b)
|
Antitrust Laws
|
9.03
|
Appraisal Shares
|
2.01(d)
|
Article 10.13
|
2.01(d)
|
ASES
|
9.03
|
Authorizations
|
3.22(f)
|
Bankruptcy and Equity Exception
|
3.04(a)
|
BCBSA
|
9.03
|
Book-Entry Shares
|
2.02(b)
|
Burdensome Condition
|
6.03(c)
|
Business Day
|
9.03
|
CARES Act
|
9.03
|
Certificates
|
2.02(b)
|
Closing
|
1.02
|
Closing Date
|
1.02
|
CMS
|
9.03
|
Code
|
9.03
|
Company
|
Preamble
|
Company Acquisition Agreement
|
5.02(a)
|
Company Actuarial Analyses
|
3.09
|
Company Articles
|
3.01
|
Company Balance Sheet
|
3.06(e)
|
Company Benefit Plan
|
9.03
|
Company Board
|
Recitals
|
Company Board Recommendation
|
3.04(b)
|
Company Bylaws
|
3.01
|
Company Common Stock
|
Recitals
|
Company Concession
|
6.03(a)
|
Company Disclosure Letter
|
Article III
|
Company Intellectual Property
|
9.03
|
Company Material Adverse Effect
|
9.03
|
Company Performance Share Unit
|
9.03
|
Company Preferred Stock
|
3.02(a)
|
Company PSU
|
9.03
|
Company Record Date
|
6.01(a)
|
Company Registered Intellectual Property
|
3.24(a)
|
Defined Term
|
Location
of Definition
|
Company Restricted Share
|
9.03
|
Company Restricted Stock Unit
|
9.03
|
Company Restriction
|
6.03(c)
|
Company RSA
|
9.03
|
Company RSU
|
9.03
|
Company SEC Documents
|
3.06(a)
|
Company Statutory Financial Statements
|
3.07(a)
|
Company Stock Plan
|
9.03
|
Company Stockholder Approval
|
3.04(b)
|
Company Stockholders Meeting
|
6.01(a)
|
the Company Subsidiaries
|
3.01
|
Company Takeover Proposal
|
9.03
|
Company Termination Fee
|
6.07(b)
|
Company’s knowledge
|
9.03
|
Confidentiality Agreement
|
6.02
|
Consent
|
3.05(b)
|
Continuing Employees
|
6.05(a)
|
Contract
|
3.05(a)
|
control
|
9.03
|
Controlled Group
|
3.18(d)
|
Copyrights
|
9.03
|
COVID-19
|
9.03
|
COVID-19 Measures
|
9.03
|
DE Certificate of Merger
|
1.03
|
De Minimis Company Restriction
|
6.03(c)
|
DGCL
|
Recitals
|
DOH
|
3.20(a)
|
DOJ
|
6.03(c)
|
DOT
|
3.18(b)
|
Effective Time
|
1.03
|
Environmental Authorizations
|
3.23(a)
|
Environmental Claims
|
9.03
|
Environmental Law
|
9.03
|
Equity Interests
|
3.02(a)
|
ERISA
|
3.18(c)
|
Exchange Act
|
9.03
|
Exchange Fund
|
2.02(a)
|
Excluded Shares
|
2.01(b)
|
Families First Act
|
9.03
|
FCPA
|
3.22(d)
|
Form A
|
9.03
|
Form E
|
9.03
|
FTC
|
6.03(c)
|
Defined Term
|
Location
of Definition
|
GAAP
|
3.02(e)
|
Government Sponsored Health Care Programs
|
9.03
|
Governmental Entity
|
3.05(b)
|
Hazardous Materials
|
9.03
|
Health Care Laws
|
9.03
|
Health Care Programs
|
9.03
|
HSR Act
|
3.05(b)
|
Incentive Law
|
3.16(o)
|
Indebtedness
|
9.03
|
Indemnified Persons
|
6.06(a)
|
Insurance Contract
|
9.03
|
Insurance Laws
|
9.03
|
Insurance Regulator
|
9.03
|
Intellectual Property
|
9.03
|
Intervening Event
|
9.03
|
Investment Assets
|
9.03
|
Investment Guidelines
|
3.11
|
IT Assets
|
9.03
|
Judgment
|
3.05(a)
|
knowledge of the Company
|
9.03
|
Law
|
3.05(a)
|
Leased Real Property
|
3.19(b)
|
Leases
|
3.19(b)
|
Legal Restraints
|
7.01(a)
|
Liens
|
3.03(b)
|
Maximum Premium
|
6.06(b)
|
Measurement Date
|
3.02(a)
|
Merger
|
Recitals
|
Merger Consideration
|
2.01(c)
|
Merger Sub
|
Preamble
|
Nonqualified Deferred Compensation Plan
|
3.18(i)
|
Notice of Adverse Recommendation Change
|
5.02(f)
|
NYSE
|
3.02(e)
|
OCI
|
3.22(a)
|
OITE
|
3.22(a)
|
OSS
|
9.03
|
Outside Date
|
8.01(b)(i)
|
Owned Real Property
|
3.19(a)
|
Owned Real Property Leases
|
3.19(a)
|
Parent
|
Preamble
|
Parent Disclosure Letter
|
Article IV
|
Parent Material Adverse Effect
|
9.03
|
Parent Termination Fee
|
6.07(c)
|
Defined Term
|
Location
of Definition
|
parties
|
Preamble
|
party
|
Preamble
|
Patents
|
9.03
|
Paying Agent
|
2.02(a)
|
Payment
|
6.07(d)
|
Payor
|
6.07(d)
|
Permitted Liens
|
9.03
|
Person
|
9.03
|
Personal Data
|
9.03
|
Policies
|
3.22(h)
|
POS Leased Real Property
|
3.19(b)
|
PR Certificate of Merger
|
1.03
|
PR Code
|
3.18(c)
|
PR Insurance Code
|
9.03
|
PRGCA
|
Recitals
|
Proceeding
|
3.21
|
Providers
|
9.03
|
Proxy Statement
|
3.05(b)
|
Qualifying Company Takeover Proposal
|
5.02(c)
|
Qualifying Director Share
|
9.03
|
RBC Plans
|
3.07(f)
|
Recent SEC Reports
|
Article III
|
Recipient
|
6.07(d)
|
Release
|
9.03
|
Representatives
|
5.02(a)
|
Risk-Based Capital
|
9.03
|
Risk-Based Capital Report
|
9.03
|
SAP
|
3.06(e)
|
Sarbanes-Oxley Act
|
3.06(b)
|
SEC
|
9.03
|
Secondary Payer Rules
|
3.12
|
Securities Act
|
9.03
|
Specified Company Regulatory Approvals
|
3.05(b)
|
Specified Contract
|
3.20 (a)
|
Specified Parent Regulatory Approvals
|
4.04(b)
|
Specified Permitted Investment
|
9.03
|
Specified Regulatory Approvals
|
4.04(b)
|
subsidiary
|
9.03
|
Superior Proposal
|
9.03
|
Surviving Articles
|
1.05
|
Surviving Corporation
|
1.01
|
Tax Grant
|
3.16(o)
|
Tax Return
|
9.03
|
Defined Term
|
Location
of Definition
|
Taxes
|
9.03
|
Taxing Authority
|
9.03
|
Trade Secrets
|
9.03
|
Trademarks
|
9.03
|
Transactions
|
Recitals
|
Unspecified Permitted Investment
|
9.03
|
Voting Company Debt
|
3.02(c)
|
AGREEMENT AND PLAN
OF MERGER dated as of August 23, 2021 (this “Agreement”), by and among GuideWell Mutual Holding Corporation, a Florida
not-for-profit mutual insurance holding company (“Parent”), GuideWell Merger, Inc., a Delaware corporation and a wholly
owned subsidiary of Parent (“Merger Sub”), and Triple-S Management Corporation, a Puerto Rico corporation (the “Company”).
Unless expressly stated otherwise, Parent, Merger Sub and the Company are referred to in this Agreement individually as a “party”
and collectively as the “parties”.
WHEREAS, the parties
intend that at the Effective Time, Merger Sub will be merged with and into the Company (the “Merger”) upon the terms
and subject to the conditions set forth in this Agreement and in accordance with the General Corporations Act (2009) of the Commonwealth
of Puerto Rico (the “PRGCA”) and the General Corporation Law of the State of Delaware (the “DGCL”),
with the Company surviving the Merger and becoming a wholly owned subsidiary of Parent as a result of the Merger;
WHEREAS, the Board
of Directors of the Company (the “Company Board”) has (i) determined that this Agreement, the Merger and the
other transactions contemplated hereby (collectively, the “Transactions”) are in the best interests of the Company
and its stockholders, (ii) unanimously approved and declared advisable this Agreement and the Transactions, including the Merger,
in each case on the terms and subject to the conditions set forth in this Agreement and (iii) recommended that the holders of shares
of common stock, par value $1.00 per share, of the Company (“Company Common Stock”), adopt this Agreement and directed
that this Agreement be submitted to the Company’s stockholders at the Company Stockholders Meeting;
WHEREAS, the Board
of Directors of Merger Sub has approved and declared advisable, and the Board of Directors of Parent has approved, this Agreement and
the Transactions, including the Merger, in each case on the terms and subject to the conditions set forth in this Agreement;
WHEREAS, Parent, Merger
Sub and the Company desire to make certain representations, warranties, covenants and agreements in connection with the Transactions.
NOW, THEREFORE, the
parties hereto agree as follows:
ARTICLE
I
The Merger
SECTION 1.01. The
Merger. On the terms and subject to the conditions set forth in this Agreement and in accordance with the PRGCA and the DGCL, Merger
Sub shall be merged with and into the Company at the Effective Time. At the Effective Time, the separate corporate existence of Merger
Sub shall cease and the Company shall continue as the surviving corporation (the “Surviving Corporation”).
SECTION 1.02. Closing.
The closing of the Merger (the “Closing”) shall take place at the offices of Cravath, Swaine & Moore LLP,
825 Eighth Avenue, New
York, New York 10019 at 10:00 a.m.,
New York City time (or remotely by exchange of documents and signatures (or their electronic counterparts)), on a date to be specified
and agreed by Parent and the Company, which date shall be no later than the third Business Day following the satisfaction (or, to the
extent permitted by Law, waiver by the party entitled thereto), of the conditions set forth in Article VII (other than those
conditions that by their nature are to be satisfied at the Closing, but subject to the satisfaction (or, to the extent permitted by Law,
waiver by the party entitled thereto) of such conditions, or at such other place, time and date as shall be agreed in writing by the
parties hereto. The date on which the Closing occurs is referred to in this Agreement as the “Closing Date”.
SECTION 1.03. Effective
Time. Prior to the Closing, Parent, Merger Sub and the Company shall prepare, and on the Closing Date, Parent, Merger Sub and the
Company shall (a) file with the Secretary of State of the Commonwealth of Puerto Rico, a certificate of merger (the “PR Certificate
of Merger”) executed in accordance with, and in such form as is required by, the relevant provisions of the PRGCA, and shall
make all other filings or recordings required under the PRGCA to effectuate the Merger, and (b) file with the Secretary of State
of the State of Delaware a certificate of merger (the “DE Certificate of Merger”) executed in accordance with, and
in such form as is required by, the relevant provisions of the DGCL, and shall make all other filings or recordings required under the
DGCL to effectuate the Merger. The Merger shall become effective at such time as the PR Certificate of Merger is duly filed with the
Secretary of State of the Commonwealth of Puerto Rico or at such other time as Parent and the Company shall agree and specify in the
PR Certificate of Merger in accordance with the PRGCA (the time the Merger becomes effective being referred to herein as the “Effective
Time”).
SECTION 1.04. Effects
of Merger. The Merger shall have the effects provided in this Agreement, the PR Certificate of Merger and the DE Certificate of Merger
and as set forth in Article 10.10 of the PRGCA and Section 259 of the DGCL. Without limiting the generality of the foregoing, at the
Effective Time, all of the property, rights, privileges, powers and franchises of the Company and Merger Sub will vest in the Surviving
Corporation, and all debts, liabilities and duties of the Company and Merger Sub will become the debts, liabilities and duties of the
Surviving Corporation.
SECTION 1.05. Articles
of Incorporation and Bylaws. At the Effective Time, (a) the articles of incorporation of the Company, as in effect immediately prior
to the Effective Time, shall be the articles of incorporation of the Surviving Corporation (the “Surviving Articles”),
until thereafter amended in accordance with applicable Law and the applicable provisions therein, and (b) the bylaws of the Company,
as in effect immediately prior to the Effective Time, shall be the bylaws of the Surviving Corporation, until thereafter amended in accordance
with applicable Law, the applicable provisions therein and the Surviving Articles.
SECTION 1.06. Directors
and Officers. (a) The directors of Merger Sub immediately prior to the Effective Time shall be the directors of the Surviving Corporation,
until the earlier of their resignation or removal or until their respective successors are duly elected and qualified, as the case may
be.
(b) The officers of
the Company immediately prior to the Effective Time shall be the officers of the Surviving Corporation, until the earlier of their resignation
or removal or until their respective successors are duly elected or appointed and qualified, as the case may be.
ARTICLE
II
Effect on Capital Stock; Payment for Shares
SECTION 2.01. Effect
on Capital Stock. At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company
or any holder of any shares of Company Common Stock or any shares of capital stock of Merger Sub:
(a) Capital Stock
of Merger Sub. Each issued and outstanding share of common stock of Merger Sub, par value $1.00 per share, shall automatically be
canceled and converted into and become one validly issued, fully paid and nonassessable share of common stock, par value $1.00 per share,
of the Surviving Corporation.
(b) Cancellation
of Stock Owned by the Company, Parent or Merger Sub. Each share of Company Common Stock that is owned by the Company, Parent or Merger
Sub (such shares, “Excluded Shares”), in each case immediately prior to the Effective Time, shall no longer be outstanding
and shall automatically be canceled and retired and shall cease to exist, and no consideration shall be delivered or deliverable in exchange
therefor.
(c) Conversion
of Company Common Stock. Each issued and outstanding share of Company Common Stock (other than Company RSAs (which shall be treated
as provided in Section 6.04(a)(i)), Excluded Shares and Appraisal Shares) shall be converted into the right to receive an amount
in cash equal to $36.00, without interest and less any applicable withholding Taxes (the “Merger Consideration”).
As of the Effective Time, all such shares of Company Common Stock shall no longer be outstanding and shall automatically be canceled
and retired and shall cease to exist, and each holder of any such shares of Company Common Stock shall cease to have any rights with
respect thereto, except the right to receive the Merger Consideration in accordance with Section 2.02, without interest.
(d) Appraisal Rights.
Notwithstanding anything in this Agreement to the contrary, shares of Company Common Stock that are outstanding immediately prior
to the Effective Time and that are held by any Person who has not voted in favor of the adoption of this Agreement or consented thereto
in writing and who is entitled to demand and properly demands appraisal of such shares pursuant to, and who complies in all respects
with, Article 10.13 of the PRGCA (“Article 10.13”) (such shares, “Appraisal Shares”) shall not
be converted into the right to receive the Merger Consideration as provided in Section 2.01(c), but instead, at the
Effective Time, by virtue of the Merger and without any action on the part of the holder thereof, shall be automatically canceled and
retired and shall cease to exist and shall represent the right to receive only those
rights provided under
Article 10.13; provided, however, that if any such holder shall fail to perfect or otherwise shall waive, withdraw or lose
the right to appraisal under Article 10.13 or a court of competent jurisdiction shall determine that such holder is not entitled
to the relief provided by Article 10.13, then the right of such holder to receive those rights under and to be paid such consideration
as is determined pursuant to Article 10.13, shall cease and such Appraisal Shares shall be deemed to have been converted as of the
Effective Time into, and shall represent only the right to receive, the Merger Consideration as provided in Section 2.01(c).
Any portion of the aggregate Merger Consideration made available to the Paying Agent pursuant to Section 2.02 to pay
for Appraisal Shares for which appraisal rights have been perfected will be returned to Parent upon demand. The Company shall serve prompt
notice to Parent of any demands received by the Company for appraisal of any shares of Company Common Stock, any withdrawals of any such
demands or any other instruments served pursuant to the PRGCA and received by the Company relating to the rights of appraisal of the
holders of shares of Company Common Stock, and Parent shall have the right to participate in and, after the Effective Time, direct all
negotiations and Proceedings with respect to such demands. Prior to the Effective Time, the Company shall not, without the prior written
consent of Parent, make any payment with respect to, or settle or offer to settle, waive any failure to timely deliver a written demand
for appraisal or to timely take any other action to exercise appraisal rights in accordance with Article 10.13, or otherwise negotiate
any such demands, or agree to do any of the foregoing.
SECTION 2.02. Payment
of Merger Consideration. (a) Paying Agent. Prior to the Effective Time, Parent shall select a bank or trust company reasonably
acceptable to the Company to act as paying agent (the “Paying Agent”) for the payment of the Merger Consideration
as provided in Section 2.01(c). On or prior to the Effective Time, Parent shall make available to the Paying Agent the Merger
Consideration to be paid in respect of the shares of Company Common Stock converted into the right to receive the Merger Consideration
pursuant to Section 2.01(c) (such cash being hereinafter referred to as the “Exchange Fund”).
(b) Exchange Procedure.
Promptly after the Effective Time (but not later than five Business Days thereafter), the Paying Agent shall mail to each holder
of record of a certificate or certificates, or a non-certificated share or non-certificated shares, that immediately prior to the Effective
Time represented outstanding shares of Company Common Stock (the “Certificates” or “Book-Entry Shares”,
respectively) which were converted into the right to receive the Merger Consideration pursuant to Section 2.01(c), (i) a
letter of transmittal (which shall specify that delivery shall be effected, and risk of loss and title to the Certificates or Book-Entry
Shares, as applicable, shall pass, only upon delivery of the Certificates or Book-Entry Shares, as applicable, to the Paying Agent) and
(ii) instructions for use in effecting the surrender of the Certificates or Book-Entry Shares, as applicable, in exchange for the
Merger Consideration. Upon (A) in the case of a Certificate, surrender of such Certificate to the Paying Agent for cancellation,
together with such letter of transmittal, duly executed, and such other documents as may reasonably be required by the Paying Agent,
or (B) in the case of Book-Entry Shares, receipt of an “agent’s message” by the Paying Agent (or such other evidence,
if any, of the transfer as the Paying Agent may reasonably request), the holder of such Certificate
or Book-Entry Share,
as applicable, shall be entitled to receive in exchange therefor the Merger Consideration for each share of Company Common Stock theretofore
represented by such Certificate or Book-Entry Share, as applicable, pursuant to Section 2.01(c), and the Certificate
or Book-Entry Share, as applicable, so surrendered shall forthwith be canceled. In the event of a transfer of ownership of Company Common
Stock that is not registered in the transfer records of the Company, payment may be made to a Person other than the Person in whose name
the Certificate or Book-Entry Share, as applicable, so surrendered is registered, if such Certificate or Book-Entry Share, as applicable,
shall be properly endorsed or otherwise be in proper form for transfer and the Person requesting such payment shall pay any transfer
or other Taxes required by reason of the payment to a Person other than the registered holder of such Certificate or Book-Entry Share,
as applicable, or establish to the satisfaction of Parent that such Tax has been paid or is not applicable. Until surrendered as contemplated
by this Section 2.02, each Certificate or Book-Entry Share shall be deemed at any time after the Effective Time to represent
only the right to receive upon such surrender the Merger Consideration in accordance with this Article II. No interest
shall be paid or accrue on the cash payable upon surrender of any Certificate or Book-Entry Share.
(c) No Further
Ownership Rights in Company Common Stock. The Merger Consideration paid in accordance with the terms of this Article II
upon the surrender of any Certificate or Book-Entry Share shall be deemed to have been paid in full satisfaction of all rights pertaining
to the shares of Company Common Stock that such Certificate or Book-Entry Share represented immediately prior to the Effective Time.
After the Effective Time, there shall be no further registration of transfers on the stock transfer books of the Surviving Corporation
of shares of Company Common Stock that were outstanding immediately prior to the Effective Time. If, after the Effective Time, any Certificates
or Book-Entry Shares are presented to the Surviving Corporation or the Paying Agent for any reason, they shall be canceled and exchanged
as provided in this Article II. No cash payment with respect to the Merger Consideration shall be paid to the holder
of any unsurrendered Certificate or Book-Entry Share until the surrender of such Certificate or Book-Entry Share in accordance with this
Section 2.02.
(d) Termination
of Exchange Fund. Any portion of the Exchange Fund that remains undistributed to the holders of Certificates or Book-Entry Shares
for one year after the Effective Time shall be delivered to Parent, upon demand, and any former holder of Company Common Stock entitled
to payment of the Merger Consideration who has not theretofore complied with this Article II shall thereafter look only
to Parent for payment of its claim for the Merger Consideration.
(e) No
Liability. None of Parent, Merger Sub, the Surviving Corporation or the Paying Agent shall be liable to any Person in respect
of any cash from the Exchange Fund delivered to a public official pursuant to any applicable abandoned property, escheat or similar
Law. If any Certificate or Book-Entry Share has not been surrendered prior to the 24-month anniversary of the Effective Time (or, if
earlier, immediately prior to the date on which the Merger Consideration in respect of such Certificate
or Book-Entry Share
would otherwise escheat to or become the property of any Governmental Entity), any such Merger Consideration in respect of such Certificate
or Book-Entry Share shall, to the extent permitted by applicable Law, become the property of the Surviving Corporation, free and clear
of all claims or interest of any Person previously entitled thereto.
(f) Investment
of Exchange Fund. The Paying Agent shall invest any cash included in the Exchange Fund, as directed by Parent, on a daily basis.
Any interest and other income resulting from such investments shall be paid to Parent. To the extent that there are losses with respect
to such investments, such that the Exchange Fund diminishes below the level required to make prompt payments of the Merger Consideration
as contemplated hereby, Parent shall promptly replace or restore the portion of the Exchange Fund lost through investments so as to ensure
that the Exchange Fund is, at all times, maintained at a level sufficient to make such payments. No such investment or any loss thereon
shall affect the amounts payable pursuant to this Article II.
(g) Lost Certificates.
If any Certificate shall have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the Person claiming
such Certificate to be lost, stolen or destroyed and, if required by the Paying Agent or by Parent, the posting by such Person of a bond
in such reasonable and customary amount as indemnity against any claim that may be made against it with respect to such Certificate,
the Paying Agent shall deliver in exchange for such lost, stolen or destroyed Certificate the applicable Merger Consideration to be paid
in respect of the shares of Company Common Stock represented by such Certificate, as contemplated by this Article II.
(h) Adjustments.
If, during the period between the date of this Agreement and the Effective Time, any change in the outstanding shares of capital stock
of the Company shall occur as a result of any reclassification, recapitalization, stock split or combination, exchange or readjustment
of shares, or any stock dividend thereon with a record date during such period, the Merger Consideration and any other amounts payable
pursuant to this Agreement shall be appropriately adjusted; provided that this clause (h) shall not be construed to permit the
Company to take any action with respect to its capital stock that is prohibited by Section 5.1.
(i) Withholding
Rights. Each of the Surviving Corporation, Merger Sub, Parent and the Paying Agent shall be entitled to deduct and withhold from
the consideration otherwise payable pursuant to this Agreement such amounts as may be required to be deducted and withheld with respect
to the making of such payment under any applicable Tax Law. Amounts so withheld and paid over to the appropriate Taxing Authority shall
be treated for all purposes of this Agreement as having been paid to the Person in respect of which such deduction or withholding was
made.
ARTICLE
III
Representations and Warranties of the Company
Except as (a) specifically
disclosed in the reports, schedules, forms, statements and other documents filed or furnished by the Company with the SEC since January
1, 2019 and publicly available on the internet website of the SEC at least two
Business Days prior
to the date of this Agreement (other than any disclosures contained in any section entitled “Risk Factors”, set forth
in any “Forward-Looking Statements” disclaimer or that are cautionary, non-specific, predictive or forward-looking in nature)
(the “Recent SEC Reports”) (it being agreed that any matter disclosed in the Recent SEC Reports shall be deemed to
qualify the Company’s representations and warranties hereunder only to the extent that it is reasonably apparent from the face
of such disclosure in such Recent SEC Report that such disclosure is applicable to such representations and warranties) or (b) set forth
in the disclosure letter (with specific reference to the Section or subsection of this Agreement to which the information stated in such
disclosure relates; provided that information contained in any section or subsection of the disclosure letter shall be deemed
to be disclosed with respect to any other Section or subsection of this Agreement to the extent that it is reasonably apparent from the
face of such disclosure that such information is applicable to such other Section or subsection of this Agreement) dated the date hereof
and delivered by the Company to Parent and Merger Sub immediately prior to the execution of this Agreement (the “Company Disclosure
Letter”), the Company represents and warrants to Parent and Merger Sub as follows:
SECTION 3.01. Organization,
Standing and Power. Each of the Company and the Company Subsidiaries is duly organized, validly existing and in good standing (where
applicable as a legal concept) under the laws of the jurisdiction in which it is organized and has full corporate power and authority
necessary to enable it to own, lease or otherwise hold its properties and assets and to conduct its business as presently conducted,
except in the case of a Company Subsidiary as has not had and would not, individually or in the aggregate, reasonably be expected to
(i) have a Company Material Adverse Effect or (ii) prevent or materially impair or delay the consummation of the Merger and the other
Transactions or the ability of the Company to perform its obligations under this Agreement (this clause (ii), a “Company Impairment
Effect”). The Company has made available to Parent true, correct and complete copies of the articles of incorporation of the
Company, as amended to the date of this Agreement (as so amended, the “Company Articles”), and the bylaws of the Company,
as amended to the date of this Agreement (as so amended, the “Company Bylaws”), and the comparable organizational
documents of each Company Subsidiary, in each case as amended to the date of this Agreement. The Company Articles and the Company Bylaws
and the comparable organizational documents of the Company Subsidiaries are in full force and effect, and neither the Company nor any
of the Company Subsidiaries is in violation of any of their provisions. The Company has made available to Parent true, correct and complete
copies of the minutes (or, in the case of minutes that have not yet been finalized, drafts thereof) of all meetings of the stockholders
of the Company, the Company Board and each committee of the Company Board, in each case held since January 1, 2019 and prior to the date
hereof (which may be redacted to remove any deliberations with respect to the Transactions and any other strategic transaction considered
by the Company).
SECTION 3.02. Capital
Structure. (a) The authorized capital stock of the Company consists of 200,000,000 shares of Company Common Stock and 100,000,000
shares of preferred stock, par value $1.00 per share (the “Company Preferred Stock”). At the close of business
on August 19, 2021 (such date and time, the
“Measurement Date”),
(i) 23,795,952 shares of Company Common Stock were issued and outstanding (265,752 of which were unvested Company RSAs), (ii) no shares
of Company Preferred Stock were issued and outstanding, (iii) no shares of Company Common Stock were held by the Company in its
treasury, and (iv) 1,840,671 additional shares of Company Common Stock were reserved and available for issuance pursuant to the
Company Stock Plan (of which 1,033,230 shares of Company Common Stock were subject to outstanding Company Performance Share Units (assuming
achievement of any applicable performance criteria at the target level) and 150,092 shares of Company Common Stock were subject to outstanding
Company Restricted Stock Units). As of the Measurement Date, no (A) shares of capital stock or other voting securities of, (B) other
equity or voting interests in, (C) securities convertible into or exchangeable for, or options, warrants or other rights to acquire or
receive any, capital stock, voting securities or other equity interests in, or (D) stock appreciation rights, “phantom”
stock rights, or other rights that give the holder thereof any economic or voting interest of a nature accruing to the holders of capital
stock in (clauses (A), (B), (C) and (D), collectively, “Equity Interests”), the Company, and no other obligation to
make any payments based on the price or value of any Equity Interest in the Company or dividends (or other distributions) paid thereon
or revenues, earnings or financial performance or any other attribute of the Company, in each case other than pursuant to the vesting,
exercise or settlement of Company RSAs, Company PSUs and Company RSUs, were issued, reserved for issuance or outstanding except as set
forth in this Section 3.02(a). From and after the Measurement Date through the date of this Agreement, the Company has not
(i) issued any Equity Interests or (ii) incurred any obligation to make any payments based on the price or value of any Equity Interests
in the Company or dividends (or other distributions) paid thereon or revenues, earnings or financial performance or any other attribute
of the Company, in each case other than pursuant to the vesting, exercise or settlement of Company RSAs, Company PSUs and Company RSUs
and other purchase rights and stock awards granted pursuant to the Company Stock Plan, in each case that were outstanding as of the Measurement
Date, and in accordance with their respective terms as in effect at such time.
(b) All issued and
outstanding Equity Interests in the Company are, and at the time of issuance all Equity Interests in the Company that may be issued prior
to the Effective Time, including all shares that may be issued pursuant to the Company Stock Plan, will be, duly authorized, validly
issued, fully paid and nonassessable and not subject to or issued in violation of any purchase option, call option, right of first refusal,
preemptive right, subscription right or any similar right under any provision of the PRGCA, the Company Articles, the Company Bylaws
or any Contract to which the Company is a party or otherwise bound.
(c) There are no bonds,
debentures, notes or other Indebtedness of the Company that may have at any time (whether actual or contingent) the right to vote, or
that are convertible into or exchangeable for securities having the right to vote, on any matters on which holders of shares of Company
Common Stock may vote (“Voting Company Debt”) or any securities that are convertible into or exchangeable for, or
options, warrants or other rights to acquire or receive any, Voting Company Debt.
(d) Except pursuant
to the vesting, exercise or settlement of Company RSAs, Company PSUs and Company RSUs, in each case in accordance with their respective
terms as in effect at such time or in accordance with this Agreement, there are not any outstanding obligations of the Company or any
Company Subsidiary to issue, deliver or sell, or cause to be issued, delivered or sold, any Equity Interests in the Company or any Company
Subsidiary. There are not any outstanding obligations of the Company or any Company Subsidiary to directly or indirectly redeem, repurchase
or otherwise acquire any Equity Interests in the Company or any Company Subsidiary, except for (A) acquisitions of shares of Company
Common Stock in connection with the surrender of shares of Company Common Stock by holders of Company RSAs, (B) the withholding of shares
of Company Common Stock to satisfy Tax obligations with respect to the exercise, settlement or vesting of Company RSAs, Company PSUs
or Company RSUs or (C) the acquisition by the Company of Company RSAs, Company PSUs or Company RSUs in connection with the forfeiture
of such awards, in each case in accordance with their respective terms. Neither the Company nor any of the Company Subsidiaries is party
to any agreement with respect to the voting, transfer or registration of any capital stock or voting securities of, or other Equity Interests
in, the Company or any Company Subsidiary. Except as contemplated by this Agreement, neither the Company nor any of the Company Subsidiaries
is party to any agreement pursuant to which any Person is entitled to elect, designate or nominate any director of the Company or any
of the Company Subsidiaries. No Company Subsidiary owns any shares of capital stock of the Company.
(e) All Company RSAs,
Company PSUs and Company RSUs are evidenced by written award agreements, in each case substantially in the forms that have been made
available to Parent, except that such agreements may differ from such forms with respect to the number of Company RSAs, Company PSUs
and Company RSUs covered thereby and the vesting schedule and expiration date applicable thereto. Each Company RSA, Company PSU and Company
RSU may, by its terms, be treated in accordance with Section 6.04.
(f) Section 3.02(f)
of the Company Disclosure Letter sets forth a true, correct and complete list of all Company RSAs, Company PSUs and Company RSUs outstanding
as of the Measurement Date, specifying, on a holder-by-holder basis, (i) the name of each holder, (ii) the number of shares of Company
Common Stock subject thereto, (iii) the grant date thereof, (iv) the expiration or vesting date thereof, (v) the performance-based vesting
conditions and (vi) the number of shares of Company Common Stock that would be issuable assuming applicable performance-based vesting
conditions are achieved at the target level, in each case to the extent applicable. With respect to each grant of Company RSAs, Company
PSUs and Company RSUs, each such grant was (A) made in accordance with the terms of the applicable Company Stock Plan, the Exchange Act
and all other applicable Laws, and the rules and regulations of the New York Stock Exchange (“NYSE”) and (B) properly
accounted for in accordance with generally accepted accounting principles in the United States (“GAAP”) or the applicable
statutory accounting principles prescribed or permitted by applicable Insurance Regulators applied on a consistent basis (“SAP”),
as applicable, in the financial
statements (including
the related notes) of the Company and disclosed in the Company SEC Documents in accordance with the Exchange Act and all other applicable
Laws.
SECTION 3.03. Company
Subsidiaries; Equity Interests. (a) Section 3.03(a) of the Company Disclosure Letter sets forth a true, correct and complete
list as of the date of this Agreement of all Company Subsidiaries and their respective jurisdictions of organization. No Equity Interests
in any Company Subsidiary were issued, reserved for issuance or outstanding except as set forth in Section 3.03(a) of the Company
Disclosure Letter.
(b) All issued and
outstanding Equity Interests in each Company Subsidiary (i) are duly authorized, validly issued, fully paid and nonassessable and are
not subject to or issued in violation of any purchase option, call option, right of first refusal, preemptive right, subscription right
or any similar right under applicable Laws, any provision of the organizational documents of such Company Subsidiary or any Contract
to which such Company Subsidiary or stockholder of such Company Subsidiary is a party or otherwise bound and (ii) are either (A) owned
by the Company, by another Company Subsidiary or by the Company and one or more other Company Subsidiaries, free and clear of all pledges,
liens, charges, mortgages, deeds of trust, encumbrances, options, rights of first refusal or offer, claims, restrictions and security
interests of any kind or nature whatsoever (collectively, “Liens”) and free of any restriction on the right to vote,
sell or otherwise dispose of such Equity Interests (other than restrictions under applicable securities Laws) or (B) Qualifying Director
Shares. The Company has made available to Parent drafts of all Contracts governing the Qualifying Director Shares.
(c) Except for its
Equity Interests in the Company Subsidiaries, the Company does not own, directly or indirectly, any capital stock, membership interest,
partnership interest, joint venture interest or other Equity Interest in any Person. Other than the Company Subsidiaries, there is no
Person whose results of operations, cash flows, changes in stockholders’ equity or financial position are consolidated in the financial
statements of the Company. Neither the Company nor any of the Company Subsidiaries has any obligation to acquire any Equity Interest,
or any agreement or commitment to provide funds to or make any investment (in the form of a loan, capital contribution or otherwise)
in, any Person.
SECTION 3.04. Authority;
Execution and Delivery; Enforceability.
(a) The Company has all requisite corporate power and authority to execute and deliver this Agreement and, subject to obtaining the Company
Stockholder Approval, to consummate the Transactions. The execution, delivery and performance by the Company of this Agreement and the
consummation by the Company of the Transactions have been duly authorized by all necessary corporate action on the part of the Company,
subject to obtaining the Company Stockholder Approval. The Company has duly executed and delivered this Agreement, and, assuming due
authorization, execution and delivery by Parent and Merger Sub, this Agreement constitutes its legal, valid and binding obligation, enforceable
against it in accordance with its terms (except insofar as such enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium or other Laws of
general applicability relating to or
affecting creditors’ rights, or by principles governing the availability of equitable remedies (the “Bankruptcy and Equity
Exception”)).
(b) The Company Board,
at a meeting duly called and held, duly and unanimously adopted resolutions (i) determining that this Agreement and the Transactions,
including the Merger, are in the best interests of the Company and its stockholders, (ii) approving and declaring advisable this
Agreement and the Transactions, including the Merger, in each case on the terms and subject to the conditions set forth in this Agreement
and (iii) recommending that the holders of shares of Company Common Stock adopt this Agreement and directing that this Agreement be submitted
to the Company’s stockholders at the Company Stockholders Meeting (the recommendation set forth in subclauses (i), (ii) and (iii),
the “Company Board Recommendation”), which resolutions, except to the extent permitted by Section 5.02(f),
have not been rescinded, modified or withdrawn in any way. Except for the adoption of this Agreement by the affirmative vote of holders
of a majority of the outstanding shares of Company Common Stock at the Company Stockholders Meeting, or any adjournment or postponement
thereof (the “Company Stockholder Approval”), no other vote or approval of the holders of Company Common Stock or
any other Equity Interests of the Company is necessary to adopt this Agreement, and no other corporate proceedings on the part of the
Company are necessary to authorize the execution and delivery of this Agreement or to consummate the Merger or the other Transactions
(other than the filing of the PR Certificate of Merger with the Secretary of State of the Commonwealth of Puerto Rico and the DE Certificate
of Merger with the Secretary of State of the State of Delaware).
(c) No state or territorial
takeover statute, “business combination”, “control share acquisition”, “fair price”, “moratorium”
or similar Law, and no analogous provision in the Company Articles or the Company Bylaws, applies to the Company with respect to this
Agreement, the Merger or any other Transaction. There is no stockholder rights plan, “poison pill” antitakeover plan or similar
device in effect to which the Company or any of the Company Subsidiaries is subject, party or otherwise bound.
SECTION 3.05. No
Conflicts; Consents. (a) The execution and delivery by the Company of this Agreement does not, and the consummation of the Merger
and the other Transactions will not, conflict with, or result in any violation of, or default (with or without notice or lapse of time,
or both) under, or give rise to a right of termination, cancellation, first offer, first refusal, modification or acceleration of any
right, obligation or loss of a benefit under, or result in the creation of any Lien upon any of the properties or assets of the Company
or any Company Subsidiary under, or require any consent under, any provision of (i) the Company Articles, the Company Bylaws or the comparable
organizational documents of any Company Subsidiary, (ii) any Authorization of the Company or any Company Subsidiary or any contract,
lease, indenture, note, bond, loan, agreement, arrangement, understanding or other instrument, including any amendment thereto (a “Contract”),
to which the Company or any Company Subsidiary is a party or by which any of them or any of their respective properties or assets are
bound or (iii) subject to the filings and other matters referred to in Section 3.05(b), any judgment, order, injunction,
decree, charge, writ, ruling, determination, directive, award or settlement, whether civil, criminal or administrative and whether formal
or informal
(“Judgment”) or transnational,
national, federal, state, local, provincial, municipal, domestic or foreign statute, constitution, law (including common law), ordinance,
code, permit, rule, regulation or ruling (including any federal, state, territorial or local directive or other requirement that relates
to Medicare or Medicaid) (“Law”) applicable to the Company or any Company Subsidiary or their respective properties
or assets, other than, in the case of clauses (ii) and (iii) above, any such items that have not had and would not reasonably be expected
to have, individually or in the aggregate, a Company Material Adverse Effect (provided that clause (vii) of the proviso of the
definition thereof shall be disregarded for purposes of this Section 3.05(a)) or a Company Impairment Effect.
(b) No consent, waiver,
approval, license, permit, order or other authorization (“Consent”) of, or registration, declaration, notice or filing
with or from, any transnational, national, federal, state, territorial, local, provincial, municipal or other government, domestic or
foreign, or any court of competent jurisdiction, administrative or regulatory agency, body or commission or other governmental or quasi-governmental
(including self-regulatory) authority or instrumentality, domestic or foreign (each, a “Governmental Entity”), is
required to be obtained or made by or with respect to the Company or any Company Subsidiary in connection with the execution, delivery
and performance of this Agreement or the consummation of the Transactions, other than (i) compliance with and filings under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) and any other applicable Antitrust Law as set
forth in Section 3.05(b) of the Company Disclosure Letter (including the antitrust notification and approvals required under non-U.S.
jurisdictions, as set forth in Section 3.05(b) of the Company Disclosure Letter) (collectively, the “Antitrust Approvals”),
(ii) the Consents of, and filings with, the state and territorial insurance departments and federal, state and territorial departments
of health and other Consents and filings required under the applicable Health Care Laws or Insurance Laws as set forth in Section 3.05(b)
of the Company Disclosure Letter (collectively, the “Specified Company Regulatory Approvals”), (iii) the Specified
Parent Regulatory Approvals (assuming the accuracy of the representations and warranties made in Section 4.04(b) and the completeness
of Section 4.04(b) of the Parent Disclosure Letter), (iv) the filing with the SEC of (A) the letter to stockholders, notice of meeting,
form of proxy and proxy statement relating to the Company Stockholders Meeting and any annexes, schedules or exhibits filed in connection
therewith, in each case as amended or supplemented from time to time (collectively, the “Proxy Statement”) and (B)
such reports and filings under the Exchange Act as may be required in connection with this Agreement, the Merger and the other Transactions,
(v) the filing of the PR Certificate of Merger with the Secretary of State of the Commonwealth of Puerto Rico and the DE Certificate
of Merger with the Secretary of State of the State of Delaware and (vi) such filings as may be required under the rules and regulations
of NYSE in connection with this Agreement, the Merger and the other Transactions.
SECTION 3.06. SEC
Documents; Undisclosed Liabilities; Internal Controls. (a) The Company has timely filed or furnished, as applicable, all reports,
schedules, forms, statements and other documents (including exhibits and other information incorporated therein) required to be filed
or furnished, as applicable, by the Company with the SEC since January 1, 2019 (such documents, together with any
documents filed or furnished, as applicable,
by the Company with the SEC during such period on a voluntary basis, the “Company SEC Documents”). The Company has
made available to Parent true, correct and complete unredacted copies of all documents filed as exhibits to the Company SEC Documents
subject to a request to the staff of the SEC for confidential treatment. The Company has not submitted any request for confidential treatment
of documents filed as exhibits to the Company SEC Documents that is currently pending or that has otherwise not been acted upon by staff
of the SEC. None of the Company Subsidiaries is, or at any time since January 1, 2019 has been, required to file any reports, schedules,
forms, statements or other documents with the SEC.
(b) As of their respective
effective dates (in the case of Company SEC Documents that are registration statements filed pursuant to the requirements of the Securities
Act) and as of their respective SEC filing dates (in the case of all other Company SEC Documents), each Company SEC Document complied
as to form in all material respects with the applicable requirements of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act
of 2002 (together with the rules and regulations promulgated thereunder, the “Sarbanes-Oxley Act”), and did not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading. Except to the extent that information
contained in any Company SEC Document has been revised or superseded by a later filed or furnished Company SEC Document, none of the
Company SEC Documents (including any such later filed or furnished Company SEC Document) contains any untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. No executive officer of the Company has failed in any respect to make the
certifications required of him or her under Sections 302 or 906 of the Sarbanes-Oxley Act. As of the date of this Agreement, there
are no outstanding or unresolved comments in any comment letters of the staff of the SEC received by the Company relating to the Company
SEC Documents, and none of the Company SEC Documents is, to the knowledge of the Company, the subject of ongoing SEC review.
(c) The Company is,
and at all times since January 1, 2019 has been, in compliance in all material respects with the applicable listing and corporate governance
rules and regulations of the NYSE.
(d) The audited annual
consolidated financial statements and the unaudited quarterly consolidated financial statements (including, in each case, the notes thereto)
of the Company included in the Company SEC Documents when filed (i) complied as to form in all material respects with the published
rules and regulations of the SEC with respect thereto, (ii) were prepared in accordance with GAAP (except, in the case of such unaudited
quarterly consolidated financial statements, as permitted by Form 10-Q of the SEC or other rules and regulations of the SEC) applied
on a consistent basis during the periods involved (except as may be expressly indicated in the notes thereto) and (iii) fairly presented
in all material respects the consolidated financial position of the Company and the Company Subsidiaries as of the dates thereof and
the consolidated results of their operations, cash flows and stockholders’ equity for the
periods covered thereby
(subject, in the case of unaudited quarterly consolidated financial statements, to normal recurring year-end adjustments).
(e) Except as reflected
or reserved against in the consolidated balance sheet of the Company as of December 31, 2020 included in the Company SEC Documents or
specifically disclosed in the notes thereto (such balance sheet and the notes thereto, the “Company Balance Sheet”),
neither the Company nor any Company Subsidiary has any material liability or obligation of any nature (whether accrued, absolute, contingent
or otherwise, and whether or not required to be recorded or reflected on a balance sheet in accordance with GAAP or SAP, as applicable)
other than (i) liabilities or obligations incurred pursuant to the terms of this Agreement or (ii) liabilities or obligations
incurred in the ordinary course of business consistent with past practice since December 31, 2020.
(f) Neither the Company
nor any of the Company Subsidiaries is a party to, nor does it have any commitment to become a party to, any joint venture, off-balance
sheet partnership or any similar Contract (including any Contract relating to any transaction or relationship between or among the Company
or one of the Company Subsidiaries, on the one hand, and any unconsolidated affiliate, on the other hand) or any “off-balance sheet
arrangements” (as defined in Item 303(a) of Regulation S-K of the SEC), where the result, purpose or intended effect of such arrangement
or Contract is to avoid disclosure of any material transaction involving, or material liabilities of, the Company or any of the Company
Subsidiaries in the Company Balance Sheet, the Company SEC Documents or the Company Statutory Financial Statements.
(g) The Company has
established and maintains, and at all times since January 1, 2019 has maintained, “disclosure controls and procedures” (as
such term is defined in paragraph (e) of Rule 13a-15 under the Exchange Act) as required by Rule 13a-15 under the Exchange Act that are
reasonably designed to ensure that all information required to be disclosed by the Company in the reports that it files or furnishes
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the
SEC, and that all such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions
regarding required disclosure and to make the certifications required pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act.
Neither the Company nor any of the Company Subsidiaries has outstanding, or has arranged any outstanding, “extensions of credit”
to directors or executive officers within the meaning of Section 402 of the Sarbanes-Oxley Act.
(h) The Company has
established and maintains, and at all times since January 1, 2019 has maintained, a system of “internal control over financial
reporting” (as such term is defined in paragraph (f) of Rule 13a-15 under the Exchange Act) sufficient to provide reasonable assurance
(i) regarding the reliability of the Company’s and the Company Subsidiaries’ financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP, SAP and actuarial principles, as applicable, (ii) that transactions are recorded
as necessary to permit preparation of financial statements in accordance with GAAP, SAP and actuarial principles, as
applicable, (iii) that
receipts and expenditures of the Company are being made only in accordance with the authorization of management and directors of the
Company and (iv) regarding prevention or timely detection of any unauthorized acquisition, use or disposition of the Company’s
assets that could have a material effect on the Company’s financial statements. The Company’s management has completed an
assessment of the effectiveness of the Company’s internal control over financial reporting in compliance with the requirements
of Section 404 of the Sarbanes-Oxley Act for the year ended December 31, 2020, and such assessment concluded that such controls
were effective. Since January 1, 2019, none of the Company, the Company’s outside auditors, the Company Board or the audit committee
of the Company Board has received any oral or written notification of (x) any “significant deficiencies” or “material
weaknesses” in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the Company’s ability to record, process, summarize and report financial information or (y) any fraud, whether or not material,
that involves management or other employees who have a significant role in the Company’s internal control over financial reporting,
all of which information described in clauses (x) and (y) above has been made available by the Company to Parent prior to the date hereof.
To the knowledge of the Company, there is no reason to believe that the Company’s outside auditors and its chief executive officer
and chief financial officer will not be able to give the certifications and attestations required pursuant to the rules and regulations
adopted pursuant to Section 404 of the Sarbanes-Oxley Act, without qualification, when next due. For purposes of this Agreement,
the terms “significant deficiency” and “material weakness” have the meanings assigned to them in Appendix A of
Auditing Standard No. 5 of the Public Company Accounting Oversight Board, as in effect on the date of this Agreement.
(i) (x) From January
1, 2019 through December 31, 2020, there was no transaction, or series of similar transactions, agreements, arrangements or understandings,
to which the Company or any of the Company Subsidiaries was a party that was required to be disclosed under Item 404 of Regulation S-K
promulgated under the Securities Act and (y) since January 1, 2021, to the knowledge of the Company, there have not been, and there are
not any currently proposed, transactions, or series of similar transactions, agreements, arrangements or understandings, to which the
Company or any of the Company Subsidiaries was or is to be a party that would be required to be disclosed under Item 404 of Regulation
S-K promulgated under the Securities Act.
SECTION 3.07. Statutory
Statements; Examinations; Filings. (a) The Company has made available to Parent true, correct and complete copies of (i) the audited
statutory annual statements for the years ended December 31, 2020 and 2019 and (ii) the unaudited statutory quarterly statements
for the quarter ended June 30, 2021 for each insurance Company Subsidiary as filed with the applicable Insurance Regulator of its respective
state of domicile and (iii) the Risk-Based Capital Reports for the years ended December 31, 2020 and 2019 (collectively, the “Company
Statutory Financial Statements”). Except as set forth therein, each of the Company Statutory Financial Statements, as of the
date of the applicable filing, (x) have been prepared in all material respects in accordance with SAP applied on a consistent basis during
the periods involved (except as may be indicated in the notes thereto or in the related statutory
reports and actuarial opinions for each
insurance Company Subsidiary), (y) fairly presented in all material respects the statutory financial condition and results of operations
of each respective insurance Company Subsidiary for the periods shown (subject, in the case of unaudited statements, to normal year-end
adjustments that are not, individually or in the aggregate, material to the insurance Company Subsidiary, taken as a whole) and (z) was
derived from the books and records of each respective insurance Company Subsidiary.
(b) Since January
1, 2019, each of the applicable insurance Company Subsidiaries has timely filed or submitted (taking into account any permitted extensions)
all material Company Statutory Financial Statements, together with all exhibits, interrogatories, notes, schedules, actuarial opinions,
affirmations and certifications, in each case, required by applicable Insurance Laws to be filed with or submitted to the appropriate
Insurance Regulator of each jurisdiction in which it is licensed, authorized or otherwise eligible with respect to the conduct of the
business of insurance or reinsurance, as applicable.
(c) The Company has
made available to Parent, to the extent permitted by applicable Law, true, correct and complete copies of all material examination reports
(and has notified Parent of any pending material examinations) of any Insurance Regulators received by it or any of the Company Subsidiaries
on or after January 1, 2019 through the date of this Agreement, relating to the Company or any Company Subsidiaries. All material deficiencies
or violations noted in such examination reports have been cured or resolved to the satisfaction of the applicable Insurance Regulator.
Without limiting the generality of the foregoing, there are no unpaid claims or assessments made in writing or, to the knowledge of the
Company, threatened against the Company or any of the Company Subsidiaries, whether or not due, by any insurance guaranty associations,
joint underwriting association, residual market facility or assigned risk pool or similar organizations, other than (i) unpaid claims
or assessments disclosed, provided for, reflected in, reserved against or otherwise described in the Company Statutory Financial Statements
provided or made available to Parent or (ii) immaterial unpaid claims or assessments.
(d) The Company has
made available to Parent all material written inquiries or comments received by the Company or any Company Subsidiary since January 1,
2019 with respect to any of the Company Statutory Financial Statements from any Governmental Entity.
(e) Since January 1,
2019, neither the Company nor any of the applicable Company Subsidiaries has suffered a decrease in its Risk-Based Capital to “Company
Action Level”.
(f) The Company has
made available to Parent true, correct, and complete copies of all Risk-Based Capital plans relating to the Company or any of the Company
Subsidiaries in effect as of the date hereof (“RBC Plans”). All RBC Plans have been approved by all applicable Insurance
Regulators and the Company and the Company
Subsidiaries, are
currently, and have since approval by the applicable Insurance Regulators been, in compliance with such RBC Plans in all material respects.
(g) The Company has
reasonably concluded that all reinsurance, coinsurance or similar recoverable amounts reflected in the Company Statutory Financial Statements
are collectible in all material respects, and the Company has no knowledge of any material adverse change in the financial condition
of its reinsurers that might have an adverse effect on their ability to honor their reinsurance, coinsurance or similar commitments.
SECTION 3.08. Insurance
Contract Benefits. Except as would not reasonably be expected to be, individually or in the aggregate, material to the Company and
the Company Subsidiaries, taken as a whole, since January 1, 2019, all benefits payable to any Person under any Insurance Contract of
any Company Subsidiary have been paid (or provision as required under SAP for payment thereof has been made) in accordance with the terms
of the Insurance Contracts under which they arose and applicable Law, and such payments were not delinquent and were paid without fines
or penalties.
SECTION 3.09. Reserves.
The reserves and related actuarial items in the Company Statutory Financial Statements (as of their respective dates): (i) were
computed in accordance with presently accepted actuarial standards consistently applied and were fairly stated, in accordance with sound
actuarial principles, (ii) were based on actuarial assumptions which produced reserves at least as great as those called for in any contract
provision as to reserve basis and method, and were in accordance with all other policy or contract provisions, (iii) met the requirements
of applicable Law and, to the Company’s knowledge, were at least as great as the minimum aggregate amounts required by the states
or jurisdictions in which the statement was filed, (iv) made a good and sufficient provision for all of the Company’s and the Company
Subsidiaries’ obligations not yet due as of December 31, 2020 but guaranteed under the terms of the applicable policies, (v) were
computed on the basis of assumptions consistent with those used in computing the corresponding items in the annual statement of the preceding
year-end and (vi) included provisions for the actuarial reserves and related statement items which ought to have been established,
in each case in all material respects. The Company has delivered or made available to Parent a true, correct and complete copy of any
material actuarial reports prepared by actuaries, independent or otherwise, with respect to the Company or any applicable Company Subsidiary
from January 1, 2019 through the date of this Agreement, and all attachments, addenda, supplements and modifications thereto (“Company
Actuarial Analyses”). The information and data furnished by the Company or any applicable Company Subsidiary to its actuaries
in connection with the preparation of the Company Actuarial Analyses were accurate in all material respects.
SECTION 3.10. Capital
or Surplus Maintenance. Neither the Company nor any of the Company Subsidiaries is, or since January 1, 2019 has at any time been,
subject to any requirement to maintain capital or surplus amounts or levels, or subject to any restriction on the payment of dividends
or other distributions, except for
requirements or restrictions under applicable
Laws of general application or rating requirements of any insurance company rating agency.
SECTION 3.11. Investments.
(a) A copy of the Company’s policies with respect to the investment of the Investment Assets is set forth in Section 3.11
of the Company Disclosure Letter (the “Investment Guidelines”), and the composition of the Investment Assets complies
in all material respects with the Investment Guidelines and all investment restrictions under applicable Law.
(b) Except for Investment
Assets that matured or were sold, redeemed or otherwise disposed of after June 30, 2021, each of the Company and the Company Subsidiaries,
as applicable, has good and marketable title to all of the material Investment Assets it purports to own, free and clear of all Liens
except Permitted Liens.
SECTION 3.12. Medicare
Secondary Payer Rules. All actions taken or failed to have been taken by the Company and the Company Subsidiaries and their respective
Representatives in connection with the insuring or administration of healthcare plans maintained for the Company’s or the Company
Subsidiaries’ employer clients or other clients have been taken or omitted in compliance in all material respects with the so-called
“Medicare Secondary Payer Rules”, and all applicable federal Laws, as supplemented by the regulations of the Department of
Health and Human Services, concerning Medicare Secondary Payer liability (“Secondary Payer Rules”). No healthcare
plan administered or insured by any of the Company and Company Subsidiaries has any material liability of any nature (including but not
limited to any liability under the Code, ERISA, the Social Security Act and Age Discrimination in Employment Act) to the United States
of America or to any other Person with respect to the Secondary Payer Rules. Neither the Company nor any of the Company Subsidiaries
nor any of their respective Representatives have incurred any material liability with respect to acts taken or omitted prior to Closing
under existing or prior contracts with its employer clients or other clients for any excise tax liability under Section 5000 of the Code.
SECTION 3.13. Insurance
Agents and Administrators. The Company, the Company Subsidiaries, and, to the knowledge of the Company, each of their respective
Agents and Administrators have solicited, negotiated, issued, sold, produced, placed, managed and marketed Policies in compliance with
applicable Laws in all material respects in the respective jurisdictions in which such products have been sold. To the knowledge of the
Company, each Agent or Administrator (a) was duly licensed as required by Law in the particular jurisdiction in which such Agent or Administrator
wrote, sold, produced, managed or marketed such Policies (for the type of business written, sold, produced, managed or marketed on behalf
of the Company or any Company Subsidiary), except for such failures to be licensed that are immaterial, and (b) if required by applicable
Law, was duly appointed by the Company or the applicable Company Subsidiary, except for such failures to be duly appointed that are immaterial.
Since January 1, 2019, neither the Company nor any Company Subsidiary has received any notice from any Governmental Entity that an Agent
or Administrator is in material violation of any applicable Law relating to the solicitation, negotiation, issuance, sale,
production, placement, management, marketing
or writing of Policies for the Company and the Company Subsidiaries.
SECTION 3.14. The
Proxy Statement. The Proxy Statement, at the time it is filed with the SEC, at the time it is first mailed to the holders of shares
of Company Common Stock and at the time of the Company Stockholders Meeting, will not contain any untrue statement of a material fact
or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading, and will comply as to form in all material respects with the requirements of
the Exchange Act. Notwithstanding the foregoing, no representation or warranty is made by the Company with respect to statements included
or incorporated by reference in the Proxy Statement based on information supplied in writing by or on behalf of Parent or Merger Sub
for inclusion or incorporation by reference therein.
SECTION 3.15. Absence
of Certain Changes or Events. (a) From December 31, 2020 to the date of this Agreement, there has not been any change, event, effect,
fact, circumstance, development or occurrence that has had or would reasonably be expected to have, individually or in the aggregate,
a Company Material Adverse Effect.
(b) From June 30,
2021 to the date of this Agreement, the Company and the Company Subsidiaries have conducted their respective businesses only in the ordinary
course of business consistent with past practice.
SECTION 3.16. Taxes.
Other than with respect to clauses (f) and (k), except as would not reasonably be expected to be, individually or in the aggregate, material
to the Company and the Company Subsidiaries, taken as a whole:
(a) The Company and
the Company Subsidiaries have filed all income and other Tax Returns that are required to be filed by them (taking into account any extensions
of time to file) and all such Tax Returns were true, complete and accurate in all respects.
(b) The Company and
the Company Subsidiaries have paid all Taxes due and owing by any of them, including any Taxes required to be withheld from amounts owing
to any employee, creditor or third party (in each case, whether or not shown on any Tax Return) on a timely basis, other than Taxes for
which adequate reserves have been established in accordance with GAAP and SAP, as applicable, on the financial statements of the Company
and the Company Subsidiaries. The Company Balance Sheet reflects adequate accruals and reserves for all Taxes of each of the Company
and the Company Subsidiaries with respect to all periods through the date thereof in accordance with GAAP and SAP, as applicable.
(c) There is not pending
or threatened in writing any audit, examination, investigation, deficiency assessment or other Proceeding with respect to any Taxes of
the Company or any of the Company Subsidiaries.
(d) No written claim
that could give rise to Taxes has been made by a Taxing Authority in a jurisdiction where the Company or any of the Company Subsidiaries
does not file Tax Returns that the Company or any of the Company Subsidiaries is or may be subject to taxation by that jurisdiction,
including that the Company or any of the non-U.S. Company Subsidiaries may be subject to U.S. federal income Tax as a result of being
engaged in a trade or business within the United States within the meaning of Section 864(b) of the Code.
(e) Neither the Company
nor any of the Company Subsidiaries has waived any statute of limitations with respect to Taxes or agreed to any extension of time with
respect to a Tax assessment or deficiency. Neither the Company nor any of the Company Subsidiaries has requested an extension of time
within which to file any Tax Return that has not since been filed, other than ordinary course extensions of no more than 6 months.
(f) Neither the Company
nor any of the Company Subsidiaries has constituted a “distributing corporation” or a “controlled corporation”
(within the meaning of Section 355(a)(1)(A) of the Code) in a distribution of stock intended to qualify as a transaction to which
Section 355 or 361 of the Code (or any similar provision of state, territorial, local or foreign Law) applies.
(g) Neither the Company
nor any of the Company Subsidiaries will be required to include any item of income in, or exclude any item of deduction from, taxable
income for any taxable period (or portion thereof) ending after the Closing Date as a result of any (i) change in or use of an improper
method of accounting for a taxable period ending on or prior to the Closing Date, (ii) closing agreement under Section 7121 of the Code
(or any similar provision of state, local or non-U.S. Tax Law), (iii) installment sale or open transaction disposition made on or prior
to the Closing Date, (iv) prepaid amount received prior to the Closing Date or (v) election under Section 108(i) of the Code.
(h) Section 3.16(h)
of the Company Disclosure Letter sets forth the (i) U.S. federal income Tax classification and (ii) Tax classification under the Law
of the jurisdiction of formation, and, if different, Tax residency, in each case, of each of the Company and the Company Subsidiaries.
(i) Neither the Company
nor any of the Company Subsidiaries is a party to any Tax allocation, sharing, indemnity or reimbursement agreement or arrangement (other
than any customary Tax indemnification provisions in ordinary course commercial agreements or arrangements that are not primarily related
to Taxes) or has any liability for Taxes of any Person (other than the Company or any of the Company Subsidiaries) under Treasury Regulations
Section 1.1502-6 (or any similar provision of state, territorial, local or foreign Law) or as a transferee or successor.
(j) There are no Liens,
except for Permitted Liens, for Taxes upon any property or assets of the Company or any of the Company Subsidiaries.
(k) Neither the Company
nor any of the Company Subsidiaries has participated in a “listed transaction” within the meaning of Treasury Regulations
Section 1.6011-4(b) (or any similar provision of state, territorial, local or foreign Law).
(l) The Company and
the Company Subsidiaries have complied in all respects with record maintenance requirements under Sections 482 and 845 of the Code
and similar provisions of state, territorial, local or foreign Tax Law in connection with related party transactions among or between
the Company and one or more of the Company Subsidiaries (or among or between the Company Subsidiaries).
(m) The Company has
made available all rulings or determinations received from a Taxing Authority and all requests for such rulings or determinations, in
each case, that would reasonably be expected to be relevant to any open or future taxable year of the Company or any Company Subsidiary.
(n) No Company Subsidiary
has liability for Taxes pursuant to Section 965 of the Code (or any similar provision of state, territorial, local or foreign Law).
(o) The tax
exemption grant (the “Tax Grant”) issued pursuant to Act No. 60 of 2019 or its predecessor law (the “Incentive
Law”) to Triple-S Blue Inc., I.I., is in full force and effect, and Triple-S Blue Inc., I.I. is in compliance with all the terms
and conditions of the Tax Grant, and with all applicable provisions of the Incentive Law and regulations issued thereunder. To the knowledge
of each of the Company and Triple-S Blue Inc., I.I., there are no facts or circumstances that would reasonably be expected to result
in a breach of any of the requirements or terms of the Tax Grant.
(p) Neither the Company
nor any of the Company Subsidiaries has in effect or has ever made an election under Section 953(d) of the Code.
SECTION 3.17. Labor
Relations. (a) Each of the Company and the Company Subsidiaries is in compliance in all material respects with all applicable Laws,
Contracts and Authorizations to which it is a party relating to employment and employment practices, including wages, hours, collective
bargaining, unemployment insurance, workers’ compensation, equal employment opportunity, classification of employees and contractors,
race, age, religion, gender and other protected classifications, national original and disability discrimination, the payment withholding
of Taxes and the termination of employment, including any obligations pursuant to the Worker Adjustment and Retraining Notification Act
of 1988 and similar state, territorial or local Law.
(b) There are no material
complaints, charges or claims against the Company or any Company Subsidiary pending or, to the knowledge of the Company, threatened to
be brought or filed with any Governmental Entity based on, arising out of, in connection with, or otherwise relating to the employment
of, or termination of employment by, the Company or any Company Subsidiary of any individual or of any provision of services to the Company
or any Company Subsidiary by any individual.
(c) Neither the Company
nor any Company Subsidiary is a party to any collective bargaining agreement or other Contract with any labor organization or other representative
of the Company’s or any Company Subsidiary’s employees, nor is any such Contract presently being negotiated, nor, to the
knowledge of the Company, are there any campaigns being conducted to authorize representation by any labor organization. There are no
ongoing labor strikes, slowdowns, work stoppages, picketing or lockouts pending or, to the knowledge of the Company, threatened, against
the Company or any Company Subsidiary.
(d) Since January
1, 2019, (i) no material allegations or reports of sexual harassment, discrimination with respect to a protected classification, including
race and gender, retaliation, workplace bullying, hostile work environment or similar misconduct have been made to the Company or any
Company Subsidiary and (ii) neither the Company nor any of the Company Subsidiaries has received or been involved in or been subject
to any material complaints, allegations, reports, claims or Proceedings relating to sexual harassment, bullying or discrimination, in
each case, committed by an employee at the level of manager or above, or alleging a workplace culture that would encourage or be conducive
to the foregoing. For avoidance of doubt, any such complaint, allegation, report, claim or Proceeding with respect to an executive officer
of the Company or any Company Subsidiary shall be considered material.
SECTION 3.18. Employee
Benefits. (a) Section 3.18(a) of the Company Disclosure Letter sets forth a true, correct and complete list as of the date of
this Agreement of each material Company Benefit Plan.
(b) With respect to
each material Company Benefit Plan, the Company has made available to Parent true, correct and complete copies of, to the extent applicable,
(i) such Company Benefit Plan, including any material amendment thereto (or, in the case of any unwritten Company Benefit Plan, a written
description thereof), other than any Company Benefit Plan that the Company or any of the Company Subsidiaries is prohibited from making
available to Parent as the result of applicable Law relating to the safeguarding of data privacy, (ii) each trust, insurance, annuity
or other funding Contract related thereto, (iii) the most recent summary plan description and any summary of material modifications prepared
for such material Company Benefit Plan, (iv) the most recent financial statements and actuarial or other valuation reports prepared with
respect thereto, (v) the most recent determination or opinion letter from the Internal Revenue Service and the Puerto Rico Department
of Treasury (“DOT”), and (vi) the most recent annual reports on Form 5500 (or comparable form) required to be filed
with the Department of Labor with respect thereto (if any) and the applicable form required under Section 1061.10 of the PR Code to be
filed with the DOT.
(c) The Company Benefit
Plans are and have been administered in compliance with their terms and with the requirements of the Employee Retirement Income Security
Act of 1974 (“ERISA”), the Code, the Puerto Rico Internal Revenue Code of 2011 (“PR Code”) and
all other applicable Law, except to the extent that noncompliance has not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect.
(d) The Company by
reason of its affiliation with any member of the Company’s “Controlled Group” (defined as any organization which
is a member of a controlled group of organizations within the meaning of Section 414(b), (c), (m) or (o) of the Code or of Section
1081.01 of the PR Code) has not incurred nor is reasonably expected to incur, any Tax, fine, Lien, penalty or other liability imposed
by ERISA, the Code, the PR Code or other applicable Law, except as has not had and would not reasonably be expected to have, individually
or in the aggregate, a Company Material Adverse Effect. Each Company Benefit Plan that is intended to be qualified within the meaning
of Section 401(a) of the Code has received a favorable determination letter or can rely on an opinion letter as to its qualification
and, to the knowledge of the Company, nothing has occurred, whether by action or failure to act, that would reasonably be expected to
cause the loss of such qualification. Each Company Benefit Plan that is intended to be qualified under Section 1081.01 of the PR Code
has received a favorable determination letter from the DOT. No nonexempt “prohibited transaction” (as such term is defined
in Sections 406 and 407 of ERISA or Section 4975 of the Code) has occurred with respect to any Company Benefit Plan, or any other
breach of fiduciary responsibility, that would reasonably be expected to result in material liability to the Company or any Company Subsidiary.
(e) No Company Benefit
Plan is subject to Title IV of ERISA or constitutes a multiemployer plan within the meaning of Section 3(37) of ERISA, and neither
the Company nor any member of its Controlled Group has at any time in the past six years sponsored or contributed to, or has or has had
any material liability or obligation in respect of, any such arrangement.
(f) There are no material
audits, inquiries, investigations or Proceedings pending or, to the knowledge of the Company, threatened by the Internal Revenue Service
or any other Governmental Entity with respect to any Company Benefit Plan (other than routine claims for benefits in the normal course).
(g) The Company does
not have any liability in respect of, or obligation to provide, post-retirement medical, life insurance or other welfare benefits for
any current or former employees of the Company or any Company Subsidiary (or the spouses, dependents or beneficiaries of any individuals),
whether under a Company Benefit Plan or otherwise, except as required to comply with Section 4980B of the Code or any similar Law.
(h) There is no Company
Benefit Plan or other agreement, plan, arrangement or Contract covering any employee of the Company or any Company Subsidiary, individually
or collectively, that would reasonably be expected to give rise directly or indirectly to any “excess parachute payment”
within the meaning of Section 280G(b)(2) of the Code. No director, officer, employee or independent contractor of the Company or
any Company Subsidiary is entitled to any gross-up, make-whole or other additional payment from the Company or any other Person in respect
of any Tax (including Taxes imposed under Section 4999 or 409A of the Code) or interest or penalty related thereto.
(i) Neither the execution
and delivery of this Agreement nor the consummation of any of the Transactions (including as a result of any termination of employment
on or following the Effective Time) will, except as expressly contemplated by this Agreement, (i) entitle any former or current director,
officer, employee or independent contractor to retention, change in control, severance, termination or similar compensation or benefits,
(ii) accelerate the time of payment or vesting, or trigger any payment or funding (through a grantor trust or otherwise) of, compensation
or benefits under, increase the amount payable or trigger any other obligation pursuant to any Company Benefit Plan, (iii) result in
any breach or violation of, or a default under, any Company Benefit Plan or (iv) limit or restrict the right of the Company to merge,
amend or terminate any Company Benefit Plan.
(j) Each Company Benefit
Plan that constitutes a “nonqualified deferred compensation plan” within the meaning of Section 409A(d)(1) of the Code
(a “Nonqualified Deferred Compensation Plan”) is and has been in material compliance with Section 409A.
SECTION 3.19. Title
to Properties. (a) Section 3.19(a)(i) of the Company Disclosure Letter sets forth a true, correct and complete list of all real
property owned by the Company or any of the Company Subsidiaries as of the date of this Agreement (the “Owned Real Property”)
and the tax identification numbers (“número de catastros”) assigned to the Owned Real Property by the Municipal
Revenue Collection Agency (“CRIM” for its Spanish acronym). The Company or a Company Subsidiary has good and marketable title
to the Company Owned Real Property, free and clear of all Liens other than any Permitted Liens, and sufficient rights of ingress and
egress to the Owned Real Property. There are no outstanding options or rights of first offer or refusal to purchase the Owned Real Property
or any material portion thereof in favor of any Person. To the knowledge of the Company, there are no condemnation, expropriation or
other proceedings in eminent domain, pending or threatened in writing, affecting any portion of the Owned Real Property. Section 3.19(a)(ii)
of the Company Disclosure Letter sets forth a true, correct and complete list of all Owned Real Property or any portion thereof that
is leased, subleased, licensed or otherwise occupied by any Person and the leases, subleases, licenses or occupancy agreements, together
with all assignments thereof and amendments, supplements and modifications thereto (collectively, the “Owned Real Property Leases”).
The Company has made available to Parent true, correct and complete copies of the Owned Real Property Leases. With respect to each Owned
Real Property Lease, (i) the Owned Real Property Lease is valid, binding and enforceable by the Company or the Company Subsidiary, as
the case may be, and, to the knowledge of the Company, each other party thereto (in each case subject to the Bankruptcy and Equity Exception),
and is in full force and effect, (ii) there is no default under the Owned Real Property Lease by the Company or any Company Subsidiary
or, to the knowledge of the Company, any other party thereto, and no event has occurred that with the lapse of time or the giving of
notice or both would constitute a default thereunder by the Company or any Company Subsidiary or, to the knowledge of the Company, any
other party thereto, (iii) there are no disputes pending or, to the Company’s knowledge, threatened with respect to the Owned Real
Property Lease, and (iv) neither the Company nor the applicable Company Subsidiary has received any
written notice of the intention of any
other party to the Owned Real Property Lease to materially amend, terminate, not renew or reduce any commitment under the Owned Real
Property Lease, nor to the Company’s knowledge is any such party threatening to do so.
(b) Section 3.19(b)
of the Company Disclosure Letter sets forth a true, correct and complete list of all real property leased by the Company or any of the
Company Subsidiaries as of the date of this Agreement other than any right to occupy, use or lease any space for use in connection with
point of sales or marketing arrangements (“POS Leased Real Property”) in the ordinary course of business consistent
with past practice (the “Leased Real Property”). The Company has made available to Parent true, correct and complete
copies of the leases, subleases, licenses or occupancy agreements, together with all assignments thereof and amendments, supplements
and modifications thereto, granting the Company or any of the Company Subsidiaries leasehold, subleasehold, licensee or occupancy interests
in the Leased Real Property (collectively, the “Leases”). With respect to each Leased Real Property and the accompanying
Lease, (i) the Company or the applicable Company Subsidiary has good and valid leasehold, subleasehold, licensee or occupancy interest
in such Leased Real Property, free and clear of all Liens, other than Permitted Liens, (ii) the Lease is valid, binding and enforceable
by the Company or the Company Subsidiary, as the case may be, and, to the knowledge of the Company, each other party thereto (in each
case subject to the Bankruptcy and Equity Exception), and is in full force and effect, (iii) there is no default under the Lease by the
Company or any Company Subsidiary or, to the knowledge of the Company, any other party thereto, and no event has occurred that with the
lapse of time or the giving of notice or both would constitute a default thereunder by the Company or any Company Subsidiary or, to the
knowledge of the Company, any other party thereto, (iv) there are no disputes pending or, to the Company’s knowledge, threatened
with respect to the Lease, and neither the Company nor the applicable Company Subsidiary has received any written notice of the intention
of any other party to the Lease to materially amend, terminate, not renew or reduce any commitment under the Lease, nor to the Company’s
knowledge is any such party threatening to do so, (v) neither the Company nor the applicable Company Subsidiary has subleased, licensed
or otherwise granted any Person the right to use or occupy the Leased Real Property or any portion thereof or has collaterally assigned
or granted any other security interest in any such leasehold estate or any interest therein and (vi) to the knowledge of the Company,
there is no condemnation or other proceeding in eminent domain, pending or threatened in writing, affecting any portion of the Leased
Real Property.
(c) Each Owned Real
Property and Leased Real Property is in good operating condition and repair and is otherwise adequate and sufficient to permit the continued
use of such property in the manner and for the purposes to which it is presently devoted in all material respects.
(d) The Company and
each of the Company Subsidiaries has good and valid title to all of its material tangible assets sufficient for the conduct of its business
as presently conducted, free and clear of all Liens, except for Permitted Liens.
SECTION 3.20. Contracts.
(a) Except for this Agreement or any Company Benefit Plan, and except for the unredacted Contracts filed by the Company as “material
contract” exhibits to the Company SEC Documents pursuant to Item 601(b)(10) of Regulation S-K under the Securities Act, Section 3.20(a)
of the Company Disclosure Letter sets forth a true, correct and complete list, and the Company has made available to Parent true, correct
and complete copies, of each Specified Contract in effect as of the date of this Agreement. For purposes of this Agreement, “Specified
Contract” means each Contract to which the Company or any Company Subsidiary is a party or by which any of them or any of their
respective properties or assets are bound:
(i) that
would be required to be but has not been filed by the Company prior to the date of this Agreement as a “material contract”
pursuant to Item 601(b)(10) of Regulation S-K under the Securities Act;
(ii)
that (A) restricts the ability of the Company or any Company Subsidiary (or that following the Closing will restrict the ability of Parent
or any of its subsidiaries) to compete in any business or with any Person, to conduct any business in any geographical area, to engage
in any line of business or to solicit any client or customer, (B) restricts the right of the Company or any of the Company Subsidiaries
(or following the Closing will restrict the ability of Parent or any of its subsidiaries) to provide or receive support or service to,
for, from, or otherwise engage in any business with, any Person, (C) requires the Company or any Company Subsidiary (or following the
Closing will require Parent or any of its subsidiaries) to conduct any business on a “most favored nations” or other preferential
basis with any third party, (D) provides for “exclusivity” or any similar requirement in favor of any third party or (E)
contains any “non-solicitation”, “non-hire” or similar provision that materially restricts the Company or any
of the Company Subsidiaries (or following the Closing will materially restrict Parent or any of its subsidiaries), in each case, other
than any Contract that (i) does not provide for and could not reasonably be expected to involve (x) annual payments or receipts equal
to or in excess of $100,000 or (y) payments or receipts in the aggregate equal to or in excess of $1,000,000 and (ii) is terminable without
penalty by the Company or any Company Subsidiary on no more than 90 days’ notice;
(iii)
that is a reinsurance Contract or Policy ceded to or assumed from a third party;
(iv)
that is an investment management agreement with an investment manager or sub-advisor that is not an affiliate of the Company;
(v) that
is an Insurance Contract or Policy that constitutes one of the Company and the Company Subsidiaries’ (a) ten largest property and
casualty Insurance Contracts or Policies measured by coverage amount, (b) ten largest health group Insurance Contracts or Policies measured
by coverage amount or (c) ten largest life Insurance Contracts or Policies measured by coverage amount, in
each case
other than any reinsurance Contracts or Policies referred to in clause (iii) above;
(vi)
that is a patient assistance program agreement and provides for or could reasonably be expected to involve annual payments or receipts
equal to or in excess of $100,000 or provides for or could reasonably be expected to involve payments or receipts in aggregate equal
to or in excess of $1,000,000;
(vii)
that is a pharmacy benefit management agreement;
(viii)
that is a Contract to which the Company or any Company Subsidiary is a party with the BCBSA;
(ix)
(A) under which the Company or any Company Subsidiary grants to any third party a license (including sublicense) to, option to or other
right to use or exploit any material Company Intellectual Property, (B) under which a third party grants to the Company or any Company
Subsidiary a license (including sublicense) to, option to or other right to use or exploit any material Intellectual Property and (C)
that restricts the right of the Company or any Company Subsidiary to use, deploy or register any material Intellectual Property, in each
case other than off-the-shelf, commercially available or “shrink-wrap” agreements entered into in the ordinary course of
business;
(x) that
provides for or could reasonably be expected to involve annual payments or receipts equal to or in excess of $1,000,000 or provides for
or could reasonably be expected to involve payments or receipts in aggregate equal to or in excess of $4,000,000 (other than any Contract
with Providers, vendors or other service providers);
(xi)
that is a Contract with a Provider that provides for payments to such Provider which, when taken together with the payments to Providers
provided for under all other Contracts listed on Section 3.20(a)(xi) of the Company Disclosure Letter, represent at least 70% of
all payments by the Company and the Company Subsidiaries to Providers for the fiscal year ended December 31, 2020;
(xii)
that is a Contract with a vendor or service provider (other than a Provider) that provides for payments to such vendor or service provider
which, when taken together with the payments to vendors and service providers provided for under all other Contracts listed on Section
3.20(a)(xii) of the Company Disclosure Letter, represent at least 70% of all payments by the Company and the Company Subsidiaries to
vendors and service providers (excluding Providers) for the fiscal year ended December 31, 2020;
(xiii)
that provides for the outsourcing of any function or part of the business of the Company or any of the Company Subsidiaries that is necessary
for the conduct of the Company and the Company Subsidiaries as currently conducted and that provides for or could reasonably be expected
to involve annual
payments
or receipts equal to or in excess of $100,000 or provides for or could reasonably be expected to involve payments or receipts in aggregate
equal to or in excess of $1,000,000;
(xiv)
that relates to Indebtedness for a principal amount equal to or in excess of $5,000,000 or to mortgaging, pledging or otherwise placing
a Lien on any material portion of the assets of the Company or any Company Subsidiary;
(xv)
that is a partnership or joint venture agreement or relates to the formation, creation, operation, management or control of any partnership
or joint venture;
(xvi)
that grants any right of first refusal, right of first offer, option to purchase or similar right with respect to any assets, rights
or properties of the Company or the Company Subsidiaries;
(xvii)
that provides for the acquisition or disposition of any assets (other than acquisitions or dispositions of assets in the ordinary course
of business consistent with past practice), business (whether by merger, sale of stock, sale of assets or otherwise) or real property,
in each case with any outstanding obligations;
(xviii)
that as a result of a change of control of the Company or any Company Subsidiary (A) requires the Company or any Company Subsidiary,
or any successor thereto or acquirer thereof, to make any payment to any Person equal to or in excess of $4,000,000, (B) gives any
Person a right to receive or elect to receive a payment equal to or in excess of $4,000,000 from the Company or any Company Subsidiary,
or any successor thereto or acquirer thereof, (C) gives any Person a right to terminate or modify in any material respect the terms
of such Contract or (D) grants any Person enhanced or additional rights under such Contract in any material respect;
(xix)
that is a settlement or similar agreement pursuant to which (A) the Company or any Company Subsidiary will be required to make annual
payments equal to or in excess of $300,000, other than any settlements related to the payment of claims to a service provider or (B)
that contains material obligations or material limitations on the conduct of the Company or any Company Subsidiary (other than customary
confidentiality obligations);
(xx)
to which any Governmental Entity is a party, other than Contracts where the Company and the Company Subsidiaries are providing insurance
services in the ordinary course of business that does not provide for and could not reasonably be expected to involve (x) annual payments
or receipts equal to or in excess of $4,000,000 or (y) payments or receipts in aggregate equal to or in excess of $5,000,000;
(xxi)
that would be required to be but has not been filed by the Company prior to the date of this Agreement pursuant to Item 404 of Regulation S-K
under the Securities Act; or
(xxii)
that is otherwise material to the Company or any Company Subsidiary;
provided that,
except for Contracts described in clauses (iii), (v) and (xx) above, the definition of “Specified Contract” shall not include
any Insurance Contract or Policy relating to insurance services entered into by the Company or any Company Subsidiary in the ordinary
course of business consistent with past practice.
(b) The Company has
made available to Parent the standard form(s) of Contract with Providers used by the Company and the Company Subsidiaries.
(c) Each of the Specified
Contracts is valid, binding and enforceable on the Company or a Company Subsidiary, as the case may be, and, to the knowledge of the
Company, each other party thereto (in each case subject to the Bankruptcy and Equity Exception), and is in full force and effect, except
for immaterial failures to be valid, binding or enforceable or to be in full force and effect. There is no material breach of or default
under any Specified Contract by the Company or any Company Subsidiary or, to the knowledge of the Company, any other party thereto, and
no event has occurred that, with or without the lapse of time or the giving of notice or both, would constitute a material breach thereof
or default thereunder by the Company or any Company Subsidiary or, to the knowledge of the Company, any other party thereto. There are
no material disputes pending or, to the Company’s knowledge, threatened with respect to any of the Specified Contracts and neither
the Company nor any of the Company Subsidiaries has received any written notice of the intention of any other party to any Specified
Contract to amend, terminate, not renew or reduce any commitment under any Specified Contract in any material respect, nor to the Company’s
knowledge is any such party threatening to do so.
SECTION 3.21. Litigation.
There is no material claim, suit, action, investigation, arbitration, proceeding, inquiry, review, subpoena, civil investigative demand
or other request for information, whether judicial or administrative (each, a “Proceeding”) pending or, to the knowledge
of the Company, threatened against or affecting the Company or any Company Subsidiary or any of their respective properties or assets.
There are no material Judgments outstanding against the Company or any Company Subsidiary.
SECTION 3.22. Compliance
with Laws; Authorizations; Policies. (a) Each of the Company and the Company Subsidiaries is, and at all times since January 1, 2019
has been, in compliance in all material respects with all Judgments and Laws applicable to it and its business, operations, assets or
properties, including all applicable Health Care Laws and Insurance Laws, and, in each case, any applicable policies and procedures promulgated
thereunder (including any policies and procedures promulgated by the Puerto Rico Commissioner of Insurance (“OCI”),
the Puerto Rico Office of
Industrial Tax Exemption (“OITE”),
Puerto Rico Department of Health (“DOH”), ASES or CMS).
(b) Since January
1, 2019, (i) neither the Company nor any of the Company Subsidiaries has received any written notice or other communication from any
Governmental Entity regarding any actual or possible failure to comply with any Judgment or Law, except for immaterial failures to so
comply, and no material fine, sanction or penalty has been imposed on any Company Subsidiary by any Governmental Entity, and (ii) neither
the Company nor any of the Company Subsidiaries has entered into any agreement or settlement with any Governmental Entity with respect
to any actual or alleged material violation of any Judgment or Law.
(c) Each of the Company
and the Company Subsidiaries is, and has at all times since January 1, 2019 been, in compliance in all material respects with the
rules, regulations and policies of the BCBSA, as applicable.
(d) Neither the Company
nor any of the Company Subsidiaries, nor any director, officer or employee of the Company or any of the Company Subsidiaries, nor, to
the Company’s knowledge, any agent or other Person acting on behalf of the Company or any of the Company Subsidiaries, directly
or indirectly, since January 1, 2017, (i) has used any funds of the Company or any of the Company Subsidiaries for unlawful contributions,
unlawful gifts, unlawful entertainment or other unlawful expenses relating to political activity, (ii) has made any unlawful payment
to foreign or domestic governmental officials or employees or to foreign or domestic political parties or campaigns from funds of the
Company or any of the Company Subsidiaries, (iii) has violated, or is in violation of, the Foreign Corrupt Practices Act of 1977 (the
“FCPA”) or any rules and regulations promulgated thereunder, the USA PATRIOT Act or any foreign or domestic anti-corruption,
anti-bribery, export, import, re-export, anti-boycott, embargo or similar Law in any jurisdiction in which the Company or any Company
Subsidiary has operated or currently operates. Neither the Company nor any of the Company Subsidiaries has, since January 1, 2017, (A)
received any written communication from any Governmental Entity or any third party alleging any of the foregoing violations or (B) made
any disclosure (voluntary or otherwise) to any Governmental Entity with respect to any alleged irregularity, misstatement, omission or
other potential violation of liability arising under or relating to any of the foregoing Laws. To the extent applicable, the Company
and the Company Subsidiaries have developed and implemented a compliance program designed to ensure compliance with the FCPA and the
applicable foregoing Laws.
(e) Since January
1, 2019, neither the Company nor any of the Company Subsidiaries, nor any of their respective officers or directors, have been convicted
of or charged with conduct that would constitute a Medicare or other “Federal health care program” (as defined in 42 U.S.C.
§ 1320a-7(b)(1)) related offense or convicted of or charged with a violation of any Law related to fraud, theft, embezzlement, breach
of fiduciary duty, kickbacks, bribes, other financial misconduct, obstruction of an investigation or controlled substances. Neither the
Company nor any of the Company Subsidiaries, nor any of their respective officers or directors, have been excluded from
participating in any
Federal health care program, been subject to sanction pursuant to 42 U.S.C. § 1320a-7a or § 1320a-8 or been convicted
of a crime described at 42 U.S.C. § 1320a 7b, or, to the extent that any such officer or director was or shall have been identified
as having been excluded from participation in any Federal health care program, the Company and the Company Subsidiaries, as applicable,
have taken all remedial action required by and in compliance with applicable Law.
(f) Each of the Company
and the Company Subsidiaries (i) has, and at all times since January 1, 2019 has had, in effect all certificates, registrations, variances,
exemptions, franchises, grants, licenses, approvals, clearances, permissions, qualifications, registrations and Consents of Governmental
Entities (collectively, “Authorizations”), (ii) has filed all reports, notices and other documents with all Governmental
Entities and (iii) has paid all fees and assessments due and payable in connection therewith, in each case necessary for it to own, lease
and operate its properties and assets and conduct its business as presently conducted (or as conducted at such time), except for immaterial
Authorizations, failures to file or failures to pay. All such Authorizations are in full force and effect and are not subject to any
administrative or judicial Proceeding that could result in any modification, termination, suspension or revocation thereof in any material
respect. Each of Company and the Company Subsidiaries are, and at all times since January 1, 2019 have been, in compliance with the terms
and requirements of all such Authorizations and, to the Company’s knowledge, no suspension or cancellation of any such Authorizations
is threatened, except for immaterial instances of noncompliance or immaterial suspensions and cancellations. None of the Company Subsidiaries
is subject to any pending, or, to the knowledge of the Company, threatened material financial or market conduct examination or other
investigation by any Governmental Entity.
(g) (i) Except as
required by applicable Health Care Laws and Insurance Laws and the insurance and reinsurance Authorizations maintained by the Company
or any of the Company Subsidiaries, as applicable, there is no (x) written agreement, memorandum of understanding, commitment letter
or similar undertaking with any Governmental Entity that is binding on the Company or any Company Subsidiary or (y) order or directive
by, supervisory letter (other than those provided on an industry or sector-wide basis) or cease-and-desist order from, any Governmental
Entity that is binding on the Company or any Company Subsidiary and (ii) neither the Company nor any of the Company Subsidiaries
have adopted any board resolution at the request of any Governmental Entity, in the case of each of clauses (i) and (ii), that (A) limits
in any material respect the ability of the Company or any Company Subsidiary to conduct their businesses, including their ability to
issue or enter into any reinsurance or retrocession treaties or agreements, slips, binders, cover notes or other similar arrangements,
(B) requires the divestiture of any material investment of the Company or any Company Subsidiary, (C) limits in any material
respect the ability of the Company or any Company Subsidiary to pay dividends or (D) requires any material investment of the Company
or any Company Subsidiary to be treated as a non-admitted asset (or the local equivalent).
(h) All policies,
policy forms, binders, slips, treaties, certificates, Insurance Contracts or reinsurance Contracts or participation agreements and other
agreements of insurance
or reinsurance, whether individual or group (including all applications, supplements, endorsements, riders and ancillary agreements in
connection therewith) and all amendments, applications and certificates pertaining thereto issued by any applicable Company Subsidiary
(“Policies”) and any and all marketing materials have been, to the extent required under applicable Law, filed with
or submitted to and approved or not objected to by the relevant Governmental Entity within the period provided for objection, and such
Policies and marketing materials comply in all material respects with the Health Care Laws and Insurance Laws applicable thereto, and
have been administered in all material respects in accordance therewith. All premium rates established by the applicable Company Subsidiaries
that are required to be filed with or submitted to or approved by Governmental Entities have been so filed, submitted or approved, the
premiums charged conform in all material respects thereto, and such premiums comply in all material respects with the Insurance Laws
applicable thereto.
SECTION 3.23. Environmental
Matters. (a) Each of the Company and the Company Subsidiaries is, and at all times since January 1, 2019 has been, in compliance
in all material respects with all Environmental Laws, and possesses and is, and at all times since January 1, 2019 has been, in compliance
in all material respects with all Authorizations required under Environmental Laws for it to conduct its business (“Environmental
Authorizations”), and none of such Environmental Authorizations are subject to any administrative or judicial proceeding that
could result in any material modification, termination or revocation thereof; (c) neither the Company nor any of the Company Subsidiaries
has received any written communication alleging that the Company or any Company Subsidiary is not in material compliance with or has
a material liability under any Environmental Law or Environmental Authorization; (d) there is no Environmental Claim pending or,
to the knowledge of the Company, threatened in writing against the Company or any Company Subsidiary; (e) there has been no Release of
or exposure to any Hazardous Material at any real property currently or, to the knowledge of the Company, formerly owned, leased or operated
by the Company or any Company Subsidiary that would reasonably be expected to form the basis of any material Environmental Claim against
the Company or any Company Subsidiary; and (f) to the knowledge of the Company, neither the Company nor any Company Subsidiary has
retained or assumed, either contractually or by operation of Law, any liabilities or obligations that form or would reasonably be expected
to form the basis of any material Environmental Claim against the Company or any Company Subsidiary.
SECTION 3.24. Intellectual
Property. (a) Section 3.24 of the Company Disclosure Letter sets forth a true, correct and complete list as of the date of this
Agreement of all Patents, Trademarks, Copyrights and Internet domain names owned by the Company or any Company Subsidiary that are registered,
issued or subject to a pending application for registration or issuance (the “Company Registered Intellectual Property”).
The material Company Registered Intellectual Property is subsisting and, to the knowledge of the Company, valid and enforceable.
(b) The Company and
the Company Subsidiaries own, are licensed or otherwise have the right to use all material Intellectual Property (including the Company
Registered Intellectual
Property) used or held for use by the Company or any Company Subsidiary in the conduct of the business of the Company and the Company
Subsidiaries as presently conducted, free and clear of any Liens, other than Permitted Liens. No Proceedings are pending or, to the knowledge
of the Company, threatened against the Company or any Company Subsidiary by any Person challenging the ownership, validity or enforceability
of any material Company Intellectual Property, and since January 1, 2019 neither the Company nor any of the Company Subsidiaries has
received any written claim or written notice from any Person asserting any such challenge.
(c) To the knowledge
of the Company, the conduct of the business of the Company and the Company Subsidiaries as presently conducted does not infringe upon,
violate or misappropriate any Intellectual Property of any other Person. There are no claims pending or, to the knowledge of the Company,
threatened against the Company or any of the Company Subsidiaries asserting any such infringement, violation or misappropriation, and
neither the Company nor any of the Company Subsidiaries has received any written claim or written notice (including any “cease
and desist” letters and invitations to license) from any Person alleging any such infringement, violation or misappropriation.
To the knowledge of the Company, no other Person has infringed upon, violated or misappropriated or is infringing, violating or misappropriating
any of the Company Intellectual Property in any material respect, and neither the Company nor any Company Subsidiary has sent to any
Person any written complaint, claim, demand or notice alleging such infringement, violation or misappropriation.
(d) Each current and
former employee of the Company or a Company Subsidiary, as a matter of course, and any consultant or independent contractor commissioned
by the Company or a Company Subsidiary, who has alone or with others contributed in any manner to, or was involved in, the creation or
development of any material Company Intellectual Property, has entered into a written agreement with the Company that obliges such
employee, consultant or independent contractor to assign to the Company such Intellectual Property.
(e) Each of the Company
and the Company Subsidiaries has used reasonable best efforts to protect and maintain the confidentiality of all Trade Secrets included
in the Company Intellectual Property. To the knowledge of the Company, neither the Company nor any of the Company Subsidiaries has disclosed,
delivered or licensed any Trade Secrets included in the Company Intellectual Property to any other Person, other than in the ordinary
course of business and subject to obligations of confidentiality. Each current and former employee of the Company or a Company Subsidiary,
as a matter of course, and any consultant or independent contractor commissioned by the Company or a Company Subsidiary who has access
to material confidential information of the Company or a Company Subsidiary, has entered into a written agreement with the Company that
requires such employee, consultant or independent contractor to protect such confidential information.
(f) To the knowledge
of the Company, the IT Assets (i) operate and perform in all material respects in accordance with their documentation and functional
specifications and otherwise as required by the Company in connection with the conduct
of its business, (ii)
since January 1, 2019 have not malfunctioned or failed in a manner that has had a material impact on the Company or any of the Company
Subsidiaries, (iii) are free from material bugs and other defects and (iv) have not been subject to any material unauthorized access
by any Person. The Company has implemented commercially reasonable backup and disaster recovery technology processes, as well as a commercially
reasonable business continuity plan, in each case consistent in all material respects with customary industry practices.
(g) (i) The conduct
of the business of each of the Company and the Company Subsidiaries is and at all times has been in compliance in all material respects
with any and all applicable Laws, (including, to the extent applicable, the Health Insurance Portability and Accountability Act, the
Health Information Technology for Economic and Clinical Health Act and related regulations), contractual requirements, and privacy policies
binding the applicable Company or Company Subsidiary solely to the extent relating to data protection or information privacy, security,
collection, use and disclosure, (ii) Personal Data collected, stored and processed by the Company or any Company Subsidiary can be used
by Parent and its subsidiaries after the Closing in the manner currently used by the Company and the Company Subsidiaries, (iii) each
of the Company and the Company Subsidiaries has used commercially reasonable efforts to protect the privacy of Personal Data that the
Company or any of the Company Subsidiaries (or any Person on behalf of the Company or the Company Subsidiaries) collect, store, use or
maintain for the conduct of their business and to prevent unauthorized use, disclosure, loss, processing, transmission or destruction
of or access to such Personal Data by any other Person, (iv) neither the Company nor any Company Subsidiary has been legally required
to provide any notices to data owners in connection with a disclosure of Personal Data, nor has the Company or any Company Subsidiary
provided any such notice and (v) there are no claims pending or, to the knowledge of the Company, threatened against the Company or any
of the Company Subsidiaries alleging a violation of any Person’s Personal Data or privacy rights.
(h) (i) The Company
and the Company Subsidiaries have complied in all material respects with all notice, attribution and other requirements of each license
applicable to OSS that is or has been used in the conduct of the business of the Company and the Company Subsidiaries; and (ii) neither
the Company nor any of the Company Subsidiaries has used or distributed any OSS in a manner that requires (A) disclosure or distribution
of any source code owned by the Company or the Company Subsidiaries, (B) license or other provision of any source code owned by the Company
or the Company Subsidiaries on a royalty-free basis or (C) the grant of any patent license, non-assertion covenant or other rights under
any Intellectual Property owned by the Company or the Company Subsidiaries.
SECTION 3.25. Insurance.
Section 3.25 of the Company Disclosure Letter sets forth a true, correct and complete list, and the Company has made available to
Parent true, correct and complete copies, of all material insurance policies owned, held by or applicable to the Company or any Company
Subsidiary (or the assets or business of either) with policy periods in effect as of the date of this Agreement and of which the Company
or any Company Subsidiary is the beneficiary. All of the insurance policies of
the Company or any Company Subsidiary
are in full force and effect, and the Company is not in default with respect to its obligations under any of such insurance policies,
except for immaterial failures to comply. No written notice of cancellation or termination has been received by the Company or any Company
Subsidiary with respect to any of their respective insurance policies, other than in connection with ordinary renewals.
SECTION 3.26. Brokers
and Other Advisors. No broker, investment banker, financial advisor or other Person, other than Goldman Sachs & Co. LLC, the
fees and expenses of which will be paid by the Company, is entitled to any broker’s, finder’s, financial advisor’s
or other similar fee or commission in connection with the Transactions based upon arrangements made by or on behalf of the Company or
any of its affiliates. The Company has made available to Parent a true, correct and complete copy of any engagement letter between the
Company and Goldman Sachs & Co. LLC relating to the Transactions.
SECTION 3.27. Opinions
of Financial Advisors. The Company has received an oral opinion of Goldman Sachs & Co. LLC (to be confirmed by delivery of a
written opinion dated as of the date hereof) to the effect that, as of the date hereof, and based upon and subject to the factors and
assumptions set forth therein, the $36.00 per share of Company Common Stock to be paid to the holders of shares of Company Common Stock
(other than Parent and its affiliates) pursuant to this Agreement is fair to such holders from a financial point of view. A signed copy
of such opinion will be made available to Parent for informational purposes only promptly following the date of this Agreement.
ARTICLE
IV
Representations and Warranties of Parent and Merger Sub
Except as set forth
in the disclosure letter (with specific reference to the Section of this Agreement to which the information stated in such disclosure
relates; provided that information contained in any section of the disclosure letter shall be deemed to be disclosed with respect
to any other Section of this Agreement to the extent that it is reasonably apparent from the face of such disclosure that such information
is applicable to such other Section of this Agreement) dated the date hereof and delivered by the Parent and Merger Sub to the Company
immediately prior to the execution of this Agreement (the “Parent Disclosure Letter”), Parent and Merger Sub, jointly
and severally, represent and warrant to the Company as follows:
SECTION 4.01. Organization,
Standing and Power. Each of Parent and Merger Sub is duly organized, validly existing and in good standing (where applicable as a
legal concept) under the laws of the jurisdiction in which it is organized and has full corporate power and authority necessary to conduct
its business as presently conducted.
SECTION 4.02. Merger
Sub. (a) Merger Sub was formed solely for the purpose of entering into the Transactions, and since the date of its incorporation,
Merger
Sub has not carried on any business,
conducted any operations or incurred any liabilities or obligations other than those incident to its formation and pursuant to this Agreement,
the performance of its obligations hereunder and matters ancillary thereto.
(b) All outstanding
shares of capital stock of Merger Sub have been validly issued and are fully paid and nonassessable and are owned, directly or indirectly,
by Parent free and clear of any Lien.
SECTION 4.03. Authority;
Execution and Delivery; Enforceability. Each of Parent and Merger Sub has all requisite corporate power and authority to execute
and deliver this Agreement and to consummate the Transactions, subject, in the case of the Merger, to the adoption of this Agreement
by Parent (or another wholly owned subsidiary of Parent), as sole stockholder of Merger Sub (which shall occur immediately following
the execution of this Agreement). The execution, delivery and performance by each of Parent and Merger Sub of this Agreement and the
consummation by it of the Transactions have been duly authorized by all necessary corporate action on the part of Parent and Merger Sub,
subject, in the case of the Merger, to the adoption of this Agreement by Parent (or another wholly owned subsidiary of Parent), as sole
stockholder of Merger Sub. Neither the approval nor adoption of this Agreement nor the consummation of the Merger or the other Transactions
requires any approval of the stockholders of Parent. Each of Parent and Merger Sub has duly executed and delivered this Agreement, and,
assuming due authorization, execution and delivery by the Company, this Agreement constitutes its legal, valid and binding obligation,
enforceable against it in accordance with its terms (subject to the Bankruptcy and Equity Exception).
SECTION 4.04. No
Conflicts; Consents. (a) The execution and delivery by each of Parent and Merger Sub of this Agreement do not, and the consummation
of the Merger and the other Transactions and compliance with the terms hereof by Parent and Merger Sub will not, result in any loss,
suspension, limitation or impairment of any right of Parent or any of its subsidiaries to own or use any assets required for the conduct
of their respective businesses as presently conducted, or conflict with, or result in any violation of, or default (with or without notice
or lapse of time, or both) under, or give rise to a right of termination, cancellation, first offer, first refusal, modification or acceleration
of any right, obligation or loss of a benefit under, or result in the creation of any Lien upon any of the properties or assets of Parent
or any of its subsidiaries under, or require any consent under, any provision of (i) the organizational documents of Parent or any of
its subsidiaries, (ii) any Authorization of Parent or any of its subsidiaries or any Contract to which Parent or any of its subsidiaries
is a party or by which any of them or any of their respective properties or assets are bound or (iii) subject to the filings and
other matters referred to in Section 4.04(b), any Judgment or Law applicable to Parent or any of its subsidiaries or their
respective properties or assets, other than, in the case of clauses (ii) and (iii) above, any such items that have not had and would
not reasonably be expected to have, individually or in the aggregate, a Parent Material Adverse Effect.
(b) No Consent of,
or registration, declaration, notice or filing with or from, any Governmental Entity, is required to be obtained or made by or with respect
to Parent or any of its subsidiaries in connection with the execution, delivery and
performance of this
Agreement or the consummation of the Transactions, other than (i) the Antitrust Approvals, (ii) the Consents of, and filings with,
the state and territorial insurance departments and federal, state and territorial departments of health and other Consents and filings
required under the applicable Health Care Laws or Insurance Laws as set forth in Section 4.04(b) of the Parent Disclosure Letter (collectively,
the “Specified Parent Regulatory Approvals” and, together with the Specified Company Regulatory Approvals, the “Specified
Regulatory Approvals”), (iii) the Specified Company Regulatory Approvals (assuming the accuracy of the representations
and warranties made in Section 3.05(b) and the completeness of Section 3.05(b) of the Company Disclosure Letter),
(iv) the filing with the SEC of such reports and filings under the Exchange Act as may be required in connection with this Agreement,
the Merger and the other Transactions, (v) the filing of the PR Certificate of Merger with the Secretary of State of the Commonwealth
of Puerto Rico and the DE Certificate of Merger with the Secretary of State of the State of Delaware and (vi) such filings as may
be required under the rules and regulations of NYSE in connection with this Agreement, the Merger and the other Transactions.
SECTION 4.05. Information
Supplied. None of the information supplied or to be supplied by or on behalf of Parent or Merger Sub for inclusion or incorporation
by reference in the Proxy Statement will, at the time it is filed with the SEC, at the time it is first mailed to the holders of shares
of Company Common Stock and at the time of the Company Stockholders Meeting, contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they are made, not misleading. Notwithstanding the foregoing, no representation or warranty is made by Parent or Merger Sub
with respect to statements included or incorporated by reference in the Proxy Statement based on information supplied in writing by or
on behalf of the Company for inclusion or incorporation by reference therein.
SECTION 4.06. Available
Funds. Parent and Merger Sub has sufficient cash, available lines of credit or other sources of immediately available funds to consummate
the Merger pursuant to the terms of this Agreement, including to pay the Merger Consideration for all of the shares of Company Common
Stock on a fully-diluted basis, to pay all related fees and expenses pursuant to this Agreement, to make payments pursuant to Section 6.04
and to perform their respective obligations under this Agreement.
SECTION 4.07. Brokers
and Other Advisors. No broker, investment banker, financial advisor or other Person, other than J.P. Morgan Securities LLC, the fees
and expenses of which will be paid by Parent, is entitled to any broker’s, finder’s, financial advisor’s or other similar
fee or commission in connection with the Transactions based upon arrangements made by or on behalf of Parent, Merger Sub or any of their
respective affiliates.
ARTICLE
V
Covenants Relating to Conduct of Business
SECTION 5.01. Conduct
of Business of the Company. Except for matters set forth in Section 5.01 of the Company Disclosure Letter or as otherwise expressly
contemplated by this Agreement or required by applicable Law (including COVID-19 Measures) or with the prior written consent of Parent
(which shall not be unreasonably withheld, conditioned or delayed), from the date of this Agreement to the Effective Time, the Company
shall, and shall cause each Company Subsidiary to, conduct its business in the ordinary course of business consistent with past practice
and use reasonable best efforts to preserve its present organization, assets, employees, Authorizations, contractors and relationships
with customers, distributors, strategic partners, Governmental Entities, licensors, licensees and others that, in each case, have material
business dealings with it; provided that (i) the Company shall notify Parent as far in advance as reasonably practicable prior
to the Company or any Company Subsidiary taking any action to comply with any mandatory COVID-19 Measure and (ii) the Company and the
Company Subsidiaries shall be permitted to take any action to comply with any COVID-19 Measures which are not mandatory if the Company
reasonably believes such COVID-19 Measures are necessary or advisable to protect the health and safety of the Company’s or any
of the Company Subsidiaries’ employees and the Company reasonably consults with Parent (but shall not need to obtain Parent’s
consent) prior to taking any such action. Without limiting the generality of the foregoing, except for matters set forth in Section 5.01
of the Company Disclosure Letter or as otherwise expressly contemplated by this Agreement or required by applicable Law (including COVID-19
Measures), from the date of this Agreement to the Effective Time, the Company shall not, and shall not permit any Company Subsidiary
to, do any of the following without the prior written consent of Parent (which shall not be unreasonably withheld, conditioned or delayed):
(a) (i) declare, set
aside or pay any dividends on, or make any other distributions (whether in cash, stock or property or any combination thereof) in respect
of, any of its capital stock or other Equity Interests, other than dividends and distributions by a wholly owned Company Subsidiary to
its parent, (ii) split, combine, reclassify, exchange or readjust any of its capital stock or other Equity Interests or issue or
authorize the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock or other
Equity Interests, other than with respect to the capital stock or other Equity Interests of a Company Subsidiary, in connection with
transactions exclusively among the Company and any Company Subsidiaries or exclusively among the Company Subsidiaries, or (iii) directly
or indirectly redeem, repurchase or otherwise acquire any Equity Interests in the Company or any Company Subsidiary, except for (A) the
withholding of shares of Company Common Stock to satisfy Tax obligations with respect to the vesting, exercise or settlement of Company
RSAs, Company PSUs or Company RSUs outstanding as of the date of this Agreement (or issued after the date hereof in accordance with the
terms of this Agreement) in accordance with their respective terms in effect at such time, (B) the acquisition by the Company of
Company RSAs, Company PSUs or Company RSUs in connection with the forfeiture of such
awards in accordance
with their respective terms in effect at such time or (C) redemptions, repurchases or acquisitions of the capital stock or other Equity
Interests of a Company Subsidiary, in connection with transactions exclusively among the Company and any Company Subsidiaries or exclusively
among the Company Subsidiaries;
(b) issue any Equity
Interests, other than (i) the issuance of shares of Company Common Stock upon the settlement of Company RSAs, Company PSUs or Company
RSUs, in each case outstanding as of the date of this Agreement (or issued after the date hereof in accordance with the terms of this
Agreement) and in accordance with their respective terms in effect at such time, or (ii) issuances by a Company Subsidiary of capital
stock or other Equity Interests to the Company or another Company Subsidiary;
(c) amend (i) the
Company Articles or the Company Bylaws or (ii) the certificate of incorporation, bylaws or other comparable organizational documents
of any Company Subsidiary in a manner adverse to Parent;
(d) propose or adopt
a plan of complete or partial liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization,
other than the Merger;
(e) acquire (i) in
a single transaction or a series of related transactions, whether by merging or consolidating with, or by purchasing Equity Interests
in or assets of, or by any other manner, any business or any corporation, partnership, limited liability company, joint venture, association
or other business organization or division thereof or any other Person or (ii) any assets or properties, other than, in the case of each
of clauses (i) and (ii), (x) any Specified Permitted Investment and (y) any Unspecified Permitted Investment so long as the amount of
consideration paid or transferred by the Company and the Company Subsidiaries in connection with such Unspecified Permitted Investment
would not exceed $4,000,000 individually, or $10,000,000 in the aggregate when taken together with all other Unspecified Permitted Investments
made under this clause (e); provided that, prior to the execution of any definitive agreements in connection with any Specified
Permitted Investment or Unspecified Permitted Investment otherwise permitted by this clause (e), the Company shall provide Parent with
prior written notice, including a reasonable summary of the terms, of such potential Specified Permitted Investment or Unspecified Permitted
Investment, as applicable, as far in advance as reasonably practicable;
(f) form any Person
that would constitute a subsidiary or affiliate of the Company, except for any Person that would constitute a subsidiary of the Company
that is formed for the sole purpose of facilitating a Specified Permitted Investment or Unspecified Permitted Investment not in violation
of clause (e) above;
(g) except as required
by the terms of any Company Benefit Plan as in effect on the date hereof or to the extent required by applicable Law or, with respect
to the actions specifically described in Section 5.01(g) of the Company Disclosure Letter, to the extent such actions are taken in the
ordinary course of business consistent with past practice or are in connection with the Company’s internal realignment plan: (i)
adopt,
enter into, terminate
or amend any collective bargaining agreement or material Company Benefit Plan; (ii) increase in any manner the compensation, bonus
or fringe or other benefits of any non-employee director or employee at the level of Vice President or above; (iii) enter into or materially
amend any employment, change in control, severance, retention or similar Contract with any non-employee director or employee at the level
of Vice President or above (other than offer letters providing for employment with newly hired employees who are hired in the ordinary
course of business that do not contain any equity or equity-based compensation, change in control, severance, retention or similar arrangements);
(iv) grant any awards under any Company Benefit Plan (including grants of stock or stock-based awards) other than grants in connection
with promotions or new hires in the ordinary course of business consistent with past practice or waive any conditions on any awards under
any Company Benefit Plan; (v) take any action to accelerate the payment of any compensation or benefit under any Company Benefit Plan;
or (vi) change any actuarial or other assumption used to calculate funding obligations with respect to any Company Benefit Plan or change
the manner in which contributions are made or the basis on which contributions are calculated;
(h) (i) terminate
the employment of any employee at the level of Vice President or above, other than due to such individual’s death, disability or
for cause (each as determined by the Company or the applicable Company Subsidiary in the ordinary course of business) or (ii) hire any
individual at the level of Vice President or above;
(i) (i) change its
fiscal year or revalue any of its material assets or (ii) make any change in accounting methods, principles or practices used by
it, except, in the case of each of clauses (i) and (ii), as may be required (A) by GAAP, SAP or actuarial principles, as applicable,
or (B) by applicable Law, including Regulation S-X under the Securities Act;
(j) sell, lease or
sublease (as lessor or sublessor), license (as licensor) or otherwise dispose of, or pledge, encumber or otherwise subject to any Lien
(other than a Permitted Lien), any material properties or assets, except (i) sales, leases, licenses, dispositions, pledges or encumbrances
(A) of or on obsolete assets in the ordinary course of business consistent with past practice, (B) of properties or assets (other than
Company Intellectual Property) with de minimis or no book value or (C) of Investment Assets in accordance with the Investment
Guidelines or (ii) permitted conduct under clauses (q) and (s) below;
(k) (i) incur,
redeem, repurchase, prepay, defease, guarantee, assume or otherwise become liable for or modify in any material respects the terms of
any Indebtedness or issue or sell any debt securities or warrants or other rights to acquire any debt securities of the Company or any
Company Subsidiary other than (A) any Indebtedness of any wholly owned Company Subsidiary owing to the Company or to another wholly owned
Company Subsidiary and (B) any Indebtedness under the Company’s existing credit facilities as in effect as of the date of this
Agreement that can be repaid at the Closing without penalty (other than customary break funding costs) or (ii) make any loans, advances,
capital contributions or investments in (including by purchase of stock or securities, property transfers or purchase of property or
assets of any
Person or otherwise)
any other Person, in each case, other than to or in (A) the Company or any wholly owned Company Subsidiary, (B) any acquisition
not in violation of clause (e) above, (C) capital contributions or advances required by the terms of any Contract in effect as of the
date hereof or (D) any extensions of risk sharing arrangements, provider capitation, related compensation mechanisms and advances of
expenses to employees, in each case in the ordinary course of business consistent with past practice;
(l) make any capital
expenditure or expenditures, or incur any obligations or liabilities in connection therewith, which, individually, is equal to or in
excess of $200,000 or, in the aggregate, are equal to or in excess of $1,000,000 (other than (i) as reflected in the Company’s
capital expenditures forecast set forth in Section 5.01(l) of the Company Disclosure Letter and (ii) any Specified Permitted Investment
or Unspecified Permitted Investment not in violation of clause (e) above);
(m) make, change or
revoke any material Tax election, change any material Tax accounting method or period, file any amended Tax Return in respect of a material
amount of Taxes, enter into any closing agreement with respect to material Taxes, request any material Tax ruling, waive or extend the
statute of limitations in respect of a material amount of Taxes or settle or compromise any material Tax liability or refund;
(n) (i) materially
amend or modify, or renew, extend or terminate, or waive or release any material rights under, any Specified Contract or any Contract
that would be a Specified Contract if in effect on the date of this Agreement or (ii) enter into any Contract that would be a Specified
Contract if in effect on the date of this Agreement, in each case, other than in the ordinary course of business consistent with past
practice;
(o) enter into or
amend any Contract if consummation of any of the Transactions (alone or in combination with any other event) or compliance by the Company
or any Company Subsidiary with the provisions hereof will conflict with, or result in any violation or breach of, or default (with or
without notice or lapse of time, or both) under, or give rise to a right of, or result in, termination, cancelation or acceleration of
any obligation, or give rise to a loss of a benefit under, or result in the creation of any Lien in or upon any of the properties or
assets of the Company or any Company Subsidiary under, or require Parent to license or to transfer any of its material Intellectual Property
or other material assets under, or give rise to any increased, additional, accelerated or guaranteed rights or entitlements under, any
provision of such Contract, other than any amendment of a Contract that does not materially worsen any of the provisions of such Contract;
(p) (i) settle any
Proceeding if such settlement (A) would require any payment by the Company or any Company Subsidiary equal to or in excess of $500,000,
other than any settlement of any property and casualty insurance claim in the ordinary course of business consistent with past practice
that requires the payment of an amount which, when taken together with the settlement amounts of all other property and casualty insurance
claims settled pursuant to this clause (i)(A), does not exceed the
amount held in reserve
by the Company and the Company Subsidiaries for all outstanding property and casualty insurance claims as of June 30, 2021 or (B) would
obligate the Company or any Company Subsidiary to take any material action or impose any material restrictions on the business of the
Company or any of the Company Subsidiaries or (ii) commence any comparable Proceeding against a third party other than any such Proceeding
commenced in the ordinary course of business consistent with past practice where the total amount of damages sought does not equal or
exceed $500,000;
(q) (i) other than
non-exclusive licenses and sublicenses granted in the ordinary course of business consistent with past practice, assign, sell, lease,
license, dispose, cancel, abandon, grant rights to or fail to renew, maintain or defend, any material Company Intellectual Property or
(ii) disclose to any third party, other than representatives of Parent or under a confidentiality agreement, any Trade Secrets included
in any material Company Intellectual Property in a way that results in the loss of intellectual property protection for such material
Company Intellectual Property;
(r) cancel, terminate
or modify in any material respect, or take any action that could permit cancellation, termination or material modification of, any material
insurance policy;
(s) enter into any
real property lease or modify, amend, renew, extend, waive, or exercise any material right or remedy under or terminate any Lease, other
than (i) leases with annual payments not to exceed $100,000 individually or $500,000 in the aggregate and (ii) leases in respect of any
POS Leased Real Property entered into in the ordinary course of business consistent with past practice;
(t) materially alter
any existing underwriting, reserving, claim handling, loss control or actuarial practice, guideline or policy of the Company or any Company
Subsidiary or any material assumption underlying any reserves or actuarial practice or policy, except as may be required by GAAP, SAP
or actuarial principles;
(u) reduce or strengthen
any reserves, provisions for losses or other liability amounts in respect of Insurance Contracts and assumed reinsurance Contracts, except
(A) as may be required by GAAP, SAP or actuarial principles, (B) as a result of loss or exposure payments to other parties in accordance
with the terms of insurance Contracts and assumed reinsurance Contracts or (C) in the ordinary course of business consistent with past
practice;
(v) reduce in any
material respect the budget or scope of the Company’s and the applicable Company Subsidiaries’ program for, or otherwise
reduce in any material respect the resources or efforts specifically dedicated by the Company and the Company Subsidiaries to, (i) the
maintenance and improvement of their respective Medicare star ratings or (ii) retrospective chart review, coding audits or the collection
of prospective home assessments or patient assessment forms, in each case other than as a result of vendor-related cost savings;
(w) terminate, suspend,
abrogate, amend or modify (i) any certificate of authority to conduct business as an insurance company, health care services organization,
agency or service provider issued by the applicable Insurance Regulator or health regulatory Governmental Entity or (ii) any other material
Authorization, in each case of (i) and (ii) in a manner material and adverse to the Company or any Company Subsidiary;
(x) acquire or dispose
of any material Investment Assets in any manner inconsistent with the Investment Guidelines;
(y) materially amend
or modify the Investment Guidelines; or
(z) authorize, commit
or agree to take any of the foregoing actions.
Nothing contained in this Agreement
shall give to Parent or Merger Sub, directly or indirectly, rights to control or direct the operation of the Company or any Company Subsidiary
prior to the Closing.
SECTION 5.02. No
Solicitation. (a) The Company shall not, and shall cause its subsidiaries and all of its and their respective directors,
officers, employees, financial advisors, legal counsel and other agents, advisors or representatives (collectively,
“Representatives”) not to, directly or indirectly, (A) solicit, initiate, encourage or facilitate any inquiries
regarding, or the submission of any proposal or offer that constitutes, or would reasonably be expected to lead to, any Company
Takeover Proposal, (B) solicit, initiate, encourage or participate in any discussions or negotiations regarding, or furnish to any
Person (other than Parent or Merger Sub) any nonpublic information with respect to or in connection with, or take any other action
to facilitate or encourage the making of, any proposal or offer that constitutes, or would reasonably be expected to lead to, any
Company Takeover Proposal or (C) execute or enter into any letter of intent, memorandum of understanding, agreement in principle,
acquisition agreement, option agreement, merger agreement, joint venture agreement, partnership agreement or any other agreement,
arrangement or understanding (whether or not binding) relating to any Company Takeover Proposal (a “Company Acquisition
Agreement”). It is agreed that any violation of the restrictions in this Section 5.02 by any of the Company’s
subsidiaries or any of its or their respective Representatives shall be a breach of this Section 5.02 by the
Company.
(b) Except as set
forth in Section 5.02(b) of the Company Disclosure Letter, the Company shall, and shall cause its subsidiaries and all of its and their
respective Representatives to, immediately (i) cease all solicitation, encouragement, discussions and negotiations regarding any
inquiry, proposal or offer pending on the date of this Agreement that constitutes, or would reasonably be expected to lead to, a Company
Takeover Proposal, (ii) request the prompt return or destruction of all confidential information previously furnished to any Person
in connection with a possible Company Takeover Proposal and (iii) terminate access to any physical or electronic data rooms relating
to a possible Company Takeover Proposal. The Company shall not, and shall cause its subsidiaries and all of its and their respective
Representatives not to, release any Person from, or waive, amend or modify any provision of, or grant any
permission under any
“standstill” provision or similar provision with respect to any capital stock of the Company in any agreement to which the
Company or any of its subsidiaries is a party; provided that the Company Board or any committee thereof shall be permitted to
grant waivers of, and not to enforce, any “standstill” or similar provision to the extent that (x) the Company Board
or any committee thereof determines in good faith (after consultation with its outside counsel) that the failure to take such action
would violate the directors’ fiduciary duties under applicable Law and (y) any such action by the Company Board or any committee
thereof does not violate any other provision of this Section 5.02. Except to the extent otherwise permitted by the foregoing sentence,
the Company shall, and shall cause its affiliates to, (i) enforce the “standstill” or similar provisions of any such agreement
and (ii) immediately take all reasonable steps within their power to terminate any waiver under any such provisions that may have been
heretofore granted to any Person other than Parent and any of Parent’s affiliates.
(c) Notwithstanding
anything to the contrary contained in Section 5.02(a) or Section 5.02(b), at any time prior to obtaining the Company Stockholder
Approval, in response to a bona fide, written Company Takeover Proposal that did not result from a material breach of this Section 5.02
and for which the Company Board or any committee thereof determines in good faith (after consultation with its outside counsel and financial
advisor) that such Company Takeover Proposal constitutes or would reasonably be expected to lead to a Superior Proposal from the Person
or group submitting such bona fide, written Company Takeover Proposal and that the failure to take such action would violate the directors’
fiduciary duties under applicable Law (a “Qualifying Company Takeover Proposal”), the Company may, subject to compliance
with Section 5.02(d), (A) enter into an Acceptable Confidentiality Agreement with such Person or group making the Qualifying
Company Takeover Proposal and thereafter furnish information with respect to the Company to such Person or group and its Representatives
pursuant to such Acceptable Confidentiality Agreement so long as the Company also provides Parent promptly, and in no event later than
24 hours after the time such information is provided or made available to such Person or group or any of its Representatives, any information
furnished to such Person or group or any of its Representatives which was not previously furnished to Parent and (B) participate
in discussions or negotiations with such Person or group and its Representatives regarding such Qualifying Company Takeover Proposal.
The Company shall notify Parent prior to furnishing any information and/or entering into any discussions or negotiations as provided
in this Section 5.02(c).
(d) The Company shall
promptly, and in no event later than 24 hours after receipt thereof, (i) advise Parent in writing of the Company’s or any of its
subsidiaries’ or its or their respective Representatives’ receipt of any Company Takeover Proposal or any inquiries regarding,
or the submission of any proposal or offer that constitutes, or would reasonably be expected to lead to, any Company Takeover Proposal
and (ii) provide to Parent an unredacted copy of any such Company Takeover Proposal or such inquiry made in writing (including any financing
commitments or other agreements related thereto) (or if such Company Takeover Proposal or inquiry is not in writing, a written description
of the material terms and conditions thereof) and unredacted copies of all other written materials, draft and final agreements (including
all schedules and exhibits thereto) and correspondence exchanged between the Company or any of its affiliates or
its or their Representatives,
on the one hand, and the Person or group or its Representatives, on the other hand, making such Company Takeover Proposal or inquiry
in connection with such Company Takeover Proposal or inquiry. From and after such notification, the Company shall keep Parent reasonably
informed on a reasonably current basis of any material developments, discussions or negotiations regarding, or changes to the material
terms and conditions of, any such Company Takeover Proposal or inquiry, including providing to Parent promptly, and in no event later
than 24 hours after receipt thereof, unredacted copies of any additional proposals, counterproposals, written materials, draft and final
agreements (including all schedules and exhibits thereto) and correspondence exchanged between the Company or any of its affiliates or
its or their Representatives, on the one hand, and the Person or group or its Representatives, on the other hand, making such Company
Takeover Proposal or inquiry in connection with such Company Takeover Proposal or inquiry.
(e) Neither the Company
Board nor any committee thereof shall (i) (A) withdraw, withhold, qualify or modify in a manner adverse to Parent or Merger
Sub, or propose publicly to withdraw, withhold, qualify or modify in a manner adverse to Parent or Merger Sub, the Company Board Recommendation,
or authorize, resolve or agree to take any such action, (B) adopt, endorse, approve or recommend, or propose publicly to adopt, endorse,
approve or recommend, or submit to the vote of any securityholders of the Company, any Company Takeover Proposal, or authorize, resolve
or agree to take any such action, (C) fail to include the Company Board Recommendation in the Proxy Statement or to recommend against
any Company Takeover Proposal that is a tender offer or exchange offer within 10 Business Days after the commencement thereof or (D) make
any public statement inconsistent with the Company Board Recommendation (any action described in this clause (i) being referred to herein
as an “Adverse Recommendation Change”) or (ii) approve, recommend, cause or permit the Company or any of its
subsidiaries to enter into, or to propose to approve, recommend or enter into, any Company Acquisition Agreement (other than an Acceptable
Confidentiality Agreement entered into in accordance with this Section 5.02), or authorize, resolve, agree or propose to take any
such action.
(f) Notwithstanding
anything to the contrary set forth in this Agreement, prior to obtaining the Company Stockholder Approval, the Company Board or any committee
thereof may make an Adverse Recommendation Change if (i) the Company Board or any committee thereof determines in good faith (after consultation
with its outside counsel and financial advisor) that, as a result of an Intervening Event, failure to take such action would violate
the directors’ fiduciary duties under applicable Law or (ii) the Company receives a Company Takeover Proposal after the date
of this Agreement that did not result from a material breach of this Section 5.02 and for which the Company Board or any committee thereof
determines in good faith (after consultation with its outside counsel and financial advisor) that such Company Takeover Proposal constitutes
a Superior Proposal and that the failure to take such action would violate the directors’ fiduciary duties under applicable Law;
provided, however, that the Company Board and each committee thereof shall not, and shall cause the Company not to, make
an Adverse Recommendation Change unless, prior to taking such action (A) the Company has provided written notice to Parent (a “Notice
of Adverse Recommendation Change”)
advising Parent that
the Company Board or any such committee intends to take such action and the reasons therefor, (B) in the case of any Notice of Adverse
Recommendation Change provided in connection with an Intervening Event, such Notice of Adverse Recommendation Change contains a reasonably
detailed description of such Intervening Event, (C) in the case of any Notice of Adverse Recommendation Change provided in connection
with a Company Takeover Proposal, such Notice of Adverse Recommendation Change specifies the material terms and conditions of the related
Superior Proposal, identifying the Person or group making such Superior Proposal and including a copy of the most current version of
the agreement or proposal and all material related documentation with respect to such Superior Proposal, (D) a period of at least four
Business Days has elapsed following Parent’s receipt of such Notice of Adverse Recommendation Change (it being understood that
any amendment or modification to any Company Takeover Proposal that is the basis for such proposed Adverse Recommendation Change shall
require a new Notice of Adverse Recommendation Change and an additional notice period (which shall be the longer of (x) two Business
Days and (y) the period remaining under the initial notice period)), (E) if requested by Parent, the Company has negotiated, and has
caused its subsidiaries and its and their Representatives to negotiate, in good faith with Parent and its Representatives during such
four-Business Day period (as may be extended pursuant to clause (D)) with respect to any changes to the terms of this Agreement proposed
by Parent during such period and (F) taking into account any changes to the terms of this Agreement proposed by Parent, the Company
Board or any committee thereof has determined in good faith (after consultation with its outside counsel and financial advisor) (1) that
it would continue to violate the directors’ fiduciary duties under applicable Law not to effect the Adverse Recommendation Change
and (2) with respect to the actions described in clause (ii) of this Section 5.02(f), that the Company Takeover Proposal received
by the Company would continue to constitute a Superior Proposal, in each case, if such changes offered by Parent were given effect.
(g) Notwithstanding
the foregoing, nothing contained in this Section 5.02 shall be deemed to relieve the Company of its obligation under Section 6.01
to submit matters to obtain the Company Stockholder Approval at the Company Stockholders Meeting; provided, however, that
if the Company Board shall have made an Adverse Recommendation Change, then in submitting such matters to the Company Stockholders Meeting,
the Company Board may recommend against such matters or submit such matters without recommendation, in which event the Company Board
shall communicate the basis for its recommendation or lack thereof to the Company’s stockholders in the Proxy Statement or an appropriate
amendment or supplement thereto to the extent it determines, after consultation with its outside legal counsel, that such action is compelled
by applicable Law; provided further that nothing in this Section 5.02(g) shall affect the right of the Company to terminate this
Agreement pursuant to and in accordance with Section 8.01(g).
(h) Nothing contained
in this Section 5.02 will prohibit the Company from (i) taking and disclosing a position contemplated by Rule 14d-9, Rule 14e-2(a)(2)
or (3) or Item 1012(a) of Regulation M-A promulgated under the Exchange Act, (ii) making any disclosure that constitutes a
“stop, look and listen” communication pursuant to
Section 14d-9(f)
promulgated under the Exchange Act or (iii) making any disclosure to the Company’s stockholders that is required by applicable
Law, which actions shall not constitute or be deemed to constitute an Adverse Recommendation Change; provided, however,
that (A) any such disclosure permitted under clause (i) above that relates to a Company Takeover Proposal (other than a “stop,
look and listen” communication) shall be deemed an Adverse Recommendation Change unless the Company Board expressly publicly reaffirms
the Company Board Recommendation in connection with such disclosure and (B) any Adverse Recommendation Change may only be made in accordance
with Section 5.02(f).
ARTICLE
VI
Additional Agreements
SECTION 6.01. Company
Stockholders Meeting; Preparation of the Proxy Statement. (a) Subject to Section 6.01(b), the Company shall take all
necessary actions in accordance with applicable Law, the Company Articles and the Company Bylaws and the rules and regulations of
NYSE to duly call, give notice of, convene and hold a meeting of its stockholders (including any adjournment, recess or postponement
thereof, the “Company Stockholders Meeting”) for the purpose of obtaining the Company Stockholder Approval as
soon as reasonably practicable after the SEC confirms that it will not review or that it has no further comments on the Proxy
Statement, including (1) establishing a record date for such Company Stockholders Meeting promptly after the date on which the
SEC confirms that it will not review or that it has no further comments on the Proxy Statement (the “Company Record
Date”) and (2) duly convening and holding the Company Stockholders Meeting no later than 45 days after the Company Record
Date. Unless the Company Board has made an Adverse Recommendation Change pursuant to Section 5.02, the Company shall use
reasonable best efforts to solicit and obtain the Company Stockholder Approval, including engaging a proxy solicitation firm for the
purpose of assisting in the solicitation of proxies for the Company Stockholders Meeting. The Company may, after consultation with
Parent, adjourn, recess or postpone the Company Stockholders Meeting only (i) to the extent required by applicable Law to ensure
that any required supplement or amendment to the Proxy Statement is provided to the stockholders of the Company within a reasonable
amount of time in advance of the Company Stockholders Meeting, (ii) to the extent required by a court of competent jurisdiction in
connection with any Proceedings in connection with this Agreement or the Transactions, (iii) if, as of the time for which the
Company Stockholders Meeting is originally scheduled (as set forth in the Proxy Statement), there are insufficient shares of Company
Common Stock represented (either in person or by proxy) to constitute a quorum necessary to conduct the business of the Company
Stockholders Meeting or Parent reasonably believes that the Company will not receive proxies sufficient to obtain the Company
Stockholder Approvals, whether or not a quorum is present, or (iv) the Company Board or any committee thereof determines in good
faith (after consultation with its outside counsel) that the failure to adjourn, recess or postpone the Company Stockholders Meeting
would violate the directors’ fiduciary duties under applicable Law. Notwithstanding the foregoing, the Company shall
not
adjourn, recess or postpone the Company
Stockholders Meeting to a date that is (x) more than 30 days after the date on which the Company Stockholders Meeting was originally
scheduled or (y) less than five Business Days prior to the Outside Date, in the case of each of (x) and (y) without the prior written
consent of Parent. Unless the Company Board has made an Adverse Recommendation Change in accordance with Section 5.02, the Company shall
keep Parent updated with respect to proxy solicitation results as reasonably requested by Parent.
(b) As promptly as
reasonably practicable (but in any event no later than 20 Business Days) after the execution of this Agreement, the Company shall prepare
the Proxy Statement in preliminary form and file it with the SEC. Subject to Section 5.02, the Company Board shall include the Company
Board Recommendation in the Proxy Statement. Parent shall provide to the Company all information concerning Parent and Merger Sub as
may be reasonably requested by the Company in connection with the Proxy Statement and shall otherwise assist and cooperate with the Company
in the preparation of the Proxy Statement and the resolution of any comments thereto received from the SEC. Each of the Company, Parent
and Merger Sub shall promptly correct any information with respect to it or provided by it for use in the Proxy Statement if and to the
extent, in the absence of such a correction, the Proxy Statement would contain a misstatement of a material fact or omit to state a material
fact necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and the Company
shall disseminate such correction to the stockholders of the Company, as determined by the Company after consultation with Parent. The
Company shall notify Parent promptly upon the receipt of any comments (whether written or oral) from the SEC and of any request (whether
written or oral) by the SEC for amendments or supplements to the Proxy Statement and shall promptly supply Parent with copies of all
such comments, requests and any other written correspondence between the Company or any of its Representatives, on the one hand, and
the SEC, on the other hand, with respect to the Proxy Statement. The Company shall use its reasonable best efforts to respond as promptly
as reasonably practicable to any comments received from the SEC concerning the Proxy Statement and to resolve such comments with the
SEC, and shall use its reasonable best efforts to cause the Proxy Statement to be disseminated to its stockholders as promptly as reasonably
practicable after the resolution of any such comments or after the SEC confirms that it will not review the Proxy Statement. Prior to
the filing of the Proxy Statement (or any amendment or supplement thereto) or any dissemination thereof to the stockholders of the Company,
or responding to any comments from the SEC with respect thereto, the Company shall provide Parent and its counsel with a reasonable opportunity
to review and to comment on such document or response, which comments the Company shall consider in good faith.
SECTION 6.02. Access
to Information; Confidentiality. Except if prohibited by any applicable Law, the Company shall, and shall cause each of the Company
Subsidiaries to, afford to Parent and its Representatives reasonable access during normal business hours, upon reasonable advance notice,
during the period prior to the Effective Time to all their respective properties, books and records, Contracts and personnel and, during
such period, the Company shall, and shall cause each Company Subsidiary to, furnish, as promptly as reasonably practicable, to Parent
(A) copies of all
correspondence between the Company or
any Company Subsidiary and any other party to a Contract with regard to any Consent that is actually or purportedly required to be taken
or obtained with respect to such Contract in connection with the announcement, pendency or consummation of the Transactions and (B) all
other information concerning its business, properties and personnel as Parent may reasonably request, including information regarding
the status and substance of any negotiations with any Governmental Entity relating to changes in the rates or other terms of any existing
Contract with such Governmental Entity; provided, however, that neither the Company nor any of the Company Subsidiaries
shall be obligated to provide such access or information if the Company or the Company Subsidiary, as applicable, determines in its reasonable
judgment that doing so would (i) violate applicable Law or an applicable Judgment, (ii) waive the protection of attorney-client
privilege, attorney work product protection or other legal privilege or (iii) in light of COVID-19 or any COVID-19 Measures, jeopardize
the health or safety of any employee of the Company, and in any such event, the Company shall, and shall cause the applicable Company
Subsidiary to, use reasonable best efforts to communicate, to the extent feasible, the applicable information in a way that would not
result in any of the outcomes described in the foregoing clauses (i), (ii) and (iii), including by entering into a joint defense agreement,
“clean team” agreement, common interest agreement or other similar arrangement. Any in-person visits conducted pursuant to
this Section 6.02 shall be conducted in accordance with any applicable COVID-19 Measures and shall be conducted in such a manner
as to not interfere unreasonably with the conduct of the business of the Company and the Company Subsidiaries. All information exchanged
pursuant to this Section 6.02 shall be subject to the confidentiality letter agreement dated April 7, 2021, between the Company
and Parent (as amended or supplemented from time to time, the “Confidentiality Agreement”). Prior to the Effective
Time, Parent, Merger Sub and their Representatives shall not have the right to conduct environmental testing or sampling at any of the
facilities or properties of the Company or any of its subsidiaries. No investigation by Parent or its Representatives shall affect or
be deemed to modify or waive the representations and warranties of the Company set forth in this Agreement.
SECTION 6.03. Consents
and Approvals. (a) Upon the terms and subject to the conditions set forth in this Agreement, each party shall use its reasonable
best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other
parties in doing, all things necessary, proper or advisable to cause the conditions to Closing to be satisfied as promptly as
reasonably practicable and to consummate and make effective, in the most expeditious manner reasonably practicable, the
Transactions, including (i) obtaining all necessary or advisable Consents from, making all necessary registrations,
declarations and filings with and taking all reasonable steps as may be necessary to obtain a Consent from or avoid a Proceeding by
any Governmental Entity or other third party with respect to this Agreement or the Transactions, (ii) furnishing all
information required to be furnished in connection with obtaining any Consents from or making any filings with any Governmental
Entity or other third party, and promptly cooperating with and furnishing information in connection with any such requirements
imposed upon any party or any of their respective subsidiaries in connection with this Agreement or the consummation of the
Transactions, (iii) executing and delivering any additional instruments necessary to
consummate the Transactions and to fully
carry out the purposes of this Agreement and (iv) defending or contesting in good faith any Proceeding brought by a third party that
could otherwise prevent or impede, interfere with, hinder or delay in any material respect the consummation of the Transactions, in the
case of each of clauses (i) through (iv), other than with respect to Consents, registrations, declarations, filings, instruments and
Proceedings relating to or under applicable Antitrust Laws, Health Care Laws and Insurance Laws, which are subject to Sections 6.03(c)
and 6.03(d). Notwithstanding anything to the contrary set forth in this Agreement, with respect to any Consent, none of Parent, Merger
Sub or any of their respective subsidiaries shall be required to, and the Company and the Company Subsidiaries shall not, without the
prior written consent of Parent, pay or agree to pay any amount as consideration therefor to, or grant or agree to grant any financial,
contractual or other concession in favor of, the Person from whom such Consent is sought, other than (i) filing and processing fees and
(ii) any such payment or concession that is solely applicable to the Company and the Company Subsidiaries (a “Company Concession”)
and, when taken together with all Company Concessions and Company Restrictions, is de minimis to the Company and the Company Subsidiaries,
taken as a whole.
(b) Subject to Section
6.03(c), Parent shall use its reasonable best efforts to take, or cause to be taken, all actions necessary to assist the Company in obtaining
all consents and approvals under the BCBSA License Agreements, including any other transfer or change of control consents or approvals
of the BCBSA needed as a result of this Agreement, the Merger or the other Transactions. Parent shall use its reasonable best efforts
to cooperate in all respects with the Company in connection with any filings or submissions requested or required by the BCBSA.
(c) Each party agrees
to (i) make an appropriate filing of a Notification and Report Form pursuant to the HSR Act within 30 days after the date of this
Agreement, unless otherwise mutually agreed to by the parties, and to make any other required filings pursuant to applicable Antitrust
Laws, Health Care Laws or Insurance Laws with respect to the Transactions as promptly as reasonably practicable and advisable following
the date hereof, including Form A, Form E, “material modification” or similar change of control applications to be filed
in each jurisdiction where required by applicable Health Care Laws or Insurance Laws with respect to the Transactions, (ii) supply
as promptly as practicable and advisable any additional information and documentary material that may be requested by any Governmental
Entity with competent jurisdiction, including pursuant to the HSR Act or any other applicable Antitrust Laws, Health Care Laws or Insurance
Laws, (iii) cooperate with any investigation, review or other inquiry by or before a Governmental Entity of competent jurisdiction relating
to the Transactions and (iv) use reasonable best efforts to take or cause to be taken all other actions necessary to cause as promptly
as reasonably practicable the expiration or termination of the applicable waiting periods under the HSR Act and any other applicable
Antitrust Laws and to obtain as promptly as reasonably practicable all consents under any applicable Antitrust Laws, Health Care Laws
and Insurance Laws that may be required by the United Stated Federal Trade Commission (the “FTC”), the United States
Department of Justice (the “DOJ”) or any other Governmental Entity with competent jurisdiction, so as to enable the
parties to consummate the Transactions without delay. In
furtherance and not
in limitation of the foregoing, each party shall use reasonable best efforts to take or cause to be taken as promptly as practicable
all actions necessary to resolve objections, if any, as may be asserted with respect to the Transactions under any applicable Antitrust
Law, Health Care Laws or Insurance Laws; provided, however, without the prior written consent of each party, none of Parent,
Merger Sub or Company shall be required to defend any lawsuit brought by a Governmental Entity or other adjudicatory action initiated
by or at the behest of a Governmental Entity (and not upon the filing of a claim, challenge or complaint by any Person other than such
Governmental Entity), in each case, seeking to either (i) restrain, enjoin, prevent, prohibit, or otherwise make illegal the consummation
of the Merger or the other Transactions or (ii) impose a Burdensome Condition (as defined below). Notwithstanding anything to the contrary
set forth in this Agreement, nothing contained in this Section 6.03 shall require Parent, Merger Sub or any of their respective
subsidiaries to, and the Company and the Company Subsidiaries shall not, without the prior written consent of Parent, propose, negotiate,
effect or agree to, or execute any settlements, undertakings, consent decrees, stipulations or other agreements with any Governmental
Entity (including ASES) or with any other Person (including the BCBSA) obligating Parent, the Company or any of their respective subsidiaries
to, (i) sell, divest, license or otherwise convey or hold separate any asset or business of Parent, the Company or any of their respective
subsidiaries, (ii) terminate or alter any existing relationship, contractual right or obligation of Parent, the Company or any of their
respective subsidiaries, (iii) create any relationship, contractual right or obligation, including any payment obligation (other than
customary filing fees), of Parent, the Company or any of their respective subsidiaries or (iv) implement any limitations or restrictions
on the ability of Parent, Merger Sub or any of their respective subsidiaries to hold and exercise full rights of ownership of any Equity
Interests in the Surviving Corporation, including the right to vote such Equity Interests, or to effectively control the business or
operations of the Company or any of the Company Subsidiaries, in each case other than any action or condition described in the immediately
preceding clauses (i)-(iv) that applies solely to the Company and the Company Subsidiaries (a “Company Restriction”)
and, when taken together with all Company Concessions and Company Restrictions, is de minimis to the Company and the Company Subsidiaries,
taken as a whole (a “De Minimis Company Restriction”). The term “Burdensome Condition” shall mean
any action or condition described in clauses (i)-(iv) of the immediately preceding sentence other than any De Minimis Company Restriction.
(d) Each of Parent
and the Company shall (i) cooperate in all respects with each other in connection with any filing or submission with a Governmental
Entity by any Person in connection with the Transactions, and in connection with any investigation or other inquiry by or before a Governmental
Entity relating to the Transactions, including any proceeding initiated by a private party, including furnishing to the other party such
necessary information and reasonable assistance as the other party may request in connection with its preparation of any filing or submission
which is necessary under any applicable Antitrust Laws, Health Care Laws and Insurance Laws, (ii) give the other party reasonable prior
notice of any such filings or submissions and, to the extent reasonably practicable, of any communication with, and any inquiries or
requests for additional information from, the FTC, the DOJ, the OCI and any other Governmental Entity regarding the Merger or any of
the other Transactions, and permit
the other party to
review and discuss in advance, and consider in good faith the views of, and secure the participation of, the other party in connection
with, any such filings, submissions, communications, inquiries or requests, (iii) unless prohibited by applicable Law or by the applicable
Governmental Entity, and to the extent reasonably practicable, (A) not participate in or attend any meeting, or engage in any substantive
conversation, with any Governmental Entity in respect of the Merger or any of the other Transactions without the other party, (B) give
the other party reasonable prior notice of any such meeting or conversation, (C) in the event one party is prohibited by applicable Law
or by the applicable Governmental Entity from participating in or attending any such meeting or engaging in any such conversation, keep
such party apprised with respect thereto, (D) cooperate with one another in the filing of any substantive memoranda, white papers,
filings, correspondence or other written communications explaining or defending this Agreement, the Merger or any of the other Transactions,
articulating any regulatory or competitive argument or responding to requests or objections made by any Governmental Entity and (E) furnish
the other party with copies of all filings, submissions, correspondence and communications (and memoranda setting forth the substance
thereof) between it and its affiliates and their respective Representatives, on the one hand, and any Governmental Entity or members
of any Governmental Entity’s staff, on the other hand, with respect to this Agreement, the Merger and the other Transactions, (iv)
comply with any inquiry or request from the FTC, the DOJ, the OCI or any other Governmental Entity as promptly as reasonably practicable
and (v) consult with one another in connection with any inquiry, hearing, investigation, Proceeding or litigation by, or negotiations
with, any Governmental Entity relating to this Agreement, the Merger or any of the other Transactions, including the scheduling of, and
strategic planning for, any meetings with any Governmental Entity relating thereto. Any such additional information shall be in substantial
compliance with the requirements of applicable Law, including applicable Antitrust Laws, Health Care Laws and Insurance Laws, as the
case may be. Notwithstanding anything in this Agreement to the contrary, Parent shall, on behalf of the parties, control and lead all
communications and strategy for dealing with the FTC, the DOJ, the OCI and any other Governmental Entity with respect to the HSR Act
and any other applicable Law, including Antitrust Laws, Health Care Laws or Insurance Laws.
(e) In addition to
and without limiting any of the parties’ respective obligations in this Section 6.03, the Company and the Company Board shall
(i) take all action necessary to ensure that no state or territorial takeover statute, “business combination”, “control
share acquisition”, “fair price”, “moratorium” or similar Law is or becomes applicable to any Transaction
or this Agreement and (ii) if any state or territorial takeover statute, “business combination”, “control share
acquisition”, “fair price”, “moratorium” or similar Law becomes applicable to any Transaction or this Agreement,
take all action necessary to ensure that the Transactions may be consummated as promptly as practicable on the terms contemplated by
this Agreement and otherwise to minimize the effect of such statute or regulation on the Transactions and this Agreement.
SECTION 6.04. Equity
Awards. Prior to the Effective Time, the Company Board (or, if appropriate, any committee administering the Company Stock Plan) shall
adopt such resolutions and take such other actions (including obtaining any required consents) as may be required to effect the following:
(a) Equity
Awards Granted Prior to the Date of this Agreement.
(i) at
the Effective Time, each Company RSA outstanding as of the date of this Agreement and immediately prior to the Effective Time, whether
or not vested, will be converted, in full satisfaction of the rights of the holder thereof and without any action on the part of such
holder, into the right to receive the Merger Consideration, without interest;
(ii)
at the Effective Time, each award of Company PSUs outstanding as of the date of this Agreement and immediately prior to the Effective
Time, whether or not vested, will be canceled and converted, in full satisfaction of the rights of the holder thereof and without any
action on the part of such holder, into the right to receive an amount in cash equal to the product of (A) the Merger Consideration and
(B) the number of shares of Company Common Stock covered by each such award immediately prior to the Effective Time, determined based
on target performance; and
(iii)
at the Effective Time, each award of Company RSUs outstanding as of the date of this Agreement and immediately prior to the Effective
Time, whether or not vested, will be canceled and converted, in full satisfaction of the rights of the holder thereof and without any
action on the part of such holder, into the right to receive an amount in cash equal to the product of (A) the Merger Consideration and
(B) the number of shares of Company Common Stock covered by such award as of immediately prior to the Effective Time.
(b) Equity Awards
Granted Following the Date of this Agreement. At the Effective Time, each award of Company RSUs or Company PSUs granted following
the date of this Agreement and outstanding immediately prior to the Effective Time, whether or not vested, will be canceled and converted,
in full satisfaction of the rights of the holder thereof and without any action on the part of such holder, into the right to receive
an amount in cash equal to the product of (i) the Merger Consideration and (ii) the number of shares of Company Common Stock covered
by such award as of immediately prior to the Effective Time (determined, in the case of Company PSUs, based on target performance), payable
on the date the award of Company RSUs or Company PSUs, respectively, would have otherwise vested pursuant to its vesting schedule, subject
to the holder’s continuing employment as of each such vesting date or as otherwise provided in and pursuant to the terms and conditions
of the award agreements for such Company RSUs and Company PSUs, which terms and conditions shall be no more favorable than those with
respect to awards granted prior to the date of this Agreement.
(c) All amounts payable
pursuant to this Section 6.04 shall be subject to any required withholding of Taxes and shall be paid without interest as soon as practicable
following the applicable payment date specified herein, and may be paid through the payroll system of the Surviving Corporation.
(d) The Company shall
ensure that, following the Effective Time, no current or former participant in any Company Stock Plan or other Company Benefit Plan
shall have any right thereunder to acquire
any capital stock of the Company, any Company Subsidiary or the Surviving Corporation and its subsidiaries or any other equity interest
therein.
SECTION 6.05. Continuing
Employee Matters. (a) For a period from the Effective Time through the first anniversary of the Effective Time, each employee of
the Company or a Company Subsidiary who remains in the employment of the Surviving Corporation and its subsidiaries (the “Continuing
Employees”) shall receive from the Surviving Corporation or a subsidiary (i) a base salary, wage or commission rate at least
equal to the base salary, wage or commission rate provided to such Continuing Employee by the Company or such Company Subsidiary immediately
prior to the Effective Time, (ii) incentive compensation opportunities no less favorable than the incentive compensation opportunities
provided to such Continuing Employee by the Company or such Company Subsidiary immediately prior to the Effective Time (including the
target value of annual equity-based compensation awards historically granted to such Continuing Employee prior to the Effective Time,
but excluding any one-time, special or transaction-related incentive compensation opportunities), which incentive compensation opportunities
will be subject to the terms and conditions of Parent’s incentive compensation programs and (iii) other employee benefits that
are no less favorable in the aggregate to the benefits provided by the Company or any Company Subsidiary to such Continuing Employee
immediately prior to the Effective Time; provided that, for the avoidance of doubt, neither Parent nor the Surviving Corporation
nor any of Parent’s subsidiaries shall have any obligation to issue, or adopt any plans or arrangements providing for the issuance
of, Equity Interests to any Continuing Employee. Unless as otherwise provided herein, nothing in this Agreement shall confer upon any
Continuing Employee any right to continue in the employ or service of Parent, the Surviving Corporation or any affiliate of Parent, or
shall interfere with or restrict in any way the rights of Parent, the Surviving Corporation or any affiliate of Parent, which rights
are hereby expressly reserved, to discharge or terminate the services of any Continuing Employee, at any time, for any reason whatsoever,
with or without cause.
(b) With respect to
any “employee benefit plan,” as defined in Section 3(3) of ERISA, or other benefit plan or arrangement maintained by Parent
or its affiliates in which any Continuing Employee is eligible to participate on or after the Effective Time, as of the Effective Time,
Parent shall cause the Surviving Corporation to recognize the service of each Continuing Employee with the Company or any Company Subsidiary
(as well as service with any predecessor employer) as if such service had been performed with Parent as of the Effective Time for all
purposes under any benefit plan maintained by Parent (other than (i) any post-employment health or post-employment welfare plan or defined
benefit pension plan or (ii) any severance plan to the extent a Continuing Employee is covered under another severance arrangement with
the Company (excluding any severance payable pursuant to applicable Law)) (in each case, solely to the extent that Parent makes such
plan or program available to employees of the Surviving Corporation and not in any case where such credit would result in duplication
of benefits for the same period of service), but not for purposes of any other employee benefit plan of Parent.
(c) With respect to
any health and welfare plan maintained by Parent or its affiliates in which Continuing Employees are eligible to participate after the
Effective Time, Parent shall, and shall cause its affiliates, including the Surviving Corporation, to, use reasonable best efforts to
(i) waive, or cause to be waived, all limitations as to preexisting conditions or exclusions, actively-at-work requirements and
waiting periods with respect to participation and coverage requirements applicable to each Continuing Employee (and his or her eligible
dependents) to the extent such conditions and exclusions were satisfied or did not apply to such employees under the welfare plans of
the Company prior to the Effective Time and (ii) provide each Continuing Employee with credit for any co-payments, deductibles and similar
expenses incurred by each Continuing Employee (and his or her eligible dependents) during the calendar year in which the Effective Time
occurs in satisfying any analogous deductible or out-of-pocket requirements to the extent applicable under the relevant benefit plan
in which each Continuing Employee (and his or her eligible dependents) will be eligible to participate from and after the Effective Time.
(d) Without limiting
the generality of Section 9.07, this Section 6.05 shall be binding upon, and shall inure solely to the benefit of each of the parties
to this Agreement and their respective successors and assigns, and nothing in this Section 6.05, express or implied, is intended
to or shall confer upon any other Person any rights, benefits or remedies of any nature whatsoever (including any right to continued
employment by or services with Parent, the Company, the Surviving Corporation, or any of their respective subsidiaries) under or by reason
of this Section 6.05. Nothing contained herein shall be construed as requiring, and the Company shall take no action that would
have the effect of requiring, Parent or the Surviving Corporation to continue any specific plans, programs, policies, arrangements, agreements
or understandings or to continue the employment of any specific person. Furthermore, no provision of this Agreement shall be construed
as prohibiting or limiting the ability of Parent or the Surviving Corporation to amend, modify or terminate any plans, programs, policies,
arrangements, agreements or understandings of Parent, the Company or the Surviving Corporation and nothing therein shall be construed
as an amendment to any such plan, program, policy, arrangement, agreement or understanding for any purpose.
SECTION 6.06. Indemnification.
(a) Parent shall assume the obligations with respect to all rights to indemnification, advancement of expenses and exculpation from
liabilities, for acts or omissions occurring at or prior to the Effective Time now existing in favor of the current or former
directors or officers (the “Indemnified Persons”) of the Company or any Company Subsidiary as provided in (and
solely to the extent as may be provided by the Company or the applicable Company Subsidiary pursuant to) the Company Articles, the
Company Bylaws, the organizational documents of any Company Subsidiary or any indemnification agreement between such Indemnified
Person and the Company or any Company Subsidiary (in each case, as in effect on the date hereof and, in the case of any
indemnification agreement, as set forth in Section 6.06(a) of the Company Disclosure Letter and of which the Company has made
available to Parent true, correct and complete copies), without further action, as of the Effective Time, and such obligations shall
survive the Merger and shall continue in full force and effect in accordance with their terms. For the avoidance of doubt, the
applicable rights of
indemnification and exculpation contemplated
by this Section 6.06 and pursuant to the terms of the Company Articles or Company Bylaws as in effect at or immediately prior to
the Effective Time shall not be impaired by any modification of such terms in any amendment or restatement of such Company Articles or
Company Bylaws following the Effective Time (including in connection with the filing of the PR Certificate of Merger and the DE Certificate
of Merger).
(b) Parent shall obtain,
or shall cause the Surviving Corporation to obtain, at or prior to the Effective Time, a prepaid (or “tail”) directors’
and officers’ liability insurance policy in respect of acts or omissions occurring at or prior to the Effective Time, covering
each Person currently covered by the Company’s or any Company Subsidiary’s directors’ and officers’ liability
insurance policies, with coverage for six years following the Effective Time on terms with respect to such coverage and amounts no less
favorable to the insureds than those of such policy in effect immediately prior to the Effective Time; provided, however,
that in no event shall Parent or the Surviving Corporation be required to expend pursuant to this Section 6.06(b) an amount in excess
of 300% of the most recent annual premium paid by the Company or any Company Subsidiary for such insurance for its current fiscal year
(such 300% threshold, the “Maximum Premium”); provided further that, if the amount necessary to procure such
prepaid (or “tail”) insurance coverage exceeds such Maximum Premium, Parent or the Surviving Corporation, as the case may
be, shall only be obligated to provide as much coverage as may be obtained for such Maximum Premium. The Company may, prior to the Effective
Time, purchase for an aggregate amount not to exceed the Maximum Premium, a six-year prepaid (or “tail”) policy on terms
and conditions providing at least substantially equivalent benefits as the current policies of directors’ and officers’ liability
insurance maintained by the Company and the Company Subsidiaries in respect of acts or omissions occurring at or prior to the Effective
Time. If such prepaid (or “tail”) policy has been obtained by the Company, it shall be deemed to satisfy all obligations
to obtain insurance pursuant to this Section 6.06(b) and the Surviving Corporation shall use its reasonable best efforts to cause such
policy to be maintained in full force and effect, for its full term, and to honor all of its obligations thereunder.
(c) In the event that
Parent, the Surviving Corporation or any of their respective successors or assigns (i) consolidates with or merges into any other
Person and is not the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys
all or substantially all of its properties and assets to any Person, then, in each such case, Parent or the Surviving Corporation shall
make proper provision so that the successors and assigns of Parent or the Surviving Corporation, as the case may be, or at Parent’s
option, Parent, assume the obligations set forth in this Section 6.06.
SECTION 6.07. Fees
and Expenses. (a) Except as set forth in Section 6.06, this Section 6.07 and Section 6.09, all fees and expenses
incurred in connection with this Agreement, the Merger and the other Transactions shall be paid by the party incurring such fees or
expenses, whether or not the Merger and the other Transactions are consummated.
(b) In the event that:
(i) the
Company terminates this Agreement pursuant to Section 8.01(g),
(ii)
Parent terminates this Agreement pursuant to Section 8.01(d) or would have been entitled to terminate this Agreement pursuant to
Section 8.01(d) prior to or at the time the Company terminates this Agreement pursuant to Section 8.01(b)(i) or 8.01(b)(iii)
or
(iii)
(A) after the date of this Agreement, a Company Takeover Proposal from a third party is made, proposed or communicated to the Company
Board or management, or is publicly made, proposed or communicated or otherwise becomes publicly known, or any Person or group publicly
proposes or announces an intention to make a Company Takeover Proposal and, in each case, not publicly withdrawn prior to the event that
gives rise to the applicable termination right, by a third party, (B) thereafter this Agreement is terminated by either Parent or
the Company pursuant to Section 8.01(b)(i) or 8.01(b)(iii), or by Parent pursuant to Section 8.01(c) and (C) within 12
months of such termination (1) any transaction included within the definition of Company Takeover Proposal is consummated or (2) the
Company or any Company Subsidiary enters into a definitive agreement providing for the consummation of any transaction within the definition
of Company Takeover Proposal, in each case whether or not involving the same Company Takeover Proposal or the Person or group making
the Company Takeover Proposal referred to in clause (A); provided that for purposes of clause (C), the term “Company Takeover
Proposal” shall have the meaning assigned to such term in Section 9.03, except that all references to “15%” in
such definition shall be deemed references to “50%”,
then the Company shall pay to Parent
(or its designee) a fee of $17,985,000 (the “Company Termination Fee”).
Any fee due under this Section 6.07(b) shall be paid by wire transfer of same-day funds to an account designated by Parent (1) in
the case of clause (i) above, prior to or simultaneously with such termination of this Agreement, (2) in the case of clause (ii) above,
within five Business Days after the date of such termination of this Agreement and (3) in the case of clause (iii) above, within five
Business Days after the earlier of (x) the date of the consummation of the applicable transaction referred to in clause (C)(1) thereof
and (y) the date of entry into the definitive agreement referred to in clause (C)(2) thereof. The parties hereto acknowledge and agree
that in no event shall the Company be required to pay the Company Termination Fee on more than one occasion, whether or not the Company
Termination Fee may be payable under more than one provision of this Agreement at the same or at different times and the occurrence of
different events. If the Company Termination Fee becomes payable in accordance with this Section 6.07, the payment to Parent or
its designee of the Company Termination Fee shall be the sole and exclusive remedy of Parent and Merger Sub for any loss suffered by
Parent or Merger Sub as a result of the failure of the Transactions to be consummated and, upon such payment in accordance with this
Section 6.07, the Company shall not have any further liability or obligation relating to or arising out of this
Agreement or the Transactions, except
in the case of fraud or willful or intentional breach of this Agreement by the Company.
(c) In the event that:
(i) the
Company or Parent terminates this Agreement pursuant to Section 8.01(b)(i) and, at the time of such termination, (A) one or more of the
conditions set forth in Section 7.01(a) (but only if the applicable Legal Restraint relates to the matters set forth in Section 7.01(b)),
Section 7.01(b), Section 7.02(d), Section 7.02(e) or Section 7.02(f) was not satisfied (or, in the case of Section 7.02(d), Section 7.02(e)
or Section 7.02(f), was not waived by Parent) and (B) all other conditions set forth in Article VII have been satisfied (or, to the extent
permitted by Law, waived by the parties entitled thereto) (or in the case of conditions which by their nature are to be satisfied at
the Closing, were capable of being satisfied as of such time),
(ii)
the Company or Parent terminates this Agreement pursuant to Section 8.01(b)(ii) (but only if the applicable Legal Restraint relates to
the matters set forth in Section 7.01(b)),
(iii)
Parent terminates this Agreement pursuant to Section 8.01(f), or
(iv)
the Company or Parent terminates this Agreement pursuant to Section 8.01(h),
then Parent shall
pay to the Company (or its designee) a fee of $17,985,000 (the “Parent Termination
Fee”). Any Parent Termination Fee due under this Section 6.07(c) shall be paid by wire transfer of same-day funds to an account
designated by the Company within five Business Days after the date of such termination of this Agreement. The parties hereto acknowledge
and agree that in no event shall Parent be required to pay the Parent Termination Fee on more than one occasion, whether or not the Parent
Termination Fee may be payable under more than one provision of this Agreement at the same time or at different times and the occurrence
of different events. If the Parent Termination Fee becomes payable in accordance with this Section 6.07, the payment to the Company or
its designee of the Parent Termination Fee shall be the sole and exclusive remedy of the Company for any loss suffered by the Company
as a result of the failure of the Transactions to be consummated and, upon such payment in accordance with this Section 6.07, neither
Parent nor Merger Sub shall have any further liability or obligation relating to or arising out of this Agreement or the Transactions,
except in the case of fraud or willful or intentional breach of this Agreement by Parent or Merger Sub, as applicable.
(d) The Company and
Parent acknowledge and agree that the agreements contained in Section 6.07(b) and 6.07(c) are an integral part of the Transactions,
and that, without these agreements, the Company and Parent would not enter into this Agreement. Accordingly, if the Company fails to
promptly pay any amount due pursuant to Section 6.07(b) or if Parent fails to promptly pay any amount due pursuant to Section 6.07(c)
(any such amount, a “Payment”), and in order to obtain such Payment, the party
entitled to receive
such Payment (the “Recipient”) commences a Proceeding against the party obligated to make such Payment (the “Payor”)
that results in a Judgment in the Recipient’s favor for such payment, the Payor shall pay to the Recipient its costs and expenses
(including attorneys’ fees and expenses) in connection with such Proceeding, together with interest on the amount of such Payment
from the date such Payment was required to be made until the date of payment at the prime rate as published in The Wall Street Journal
in effect on the date such Payment was required to be made.
(e) Each of Parent
and the Company shall comply with the provisions of Section 6.07(e) of the Company Disclosure Letter.
SECTION 6.08. Public
Announcements. Except with respect to any Adverse Recommendation Change made in accordance with the terms of this Agreement or Company
Takeover Proposal, Parent and the Company shall consult with each other before issuing, and give each other the opportunity to review
and comment upon, any press release or other public statements with respect to the Transactions, including the Merger, and shall not
issue any such press release or make any such public statement without the prior written consent of the other party (not to be unreasonably
withheld, conditioned or delayed), except in each case (i) as required by applicable Law or court process, (ii) by obligations pursuant
to the rules and regulations of any national securities exchange or national securities quotation system, or (iii) for statements that
are not inconsistent with previous press releases, public disclosures or public statements made by Parent or the Company. Each of Parent
and the Company shall consult with each other before issuing, and give the other a reasonable opportunity to review and comment upon,
any employee communication programs or internal announcements with respect to the Transactions. The parties agree that the initial press
release to be issued with respect to the Transactions shall be in the form heretofore agreed to by the parties.
SECTION 6.09. Tax
Matters. The Company shall cooperate with Merger Sub and Parent in preparing, executing and filing any Tax Returns with respect to
stock transfer, real estate transfer, documentary, stamp, recording and other similar Taxes incurred in connection with the Transactions.
The Company shall and shall cause Triple-S Blue Inc., I.I. to cooperate with Merger Sub and Parent to take all actions necessary or required
under the Tax Grant, the Incentive Law and any other applicable Law or custom, in each case, to preserve the availability of the Tax
Grant following the Transactions, including notifying any applicable Governmental Entity of the Transactions or obtaining, prior to the
Effective Time, any approval from an applicable Governmental Entity required in connection with the Transactions.
SECTION 6.10. Stockholder
Litigation. From the date of this Agreement and until the termination of this Agreement in accordance with Article VIII hereof,
the Company shall promptly advise Parent of any Proceeding commenced or, to the knowledge of the Company, threatened by a stockholder
or holder of any Equity Interests of the Company against the Company or its directors or executive officers relating to the Merger or
any of the other Transactions, and shall keep Parent reasonably informed, consult with Parent regarding and give Parent the opportunity
to participate, but not control, the defense and settlement of any such Proceeding. Without limiting the
generality of the foregoing, neither
the Company nor any of the Company Subsidiaries, nor any of their respective Representatives, shall agree to or propose any settlement
of any such Proceeding without Parent’s prior written consent (which consent shall not be unreasonably withheld, conditioned or
delayed).
SECTION 6.11. Section 16
Matters. From and after the date hereof and until the Effective Time, the Company shall take all actions as may be required to cause
any dispositions of Equity Interests of the Company in connection with this Agreement and the Transactions by each individual who is
a director or officer of the Company subject to Section 16 of the Exchange Act immediately prior to the Effective Time to be exempt
under Rule 16b-3 promulgated under the Exchange Act.
SECTION 6.12. Merger
Sub and Surviving Corporation Compliance. Parent shall cause Merger Sub or the Surviving Corporation, as applicable, to comply with
all of its respective obligations under this Agreement, and Merger Sub shall not engage in any material activities of any nature except
in connection with the Transactions and as provided in or contemplated by this Agreement (or ancillary hereto).
SECTION 6.13. Advice
of Changes. The Company and Parent shall each promptly advise the other party (i) of any notice or other communication from
any Person alleging that the consent of such Person is or may be required in connection with the Transactions and (ii) upon receiving
any communication from any Governmental Entity or third party whose consent or approval is required for consummation of the Transactions
that causes such party to believe that there is a reasonable likelihood that any such consent or approval will not be obtained or that
the receipt of any such consent or approval will be materially delayed. The Company shall as promptly as reasonably practicable notify
Parent of any notice or other communication from any party to any Specified Contract to the effect that such party has terminated or
intends to terminate or otherwise adversely modify its relationship with the Company or any of the Company Subsidiaries as a result of
the Transactions.
ARTICLE
VII
Conditions Precedent to the Merger
SECTION 7.01. Conditions
to Each Party’s Obligation. The respective obligation of each party to effect the Merger is subject to the satisfaction (or,
to the extent permitted by applicable Law, waiver by the parties entitled thereto) on or prior to the Closing Date of the following conditions:
(a) No Legal Restraints.
No applicable Law, Judgment, other legal restraint or prohibition (in each case whether temporary, preliminary or permanent in nature)
or binding order or determination by any Governmental Entity (collectively, the “Legal Restraints”) restraining, enjoining,
preventing, prohibiting or otherwise making illegal the consummation of the Merger shall be in effect;
(b) Required Approvals.
(i) The expiration or termination of any applicable waiting period (including any extension thereof) under the HSR Act shall have occurred,
(ii) all other Antitrust Approvals shall have been obtained and (iii) all Specified Regulatory Approvals shall have been obtained;
and
(c) Company Stockholder
Approval. The Company Stockholder Approval shall have been obtained.
SECTION 7.02. Conditions
to Obligations of Parent and Merger Sub. The obligations of Parent and Merger Sub to effect the Merger are further subject to the
satisfaction (or, to the extent permitted by Law, waiver by Parent and Merger Sub) on or prior to the Closing Date of the following conditions:
(a) Representations
and Warranties of the Company. The representations and warranties of the Company (i) set forth in Section 3.15(a) (Absence
of Certain Changes or Events) shall be true and correct in all respects at and as of the Closing Date as though made at and as of
such date, (ii) set forth in Section 3.02 (Capital Structure) (other than the last sentence of Section 3.02(d) and Section 3.02(f))
shall be true and correct (for purposes of determining the satisfaction of this condition, without regard to any “materiality”,
“Company Material Adverse Effect” or similar qualifications and exceptions contained therein) at and as of the Closing Date
as though made at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in
which case at and as of such specified date)) except for any de minimis inaccuracies, (iii) set forth in the first and third
sentences of Section 3.01 (Organization, Standing and Power), Section 3.03 (Company Subsidiaries, Equity Interests)
(other than the last sentence of Section 3.03(c)), Section 3.04 (Authority; Execution and Delivery; Enforceability) or Section
3.26 (Brokers and Other Advisors) shall be true and correct in all material respects, at and as of the Closing Date as though
made at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in which case
at and as of such specified date)) and (iv) set forth in Article III other than those specified in the foregoing clauses (i), (ii)
and (iii) shall be true and correct (for purposes of determining the satisfaction of this condition, without regard to any “materiality”,
“Company Material Adverse Effect” or similar qualifications and exceptions contained therein) at and as of the Closing Date
as though made at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in
which case at and as of such specified date)), other than for such failures to be true and correct that have not had and would not reasonably
be expected to have, individually or in the aggregate, a Company Material Adverse Effect;
(b) Performance
of Obligations of the Company. The Company shall have performed in all material respects all obligations required to be performed
by it under this Agreement at or prior to the Effective Time;
(c) No Company
Material Adverse Effect. Since the date of this Agreement, there shall not have been any change, event, effect, fact, circumstance,
development or occurrence that has had or would reasonably be expected to have, individually or in the aggregate, a Company Material
Adverse Effect;
(d) No Lawsuit
or Other Adjudicatory Action. There shall not be any pending lawsuit brought by any Governmental Entity or other adjudicatory action
initiated by or at the behest of any Governmental Entity (and not upon the filing of a claim, challenge or complaint by any Person other
than such Governmental Entity), in either case, seeking to (A) restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation
of the Merger or the other Transactions or (B) impose a Burdensome Condition;
(e) No Legal Restraints.
No Legal Restraint imposing a Burdensome Condition shall be in effect;
(f) Third-Party
Consents. All consents and approvals of third parties with respect to the Contracts set forth in Section 7.02(f) of the Company
Disclosure Letter shall have been obtained in accordance with Section 6.03(a); and
(g) Company Officer’s
Certificate. Parent and Merger Sub shall have received from the Company a certificate, dated the Closing Date and signed on behalf
of the Company by the Company’s Chief Executive Officer or Chief Financial Officer, certifying that the conditions set forth in
clauses (a), (b) and (c) of this Section 7.02 have been satisfied.
SECTION 7.03. Conditions
to Obligations of the Company. The obligation of the Company to effect the Merger is further subject to the satisfaction (or, to
the extent permitted by Law, waiver by the Company) on or prior to the Closing Date of the following conditions:
(a) Representations
and Warranties of Parent and Merger Sub. The representations and warranties of Parent and Merger Sub (i) set forth in Sections 4.01
(Organization, Standing and Power), 4.02 (Merger Sub), 4.03 (Authority; Execution and Delivery; Enforceability)
or 4.07 (Brokers and Other Advisors) shall be true and correct in all material respects, at and as of the Closing Date as though
made at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in which case
at and as of such specified date)) and (ii) set forth in Article IV other than those specified in the foregoing clause (i) shall
be true and correct (for purposes of determining the satisfaction of this condition, without regard to any “materiality”,
“Parent Material Adverse Effect” or similar qualifications and exceptions contained therein) at and as of the Closing Date
as though made at and as of such date (except to the extent such representation and warranty expressly relates to a specified date (in
which case at and as of such specified date)), other than for such failures to be true and correct that have not had and would not reasonably
be expected to have, individually or in the aggregate, a Parent Material Adverse Effect;
(b) Performance
of Obligations of Parent and Merger Sub. Each of Parent and Merger Sub shall have performed in all material respects all obligations
required to be performed by it under this Agreement as of the Effective Time; and
(c) Parent Officer’s
Certificate. The Company shall have received from Parent a certificate, dated the Closing Date and signed on behalf of Parent by
a duly authorized officer of Parent, certifying that the conditions set forth in clauses (a) and (b) of this Section 7.03 have been
satisfied.
ARTICLE
VIII
Termination; Amendment and Waiver
SECTION 8.01. Termination.
This Agreement may be terminated and the Transactions abandoned at any time prior to the Effective Time (whether before or after receipt
of the Company Stockholder Approval, except as otherwise expressly noted):
(a) by mutual written
consent of Parent, Merger Sub and the Company;
(b) by either Parent
or the Company:
(i) if
the Merger shall not have been consummated on or before May 23, 2022 (such date, the “Outside Date”); provided
that notwithstanding the foregoing, the right to terminate this Agreement pursuant to this Section 8.01(b)(i) shall not be available
to a party if the failure of the Merger to be consummated on or before the Outside Date is the result of a material breach of this Agreement
by such party;
(ii)
if any Legal Restraint permanently restraining, enjoining, preventing, prohibiting or otherwise making illegal the consummation of the
Merger shall be in effect and shall have become final and non-appealable; or
(iii)
if the Company Stockholder Approval shall not have been obtained at the Company Stockholders Meeting duly convened therefor (or any adjournment
or postponement thereof) and at which a vote by the Company’s stockholders on the adoption of this Agreement was taken;
(c) by Parent, if
the Company breaches any of its representations or warranties or fails to perform any of its covenants or obligations contained in this
Agreement, which breach or failure to perform (i) would give rise to the failure of a condition set forth in Section 7.02(a)
or 7.02(b) and (ii) cannot be cured or, if capable of being cured, has not been cured prior to the earlier of (x) 30 days after
the giving of written notice to the Company of such breach and (y) the Outside Date (provided that Parent and Merger Sub are not
then in material breach of this Agreement);
(d) by Parent, prior
to receipt of the Company Stockholder Approval, if (1) an Adverse Recommendation Change has occurred or (2) the Company shall have
materially breached its obligations under Section 5.02, which material breach, if capable of being cured, has not been cured within
five days after Parent has given written notice to the Company of such breach; provided that any material breach by the Company
of its
obligations under
Section 5.02 which directly or indirectly results in the submission of a Company Takeover Proposal shall not be capable of being
cured;
(e) by the Company,
if Parent or Merger Sub breaches any of its representations or warranties or fails to perform any of its covenants or obligations contained
in this Agreement, which breach or failure to perform (i) would give rise to the failure of a condition set forth in Section 7.03(a)
or 7.03(b) and (ii) cannot be cured or, if capable of being cured, has not been cured prior to the earlier of (x) 30 days after
the giving of written notice to Parent or Merger Sub of such breach and (y) the Outside Date (provided that the Company is not
then in material breach of this Agreement);
(f) by Parent, if
any Legal Restraint imposing a Burdensome Condition shall be in effect and shall have become final and non-appealable;
(g) by the Company,
prior to receipt of the Company Stockholder Approval, in order to effect an Adverse Recommendation Change and concurrently enter into
a definitive agreement providing for a Superior Proposal; provided that the Company has complied in all material respects with
the terms of Section 5.02(f); or
(h) by the Company
or Parent, if (i) a Governmental Entity has brought a lawsuit or (ii) an adjudicatory action has been initiated by or at the behest of
a Governmental Entity (and not upon the filing of a claim, challenge or complaint by any Person other than such Governmental Entity),
in either case, seeking to (A) restrain, enjoin, prevent, prohibit or otherwise make illegal the consummation of the Merger or the other
Transactions or (B) impose a Burdensome Condition, and Parent or Merger Sub has notified the Company that it refuses, or has withheld
its consent from the Company, to defend such lawsuit or adjudicatory action.
SECTION 8.02. Effect
of Termination. In the event of termination of this Agreement by either the Company or Parent as provided in Section 8.01, this
Agreement shall forthwith become void and have no force and effect (other than Section 3.26, 4.07, the second to last sentence of
Section 6.02, Section 6.07, this Section 8.02 and Article IX, which provisions shall survive such termination), without
any liability or obligation on the part of Parent or Merger Sub, on the one hand, or the Company, on the other hand, except that no such
termination shall relieve any party from liability arising out of or resulting from fraud or the willful and material breach by such
party of any provision set forth in this Agreement prior to the date of such termination. For purposes of this Agreement, “willful
and material breach” means a deliberate act or failure to act, which act or failure to act constitutes in and of itself a material
breach of this Agreement that the breaching party is aware would, or would reasonably be expected to, breach its obligations under this
Agreement. No termination hereof shall affect the parties’ respective obligations under the Confidentiality Agreement, all of which
obligations shall survive any termination hereof in accordance with their terms.
SECTION 8.03. Amendment;
Extension; Waiver. This Agreement may be amended, modified and supplemented in any and all respects only by an instrument in writing
signed on behalf of each of the parties. Any agreement on the part of a party to
any extension or waiver with respect
to this Agreement shall be valid only if set forth in an instrument in writing signed on behalf of such party. At any time prior to the
Effective Time, the parties (treating Parent and Merger Sub as one party for this purpose) may (i) extend the time for the performance
of any of the obligations or other acts of the other party, (ii) waive any inaccuracies in the representations and warranties of
the other party contained in this Agreement or in any document delivered pursuant to this Agreement or (iii) waive compliance by
the other party with any of the agreements or conditions contained in this Agreement. Notwithstanding the foregoing, there shall be made
no amendment, modification or supplement to this Agreement (i) after receipt of the Company Stockholder Approval which requires further
approval by the stockholders of the Company without the further approval of such stockholders or (ii) after the Effective Time. The failure
of any party to this Agreement to assert any of its rights under this Agreement or otherwise shall not constitute a waiver of such rights.
ARTICLE
IX
General Provisions
SECTION 9.01. Nonsurvival
of Representations and Warranties. None of the representations and warranties in this Agreement or in any document or instrument
delivered pursuant to or in connection with this Agreement shall survive the Effective Time. This Section 9.01 shall not limit any
covenant or agreement contained in this Agreement or in any document or instrument delivered pursuant to or in connection with this Agreement,
that by its terms applies or contemplates performance in whole or in part after the Effective Time.
SECTION 9.02. Notices.
To be effective under this Agreement, all notices, requests, claims, demands and other communications under this Agreement shall be in
writing and shall be deemed given on the date received if delivered personally or by mail or courier service (with proof of delivery),
or on the date sent if sent by facsimile transmission (with confirmation) or electronic mail transmission to the parties at the following
addresses (or at such other address for a party as shall be specified by like notice):
(a) if to Parent or
Merger Sub, to:
GuideWell Mutual Holding
Corporation
4800 Deerwood Campus Parkway
Jacksonville, Florida 32246
Attention: Charles Joseph
Email: charles.joseph@bcbsfl.com
with a copy (which shall
not constitute notice) to:
Cravath, Swaine & Moore LLP
Worldwide Plaza
825 Eighth Avenue
New York, NY 10019
E-mail: mngo@cravath.com; awark@cravath.com
Attention: Minh Van Ngo; Andrew M. Wark
(b) if to the Company,
to:
Triple-S Management Corporation
1441 F.D. Roosevelt Avenue
San Juan, Puerto Rico
00920
Attention: Carlos Rodriguez
Ramos
Email: crodrig@ssspr.com
with a copy (which shall
not constitute notice) to:
Davis Polk & Wardwell
LLP
450 Lexington Avenue
New York, New York 10017
Attention: Phillip R. Mills
Email: phillip.mills@davispolk.com
and
Pietrantoni Mendez & Alvarez
LLC
Popular Center 19th Floor
208 Ponce de León Ave.
San Juan, PR 00918
Attention: Manuel Rodríguez Boissén
Email: mrodriguez@pmalaw.com
SECTION 9.03. Definitions.
For purposes of this Agreement:
“Acceptable
Confidentiality Agreement” means a customary confidentiality agreement that contains provisions that are no less favorable
in any material respect to the Company than those contained in the Confidentiality Agreement (it being understood that such confidentiality
agreement need not include any “standstill” or similar provision).
“Administrator”
means each program manager, managing general agent, third party administrator or claims adjuster or manager, at the time such Person
is or was
managing or administering
business (including the administration, handling or adjusting of claims) for or on behalf of a Company Subsidiary.
An “affiliate”
of any Person means another Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is
under common control with, such first Person. As used herein, “control” means the possession, directly or indirectly,
of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities
or other interests, by contract or otherwise.
“Agent”
means each insurance agent, general agent, agency, authorized representative, producer, broker, reinsurance intermediary, program manager,
managing general agent and managing general underwriter, at the time such Person is or was writing, selling, producing, underwriting,
soliciting, negotiating, marketing, placing or administering business for or on behalf of a Company Subsidiary, including any employees
of the Company or the Company Subsidiaries.
“Antitrust
Laws” means the HSR Act, the Sherman Antitrust Act of 1890, and the rules and regulations promulgated thereunder, the Clayton
Act of 1914, and the rules and regulations promulgated thereunder, the Federal Trade Commission Act of 1914, and the rules and regulations
promulgated thereunder, and any other federal, state, territorial and foreign statutes, rules, regulations, orders, decrees, administrative
and judicial doctrines and other Laws that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect
of monopolization or restraint of trade or lessening of competition through merger or acquisition.
“ASES”
means the Administración de Seguros de Salud de Puerto Rico.
“BCBSA”
means the Blue Cross and Blue Shield Association.
“BCBSA License
Agreements” means (i) the Blue Shield License Agreement by and between BCBSA and the Company, including revisions, if any,
adopted by Member Plans through the November 19, 2009 meeting and (ii) the Blue Cross License Agreement by and between BCBSA and the
Company, including revisions, if any, adopted by Member Plans through the November 19, 2009 meeting.
A “Business
Day” means any day other than a Saturday, Sunday or any day on which banks are required or authorized by Law to close in New York,
New York or San Juan, Puerto Rico.
“CARES Act”
means the Coronavirus Aid, Relief, and Economic Security Act.
“CMS”
means the Centers for Medicare & Medicaid Services.
“Code”
means the Internal Revenue Code of 1986, as amended.
“Company
Benefit Plan” means each “employee benefit plan” as defined in Section 3(3) of ERISA and each other employment,
consulting, bonus, pension, profit sharing, retirement, deferred compensation, incentive compensation, equity-based compensation, vacation,
paid-time off, fringe benefit, severance, change in control, retention, disability, death benefit, hospitalization, medical, welfare
benefit, post-employment or retirement or other compensatory or employee benefit plan, agreement, policy, program, arrangement or understanding,
in each case (i) sponsored, maintained or contributed to, or required to be sponsored, maintained or contributed to, by the Company,
any Company Subsidiary or any Commonly Controlled Entity for the benefit of any former or current director, officer, employee or independent
contractor or (ii) with respect to which the Company or any Company Subsidiary would reasonably be expected to have any liability.
“Company
Intellectual Property” means any Intellectual Property owned or licensed by the Company or any Company Subsidiary.
“Company
Material Adverse Effect” means any change, event, effect, fact, circumstance, development or occurrence that, individually
or in the aggregate with other changes, events, effects, facts, circumstances, developments or occurrences, has a material adverse effect
on the business, properties, assets, financial condition, financial performance or results of operations of the Company and the Company
Subsidiaries, taken as a whole; provided, however, that none of the following, nor any change, event, effect, fact, circumstance
development or occurrence to the extent or arising out of or relating to the following, shall be deemed either alone or in combination
to constitute or be taken into account in determining whether a “Company Material Adverse Effect” has occurred or may, would
or could occur: (i) general conditions affecting the health care services or insurance industries in the geographic regions or product
markets in which the Company and the Company Subsidiaries operate, (ii) general market, economic or regulatory, legislative or political
conditions or securities, credit, currency, financial or other capital or credit markets conditions, (iii) any change (or proposed change)
in applicable Law, COVID-19 Measures, GAAP, SAP, actuarial policies or accounting standards (or interpretation or enforcement thereof),
(iv) geopolitical conditions, the outbreak or escalation of hostilities, acts of war, cyberattacks, sabotage or terrorism, (v) any
hurricane, tornado, flood, volcano, earthquake, epidemic, pandemic (including COVID-19) or other natural or man-made disaster, (vi) the
failure, in and of itself, of the Company to meet any internal or published projections, forecasts, estimates or predictions in respect
of revenues, earnings or other financial or operating metrics (it being understood that the underlying factors or occurrences giving
rise or contributing to such failure shall be taken into account in determining whether there has been a Company Material Adverse Effect),
(vii) the announcement, performance, pendency or consummation of the Transactions, including the impact of any of the foregoing on any
relationships, contractual or otherwise, with customers, suppliers, employees or regulators, (viii) the taking of any action expressly
required by the terms of this Agreement or (ix) any actions taken or omitted to be taken by the Company or its subsidiaries upon the
prior written request of Parent, except, in the case of clause (i), (ii), (iii), (iv) or (v), if the Company and the Company Subsidiaries,
taken as a whole, are disproportionately affected thereby as compared with other similarly sized participants in
the health care services
or insurance industries in the geographic regions or product markets in which the Company and the Company Subsidiaries operate.
“Company
Performance Share Unit” or “Company PSU” means each restricted stock unit subject to performance-based vesting
criteria payable in, or whose value is determined with reference to the value of, shares of Company Common Stock, whether granted pursuant
to the Company Stock Plan or otherwise.
“Company
Restricted Share” or “Company RSA” means each share of Company Common Stock subject to vesting or forfeiture,
whether granted pursuant to the Company Stock Plans or otherwise.
“Company
Restricted Stock Unit” or “Company RSU” means each restricted stock unit payable in, or whose value is determined
with reference to the value of, shares of Company Common Stock, whether granted pursuant to the Company Stock Plan or otherwise.
“Company
Stock Plan” means the Company’s 2017 Incentive Plan, in each case, as amended and including all sub-plans thereunder.
“Company
Subsidiaries” means the Company’s subsidiaries.
“Company
Takeover Proposal” means any inquiry, proposal or offer from any Person or group relating to, in a single transaction or series
of related transactions, any (a) direct or indirect acquisition or license of 15% or more of the consolidated assets of the Company and
the Company Subsidiaries (based on the fair market value thereof) or assets comprising 15% or more of the consolidated revenues, net
income or EBITDA of the Company and the Company Subsidiaries, including in any such case through the acquisition of one or more Company
Subsidiaries owning such assets, (b) direct or indirect acquisition of 15% or more of the outstanding Company Common Stock or the outstanding
voting power of the Company (or any other Equity Interests representing such voting power giving effect to any right of conversion or
exchange thereof), (c) tender offer or exchange offer that if consummated would result directly or indirectly in any Person or group
(or the stockholders of any Person or group) beneficially owning 15% or more of the outstanding Company Common Stock or the outstanding
voting power of the Company (or any other Equity Interests representing such voting power giving effect to any right of conversion or
exchange thereof), (d) merger, consolidation, share exchange, business combination, reorganization, recapitalization, liquidation, dissolution
or other transaction involving the Company or any of the Company Subsidiaries which would result in any Person or group (or the stockholders
of any Person or group) beneficially owning, directly or indirectly, 15% or more of the outstanding Company Common Stock or the outstanding
voting power of the Company or of the surviving entity in a merger involving the Company or the resulting direct or indirect parent of
the Company or such surviving entity (or any Equity Interests representing such voting power giving effect to any right of conversion
or exchange thereof), or (e) any combination of the foregoing. For the avoidance of doubt, the Merger and the other Transactions shall
not be deemed a Company Takeover Proposal.
“COVID-19”
means SARS-CoV-2 or COVID-19, and any evolutions or mutations thereof or related or associated epidemics, pandemics or disease outbreaks.
“COVID-19
Measures” means any quarantine, ‘shelter in place,’ ‘stay at home,’ workforce reduction, social distancing,
shut down, closure, sequester, safety or similar Law, order, directive, guideline, pronouncement, or recommendation promulgated by any
industry group or any Governmental Entity, including the Centers for Disease Control and Prevention and the World Health Organization,
or an industry group providing for business closures, in each case, in connection with or in response to COVID-19, including the CARES
Act and Families First Act.
“Environmental
Claims” means any and all Proceedings, Judgments, directives, Liens, investigations or notices of noncompliance or violation
or other written demands by or from any Person alleging liability of any kind (including liability for the costs of enforcement proceedings,
investigations, cleanup, governmental response, removal or remediation, natural resource damages, property damages, personal injuries,
medical monitoring, penalties, contribution, indemnification and injunctive relief) arising out of, based on or resulting from (A) the
presence or Release of, or exposure to, any Hazardous Material at any location, or (B) the failure to comply with any Environmental Law
or Environmental Authorization.
“Environmental
Law” means any Law or Judgment relating to pollution, or the protection of the environment (including ambient air, surface
water, groundwater, land surface or subsurface strata or sediments), natural resources or endangered, threatened species or, as relates
to exposure to hazardous or toxic materials, human health and safety.
“Exchange
Act” means the Securities Exchange Act of 1934, together with the rules and regulations promulgated thereunder.
“Families
First Act” means the Families First Coronavirus Response Act.
“Form A”
means that certain statement of change of control form required under Rule 83 of the OCI.
“Form E”
means that certain pre-acquisition notification form required under Rule 83 of the OCI.
“Government
Sponsored Health Care Programs” means (i) the Medicare program established under and governed by the applicable provisions
of Title XVIII of the Social Security Act, the regulations promulgated thereunder and any sub-regulatory guidance issued, (ii) the Medicaid
program governed by the applicable provisions of Title XIX of the Social Security Act, the Children’s Health Insurance Program
(CHIP) governed by the applicable provisions of Title XXI of the Social Security Act and the regulations promulgated thereunder,
as well as any state or territory’s Laws implementing the Medicaid program, (iii) the Federal Employees Health Benefit Program
(FEHBP), (iv) TRICARE and (v) the health insurance program governed by Puerto Rico Act No. 72-1993.
“Hazardous
Materials” means any petroleum or petroleum products, byproducts or distillates, ozone depleting substances, heavy metals,
radioactive materials or wastes, asbestos in any form, polychlorinated biphenyls, hazardous or toxic substances or wastes and any other
chemical, material, substance or waste that is prohibited or regulated, or that may result in liability, under any Environmental Law.
“Health Care
Laws” means all applicable Laws relating to: (i) the licensure, certification, qualification or authority to transact business
in connection with the provision of, payment for, or arrangement of, health care services, health benefits or health insurance (including,
without limitation, Puerto Rico Act 77 of June 19, 1957 (the “PR Insurance Code”) and the Bill of Rights and Responsibilities
of the Patient Act and the rules, regulations and guidance promulgated thereunder), including Laws that regulate Providers, managed care,
third party payors and Persons bearing the financial risk for, or providing administrative or other functions in connection with, the
provision of, payment for or arrangement of health care services and, including all Laws relating to Health Care Programs pursuant to
which any applicable Company Subsidiary is required to be licensed or authorized to transact business; (ii) health care or insurance
fraud or abuse, including the solicitation or acceptance of improper incentives involving persons operating in the health care industry,
patient referrals or Provider incentives generally, including the following statutes: the Federal anti-kickback law (42 U.S.C. §
1320a-7b), the Stark Law (42 U.S.C. § 1395nn), the Federal False Claims Act (31 U.S.C. §§ 3729, et seq.), the Federal
Civil Monetary Penalties Law (42 U.S.C. § 1320a-7a), the Federal Program Fraud Civil Remedies Act (31 U.S.C. § 3801 et seq.)
and the Federal Health Care Fraud Law (18 U.S.C. § 1347); (iii) the provision of administrative, management or other services related
to any Health Care Programs, including the administration of health care claims or benefits or processing or payment for health care
items and services, treatment or supplies furnished by Providers, including the provision of the services of third party administrators,
utilization review agents and Persons performing quality assurance, credentialing or coordination of benefits; (iv) the licensure, certification,
qualification or authority to transact business in connection with the provision of, or payment for, pharmacy services, along with the
requirements of the U.S. Drug Enforcement Administration in connection therewith, including 21 U.S.C. § 801 et. seq., commonly referred
to as the “Controlled Substances Act” and any similar state or territorial Laws governing the prescribing or dispensing of
controlled substances; (v) the Consolidated Omnibus Budget Reconciliation Act of 1985; (vi) ERISA; (vii) the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003; (viii) the Medicare Improvements for Patients and Providers Act of 2008; (ix) privacy, security,
integrity, accuracy, transmission, storage or other protection of information about or belonging to actual or prospective participants
in the Company’s Health Care Programs or other lines of business, including the Health Insurance Portability and Accountability
Act of 1996 (Pub. L. No. 104-191), as amended by the Health Information Technology for Economic and Clinical Health Act (Pub. L. No.
111-5), including any other applicable Laws relating to medical information; (x) the Patient Protection and Affordable Care Act (Pub.
L. 111-148) as amended by the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111-152); (xi) the claims made or promotional
or marketing efforts undertaken by the Company or any of the Company Subsidiaries with respect to prescription drugs or controlled substances;
(xii) 42 U.S.C. § 1320a-7a(a)(5), 42 C.F.R. §
1003.101, commonly
referred to as the “Beneficiary Inducement Law”; (xiii) the U.S. Food and Drug Administration; (xiv) restricting the corporate
practice of medicine or fee splitting by licensed healthcare professionals; (xv) the practice of pharmacy, the operation of pharmacies,
the wholesale distribution, dispensing, labeling, packaging, repackaging, advertising, adulteration or compounding of drug products or
controlled substances; (xvi) the provision of pharmacy benefit management, utilization review and healthcare discount card programs and
services; (xvii) federal, state or territorial Laws related to billing or claims for reimbursement for health care items and services
submitted to any third party payor; (xviii) healthcare risk sharing products, services and arrangements; (xix) any state or territorial
unfair and deceptive trade acts; (xx) the Families First Act, CARES Act and other Laws promulgated in connection with or in response
to COVID-19; (xxi) the administration of health care claims or benefits or processing or payment for health care services, treatment
or supplies furnished by Providers, including Laws that regulate third-party administrators, utilization review agents and persons performing
quality assurance, credentialing or coordination of benefits; (xxii) the contracting, appointment, training, and payment of Agents; and
(xxiii) any other health care Laws not specifically listed that are applicable to the operations, business, conduct, or licensure of
the Company or the Company Subsidiaries.
“Health Care
Programs” means all lines of business, programs and types of services offered by the Company or any of the Company Subsidiaries
or Parent or any of its subsidiaries that involve or relate to providing, arranging to provide, reimbursing, or otherwise administering
health care services, as applicable, including Government Sponsored Health Care Programs, commercial risk (individual, small group, large
group), workers compensation, the Federal Employee Program of the BCBSA, administrative services only (ASO) and network rental, including
self-funded group health plans.
“Indebtedness”
means, with respect to any Person, without duplication, all obligations (including all obligations in respect of principal, accrued interest,
penalties (including prepayment and early termination penalties), fees and premiums) of such Person: (a) for borrowed money (including
the issuance of any debt security and obligations in respect of drawings under overdraft facilities), (b) evidenced by notes, bonds,
debentures or similar Contracts, (c) for the deferred purchase price of property, goods or services (other than trade payables or accruals
incurred in the ordinary course of business consistent with past practice), including “earn-outs,” post-closing price adjustments,
and “seller notes” payable with respect to the acquisition of any business, assets or securities, (d) under capital
leases (in accordance with GAAP, SAP or actuarial principles), (e) in respect of outstanding letters of credit, bank guarantees and bankers’
acceptances, (f) for Contracts relating to interest rate or currency rate protection, swap agreements, collar agreements, forward agreements,
futures agreements and similar hedging and derivative agreements or (g) any guarantee in respect of any of the foregoing.
“Insurance
Contract” means any Contract related to insurance, annuity or health care plans.
“Insurance
Laws” means all Laws, subregulatory guidance, bulletins, licensure standards, permits or other requirements applicable to the
business of insurance or reinsurance or the regulation of insurance or reinsurance companies, whether federal, national, provincial,
state, territorial, local, foreign or multinational, and all applicable orders, directives of, and market conduct recommendations resulting
from market conduct examinations of, Insurance Regulators (including, for the avoidance of doubt, any regulations, policies or procedures
issued by the OCI).
“Insurance
Regulator” means any Governmental Entity regulating the business of insurance or reinsurance, or regulating insurance or insurance
companies, under Insurance Laws, including, for the avoidance of doubt, the OCI.
“Intellectual
Property” means all intellectual property and other similar or equivalent proprietary rights throughout the world, including
moral rights, whether registered or unregistered, including such rights in and to: (a) any patent (including all renewals, reissues,
divisions, continuations, continuations-in-part, reexaminations, supplemental examinations, inter partes reviews, post-grant oppositions,
substitutions and extensions thereof), patent application, patent disclosure and other patent right, invention and discovery (whether
or not patentable or reduced to practice) and any design or utility model (collectively, “Patents”); (b) any trademark,
service mark, trade name, business name, corporate name, brand name, design, logo, trade dress, social media user names, identifiers,
handles and other indicia of origin, including any registration and any application for registration therefor, together with all goodwill
associated therewith (collectively, “Trademarks”); (c) any copyright, work of authorship (whether or not copyrightable),
and related rights, software, programs, data and databases in any form (including any documentation thereof), design rights, including
any registration and any application for registration therefor (collectively, “Copyrights”); (d) all data, databases,
formulae, processes, methods, techniques, know-how and other proprietary or confidential information, however documented, including all
trade secrets within the meaning of applicable Law (collectively, “Trade Secrets”); and (e) any Internet domain name
(including top-level domain names and global top-level domain names).
“Intervening
Event” means a material development or change in circumstances relating to the Company or any Company Subsidiary (other than
(a) a Company Takeover Proposal, (b) changes in the price of Company Common Stock, in and of itself (however, the underlying reasons
for such changes may constitute an Intervening Event) or (c) the fact that, in and of itself, the Company exceeds any internal or published
projections, estimates or expectations of the Company’s revenue, earnings or other financial performance or results of operations
for any period (however, the underlying reasons for such events may constitute an Intervening Event)) that occurs or arises after the
execution and delivery of this Agreement and on or prior to the date of the Company Stockholder Approval and was not known to or reasonably
foreseeable by the Company Board or any committee thereof prior to the execution and delivery of this Agreement.
“Investment
Assets” means all bonds, stocks, mortgage loans and other investments that were carried on the books and records of the Company
and the Company Subsidiaries as of the date of this Agreement.
“IT Assets”
means computers, software, middleware, servers, workstations, routers, hubs, switches, data communications lines and other information
technology equipment, and all associated documentation, in each case owned by or licensed to the Company or any Company Subsidiary.
“knowledge
of the Company” or “Company’s knowledge” means the actual knowledge of the individuals set forth on
Section 9.03 of the Company Disclosure Letter.
“OSS”
means any computer software program whose source code is published and made available under a license meeting the Open Source Definition
(as promulgated by the Open Source Initiative) or the Free Software Definition (as promulgated by the Free Software Foundation).
“Parent Material
Adverse Effect” means any change, effect, event, circumstance, fact, development or occurrence that prevents or materially
impairs or delays the consummation of the Merger and the other Transactions or the ability of Parent or Merger Sub to perform its obligations
under this Agreement.
“Permitted
Liens” means (a) any Lien for Taxes or utilities not yet due and payable or Liens for Taxes being contested in good faith and,
in each case, for which adequate accruals or reserves have been established on the financial statements of the Company in accordance
with GAAP or SAP, as applicable; (b) zoning, building codes and other similar land use Laws imposed by any Governmental Entity having
jurisdiction over such real property and which are not violated by the current use or occupancy of such real property; (c) utility easements,
rights of way and similar recorded agreements, easements, covenants, reservations, restrictions and other matters of record; provided,
however, that the Liens described in clauses (b) and (c) do not or would not reasonably be expected to, individually or in the
aggregate, materially impair the ability of the Company or any of the Company Subsidiaries to use, occupy or operate the real property
to which they relate in substantially the same manner as currently conducted (and excluding in all events any Liens securing the payment
of money); (d) Liens granted in the ordinary course of business in connection with the insurance or reinsurance business of the Company
or the Company Subsidiaries on cash and cash equivalent instruments or other investments; (e) statutory landlord Liens contained in the
Leases; and (f) construction, mechanic’s, materialmen’s, laborer’s, workmen’s, repairmen’s, carrier’s
and similar Liens, including all statutory Liens, arising or incurred in the ordinary course of business consistent with past practice;
provided, however, that the underlying obligations are not yet due and payable or are being contested in good faith by
appropriate proceedings and, in each case, for which adequate accruals or reserves have been established on the financial statements
of the Company (if such accruals or reserves are required pursuant to GAAP, SAP or actuarial principles, as applicable).
A “Person”
means any natural person, firm, corporation, partnership, company, limited liability company, trust, joint venture, association, organization,
Governmental Entity or other entity.
“Personal
Data” means all data that identifies an individual or, in combination with any other information or data available to the Company
or any Company Subsidiary, is capable of identifying an individual.
“Providers”
means all physicians, physician groups, medical groups, and other groups of health care practitioners, independent practice associations
and other provider networks, dentists, optometrists, pharmacies and pharmacists, radiologists, radiology centers, laboratories, mental
health professionals, community health centers, clinics, surgicenters, accountable care organizations, chiropractors, physical therapists,
nurses, nurse practitioners, physician’s assistants, hospitals, skilled nursing facilities, extended care facilities, other health
care or services facilities, durable medical equipment suppliers, home health agencies, alcoholism or drug abuse centers and any other
specialty, ancillary or allied health professional or facility.
“Qualifying
Director Share” means any share of capital stock of a subsidiary that is a “stock insurer” (as defined in the PR
Insurance Code) that is owned by a director of such subsidiary. Qualifying Director Shares shall be disregarded for purposes of determining
whether a subsidiary of a Person is considered “wholly owned” by such Person.
“Release”
means any release, spill, emission, leaking, dumping, injection, pouring, pumping, deposit, disposal, discharge, dispersal, leaching
or migration into or through the indoor or outdoor environment.
“Risk-Based
Capital” means the minimum amount of capital required under Chapter 45 of the PR Insurance Code to support insurance business
operations and to underwrite coverage.
“Risk-Based
Capital Report” means written statements, together with all material exhibits, interrogatories, notes, schedules and any actuarial
opinions, affirmations or certifications or other supporting documents in connection therewith, submitted by the Company or any applicable
Company Subsidiary to any Governmental Entity or other Person with respect to Risk-Based Capital.
“SEC”
means the United States Securities and Exchange Commission.
“Securities
Act” means the Securities Act of 1933, together with the rules and regulations promulgated thereunder.
“Specified
Permitted Investment” shall have the meaning set forth in Section 5.01(e)(i) of the Company Disclosure Letter.
A “subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests of which
is
sufficient to elect
at least a majority of its board of directors or other governing body (or, if there are no such voting interests, more than 50% of the
Equity Interests in which) is owned directly or indirectly by such first Person.
“Superior
Proposal” means any bona fide binding written offer which is made by a third party or group which, if consummated, would result
in such third party or group (or in the case of a direct merger, consolidation, share exchange or other similar transaction between such
third party or group and the Company, the stockholders of such third party or group) beneficially owning, directly or indirectly, more
than 50% of the outstanding Company Common Stock or the outstanding voting power of the Company (or any other Equity Interests representing
such voting power giving effect to any right of conversion or exchange thereof) or all or substantially all the consolidated assets of
the Company and the Company Subsidiaries that the Company Board or any committee thereof determines in good faith, after consultation
with its outside counsel and financial advisor, (a) is more favorable to the Company’s stockholders from a financial point of view
than the Transactions, taking into account all terms and conditions of such offer (including all legal, regulatory, financial, timing
and other aspects of such offer, including the identity of the Person making the proposal) as well as this Agreement and all changes
to the terms of the Transactions proposed by Parent in response to such offer or otherwise and (b) is reasonably likely to be completed
on the terms proposed, taking into account all terms and conditions of such offer (including all legal, regulatory, financial, timing
and other aspects of such offer, including the identity of the Person making the proposal) as well as this Agreement and all changes
to the terms of the Transactions proposed by Parent in response to such offer or otherwise.
“Tax Return”
means all returns, declarations, statements, reports, filings, claims for refund, schedules, forms and information returns submitted
to any Governmental Entity with respect to or relating to Taxes and any amendments thereto.
“Taxes”
means any and all taxes, customs, tariffs, imposts, levies, duties, fees or other like assessments or charges of any kind imposed by
a Governmental Entity, in each case in the nature of a tax, together with all interest, penalties and additions imposed with respect
to such amounts.
“Taxing Authority”
means any Governmental Entity exercising regulatory authority in respect of any Taxes.
“Unspecified
Permitted Investment” shall have the meaning set forth in Section 5.01(e)(ii) of the Company Disclosure Letter.
SECTION 9.04. Interpretation.
The headings contained in this Agreement and in the table of contents to this Agreement are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement. References to “this Agreement” shall include the Company
Disclosure Letter. All Exhibits annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as
if set forth in full herein. Any terms used in the Company Disclosure Letter, any Exhibit or any certificate or other document made or
delivered
pursuant hereto but not otherwise defined
therein shall have the meaning as defined in this Agreement. The definitions of terms herein shall apply equally to the singular and
plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine
and neuter forms. The word “will” shall be construed to have the same meaning as the word “shall”. The words
“include”, “includes” and “including” shall be deemed to be followed by the phrase “without
limitation”. The word “extent” in the phrase “to the extent” shall mean the degree to which a subject or
other thing extends, and such phrase shall not mean simply “if”. The word “or” shall not be exclusive. The phrase
“date hereof” or “date of this Agreement” shall be deemed to refer to August 23, 2021. Unless the context requires
otherwise (i) any definition of or reference to any Contract, instrument or other document or any Law herein shall be construed
as referring to such Contract, instrument or other document or Law as from time to time amended, supplemented or otherwise modified,
(ii) any reference herein to any Person shall be construed to include such Person’s successors and assigns, (iii) the words
“herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this
Agreement in its entirety and not to any particular provision hereof and (iv) all references herein to Articles, Sections and Exhibits
shall be construed to refer to Articles and Sections of, and Exhibits to, this Agreement. Wherever the term “group” is used
in this Agreement, it is used as defined in Rule 13d-5 under the Exchange Act. As used in this Agreement, the term “beneficial
ownership” (and its correlative terms) shall have the meaning assigned to such term in Rule 13d-3 under the Exchange Act. The term
“made available” or words of similar import shall mean that the relevant documents, instruments or materials were (i) posted
and made available to Parent in the due diligence data site maintained by the Company for the purpose of the Transactions not later than
the day prior to the date of this Agreement, (ii) delivered by a Representative of the Company via electronic mail to a Representative
of Parent not later than the day prior to the date of this Agreement or (iii) publicly available by virtue of the Company’s filing
of a publicly available report, form or schedule with the SEC pursuant to the Securities Act or the Exchange Act not later than two Business
Days prior to the date of this Agreement, except, in each case, to the extent the contents of such documents, instruments or materials
are redacted. This Agreement shall be construed without regard to any presumption or rule requiring construction or interpretation against
the party drafting or causing any instrument to be drafted.
SECTION 9.05. Severability.
If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule or law, or public policy,
all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect. Upon such determination that
any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify
this Agreement so as to effect the original intent of the parties as closely as possible in an acceptable manner such that the Transactions
are consummated to the fullest extent possible.
SECTION 9.06. Counterparts.
This Agreement may be executed in one or more counterparts, all of which shall be considered one and the same agreement and shall become
effective when one or more counterparts have been signed by each of the parties and delivered to the other parties. Delivery of an executed
counterpart of a
signature page of this Agreement by
facsimile or other electronic image scan transmission (including by portable document format (.pdf)) shall be deemed to be an original
and effective as delivery of a manually executed counterpart of this Agreement.
SECTION 9.07. Entire
Agreement; Third-Party Beneficiaries; No Other Representations or Warranties. (a) This Agreement and the Confidentiality
Agreement (i) constitute the entire agreement, and supersede all prior agreements and understandings, both written and oral,
among the parties and their affiliates, or any of them, with respect to the subject matter hereof and thereof, and (ii) are not
intended to confer upon any Person other than the parties any rights or remedies, except (A) the right of a party hereto on behalf
of its stockholders or members, as applicable, to pursue damages suffered by such party and its stockholders or members, as
applicable, (including claims for damages based on the loss of the economic benefits of the Merger) in the event of wrongful
termination of this Agreement by the other party hereto (or any of its subsidiaries), which right is hereby expressly acknowledged
and agreed by the parties hereto and (B) pursuant to Section 6.06, which is intended to be for the benefit of the Indemnified
Persons and the other Persons covered by the insurance provided pursuant thereto.
(b) Except for the
representations and warranties contained in Article III or in any certificate delivered to Parent in connection with the consummation
of the Merger, each of Parent and Merger Sub acknowledges that neither the Company nor any Person on behalf of the Company makes any
other express or implied representation or warranty with respect to the Company or any of the Company Subsidiaries or with respect to
any other information made available to Parent or Merger Sub in connection with the Transactions.
(c) Except for the
representations and warranties contained in Article IV, or in any certificate delivered to the Company in connection with the consummation
of the Merger, the Company acknowledges that none of Parent, Merger Sub or any other Person on behalf of Parent or Merger Sub makes any
other express or implied representation or warranty with respect to Parent or Merger Sub or with respect to any other information made
available to the Company in connection with the Transactions.
SECTION 9.08. Governing
Law. This Agreement shall be governed by, and construed in accordance with, the Laws of the State of Delaware, regardless of the
laws that might otherwise govern under applicable principles of conflicts of laws thereof, except to the extent that the Laws of the
Commonwealth of Puerto Rico are mandatorily applicable to this Agreement, the Transactions or the PR Certificate of Merger.
SECTION 9.09. Assignment.
Neither this Agreement nor any of the rights, interests or obligations under this Agreement shall be assigned, in whole or in part, by
operation of law or otherwise by any of the parties without the prior written consent of the other parties, except that either Parent
or Merger Sub may assign, in its sole discretion, any of or all its rights and interests under this Agreement to Parent (in the case
of Merger Sub) or to any direct or indirect wholly owned subsidiary of Parent, but no such assignment shall (i) relieve Parent or Merger
Sub, as applicable, of any of its
obligations under this Agreement or
(ii) be permissible if it would reasonably be expected to result in the imposition of withholding tax on the transactions contemplated
by this Agreement in excess of any amounts that would have been imposed had such assignment not occurred. Any purported assignment without
such consent shall be void. Subject to the preceding sentences, this Agreement will be binding upon, inure to the benefit of, and be
enforceable by, the parties hereto and their respective successors and assigns.
SECTION 9.10. Specific
Enforcement; Jurisdiction. (a) The parties hereto acknowledge and agree that irreparable damage would occur and that the parties
hereto would not have any adequate remedy at law in the event that any of the provisions of this Agreement were not performed in
accordance with its specific terms or were otherwise breached, and that monetary damages, even if available, would not be an
adequate remedy therefor. It is accordingly agreed that the parties hereto shall be entitled to an injunction or injunctions, or any
other appropriate form of equitable relief, to prevent breaches of this Agreement and to enforce specifically the performance of the
terms and provisions of this Agreement in any court referred to in Section 9.10(b), without the necessity of providing any bond
or other security or proving actual damages or the inadequacy of monetary damages as a remedy, this being in addition to any other
remedy to which they are entitled at law or in equity. Each of the parties acknowledges and agrees that the right of specific
enforcement is an integral part of the Transactions and without such right, none of the parties would have entered into this
Agreement. Each of the parties further agrees not to oppose a remedy of specific enforcement on the basis that the other party has
an adequate alternative remedy at law.
(b) Each of the parties
hereto hereby irrevocably submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware (or, if such court
shall be unavailable, any state or federal court sitting in the State of Delaware) for the purpose of any Proceeding arising out of or
relating to this Agreement, the Merger or any of the other Transactions, and each of the parties hereby irrevocably agrees that all claims
with respect to such Proceeding may be heard and determined exclusively in such court. Each of the parties hereto (i) consents to submit
itself to the personal jurisdiction of the Court of Chancery of the State of Delaware (or, if such court shall be unavailable, any state
or federal court sitting in the State of Delaware) in the event any Proceeding arises out of this Agreement, the Merger or any of the
other Transactions, (ii) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for
leave from any such court, (iii) irrevocably consents to the service of process in any Proceeding arising out of or relating to this
Agreement, the Merger or any of the other Transactions, on behalf of itself or its property, in accordance with Section 9.02 (provided
that nothing in this Section 9.10(b) shall affect the right of any party to serve legal process in any other manner permitted
by Law) and (iv) agrees that it will not bring any Proceeding relating to this Agreement, the Merger or any of the other Transactions
in any court other than the Court of Chancery of the State of Delaware (or, if such court shall be unavailable, any state or federal
court sitting in the State of Delaware). The parties hereto agree that a final trial court judgment in any such Proceeding shall be conclusive
and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by Law. The foregoing shall not restrict
any party’s right to seek any post-judgment relief regarding, or any appeal from, such final trial court judgment, or to bring
suit for the recognition
or enforcement of any judgment obtained in any court sitting in the State of Delaware or in any other court of competent jurisdiction
following final determination of the applicable matter.
SECTION 9.11. WAIVER
OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE MERGER OR ANY OF THE OTHER TRANSACTIONS. EACH
PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT
SUCH PARTY WOULD NOT, IN THE EVENT OF ANY PROCEEDING, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT MAKES THIS WAIVER
VOLUNTARILY AND THAT THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER
AND CERTIFICATIONS IN THIS SECTION 9.11.
[Remainder of
page intentionally blank; signature pages follow.]
IN WITNESS WHEREOF,
Parent, Merger Sub and the Company have duly executed this Agreement, all as of the date first written above.
|
GUIDEWELL MUTUAL HOLDING CORPORATION, as Parent,
|
|
|
|
By
|
|
|
|
|
/s/ Patrick J. Geraghty
|
|
|
Name:
|
Patrick J. Geraghty
|
|
|
Title:
|
President & Chief Executive Officer
|
|
GUIDEWELL MERGER, INC., as Merger Sub,
|
|
|
|
by
|
|
|
|
|
/s/ Thurman Justice
|
|
|
Name:
|
Thurman Justice
|
|
|
Title:
|
President
|
[Signature Page to Merger Agreement]
|
TRIPLE-S MANAGEMENT CORPORATION, as the Company,
|
|
|
|
By:
|
/s/ Roberto García-Rodríguez
|
|
|
Name:
|
Roberto García-Rodríguez
|
|
|
Title:
|
President and Chief Executive Officer
|
[Signature Page to Merger Agreement]
ANNEX B
200 West Street I New York,
NY 10282-2198
Tei: 212-902-1000 I Fax: 212-902-3000
PERSONAL AND CONFIDENTIAL
August 23, 2021
Board of Directors
Triple-S Management Corporation
1441 F.D. Roosevelt Ave.
San Juan, P.R. 00936
Ladies and Gentlemen:
You
have requested our opinion as to the fairness from a financial point of view to the holders (other than GuideWell Mutual Holding Corporation
("Parent") and its affiliates) of the outstanding shares of common stock, par value $1.00 per share (the "Shares"),
of Triple-S Management Corporation (the "Company") of the $36.00 in cash per Share to be paid to such holders pursuant to the
Agreement and Plan of Merger, dated as of August 23, 2021 (the "Agreement"), by and among Parent, GuideWell Merger, Inc., a
wholly owned subsidiary of Parent ("Merger Sub"), and the Company.
Goldman
Sachs & Co. LLC and its affiliates are engaged in advisory, underwriting and financing, principal investing, sales and trading, research,
investment management and other financial and non-financial activities and services for various persons and entities. Goldman Sachs &
Co. LLC and its affiliates and employees, and funds or other entities they manage or in which they invest or have other economic interests
or with which they co-invest, may at any time purchase, sell, hold or vote long or short positions and investments in securities, derivatives,
loans, commodities, currencies, credit default swaps and other financial instruments of the Company, Parent, any of their respective
affiliates and third parties or any currency or commodity that may be involved in the transaction contemplated by the Agreement (the
"Transaction"). We have acted as financial advisor to the Company in connection with, and have participated in certain of the
negotiations leading to, the Transaction. We expect to receive fees for our services in connection with the Transaction, all of which
are contingent upon consummation of the Transaction, and the Company has agreed to reimburse certain of our expenses arising, and indemnify
us against certain liabilities that may arise, out of our engagement. We have provided certain financial advisory and/or underwriting
services to the Company and/or its affiliates from time to time for which our Investment Banking Division has received, and may receive,
compensation. We also have provided certain financial advisory and/or underwriting services to Parent and/or its affiliates from time
to time for which our
Securities and Investment Services Provided
by Goldman Sachs & Co. LLC
Board of Directors
Triple-S Management Corporation
August 23, 2021
Page 2
Investment
Banking Division has received, and may receive, compensation, including having acted as financial advisor to Availity, LLC, an affiliate
of Parent, in connection with a strategic investment in July 2021. We may also in the future provide financial advisory and/or underwriting
services to the Company, Parent and their respective affiliates for which our Investment Banking Division may receive compensation.
In
connection with this opinion, we have reviewed, among other things, the Agreement; annual reports to stockholders and Annual Reports
on Form 10-K of the Company for the five fiscal years ended December 31, 2020; certain interim reports to stockholders and Quarterly
Reports on Form 10-Q of the Company; certain other communications from the Company to its stockholders; certain publicly available research
analyst reports for the Company; certain internal financial analyses and forecasts for the Company prepared by its management, as approved
for our use by the Company (the "Forecasts"), including certain analyses related to the expected impact of certain tax attributes
of the Company, as approved for our use by the Company (the "Tax Attributes"). We have also held discussions with members of
the senior management of the Company regarding their assessment of the past and current business operations, financial condition and
future prospects of the Company; reviewed the reported price and trading activity for the Shares; compared certain financial and stock
market information for the Company with similar information for certain other companies the securities of which are publicly traded;
reviewed the financial terms of certain recent business combinations in the managed care industry and in other industries; and performed
such other studies and analyses, and considered such other factors, as we deemed appropriate.
For
purposes of rendering this opinion, we have, with your consent, relied upon and assumed the accuracy and completeness of all of the financial,
legal, regulatory, tax, accounting and other information provided to, discussed with or reviewed by, us, without assuming any responsibility
for independent verification thereof. In that regard, we have assumed with your consent that the Forecasts, including the Tax Attributes,
have been reasonably prepared on a basis reflecting the best currently available estimates and judgments of the management of the Company.
We have not made an independent evaluation or appraisal of the assets and liabilities (including any contingent, derivative or other
off-balance-sheet assets and liabilities) of the Company or any of its subsidiaries, and we have not been furnished with any such evaluation
or appraisal. We are not actuaries and our services did not include any actuarial determination or evaluation by us or any attempt to
evaluate actuarial assumptions and we have relied on your actuaries with respect to reserve adequacy. In that regard, we have made no
analysis of, and express no opinion as to, the adequacy of the loss and loss adjustments expenses reserves of the Company. We have assumed
that all governmental, regulatory or other consents and approvals necessary for the consummation of the Transaction will be obtained
without any adverse effect on the Company or on the expected benefits of the Transaction in any way meaningful to our analysis. We have
assumed that the Transaction will be consummated on the terms set forth in the Agreement, without the waiver or modification of any term
or condition the effect of which would be in any way meaningful to our analysis.
Our
opinion does not address the underlying business decision of the Company to engage in the Transaction, or the relative merits of the
Transaction as compared to any strategic alternatives that may be available to the Company; nor does it address any legal, regulatory,
tax or accounting matters. This opinion addresses only the fairness from a financial point of view to
Board of Directors
Triple-S Management Corporation
August 23, 2021
Page 3
the
holders (other than Parent and its affiliates) of Shares, as of the date hereof, of the $36.00 in cash per Share to be paid to such holders
pursuant to the Agreement. We do not express any view on, and our opinion does not address, any other term or aspect of the Agreement
or Transaction or any term or aspect of any other agreement or instrument contemplated by the Agreement or entered into or amended in
connection with the Transaction, including, the fairness of the Transaction to, or any consideration received in connection therewith
by, the holders of any other class of securities, creditors, or other constituencies of the Company; nor as to the fairness of the amount
or nature of any compensation to be paid or payable to any of the officers, directors or employees of the Company, or class of such persons,
in connection with the Transaction, whether relative to the $36.00 in cash per Share to be paid to the holders (other than Parent and
its affiliates) of Shares pursuant to the Agreement or otherwise. We are not expressing any opinion as to the prices at which the Shares
will trade at any time or, as to the potential effects of volatility in the credit, financial and stock markets on the Company, Parent
or the Transaction, or as to the impact of the Transaction on the solvency or viability of the Company, Parent or Merger Sub or the ability
of the Company, Parent or Merger Sub to pay their respective obligations when they come due. Our opinion is necessarily based on economic,
monetary, market and other conditions as in effect on, and the information made available to us as of, the date hereof and we assume
no responsibility for updating, revising or reaffirming this opinion based on circumstances, developments or events occurring after the
date hereof. Our advisory services and the opinion expressed herein are provided for the information and assistance of the Board of Directors
of the Company in connection with its consideration of the Transaction and such opinion does not constitute a recommendation as to how
any holder of Shares should vote with respect to such Transaction or any other matter. This opinion has been approved by a fairness committee
of Goldman Sachs & Co. LLC.
Based
upon and subject to the foregoing, it is our opinion that, as of the date hereof, the $36.00 in cash per Share to be paid to the holders
(other than Parent and its affiliates) of Shares pursuant to the Agreement is fair from a financial point of view to the holders (other
than Parent and its affiliates) of Shares.
Very truly yours,
/s/ GOLDMAN SACHS & CO. LLC
|
|
(GOLDMAN SACHS & CO. LLC)
ANNEX C
Article
10.13 of the General Corporation Law of Puerto Rico
Article 10.13. Appraisal
Rights
|
(a)
|
Any stockholder
of a corporation organized under the Commonwealth who:
|
|
(1)
|
Holds
shares of stock on the date of the making of a demand pursuant to subsection (d) of this
section with respect to such shares;
|
|
(2)
|
continuously
holds such shares through the effective date of the merger or consolidation;
|
|
(3)
|
has otherwise
complied with subsection (d) of this section, and
|
|
(4)
|
has neither
voted in favor of the merger or consolidation nor consented thereto in writing pursuant to
§ 3657 of this title shall be entitled to an appraisal by the Court of First Instance
(Superior Part) of the fair value of the stockholder's shares of stock under the circumstances
described in subsections (b) and (c) of this section.
|
As used
in this section, the word 'stockholder' means a holder of record of stock in a stock corporation and also a member of record of a nonstock
corporation. The words 'stock' and 'share' mean and include what is ordinarily meant by those words and also membership or membership
interest of a member of a nonstock corporation. The words 'depository receipt' mean a receipt or other instrument issued by a depository
representing an interest in one (1) or more shares, or fractions thereof, of stock of a corporation, which stock is deposited with the
depository.
|
(b)
|
Appraisal
rights shall be available for the shares of any class or series of stock of a constituent
corporation in a merger to be effected pursuant to §§ 3731, 3732, 3735, 3738 and
3739 of this title:
|
|
(1)
|
Provided
that no appraisal rights under this section shall be available for the shares of any class
or series of stock, which stock, or depository receipts in respect thereof, at the record
date fixed to determine the stockholders entitled to receive notice of the meeting of stockholders
to act upon the agreement of merger or consolidation, were either:
|
|
(A)
|
Listed
on a National Stock Exchange or the National Association of Securities Dealers Automated
Quotation System National Market (NASDAQ-NMS), or
|
|
(B)
|
held of
record by more than two thousand (2,000) holders. No appraisal rights shall be available
for any shares of stock of the constituent corporation surviving a merger if the merger did
not require for its approval the vote of the stockholders of the surviving corporation as
provided in § 3731(f) of this title.
|
|
(2)
|
Notwithstanding
clause (1) of this subsection, appraisal rights under this section shall be available for
the shares of any class or series of stock of a constituent corporation if the holders thereof
are required by the terms of an agreement of merger or consolidation pursuant to §§
3731, 3732, 3735, 3738 and 3739 of this title to accept for such stock anything except:
|
|
(A)
|
Shares
of stock of the corporation surviving or resulting from such merger or consolidation, or
depository receipts in respect thereof;
|
|
(B)
|
shares
of stock of any other corporation, or depository receipts in respect thereof, which at the
effective date of the merger or consolidation shall be either listed on a National Stock
Exchange or the National Market System or the National Association of Securities
|
Dealers
Automated Quotation System (NASDAQ-NMS) or held of record by more than two thousand (2,000) holders;
|
(C)
|
cash in
lieu of fractional shares or fractional depository receipts described in the foregoing paragraphs
(A) and (B) of this clause, or
|
|
(D)
|
any combination
of the shares of stock and cash in lieu of fractional shares or fractional depository receipts
described in the foregoing paragraphs (A) through (C) of this clause.
|
|
(3)
|
In the
event all of the stock of a subsidiary domestic corporation party to a merger effected under
§ 3732 of this title is not owned by the parent corporation immediately prior to the
merger, appraisal rights shall be available for the shares of the subsidiary domestic corporation.
|
|
(c)
|
Any corporation
may provide in its certificate of incorporation that appraisal rights under this section
shall be available for the shares of any class or series of its stock as a result of an amendment
to its certificate of incorporation, any merger or consolidation in which the corporation
is a constituent corporation or the sale of all or substantially all of the assets of the
corporation. If the certificate of incorporation contains such a provision, the procedures
of this section, including those set forth in subsections (d) and (e) of this section, shall
apply as nearly as is practicable.
|
|
(d)
|
Appraisal
rights shall be perfected as follows:
|
|
(1)
|
If a proposed
merger or consolidation for which appraisal rights are provided under this section is to
be submitted for approval at a meeting of stockholders, the corporation, not less than twenty
(20) days prior to the meeting, shall notify each of its stockholders who was such on the
record date for notice of such meeting with respect to shares for which appraisal rights
are available pursuant to subsections (b) and (c) of this section that appraisal rights are
available for any or all of the shares of the constituent corporations, and shall include
in such notice a copy of this section. Each stockholder electing to demand the appraisal
of such stockholder's shares shall deliver to the corporation, before the taking of the vote
on the merger or consolidation, a written demand for appraisal of such stockholder's shares.
Such demand shall be sufficient if it reasonably informs the corporation of the identity
of the stockholder and that the stockholder intends thereby to demand the appraisal of such
stockholder's shares. A proxy or vote against the merger or consolidation shall not constitute
such a demand. A stockholder electing to take such action must do so by a separate written
demand as herein provided. Within ten (10) days after the effective date of such merger or
consolidation, the surviving or resulting corporation shall notify each stockholder of each
constituent corporation who has complied with this subsection and has not voted in favor
of or consented to the merger or consolidation of the date that the merger or consolidation
has become effective, or
|
|
(2)
|
if the
merger or consolidation was approved pursuant to §§ 3657 and 3733 of this title,
then either a constituent corporation before the effective date of the merger or consolidation
or the surviving or resulting corporation within ten (10) days thereafter shall notify each
of the holders of any stock of such constituent corporation who are entitled to appraisal
rights of the approval of the merger or consolidation and that appraisal rights are available
for any or all shares of stock of such constituent corporation. Such notice shall include
a copy of this section. Such notice may, and, if given on or after the effective date of
the merger or consolidation, also notify such stockholders of the effective date of the merger
or consolidation. Any stockholder entitled to appraisal rights may, within twenty (20) days
after the date of mailing of such notice, demand in writing
|
from
the surviving or resulting corporation the appraisal of such holder's shares. Such demand shall be sufficient if it reasonably informs
the corporation of the identity of the stockholder and that the stockholder intends thereby to demand the appraisal of such holder's
shares. If such notice did not notify stockholders of the effective date of the merger or consolidation, either each such constituent
corporation shall:
|
(A)
|
Send a
second notice before the effective date of the merger or consolidation notifying each of
the holders of stock of such constituent corporation that are entitled to appraisal rights
of the effective date of the merger or consolidation, or
|
|
(B)
|
the corporation
surviving or resulting from the merger or consolidation shall send such a second notice to
all such holders on or within ten (10) days after such effective date.
|
Provided,
however, that if such second notice is sent more than twenty (20) days following the sending of the first notice, such second notice
need only be sent to each stockholder who is entitled to appraisal rights and who has demanded appraisal of such holder's shares in accordance
with this subsection. An affidavit of the secretary or assistant secretary or of the transfer agent of the corporation that is required
to give either notice that such notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.
For purposes of determining the stockholders entitled to receive either notice, as the case may be, each constituent corporation may
fix, in advance, a record date that shall be not more than ten (10) days prior to the date the notice is given, provided, that if the
notice is given on or after the effective date of the merger or consolidation, the record date shall be such effective date. If no record
date is fixed and the notice is given prior to the effective date, the record date shall be the close of business on the next day preceding
the day on which the notice is given.
|
(e)
|
Within
one hundred and twenty (120) days after the effective date of the merger or consolidation,
the surviving or resulting corporation or any stockholder who has complied with subsections
(a) and (d) of this section and is otherwise entitled to appraisal rights, may commence an
appraisal proceeding by filing a petition in the Court of First Instance (Superior Part)
demanding a determination of the value of the stock of all such stockholders. Notwithstanding
the foregoing, at any time within sixty (60) days after the effective date of the merger
or consolidation, any stockholder shall have the right to withdraw his/her demand for appraisal
and to accept the terms offered upon the merger or consolidation. Within one hundred and
twenty (120) days after the effective date of the merger or consolidation, any stockholder
who has complied with the requirements of subsections (a) and (d) of this section, upon written
request, shall be entitled to receive from the corporation surviving the merger or resulting
from the consolidation a statement setting forth the aggregate number of shares not voted
in favor of the merger or consolidation and with respect to which demands for appraisal have
been received and the aggregate number of holders of such shares. Such written statement
shall be mailed to the stockholder within ten (10) days after such stockholder's written
request for such a statement is received by the surviving or resulting corporation or within
ten (10) days after expiration of the period for delivery of demands for appraisal under
subsection (d) of this section, whichever is later.
|
|
(f)
|
Upon the
filing of any such petition by a stockholder, service of a copy thereof shall be made upon
the surviving or resulting corporation, which shall within twenty (20) days after such service
file in the office of the Department of State in which the petition was filed a duly verified
list containing the names and
|
addresses
of all stockholders who have demanded payment for their shares and with whom agreements as to the value of their shares have not been
reached by the surviving or resulting corporation. If the petition shall be filed by the surviving or resulting corporation, the petition
shall be accompanied by such a duly verified list. The Department of State, if so ordered by the court, shall give notice of the time
and place fixed for the hearing of such petition by registered or certified mail to the surviving or resulting corporation and to the
stockholders shown on the list at the addresses therein stated. Such notice shall also be published at least one (1) week before the
day of the hearing, in one (1) or more newspapers of general circulation in the City of San Juan, Puerto Rico, or such other publication
as the court deems advisable. The forms of the notices by mail and by publication shall be approved by the court, and the costs thereof
shall be borne by the surviving or resulting corporation.
|
(g)
|
At the
hearing on such petition, the Court of First Instance (Superior Part) shall determine the
stockholders who have complied with this section and who have become entitled to appraisal
rights. The court may require the stockholders who have demanded an appraisal for their shares
and who hold stock represented by certificates to submit their certificates of stock to the
Department of State for notation thereon of the pendency of the appraisal proceedings. If
any stockholder fails to comply with such direction, the court may dismiss the proceedings
as to such stockholder.
|
|
(h)
|
After the
court determines the stockholders entitled to an appraisal, the Court of First Instance (Superior
Part) shall determine the fair value of the shares taking into account a fair interest rate
if any is to be paid upon the amount determined to be the fair value. In determining such
fair value, the court shall take into account all relevant factors. In determining a fair
rate of interest, the court shall take into account all relevant factors, including the interest
rate that the surviving or resulting corporation would have had to pay to borrow money on
loan during the course of the proceedings. When the court determines the value of the shares,
it shall not take into account any element of value arising from the accomplishment or expectation
of the merger or consolidation. Upon application by the surviving or resulting corporation
or by any stockholder entitled to participate in the appraisal proceeding, the court may,
in its discretion, allow discovery or any other pre trial proceeding and may proceed to judge
the matter of appraisal prior to the final determination of the stockholders entitled to
the appraisal of his/her shares. Any stockholder whose name appears on the list filed by
the surviving or resulting corporation pursuant to subsection (f) of this section and who
has submitted such stockholder's certificates of stock to the Department of State, if such
is required, may participate fully in all proceedings until it is finally determined that
such stockholder is not entitled to appraisal rights under this section.
|
|
(i)
|
The court
shall direct the payment of the fair value of the shares, together with interest, if any,
by the surviving or resulting corporation to the stockholders entitled thereto. In the
case of holders of uncertificated stock, payment shall be so made to each such stockholder,
and the case of holders of shares represented by certificates upon the surrender to the corporation
of the certificates representing such stock. The court's ruling may be enforced as other
decrees in the Court of First Instance (Superior Part) may be enforced, whether such surviving
or resulting corporation be a domestic or foreign corporation.
|
|
(j)
|
The costs
of the proceeding may be determined by the court and impose them upon the parties as the
court deems equitable in the circumstances. Upon application of a stockholder, the court
may order all or a portion of the expenses incurred by any stockholder in connection with
the appraisal proceeding,
|
including,
without limitation, reasonable attorney fees and the fees and expenses of experts, to be charged pro rata against the value of all the
shares entitled to an appraisal.
|
(k)
|
As of the
effective date of the merger or consolidation, no stockholder who has demanded appraisal
rights as provided in subsection (d) of this section shall be entitled to vote such stock
for any purpose or to receive payment of dividends or other distributions on the stock (except
dividends or other distributions payable to stockholders of record at a date which is prior
to the effective date of the merger or consolidation). Provided, that if no petition for
an appraisal shall be filed within the time provided in subsection (e) of this section, or
if such stockholder shall deliver to the surviving or resulting corporation a written withdrawal
of such stockholder's demand for an appraisal and an acceptance of the merger or consolidation,
either within sixty (60) days after the effective date of the merger or consolidation as
provided in subsection (e) of this section or thereafter with the written approval of the
corporation, then the right of such stockholder to an appraisal shall cease. Notwithstanding
the foregoing, no appraisal proceeding in the Court of First Instance (Superior Part) shall
be dismissed as to any stockholder without the approval of the court, and the court may be
condition such approval upon such terms as it deems just.
|
|
(l)
|
The shares
of the surviving or resulting corporation to which the shares of such objecting stockholders
would have been converted had they assented to the merger or consolidation shall have the
status of authorized and unissued shares of the surviving or resulting corporation.
|
Artículo 10.13.
Derechos de Avalúo
|
(a)
|
Cualquier
accionista de una corporación organizada en el Estado Libre Asociado que:
|
|
(1)
|
Posea
acciones de capital en la fecha en que se haga un requerimiento, según lo dispuesto
en el inciso (d) de esta sección respecto a dichas acciones;
|
|
(2)
|
continuamente
ha poseído dichas acciones hasta la fecha de efectividad de la fusión o consolidación;
|
|
(3)
|
ha cumplido
con lo dispuesto en el inciso (d) de esta sección, y
|
|
(4)
|
no ha
votado a favor de fusión o consolidación ni ha dado su consentimiento escrito
a la fusión o consolidación, a tenor con la sec. 3657 de este título,
tendrá derecho al avalúo por parte del Tribunal de Primera Instancia (Sala
Superior) del valor justo de sus acciones de capital, con arreglo a las circunstancias descritas
en los incisos (b) y (c) de esta sección.
|
Tal como
se usa en esta sección, la palabra ‘accionista‘ significa el tenedor inscrito de acciones de una corporación
de acciones de capital, y también un miembro inscrito de una corporación sin acciones. Las palabras ‘acciones de
capital‘ y ‘acción‘ significan e incluyen lo que por lo general se entiende por dichos términos, como
también la condición de miembro o el interés que los miembros de una corporación sin acciones tengan en la
misma. Las palabras ‘recibo de depositario‘ significan un recibo u otro instrumento emitido por un depositario y que represente
un interés en una o más acciones, o fracciones de las mismas, del capital corporativo de una corporación que está
depositado con dicho depositario.
|
(b)
|
Las acciones
de cualquier clase o series de acciones de una corporación constituyente en una fusión
que se efectúe con arreglo a las disposiciones de las secs. 3731, 3732, 3735, 3738
y 3739 de este título, podrán tener derechos de avalúo:
|
|
(1)
|
Siempre
y cuando que los derechos de avalúo conferidos al amparo de esta sección no
se les conceden a las acciones de cualquier clase o series de acciones si dichas acciones
o recibos de depositario en cuanto a las mismas, a la fecha de registro fijada para determinar
los accionistas con derecho a ser convocados a la reunión de accionistas y votar en
la misma para tomar acción en relación con la fusión o consolidación,
estuviesen:
|
|
(A)
|
Registradas
en un mercado nacional de valores o en el Sistema Nacional de Cotización de Mercado
de la Asociación Nacional de Corredores de Valores (NASDAQ NMS), o
|
|
(B)
|
inscritas
en los libros de la corporación a favor de más de dos mil (2,000) accionistas.
El derecho de avalúo no se concederá a las acciones de capital de la corporación
constituyente que subsista de una fusión, si dicha fusión no requirió
la aprobación del voto de los accionistas de la corporación que subsista, según
lo dispuesto en la sec. 3731(f) de este título.
|
|
(2)
|
No obstante
las disposiciones de la cláusula (1) de este inciso, los derechos de avalúo
que concede esta sección serán concedidos a las acciones de cualquier clase
o serie de acciones de una corporación constituyente, si los términos del acuerdo
de fusión o de consolidación con arreglo a las secs. 3731, 3732, 3735, 3738
y 3739 de este título requieren a los accionistas de la corporación constituyente
que acepten, a cambio de tales acciones, todo excepto:
|
|
(A)
|
Acciones
de capital de la corporación que subsista o se origine de tal fusión o consolidación
o recibos de depositario en cuanto a las mismas;
|
|
(B)
|
acciones
de capital de cualquier otra corporación, o recibos de depositario en cuanto a las
mismas que, a la fecha de vigencia de la fusión o la consolidación, esté
incluida en una lista de un mercado nacional de valores o en el Sistema Nacional de Cotización
de Mercado de la Asociación Nacional de Corredores de Valores (NASDAQ NMS) o sean
acciones inscritas, según conste en los libros de la corporación, a favor de
más de dos mil (2,000) accionistas;
|
|
(C)
|
dinero
en efectivo a cambio de acciones accionarias de las corporaciones o de recibos de depositario
fraccionarios descritos en los párrafos (A) y (B) de esta cláusula, o
|
|
(D)
|
cualquier
combinación de las acciones de capital y dinero en efectivo a cambio de las acciones
fraccionarias o los recibos de depositario fraccionarios, descritas en los párrafos
(A) a (C) de esta cláusula.
|
|
(3)
|
En caso
de que no todas las acciones de una corporación subsidiaria doméstica que sea
parte de una fusión regida por la sec. 3732 de este título sean propiedad de
la corporación matriz, inmediatamente antes de la fusión, se le concederán
derechos de avalúo a las acciones de la corporación subsidiaria doméstica.
|
|
(c)
|
Cualquier
corporación podrá disponer, en su certificado de incorporación, la concesión
de derechos de avalúo al amparo de esta sección a las acciones de cualquier
clase o series de sus acciones, como resultado de una enmienda al certificado de incorporación
o de cualquier fusión o consolidación en la cual la corporación sea
una corporación constituyente o de la venta de todos o casi todos los activos de la
corporación. Si el certificado de incorporación contiene tal disposición,
los procedimientos de esta sección, incluso los establecidos en los incisos (d) y
(e) de esta sección, regirán hasta donde sea práctico.
|
|
(d)
|
Los derechos
de avalúo serán perfeccionados como sigue:
|
|
(1)
|
Cuando
una reunión de accionistas contemple someter para aprobación un plan de fusión
o de consolidación para el cual se intenta reconocer el derecho de avalúo,
según esta sección, la corporación, con al menos veinte (20) días
de anticipación a la reunión, notificará a cada uno de los accionistas
inscritos a la fecha de registro para dicha reunión con respecto a las acciones para
las cuales los derechos de avalúo están disponibles, según los incisos
(b) y (c) de esta sección, qué derechos de avalúo están disponibles
para cualquiera o todas las acciones de las corporaciones constituyentes, y tal notificación
incluirá una copia de esta sección. Todo accionista que seleccione exigir el
avalúo de sus acciones, entregará a la corporación, antes de votar en
relación con la fusión o consolidación, una petición escrita
de avalúo de sus acciones. Tal petición se entenderá suficiente en derecho,
si la misma informa razonablemente a la corporación la identidad del accionista y
la intención del mismo de exigir el avalúo de sus acciones. El haber concedido
un poder para votar o el voto en contra de la fusión o la consolidación no
constituye una petición para esos efectos. El accionista que elija proceder de este
modo, tendrá que hacerlo mediante una petición escrita por separado según
se dispone aquí. Durante los diez (10) días siguientes a la fecha de vigencia
de tal fusión o consolidación, la corporación que subsista o que se
origine notificará la fecha de vigencia de tal fusión o consolidación
a los accionistas de cada corporación constituyente que hayan cumplido con las disposiciones
de este inciso y no hayan votado a favor de la fusión o la consolidación o
no hayan consentido a la misma, o
|
|
(2)
|
si la
fusión o consolidación fue aprobada según las secs. 3657 y 3733 de este
título, entonces, cualesquiera de las corporaciones constituyentes o la corporación
que sobreviva o resulta de la fusión o consolidación, deberá notificar,
antes de la fecha de vigencia de la fusión o consolidación o dentro de los
diez (10) días siguientes a la misma, respectivamente, a
|
cada
uno de los accionistas con derechos de avalúo la fecha de vigencia de la fusión o de la consolidación, y que todas
las acciones de la corporación constituyente podrán ejercitar derechos de avalúo. Tal notificación deberá
incluir una copia de esta sección. Tal notificación podrá, y si se hace en o después de la fecha de vigencia
de la fusión o consolidación, deberá notificarle a los accionistas la fecha de vigencia de la fusión o consolidación.
Todo accionista con derecho a avalúo podrá exigir, dentro de los veinte (20) días siguientes a la fecha del envío
de dicha notificación, y por escrito, el avalúo de sus acciones a la corporación que subsista o se origine. Tal
petición se entenderá suficiente en derecho, si la misma informa a la corporación la identidad del accionista y
la intención del mismo de exigir el avalúo de sus acciones. Si tal notificación no le informó a los accionistas
la fecha de vigencia de la fusión o consolidación, se deberá:
|
(A)
|
Enviar
una segunda notificación antes de la fecha de vigencia de la fusión o consolidación
informando a todo accionista con derecho a avalúo la fecha de vigencia de la fusión
o consolidación, o
|
|
(B)
|
la corporación
que sobreviva o resulte de la fusión o consolidación deberá enviar una
segunda notificación a todo accionista con derecho a avalúo dentro de los diez
(10) días siguientes a la misma.
|
Sujeto,
sin embargo, a que si la segunda notificación se envía pasados veinte (20) días, desde el envío de la primera
notificación, la segunda notificación sólo deberá enviarse a aquellos accionistas con derecho de avalúo
que exigieron el avalúo de sus acciones, según provisto en este inciso. Una declaración jurada en la que se afirme,
por el secretario o subsecretario o por el agente de traspaso de la corporación, que cualesquiera de las notificaciones fueron
enviadas, será, en ausencia de fraude, prueba prima facie de los hechos allí consignados. Para propósitos de determinar
los accionistas con derecho a recibir la notificación o notificaciones, según sea el caso, cada corporación constituyente
podrá fijar con antelación a la fecha de vigencia de la fusión o consolidación, una fecha de registro, la
cual no podrá exceder de diez (10) días antes de la fecha de la notificación, y sujeto a que si la notificación
se dio pasada la fecha de vigencia, la fecha de registro será dicha fecha de vigencia. Si no se fijó una fecha de registro
y la notificación se dio antes de la fecha de vigencia de la fusión o consolidación, la fecha de registro será
al cierre de negocios del día que precede inmediatamente al día que se hace la notificación.
|
(e)
|
Dentro
de los ciento veinte (120) días siguientes a la fecha de vigencia de la fusión
o consolidación, la corporación que subsista o se origine, o cualquier accionista
que haya cumplido con las disposiciones de los incisos (a) y (d) de esta sección,
y que de otro modo adquiera derecho de avalúo, podrá presentar una petición
ante el Tribunal de Primera Instancia (Sala Superior) en reclamo de una determinación
del valor de la totalidad de las acciones de tales accionistas. No obstante, durante los
sesenta (60) días siguientes a la fecha de vigencia de la fusión o consolidación,
cualquier accionista estará facultado para retirar su petición de avalúo
y aceptar los términos ofrecidos en la fusión o consolidación. Durante
los ciento veinte (120) días siguientes a la fecha de vigencia de la fusión
o consolidación, cualquier accionista que haya cumplido con los requisitos de los
incisos (a) y (d) de esta sección aquí relacionados, y mediante petición
escrita, tendrá derecho a recibir de la corporación que subsista la fusión
o que se origine de la corporación, una declaración que haga constar la suma
total de acciones que no votaron en favor de la fusión o la consolidación,
y para las cuales se ha recibido peticiones de avalúo, y el número total de
los tenedores de tales acciones. Tal notificación escrita se enviará al accionista
por correo durante los diez (10) días siguientes, a la fecha en que la corporación
que subsista o se origine reciba la petición escrita de tal
|
declaración
o durante los diez (10) días siguientes a la fecha de expiración del plazo para solicitar el avalúo al amparo del
inciso (d) de esta sección, cualquiera que sea más tarde.
|
(f)
|
Al accionista
presentar la petición, se entregará copia de la misma a la corporación
que subsista o se origine, cuya corporación presentará en las oficinas del
Departamento de Estado, durante los veinte (20) días siguientes a la fecha de dicho
diligenciamiento, una relación debidamente verificada de los nombres y direcciones
de todos los accionistas que hayan solicitado que se le paguen las acciones, y que no hayan
llegado a un acuerdo en cuanto al valor de sus acciones con la corporación que subsista
o se origine. Si la petición fuese presentada por la corporación que subsista
o se origine, la petición deberá acompañarse con la relación
antes expresada. El Departamento de Estado, si el tribunal lo ordenase así, notificará,
por correo certificado, la hora y lugar fijados para la vista de tal petición a la
corporación que subsista o que se origine y a los accionistas relacionados en la lista
a las direcciones que consten en la misma. Tal notificación se publicará en
uno o más periódicos de circulación general en la Ciudad de San Juan,
Puerto Rico, o cualquier otra publicación que el tribunal juzgue conveniente, con
por lo menos una semana de antelación a la celebración de la vista. La manera
de notificar por correo y por publicación requerirá la aprobación del
tribunal, y las costas de las mismas serán sufragadas por la corporación resultante
o que sobreviva.
|
|
(g)
|
Durante
la vista, el Tribunal de Primera Instancia (Sala Superior) determinará los accionistas
que han cumplido con los requisitos de esta sección, y que han adquirido el derecho
a que se valoren sus acciones. El tribunal podrá exigir que los accionistas que han
solicitado el avalúo de sus acciones y que son tenedores de acciones representadas
por certificados sometan sus certificados de acciones al Departamento de Estado para que
se anote en los mismos que hay procedimientos de avalúo pendientes. Si algún
accionista no cumpliese con tal instrucción, el tribunal podrá desestimar la
acción en relación con ese accionista en particular.
|
|
(h)
|
Luego de
determinar cuáles accionistas tienen derecho al avalúo de sus acciones, el
Tribunal de Primera Instancia (Sala Superior) determina el valor justo de las mismas, tomando
en cuenta la tasa de interés justa, si alguna ha de pagarse en consideración
al justo valor estimado. Al determinar dicho valor justo, el tribunal tomará en cuenta
todos los factores relevantes. Al determinar la tasa de interés justa, el tribunal
tomará en cuenta todos los factores relevantes, incluso la tasa de interés
que la corporación resultante o subsistente hubiese tenido que pagar para tomar dinero
a préstamo durante la duración de los procedimientos. Cuando el tribunal
determine el valor de las acciones no tomará en cuenta cualquier elemento en valor
que se origine de la fusión o consolidación o de su expectativa de otorgamiento.
A solicitud de la corporación subsistente o resultante o de cualquier accionista que
participe en un procedimiento de avalúo, el tribunal podrá, a su discreción,
permitir el descubrimiento de prueba o cualquier otro procedimiento con antelación
a juicio, y podrá juzgar el asunto del avalúo antes de la determinación
final del accionista con derecho al avalúo de sus acciones. Cualquier accionista cuyo
nombre aparezca en la relación presentada por la corporación subsistente o
resultante, según el inciso (f) de esta sección, y que haya sometido sus certificados
de acciones al Departamento de Estado si se le requiere, podrá participar plenamente
en todos los procedimientos hasta que se determine del todo que no tiene derechos de avalúo
al amparo de esta sección.
|
|
(i)
|
El tribunal
ordenará a la corporación subsistente o resultante a pagar el valor justo de
las acciones, además de los intereses, si alguno, a los accionistas con derecho a
los mismos. En caso de tenedores de acciones sin certificado, los pagos se efectuarán
de inmediato, y en los casos de tenedores de acciones
|
representadas
por certificados, se efectuarán al entregar dichos certificados a la corporación. El dictamen del tribunal podrá
hacerse cumplir, tal como los demás dictámenes del Tribunal de Primera Instancia (Sala Superior), sea la corporación
subsistente o resultante, una corporación doméstica o foránea.
|
(j)
|
El tribunal
podrá determinar las costas del procedimiento e imponerlas a las partes, según
lo juzgue equitativo ante las circunstancias prevalecientes. Mediante solicitud de un accionista,
el tribunal podrá ordenar que todos los gastos o parte de éstos, incurridos
por un accionista en relación con los procedimientos de avalúo, incluso, pero
no limitado a, honorarios razonables de abogados y los honorarios y gastos de peritos, se
impongan a prorrata contra el valor de todas las acciones con derecho de avalúo.
|
|
(k)
|
A partir
de la fecha de vigencia de la fusión o la consolidación, ningún accionista
que haya reclamado su derecho a avalúo, según el inciso (d) de esta sección,
tendrá derecho a votar dichas acciones para cualquier propósito o a recibir
pago de dividendos u otras distribuciones por sus acciones (excepto los dividendos u otras
distribuciones pagaderas a los accionistas inscritos a una fecha previa a la fecha de vigencia
de la fusión o consolidación). De no presentarse las peticiones de avalúo
durante el término provisto por el inciso (e) de esta sección, o si el accionista
entregare a la corporación subsistente o resultante una renuncia escrita a su petición
de avalúo y una aceptación de la fusión o consolidación, ya sea
durante los sesenta (60) días siguientes a la fecha de vigencia de dicha fusión
o consolidación, según se dispone en el inciso (e) de esta sección o
luego de esta fecha con la aprobación escrita de la corporación, entonces el
derecho de tal accionista a que se valoren sus acciones cesará. No obstante lo antes
dicho, ningún procedimiento de avalúo en el Tribunal de Primera Instancia (Sala
Superior) se dará por terminado, respecto a cualquier accionista sin la aprobación
del tribunal, y el tribunal podrá condicionar dicha aprobación a los términos
que juzgue equitativos.
|
|
(l)
|
Las acciones
de la corporación subsistente o resultante, a las cuales se hubiesen convertido las
acciones de los accionistas protestantes, de éstos haber consentido a la fusión
o la consolidación, tendrán la condición de acciones autorizadas y sin
emitir de la corporación que subsista o resulte.
|